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ABSTRACT 
Thoracic aortic aneurysm is a life-threatening condition which affects different parts 
of the aorta. A significant proportion of patients present with incidental aneurysmal 
disease and are physically asymptomatic at the time of their first presentation. 
However, despite their asymptomatic nature the existence of an acute aortic 
syndrome represents a life threatening disease which is associated with a high 
mortality rate. Thus the effective and efficient diagnosis and treatment of such 
patients is essential in optimizing both their quality and quantity of life.  
This thesis takes advantage of a range of structural and policy changes that have 
been undertaken at Liverpool Heart and Chest Hospital (LHCH) to evaluate the 
impact of such changes on the clinical and cost effectiveness of aortic surgery. 
Foremost amongst these changes was the reorganization of the aortic service in 
2007 to concentrate treatment in the hands of a small number of specialists. This 
thesis examines subspecialisation and reorganisation of surgical expertise and 
activity for the treatment of aortic surgery patients at LHCH resulted in significantly 
improved patient outcomes which is being achieved with cost neutral changes in 
service delivery. The thesis will assess the impact of this subspecialisation on a range 
of outcome dimensions including patient outcomes and the efficiency of resource 
utilization within the aortic service at LHCH.   
The focus of this study is in tune with increased sub-specialization in a wide range of 
therapeutic areas in hospitals throughout the UK. It is hoped that the methodology 
and findings of this study may contain lessons that may be applicable to specialisms 
outside aortic surgery throughout the NHS and assist in developing an evidence 
based health policy to inform the ever growing trend towards increased sub 
specialization. The improvements appeared to simply result from the natural 
enhancement of expertise that results from concentration of specialist surgery in 
fewer and hence more experienced hands. In this regard, centralization of thoracic 
aortic aneurysm service appears to enhance both survival. The generalizability of 
these findings and potential lessons for the provision of specialist surgery in other 
therapeutic areas await further investigation
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CHAPTER ONE 
1. INTRODUCTION 
1.1 Overview 
Thoracic aortic aneurysm is a silent disease, which in the majority of cases is 
asymptomatic. The aneurysmal aorta grows slowly and remain indolent until it 
reaches a pivotal point, at which it could either dissects or ruptures—complications 
that are bound to produce futile outcomes unless prior intervention are taken to 
avert complications. Therefore, timely detection of patients at risk of developing a 
thoracic aneurysm is imperative. Such timely detection can be achieved by 
identifying and understanding risk factors, clinical conditions, and unequivocal 
development of screening tools such as biomarkers and genetic components.1,2  In 
recent years conditions such as bicuspid aortic valve3, intracranial aneurysm 4,  and 
bovine aortic arch5, as well as a strong family history of aortic disease have all been 
shown to be associated with thoracic aortic aneurysm and dissection and not only 
this but they have been proven to increase predilection to development of aortic 
aneurysm disease. Nevertheless, a large percentage of newly identified thoracic 
aortic aneurysms are incidental findings revealed during imaging studies 
(echocardiography, computed tomography, MRI) performed for unrelated reasons.  
                                                                
1 Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am 
Coll Cardiol. 2010; 55:841–857. 
2 Davies RR, Kaple RK, Mandapati D, Gallo A, Botta DM Jr, Elefteriades JA, et al.. Natural history of ascending 
aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg. 2007; 83:1338–1344 
3 Kuzmik GA, Feldman M, Tranquilli M, Rizzo JA, Johnson M, Elefteriades JA. Concurrent intracranial and 
thoracic aortic aneurysms. J Am Coll Cardiol. 2010; 105:417–420 
4 Hornick M, Moomiaie R, Mojibian H, Ziganshin B, Almuwaqqat Z, Lee ES, et al.. ‘Bovine' aortic arch -a marker 
for thoracic aortic disease. Cardiology. 2012; 123:116–124.  
5 lbornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al.. Familial thoracic aortic aneurysms 
and dissections–incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006; 82:1400–
1405.  
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Once a patient has been diagnosed with a thoracic aortic aneurysm, it is equally 
important to closely monitor the disease progression of the aneurysm until a critical 
size is attained, at which time surgical treatment would be considered appropriate 
if the patient was deemed suitable candidate for surgical intervention6. The 
estimated growth rate of thoracic aneurysms is approximately 0.1 to 0.15 cm/year.  
If the aorta is rapidly increasing in size that will shift the paradigm and surgeons’ 
will have to make an informed choice with patients and their families to intervene 
and avert potential complications.  Surgery on the thoracic aortic arch has always 
posed equal challenges to the surgeons and patients. To the surgeon, aortic surgery 
challenges are:  
1) This is a highly specialized procedure that require set of skills that are 
learned through apprenticeship and at high volume centers.  
2) The surgeon performing the surgery should benchmark his/her intervention 
with standard high volume center outcomes and the intervention must attain 
cost-effectiveness.  
To the patients, the challenges posed are the ability to retain a certain degree of 
quality of life after the surgical intervention and certainly survival for a long term. 
The surgical outcome for aortic arch aneurysm improved consistently; however, it 
remains associated with some morbidity and mortality despite the improved 
surgical technology and brain protection strategies.  
The reported mortality in literature for an elective aortic arch operation ranges 
between 7-24%6. The required operation to repair an aneurysm and avert a 
devastating complication including aortic dissection or fatal rupture requires a 
multitude of understandings and specific set of skills.   
                                                                
6 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of 
Patients With Thoracic Aortic Disease. Circulation. 2010;121:e266-e369 
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The decision to intervene should be based on intricate understanding of aetiology 
and pathophysiology of the disease, an understanding of the natural history of aortic 
aneurysm, surgical indications and when to intervene and when not to intervene.  
The knowledge should also entail the provision of resources that could help in 
facilitating the decision and optimizing the management. The resources that could 
be utilized albeit an endovascular approach or an open surgical repair should be 
evidence based in terms of outcomes and survival.  
In the UK, it has been suggested that volume-based referral strategies are most 
appropriate for operative interventions, which are relatively infrequent, technically 
complex and with challenging post-operative care. Surgery of the thoracic aorta 
would seem to be one area where such considerations might applicable.  
The available technologies and resources of endovascular approach lead to a surge 
of such procedures to be done on the aorta. Although short-term morbidity appears 
to be reduced in hybrid repairs, it is not clear that early death is reduced. In addition 
to the uncertain long-term functionality and durability of endovascular devices, the 
substantial risk of stroke due to wire and device manipulation within the aortic 
aneurysm in particular the aortic arch is a drawback. Therefore, open aneurysm 
repair represents an option that can deliver quality outcomes and results. However, 
in order to achieve these goals; complex rearrangement in the way aortic service is 
provided needs to ensue across the country. Liverpool Heart & Chest Hospital 
(LHCH) developed a subspecialised scheme that further evolved to become an 
impact model for better aortic service provision in both elective and non-elective 
aortic surgeries. In 2007, the trust grouped a team of specialised experts to provide 
aortic surgery expertise to the widest catchment population of the Northwest of 
England and North of Wales which is estimated to be 2.8 million. LHCH became the 
first hospital to have a 24 hour on-call rota with a team on standby for aortic 
emergencies. This led to increase in surgical activity to around 180 aortic 
procedures performed each year at LHCH.  
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From a health economic evaluation perspective, an assessment of benefits derived 
from an intervention, are described as clinical outcomes and cost effectiveness. 
These are terms used to describe an improvement in the individual’s health and 
wellbeing in terms of symptoms and functioning, and the way the individual values 
their particular state of health. Due to the complexity involved sub-specialisation 
aim to improve outcomes in all areas of aortic surgery in elective and non-elective 
workload.  
The effect on costs is also of interest as it could potentially indicate whether the 
rearrangement in the service provision led to improved outcomes and can this 
coexist with reduced or neutral costs.  
  
 20 
 
1.2 Hypothesis 
1. The service rearrangement and the move from non-specialized to specialized 
aortic service at Liverpool Heart & Chest Hospital has improved clinical 
outcomes in both elective and non-elective aortic repair and was cost-
effective? 
2. The value of open surgical intervention was optimized through 
subspecialisation in elective and non-elective aortic aneurysm surgery? 
 
1.3 Research Questions and Framework 
1. What is the natural history of operated and non-operated aneurysmal 
disease? 
Much has been known of natural history and its emphasis on the importance of the 
size of the aneurysm as an indication for surgical intervention. I will examine this 
question and assess whether this co-exist with other elements or factors that could 
potentially guide the surgeon and the patient.  
 
2. What is the UK volume-outcome relationship in acute type A aortic 
dissection?  
This question aims to illustrate the volume effect of ATAD per surgeon and per 
hospital and whether this correlates to the outcomes per se.  
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3. What are the outcomes, survival and the factors that influence survival of 
aortic aneurysm elective and non-elective patients at LHCH? Does 
subspecialisation offer better results and could the volume-outcome 
relationship be applicable as a template of quality outcomes and survival 
benefit?  
Patients’ at hospitals where a high number of procedures are performed (high-
volume hospitals) have lower mortality rates than those at hospitals that are less 
experienced with the particular procedures or intervention. Hence, high-volume 
hospitals have access to broader range of resources and services including intensive 
care units, and other resources that are not available at smaller centres. By virtue, 
high-volume hospitals may be better equipped to deliver the complex perioperative 
care required for patients undergoing high-risk surgery. Such hospitals have 
concentration of experts that deliver a volume of case mix and at better outcomes.  
Hence, LHCH stand out as a tertiary centre that provides expert opinion and surgical 
expertise in the field of cardiac, thoracic and aortic surgery. The effectiveness of the 
service provision and the quality of health care provided by measuring outcomes i.e 
the morbidity and mortality and survival will be demonstrated throughout this 
thesis.  
The question of volume-outcomes relationship will be assessed utilizing LHCH 
dataset of aortic aneurysm patients. I will also evaluate whether the findings could 
prove to be a template of quality improvement.  
4. Is the concept of subspecialisation in aortic aneurysm surgery 
transferrable as an impact model in the NHS?  
In 2007, a specialised aortic service line was established at our LHCH in response to 
perceived poor outcomes from acute Type A aortic dissection repair. Prior to the 
change all elective and emergency aortic surgery were performed by general cardiac 
surgeons. Following the specialised team formation, the majority of elective aortic 
surgery and all emergency aortic surgery are currently being performed by 4 aortic 
surgeons.  
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The primary aim of the service rearrangement is to reduce operative mortality, 
morbidity and consequently to improve long term survival. This model of service 
provision is yet to be defined whether it’s transferrable to other centres where 
concentration of expertise to provide aortic aneurysm surgery could ensue.  
 
1.4 Study Setting 
The study was conducted at Liverpool Heart & Chest Hospital (LHCH) formally 
known as The Cardiothoracic Centre in 1991 and which was later renamed to LHCH 
in 2008. The hospital is also known as Broadgreen since it located in that area and is 
attached to Broadgreen Hospital that offers different services to the wider 
community of Liverpool. LHCH is a specialist tertiary hospital and became a 
foundation trust in 2008. The specialism cover all kind of cardiological spectrum of 
healthcare including interventional state of the art services. The hospital also has 
state of the art cardiothoracic and aortic services. The first aortic operation done at 
LHCH was back in 1998.  
Since then the activity has been increasing to meet the demand of wider population 
that LHCH covers. The estimated population is in the range of 2.8 million and areas 
covered are Merseyside, North West England, North Wales and the Isle of Man but 
also provides services for patients from all areas of the United Kingdom performing 
up to 1200 procedures a year.  
Over a decade ago, Mr Abbas Rashid a retired consultant cardiac and aortic surgeon 
developed the thoracic aortic aneurysm service at Liverpool Heart & Chest Hospital.  
In the UK, the aortic team and service stands unique in that they perform all elective 
and non-elective aortic surgeries. This includes complex aortic procedures, 
endovascular repair of thoracic and thoracoabdominal aortic aneurysm (TEVAR), 
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hybrid repair of thoracic aortic aneurysms and minimal invasive aortic valve 
surgery.  
Moreover, in 2007, the thoracic aortic service became the first in the UK to 
implement a subspecialized aortic on-call rota with dedicated 24 hours emergency 
on call service. The aortic team runs 4 dedicated aortic theatres a week and the work 
not only is limited to aortic surgery but we also perform conventional cardiac 
surgery as well. We run a multidisciplinary meeting to discuss complex cases with 
vascular surgeons, interventional cardiologists, interventional radiologists, 
intensivists and anaesthetists. This serves optimal quality decision making tailored 
to each and every individual patient.  
For this particular study, we utilized a prospectively collected aortic database 
between October 1998 and August 2012. 
1.5 Structure of the Thesis 
The thesis lays the foundations for a decision support framework for healthcare 
professionals. The thesis fills important gaps between what is already known and 
what new knowledge is needed to make such a framework relevant. The first half of 
the thesis lays out and explores the theoretical foundations for such a framework, 
the second half goes on to explore the implications of putting such a framework into 
practice. Each chapter builds on previous chapters to develop a rational and logical 
structure to achieve the aims and objectives of the thesis. This process now moves 
into a comprehensive examination of aortic aneurysms – the clinical context in 
which our analysis is being undertaken. 
CHAPTER ONE: Aimed at introduction, hypothesis, research questions and 
framework, thesis structure and study setting.  
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CHAPTER TWO: This chapter draws the aims Health Economic Evaluation 
requirements in thoracic aortic surgery. The chapter is also aimed at overviewing 
background of health economic evaluation tools. 
CHAPTER THREE: This chapter is aimed at background and clinical overview from 
the evidence based literature on historical, clinical features pertinent to aortic 
aneurysm surgery and its modality of diagnosis and surgical indication perspectives.  
CHAPTER FOUR: This chapter focuses on highlighting the clinical background 
literature of ATAD, its risk factors and modalities of diagnosis and management.  
CHAPTER FIVE: This chapter signifies the importance of risk stratification in 
thoracic aortic aneurysm disease and demonstrates the development of risk 
prediction model based on common variables that alters surgical outcomes in 
thoracic aortic aneurysm disease.  
CHAPTER SIX: This chapter reflects the comprehensive understanding of brain 
protection methods employed in open thoracic aortic aneurysm surgery in 
conjunction to the adjuncts used and ways of stroke avoidance. 
CHAPTER SEVEN: Highlights the indications of when to operate upon thoracic aortic 
aneurysms. It also illustrates experiences upon open repair, endovascular and draws 
a comparative between the two modalities aforementioned.  
CHAPTER EIGHT: This is the comparator when surgery is not employed and 
medical treatment is pursued. It also dwells onto the perspectives of natural history 
of thoracic aortic aneurysm disease in both operated and non-operated patients’ 
cohort.  
CHAPTER NINE: This chapter includes literature review of economic analysis and 
the concept of subspecialisation in aortic surgery. It marks the volume-outcome 
relationship and informs the economic evaluation and costing theoretical 
framework that aided in the development of analysis. 
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CHAPTER TEN: Is a constellation of the volume outcome effect nationally and 
internationally. It also highlights the need for subspecialisation and centralization of 
thoracic aortic services in the UK.   
CHAPTER ELEVEN: This chapter describes the methodology utilized to validate the 
aortic database at LHCH and derive the clinical and economic analysis.  
CHAPTER TWELVE: This entails the results attained from our analysis of clinical 
outcomes pertinent to the increased volume of aortic case mix. It demonstrates the 
outcomes of aortic arch aneurysm and acute Type A aortic dissection before and 
after subspecialisation. It will also include the cost-analysis made between two 
groups i.e. before and after subspecialisation. 
CHAPTER THIRTEEN: This chapter thoroughly discuss the analysis that formed the 
backbone of the hypothesis and answers all the research questions raised during 
this study.  
CHAPTER FOURTEEN: This chapter is aimed at conclusion and further 
recommendations. This will round up the salient points discussed and outline the 
strong points to be deduced as a take home message for further research. 
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CHAPTER TWO 
2. HEALTH ECONOMIC EVALUATION IN THORACIC 
AORTIC ANEURYSM SURGERY 
2.1 Introduction 
“Economics is the science of scarcity. The application of health economics reflects a 
universal desire to obtain maximum value for money by ensuring not just the clinical 
effectiveness, but also the cost-effectiveness of health care provision” (Alan Haycox, 
April 2009)7 
Economic evaluation in health economics is used as a tool to identify the optimal 
interventional option through a derived comparison between cost and benefits.8 
There are different applications to such tool and it has best been demonstrated by 
Ray Robinson9  who published on the difference between economics tools, their 
settings and applications. The thesis aims to understand the assessment of cost-
benefit analysis in elective and non-elective aortic aneurysm repair that typically 
carries dire results between centres and regions across the United Kingdom. It’s not 
clear whether we could apply such economic tools to assess the volume-outcome 
relationship as clearly this has not been studied before. The volume-outcomes 
relationship has been clinically supported by different groups in their published 
work which states the higher the volume of caseloads the better the outcomes185,.  
                                                                
7 Haycox, A., & Noble, E. (2003). What is health economics? Hayward Group. Retrieved 04/06/2015, from 
http://www.isciii.es/htdocs/pdf/WhatisHealthEcon.pdf. 
8 National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 
9 Economic evaluation and health care. What does it mean? BMJ. Sep 11, 1993; 307(6905): 670–673. 
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However, Kenneth Arrow, in his work on “product uncertainty” argues that the 
principles and implication of the standard demand paradigm do not apply to the 
current health market and resource utilization10.  
The vast difference in knowledge and application between the health care provider 
and the patient necessitate that there should be a tool through which patients reflect 
on their benefit gained from a particular intervention to alter their health status.  
There is a general consensus among the aortic surgeons at Liverpool Heart & Chest 
Hospital that asymptomatic patients may harbour a significant health burden arising 
from becoming aware that they have an aneurysm that can dissect and rupture at 
any given point in time due to aneurysmal size increase.  
The information given to patients on the day of consultation with members of the 
aortic team impact the overall patients’ health related quality of life (HRQoL) and 
psychological wellbeing. Regardless of whether patients are aware that surgery will 
improve their chances of survival and precludes rupture and dissection their 
functional status is likely to initially deteriorate in relation to the prospect of surgical 
intervention, a situation which might normalize with time post-surgery. The quality 
of life trajectories for both symptomatic and asymptomatic patients have yet to be 
researched particularly in patients with thoracic aortic aneurysms. In addition, there 
is no evidence that surgical interventions will improve HRQoL and is cost-effective. 
Yet, there is a need to understand the psychological burden imposed upon patients’ 
once they become aware of their diagnosis of aortic aneurysm and then establish 
how that has an impact on their health-related quality of life and explore the 
applicability of health-related quality of life tools in this type of surgery and their 
limitations.  
 
                                                                
10 The American Economic Review, UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE Vol.3 
, Number 5 
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In aortic aneurysm surgery, there is no one value-focused measure or termed 
“preference-based” to be able measures an individual’s preference for a health state, 
as opposed to an individual’s description of the state. As such, there exists a variety 
of methods for measuring preference-based health related quality of life (HRQOL).  
The impact of any significant change in healthcare provision is akin to dropping a 
large stone into a millpond. The ripples associated with the change are greatest near 
the epicentre where the stone enters the water and gradually become less as the 
concentric waves move out. As such the clinical and cost effectiveness of any 
structure of clinical provision results from a vast and complex system of intrinsically 
interrelated components. Each element within the structure is related to every other 
element and, in large part, it is the quality of this 'meshing' of elements which 
delineates the quality of healthcare provision.  
The fundamental issue, which neither clinicians or health economists to date have 
been able to address in an evidence based fashion is how a defined change in 
healthcare provision (sub-specialisation in aortic surgery) will impact upon the 
health of patients and the efficiency of the healthcare 'system' as a whole.  
Economic Evaluation helps to provide information that can be utilized in decision 
making so we could make a better choice and informed decision among competing 
healthcare interventions. It allows us to evaluate and identify measurable values and 
input such as cost and its related output i.e. benefit. It aims to provide us with a 
source that can help in determining collectively there is any improvement in welfare 
of a particular individual with comparison to current trend and practices 
(Drummond, 1990).  
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2.2 Techniques of Economic Evaluation  
Economic evaluation provides a systematic and objective framework for drawing up 
a balance sheet of costs and benefits which can assist decision-makers to make more   
informed choices. All economic evaluations have a common structure which involves 
explicit measurement of inputs (‘costs’) and outcomes (‘benefits’). The four main 
methods of economic evaluation vary in terms of their evaluation of health 
outcomes. The appropriate analytical tool to choose in any given circumstance 
depends upon three main issues. First, what is the context in which the analysis is 
being undertaken? Second, what is the focus of the economic evaluation being 
undertaken? Third, what is the nature of the comparative outcome arising from the 
competing therapeutic options? Knowledge of these three issues will provide a guide 
to the appropriate economic tool to be employed for any particular analysis. 
 
2.2.1 Cost-Minimisation Analysis 
Cost-minimisation analysis is restricted to situations in which the health benefits of 
healthcare treatments have been proven to be identical. An example would be a 
decision to prescribe a generic drug instead of a brand- name drug, achieving the 
same outcome at less cost. Frequently, therefore, this technique is perceived as being 
the easiest to apply, but such a perception is misleading. Cost- minimisation analysis 
does not ignore health outcomes, but actually requires proof that outcomes are 
clinically equivalent to legitimise the use of this technique. This opens up a new and 
complex array of issues that need to be addressed prior to utilising this technique. 
What do we mean by ‘clinical equivalence’ and what evidence is required to support 
such equivalence (non-inferiority trials, equivalence trials or real-world audit data)? 
Such theoretical considerations need to be addressed if cost-minimisation analysis 
is to be appropriately employed as a valid technique of economic evaluation.  
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What is clear, however, is that it is highly inappropriate to simply assume clinical 
equivalence between competing therapies as a justification for the use of cost-
minimisation analysis. 
 
2.2.2 Cost-Effectiveness Analysis 
The term ‘cost-effectiveness analysis’ properly refers to an evaluation where the 
outcomes are one-dimensional.  Cost-effectiveness analysis is therefore used in 
health economics to compare the financial costs of therapies whose outcomes can 
be measured purely in terms of health effect (for example, years of life saved, ulcers 
healed). For instance, if we wanted to compare the use of a proton pump inhibitor to 
relieve severe reflux oesophagitis with the use of H2 blockers to achieve the same 
end, we could calculate the costs per patient relieved of symptoms for each therapy. 
Cost-effectiveness analysis is the most commonly applied form of economic analysis 
in the health economics literature, and is frequently used in drug therapy. However, 
it does not allow comparisons to be made between courses of action that have 
completely different therapeutic outcomes. 
 
2.2.3 Cost–Utility Analysis 
Cost–utility analysis is similar to cost- effectiveness analysis in that there is a defined 
outcome, and the cost to achieve that outcome is measured in money. However, in 
cost–utility analysis the outcome is measured in terms of survival and quality of Life. 
Since the endpoint may not be directly dependent on the disease state, cost–utility 
analysis can, in theory, compare courses of action in different areas of medicine. In 
practice, this is not so easy, since QALYs remain subject to much philosophical and 
technical criticism.  
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2.2.4 Cost–Benefit Analysis 
In cost–benefit analysis the benefit is measured as the associated economic benefit 
of an intervention, and hence both costs and benefits are expressed in money. 
Cost–benefit analysis may ignore many intangible but very important benefits that 
are difficult to measure in monetary terms (for example, relief of anxiety). It could 
also be seen to discriminate against those for whom a return to productive 
employment is unlikely (for example, the elderly or the unemployed).  
However, the virtue of this analysis is that it enables comparisons to be made 
between schemes in very different areas of healthcare, and even with schemes 
outside the field of medicine. For example, using cost–benefit analysis, the costs and 
benefits of expanding university education (the benefits of improved education and 
hence productivity) can be compared with establishing a back pain service 
(enhancing productivity by returning patients to work). This approach is not widely 
accepted for use in health economics. 
 
2.3 Evaluating Resource Use 
2.3.1 Costing in the NHS 
The NHS was founded in 1948 with a modest budget of 437 million pounds however 
since this date.  The budget has been growing at a rate of approximately 4% per year 
11(see figure 2.3.1). 
                                                                
11 Gateway reference: 9006/11400; Doh-NHS Costing Publications 
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The NHS was founded on the basis of providing equal access for equal need and is 
therefore funded from general taxation to enable the service to be provided free at 
the point of delivery hence moving the allocation of resources away from the 
willingness and ability to pay of the patient. As the NHS moves into the 21st century 
it faces an ever increasing demand for service delivery juxtaposed with an ever 
increasing constrain on available resources. As a consequence, the system requires 
each element of its service to generate the greatest possible outcome from the 
resources that it consumes.  
The fundamental principle on which health economic evaluation is undertaken is 
that of 'opportunity cost'. This principle emphasizes that the true 'cost' of using 
resources in any particular manner is their subsequent unavailability for use in the 
provision of some alternative service. Hence the true cost of resources consumed in 
the provision of aortic surgery is the outcome that would have been generated 
(additional alternative cardiothoracic procedures) had the surgical expertise and 
resources been used in some alternative manner.  
Whilst acknowledging the theoretical superiority of the concept of opportunity cost 
it is generally recognized to be an immensely difficult concept to operationalize in 
mainstream clinical practice. The alternative use of resources consumed in the 
provision of aortic surgery (either within cardiothoracic surgery or elsewhere) 
cannot be reliably ascertained. As such (and in line with the vast majority of resource 
analyses undertaken within the NHS) this study restricts any resource analysis to 
evaluating the physical amount of resources consumed and the associated cost 
imposed on the NHS. The manner in which this has been achieved and the sources 
of cost data utilized are outlined below.    
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2.3.2 NHS National Reference Costs 
The UK Department of Health (DoH) is mandated to ensure efficient use of NHS 
resources. To achieve this, they developed a costing system which attempted to 
identify a nationally relevant cost of providing every type of procedure provided by 
the National Health Service.  Each provider within the NHS is mandated to allocate 
their resource use and associated cost between each of the procedures that were 
carried out and submit this information to the DoH on an annual basis. Given the 
'shared' nature of much NHS resource use such allocations were hugely difficult and, 
in large part, the final cost identified was largely dependent on the allocation 
procedure used to divide shared costs between individual procedures. Despite its 
limitations this process enabled DoH to identify average cost for various procedures 
across NHS organizations after eliminating outliers. This also helped hospitals to 
bench mark their cost against other providers in the sector.  
The exercise provided also required a common structure of 'outputs' to be identified 
and this facilitated clear definitions of procedures known to be developed in the 
form of OPCS codes. Payment by result was introduced in England in 2005 which 
reimbursed provider organizations through national tariff only for completed spells 
for regular procedures carried out. High cost low volume specialist procedures (for 
example cancer interventions) are excluded from this model of reimbursement and 
continue to be based on demand, capacity and affordability. This new funding system 
created severe turbulence both on the part of providers and also of commissioners 
of care and, in extreme cases, caused severe financial problems for provider units12.  
 
 
 
                                                                
12 Transparency and accountability: using better data to drive performance in the NHS. The Health and Social 
Care Information Centre 
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2.3.3 Activity Based Costing 
Activity-based costing was first clearly defined in 1987 by Robert S. Kaplan and W. 
Bruns as a chapter in their book 13. They initially focused on manufacturing industry 
where increasing technology and productivity improvements have reduced the 
relative proportion of the direct costs of labour and materials, but have increased 
relative proportion of indirect costs. For example, increased automation has reduced 
labour, which is a direct cost, but has increased depreciation, which is an indirect 
cost. 
Like manufacturing industries, financial institutions have diverse products and 
customers, which can cause cross-product, cross-customer subsidies. Since 
personnel expenses represent the largest single component of non-interest expense 
in financial institutions, these costs must also be attributed more accurately to 
products and customers. Activity based costing, even though originally developed 
for manufacturing, may even be a more useful tool for doing this. 
Activity-based costing was later explained in 1999 by Peter F. Drucker in the book 
Management Challenges of the 21st Century14. He states that traditional cost 
accounting focuses on what it costs to do something, for example, to cut a screw 
thread; activity-based costing also records the cost of not doing, such as the cost of 
waiting for a needed part. An activity-based costing record the costs that traditional 
cost accounting doesn’t do. The overhead costs assigned to each activity comprise 
an activity cost pool. 
 
                                                                
13  Kaplan, Robert S. and Bruns, W. Accounting and Management: A Field Study Perspective (Harvard Business 
School Press, 1987) 
14 Sapp, Richard, David Crawford and Steven Rebishcke.  Journal of Bank Cost and Management Accounting 
(Volume 3, Number 2), 1990 
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2.4 Costing at Liverpool Heart and Chest Hospital 
2.4.1 Patient-Level Information and Costing Systems (PLICS) 
Patient-level information and costing systems (PLICS) represent a change in the 
costing methodology in the NHS from a predominantly "top down" allocation 
approach, based on averages and apportionments, to a more direct and 
sophisticated approach based on the actual interactions and events related to 
individual patients and the associated costs. Patient-level costing is defined by the 
ability to measure the resources consumed by individual patients. Patient-level costs 
are calculated by tracing resources actually used by a patient and the associated 
costs by using actual costs incurred by the organization in providing a service or 
event. Patient-level costing is the resourcing consequences of clinical activity and is 
primarily informed by the measurement of that clinical activity. Clinical validity is 
therefore underpinned by the accuracy and legitimacy of that core activity data. This 
necessitates the involvement of clinical staff in the definition, documentation and 
authentication15, 16.  
High cost treatments and procedures in specialty hospitals should also be allocated 
to individual patients on an activity basis. As far as is possible overheads should be 
allocated to these areas prior to allocation to patients, on the closest proxy to 
activity. It is not acceptable however to allocate any of the above resources as 
"overheads". In the event that data is missing proxy allocations must be created.  
These might include standard costs (e.g. prosthesis by procedure) or service weights 
(i.e. data from other sources as substitutes). It is not sufficient to allocate ward costs 
by overall length of stay. Adjustments must be made for both the patients’ admission 
and discharge days and for their acuity (i.e. severity, co-morbidities).11,12,13,14,15 
                                                                
15 Journal of Bank Cost and Management Accounting (Volume 4, Number 1), 1991 
16 Drucker Peter F.Management Challenges of the 21st Century. New York: Harper Business, 1999. 
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PLICS in common with SLR is a change to traditional NHS costing methodology from 
top down to a bottom up approach. It captures costs at the level of individual patient 
activities.  
The aim is to understand all the activities, and the associated costs, related to the 
care provided to an individual patient through the duration of the care episode. This 
will inevitably reflect the complexities of individual cases, and provide a very 
granular level of analysis.  
The very nature of PLICS means that simply due to the volume of data to be 
considered, gaining meaningful insight into costs may be more complex. That is not 
to say that this is not a worthwhile aim, only that careful consideration must be given 
to how the data collected will be used. In simple terms, how it will be analysed and 
converted into useful information to inform decision making14,17. 
This thesis makes use of PLICS cost data from Liverpool Heart and Chest Hospital's 
service line reporting (SLR) system, enabling detailed micro-costing that is far 
superior to the use of NHS reference costs. SLR allows the trust to analyse cost and 
profitability at patient level of each service it provides rather than just overall 
profitability. Costs of resources that can be directly attributed to particular patient 
episode are ‘traced’, that is, they are allocated to the episode without any treatment 
or manipulation. Such costs include the likes of prostheses and consumables. The 
use of sophisticated consumables dispensing and supply tracking technologies 
assigns costs on the fly and allows precise tracing of resource use to the patient and 
episode on which they were used.  
                                                                
17 Kuzmik G a, Sang AX, Elefteriades J a. Natural history of thoracic aortic aneurysms. Journal of vascular 
surgery [Internet]. Elsevier Inc.; 2012 Aug [cited 2013 Jun 2];56(2):565–71.  
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This applies to drugs, and in surgery, where surgical consumables, valves, 
prostheses, anesthetic drugs etc. are all automatically attributed to the patient and 
procedure as they are used.  
Staff time is allocated with reference to employment contracts and the proportion of 
the time that is to be dedicated to each duty. That is, the cost of a particular surgeon 
for a given procedure is a function of his salary, the proportion of his contract he is 
to operate, and the time the procedure takes. Similarly, the ward costs of clinician 
can be allocated in the same way.  
These costs are then allocated based on the observed values of time for each patient 
episode. Indirect costs such as utilities and trust overheads are allocated/absorbed 
– although some of them are not directly attributable to any particular episode 
/service lines, they are divided up and shared amongst all episodes. 
 
2.4.2 Service Line Reporting (SLR)/Resources and Activity 
SLR is a statement of revenues and costs of clinical activities (and other key 
indicators in the form of a scorecard) to monitor and manage performance at service 
line level.  
A resource is a source that performs activity. Typically, resources are materials or 
other assets including human resource that are transformed or used in the process 
of activity. Organizations expend money to hire or buy resources to perform activity 
which in turn bring revenue for the organization. Resources for inpatients should be 
measurable for each day or part day from the time of entry and admission to the 
hospital until the time of discharge. For outpatients and non-admitted A&E 
attendances, the consumption of resources will be on an occasion of service basis. 
Resources should be ascribed to patients on a clinically meaningful activity basis in 
accordance with the principles of activity based costing.  
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A minimum set of costs driven by activity should include: wards, pathology, imaging, 
pharmacy services and drugs, prostheses, therapies, critical care, operating theatres, 
special procedure suites, other diagnostics, emergency department and outpatient.  
HRGs are standard groupings of clinically similar treatments which use common 
levels of healthcare resource. HRGs offer organisations the ability to understand 
their activity in terms of the types of patients they care for and the treatments they 
undertake. They enable the comparison of activity within and between different 
organisations and provide an opportunity to benchmark treatments and services to 
support trend analysis over time. HRGs are currently used as a means of determining 
fair and equitable reimbursement for care services delivered by providers. Their use 
as consistent 'units of currency' supports standardised healthcare commissioning 
across the service. They improve the flow of finances within - and sometimes beyond 
- the NHS. HRG4 has been in use for reference costs since April 2007 (for financial 
year 2006/7 onwards) and for Payment by Results (PbR) since April 2009 (for 
financial year 2009 onwards).  
HRG4 was a major revision that introduced HRGs to new clinical areas, to support 
the Department of Health's policy of Payment by Results (PbR). It includes a 
portfolio of new and updated HRG groupings that accurately record patient 
treatment to reflect current practice and anticipated trends in healthcare 13,14,15 
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CHAPTER THREE 
 
3. THORACIC AORTIC ANEURYSM DISEASE 
3.1 Introduction 
The aorta (Figure 3.1) is the main trunk of a series of vessels which convey the 
oxygenated blood to the tissues of the body for their nutrition.  
Figure 3.1. The Aorta 
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It commences at the upper part of the left ventricle, where it is about 3 cm in 
diameter, and after ascending for a short distance, arches backward and to the left 
side, over the root of the left lung; it then descends within the thorax on the left side 
of the vertebral column, passes into the abdominal cavity through the aortic hiatus 
in the diaphragm, and ends, considerably diminished in size (about 1.75 cm in 
diameter), opposite the lower border of the fourth lumbar vertebra, by dividing into 
the right and left common iliac arteries. Hence it is described in several portions such 
as the root, the ascending aorta, the arch of the aorta, and the descending aorta, 
which last is again divided into the thoracic and abdominal aortae18. 
 
3.2 The History of Aortic Surgery  
The word aneurysm is derived from the Greek words aneurusma and eurunein, 
meaning to dilate and to widen. (Figure 3.2) 
Development for treatments of aortic aneurysms through the years has focused on 
abdominal aortic aneurysms. This is in part due to larger prevalence and ease of 
detection, particularly before the advent of radiological imaging. The principles 
underpinning surgical correction of thoracic aortic aneurysms are thus based mainly 
upon abdominal aortic aneurysms (AAA).  
The initial treatments for aortic aneurysms were that of simple ligation, proximal to 
the aneurysm. A technique that had been first described for peripheral aneurysms 
by the Greek surgeon Antyllus, in the first half of the second century AD. 19,20 This 
technique was used with limited success, until 1899 when Keen operated on a 
ruptured AAA and reported a 48-day post-op survival, at which time the ligature 
eroded through the aorta despite the poor survival rates this practice continued. 
                                                                
18 Henry Gray (1821–1865).  Anatomy of the Human Body. 
19 DeBakey M. A surgical perspective. Ann. Surg. 1991;213:499–531 
20 Cooley DA. Aortic Aneurysm Operations : Past, Present, and Future. Ann Thorac Surg 1999;67:1959– 
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Marin-Theodore Tuffier is credited as the first surgeon to attempt this technique in 
TAAs21. He used catgut to ligate both proximal and distal to the aneurysm. His 
endeavour in 1901 was unsuccessful, as were attempts on a subsequent three 
patients. 
Renewed attempts to consolidate aneurysms, through the promotion of coagulation 
by means of the introduction of foreign material was tried in AAA (abdominal aortic 
aneurysm), again with limited success. Moore was the first surgeon to attempt this 
procedure on a TAA protruding from the right of the sternum in the second 
intercostal space in 186422.  
Moore placed 26 yards of iron wire within the aneurysm; initially the patient did 
well but did not survive past day 422. Surgeons attempted this technique with 
different metals, watch springs and other foreign objects, all without success. A small 
review of these practices in the 1900s revealed a 100% mortality in TAAs treated 
with the method described by Moore (n=8).  
However, the review describes a modified method by Corradi, which involved 
passing a current through the wire inserted into the aneurysm to promote 
coagulation20. This method produced more favorable results, and of the 17 patients 
undergoing this procedure 24% recovered. The most successful development in 
these coagulation methods was in 1938 by Blackmore and King.  
Their electro-thermic coagulation method gave a 27% survival rate 2-11 years post 
operatively, in a case series of 63 syphilitic aneurysms, with the majority symptom 
free. 22,23 
                                                                
21 Tuffier T. Intervention chirurgicale directe pour un anevrisme de la crosse de I’aorte: ligature du sac. Press 
Med. 1902;10:267 
22 Moore C, Murchison C. On a new method of procuring the consolidation of Fibrin in certain incurable 
Aneurisms with the Report of a case in which an Aneurism of the ascending Aorta was treated by the insertion 
of Wire. Med Chir Trans. 1864; 47:129–49. 
23 Borrie J, Griffin SG. Twenty-seven cases of syphilitic aneurysms of the thoracic aorta and it branches. 
Thorax. 1950; 5:293–324. 
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A new advancement in aneurysm treatment occurred in 1943 when Harrison and 
Chandy described cellophane wrapping as a method to induce periarterial fibrosis 
in a subclavian aneurysm.24 Reduction of the aneurysm was a long gradual process 
which in their case required 19 months. This method was tried in thoracic aortic 
aneurysms; however limited success was achieved with unpredictable results as 
reported by Poppe in 1948.  
Interestingly, Albert Einstein, who suffered from an AAA was treated with this 
method, and survived a further 5 years before rupture. 
It was not until 1951 that direct treatments for aneurysms evolved, rather than the 
indirect methods of ligation, wiring and cellophane wrapping. Charles Dubost, of 
France, resected an AAA, which was replaced with an allograft obtained from a 
young girl 3 weeks previous. In the same year Lam and Aram followed Dubost and 
resected a descending TAA with allograft replacement25. Lam’s patient survived the 
operation but developed a mediastinal abscess ultimately leading to his death. 
Despite this the operation was replicated with success by other notable surgeons 
including DeBakey and Cooley20.  
Furthermore, it led to the development of numerous allograft aortic banks 
worldwide in anticipation of a growing number of surgeries to the aorta. These 
methods were however introduced before the introduction of cardiopulmonary 
bypass and thus gave rise to a significant risk of paraplegia due to aortic ischaemia. 
It is at this time that important research to limit morbidity from the operation 
evolved including; hypothermia and shunts. Development of artificial aortic 
substitute were researched during this time, and DACRON was deemed to be the 
most suitable for graft implantation, first used by DeBakey in the 1950s, and still 
widely used in vascular surgery today. 
                                                                
24 Harrison PW, Chandy J. A Subclavain Aneurysm Cured by Cellophane Fibrosis Three Years Ago. Ann. Surg. 
1941;118:478–81 
25 Coselli JS, Green SY. A brief history of aortic surgery: insight into distal aortic repair. J Thorac Cardiovasc 
Surg. AATS; 2013;145:S123–5 
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Repair of ascending and aortic arch aneurysms still remained an unachievable goal 
through resection due to the unpreventable risk of cerebral ischaemia. This changed 
with the advent of cardiopulmonary bypass when Cooley and DeBakey were the first 
to successfully resect an ascending thoracic aortic aneurysm and replace it with an 
allograft. Repair of an aortic arch aneurysm came in 1957 with successful resection 
and replacement with a homograft, again by DeBakey19,20. These operations led to 
the widespread uptake in thoracic aortic aneurysm resection with either artificial 
DACRON or allograft replacement. In the recent past, endovascular repair began to 
excite the aortic world, particularly when Dake et al successfully repaired a thoracic 
aortic aneurysm in 199426. However, with the first endovascular grafts being FDA 
approved in 2005 little long term data is available.  
Currently, AAA is more commonly treated with an endovascular approach. With 
regards to thoracic aneurysms, endovascular repair remains a source of great 
debate, in terms of long term survival, long term durability of the grafts, and 
operative morbidity of paraplegia and stroke. Hybrid endovascular approaches to 
thoracic aortic aneurysm repair will undoubtedly remain at the forefront of modern 
research in these cases, however at present open repairs remain the standard 
treatment with more substantial data, and practice qualifying its use.  
 
 
 
 
 
                                                                
26 Dake M, Miller D, Semba C, Mitchel l R, Walker P, Liddell R. Transluminal placement of endovascular stent-
grafts for the treatment of descending thoracic aortic aneurysms. NEJM 1994;331:1792–34 
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3.3 Aetiology 
There exists conflict surrounding the aetiology of TAAs in the literature. The 
prevailing consensus, reflected in the most recent guidelines for thoracic aortic 
disease, cites medial degeneration as the primary causative factor for the majority 
of TAAs6. Historically, atherosclerosis was credited as the main cause for aortic 
aneurysms, which was based upon findings from post mortems27,28.   
Although atherosclerotic lesions are commonly associated with thoracic aneurysms, 
typically they are preceded by medial degeneration29,30. This key point is still not 
conclusive proven. Patel et al wrote a detailed review discussing the pathogenesis of 
ascending and aortic arch aneurysms30. They describe three separate pathological 
aetiologies namely; degenerative, Marfans and other inherited connective tissue 
diseases, and syphilitic aneurysms. Degenerative aneurysms undergo a classical and 
specific pathological process. Post mortem examinations reveal greatly reduced 
elastin content within the ascending aorta, the media of the aneurysms displays a 
lack of smooth muscle cells 27. Cystic medial degeneration can be observed in the 
media, which is described microscopically as fragmentation of elastin fibres. 
Although this process is widely regarded to be associated with aging, the recent 
analysis of the large Yale TAA database reveals a strong familial component31. Matrix 
metalloprotease (MMPs) are recognised to play a critical role in aneurysm 
formation32,33.  
                                                                
27 Young R, Ostertag H. Incidence etiology and risk of rupture of aoritc aneursyms. An autopsy study. Dtsh Med 
Wschr. 1987;112(1253-6). 
28 Kunz R. Aneurysms in 35,380 autopsies. Schweiz Med Wochenschr. 1980;110:142–8. 
29 Bonser RS, Pagano D, Lewis ME, Rooney SJ, Guest P, Davies P, et al. Clinical and patho-anatomical factors 
affecting expansion of thoracic aortic aneurysms. Heart [Internet]. 2000 Sep;84(3):277–83. 
30 Patel HJ, Deeb GM. Ascending and arch aorta: pathology, natural history, and treatment. Circulation. 
2008;118:188–95 
31 Coady M a, Davies RR, Roberts M, Goldstein LJ, Rogalski MJ, Rizzo J a, et al. Familial patterns of thoracic 
aortic aneurysms. Arch Surg. 1999;134:361–7. 
32 Agarwal P, Chughtai A, Matzinger FR, Kazerooni EA. Multidetector CT of Thoracic Aortic Aneurysms. RG. 
2009;29:537–53. 
33 Elefteriades JA, Farkas E a. Thoracic Aortic Aneurysm Clinically Pertinent Controversies and Uncertainties. J 
Am Coll Cadiol. 2010;55(9):841–57. 
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MMPs are still being studied in vitro and in vivo, however it is known that MMPs 
significantly contribute to proteolysis of the aorta causing the aneurysm to expand. 
It is this observation that has developed a lot of interest lately in medical treatment 
of TAAs. In the past the majority of cases could be attributed to syphilitic infection, 
however with the modern era of screening and antibiotics it is now a rarity and is 
not discussed here. In the absence of connective tissue disease, current evidence 
points toward a strong inherited genetic phenotype of accelerated medial 
degeneration as the primary culprit for TAAs. However, there are many risk factors 
that contribute to formation of a TAA, which are discussed below.  
Therefore, the likelihood that this is a multi-factorial disease, of genetics and lifestyle 
factors, is the consensus present and published in the literature. 
 
3.4 Genetically Triggered Thoracic Aneurysm 
Syndromes 
3.4.1 Marfan Syndrome 
Classically, Marfan syndrome has been the most extensively studied connective 
tissue disorder in relation to thoracic aortic disease. Marfan syndrome is an 
autosomal dominant genetic disorder of the FBN1 gene encoding for fibrillin-134. 
Usually fibrillin-1 is found in microfibrils located in the extracellular matrix. 
Microfibrils play a crucial role in maintaining the elastic fibres of connective tissues, 
and it is this that predisposes Marfans patients to TAAs35,36. It is a rare disease with 
                                                                
34 De Backer J. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype. Verh K 
Acad Geneeskd Belg. 2009;71:335–71 
35 Cury M, Zeidan F, Lobato A. Aortic disease in the young: genetic aneurysm syndromes, connective tissue 
disorders, and familial aortic aneurysms and dissections. Int J Vasc Med. 2013;2013:267215 
36 Halme T, Savunen T, Aho H, Vihersaari T, Penttinen R. Elastin and collagen in the aortic wall: changes in the 
Marfan syndrome and annuloaortic ectasia. Exp Mol Pathol. 1985;43:1–12. 
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an incidence of approximately 1 in 5000, displaying a high penetrance and variable 
phenotype.  Diagnosis is made using the 2010 revised Ghent Nosology, superseding 
diagnostic criteria primarily based on clinical features alone37. The revised criteria 
critically emphasize the presence of aortic root dilation or ectopic lentis 
(displacement or malposition of the eyes crystalline lens) in new patients without a 
family history, as a cardinal feature for a definitive diagnosis. A family history of 
Marfans syndrome, present in approximately 50% of patients, is more indicative of 
a diagnosis and thus requiring only one other factor of; an aortic root aneurysm, 
ectopic lentis, a pathogenic fibrillin-1 (FBN-1) mutation, or systemic features 
defined in the Ghent Nosology, to formulate a diagnosis. 
It is well documented that approximately 50-90% of these patients will develop 
aortic root dilation. Because of this predictable progression, Marfan syndrome has 
previously been used to extrapolate clinical findings, practice and research, to TAAs 
of different aetiologies 38,39,40. Currently, TAA guidelines segregate Marfans patients 
into a distinct subset of patients, preferentially indicating earlier surgical 
intervention for TAA. The evidence for this stems from numerous studies 
demonstrating a high association with an accelerated growth rate of the aortic root 
(0.2-0.3cm/year) 38,4041,. 
The trend of using Marfan patients for research and extrapolating this to all 
aetiologies of TAAs has long discontinued. In part, this is due to the obvious 
differences in pathogenesis and varied clinical findings, and it is now realized 
substantial variation exists. 
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3.4.2 Familial Nonsyndromic Thoracic Aortic Aneurysm 
Syndromes 
Familial Nonsyndromic Thoracic Aortic Aneurysm Syndromes are defined as 
patients who have a first degree relative that suffered an aortic aneurysm but are 
without a known associated genetic syndrome. Elefteriades et al have an extensive 
database of approximately 1200 patients who were diagnosed with TAA in 
Connecticut 33,131,. Their analysis of this database identified 21% of this cohort who 
had a first degree relative with known or likely aortic aneurysm, in the absence of a 
connective tissue disorder. Within this subset of patients an autosomal dominant 
pattern with incomplete penetrance pattern was displayed. This observation has 
been made before, but due to the rarity and absence of large databases in previous 
years has not be studied extensively 31. Elefteriades et al note that this percentage is 
likely to be higher as these results were based upon family interview and are subject 
to bias. 
Because this observation is only recently being brought to light within the research 
world genetic identification of associated genes is still in its infancy. Currently, ACTA 
2, MYH11 and TGFBR2 are implicated as the primary gene candidates associated with 
this syndrome. As genetic testing becomes more widely available and readily 
understood in the general public, ACTA 2 detection is recommended in suspected 
familial TAAs. In the future more genes may be tested but this requires further 
research and time. 
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3.4.3 Bicuspid Aortic Valve 
A bicuspid aortic valve (BAV) is well recognized as an independent risk factor for 
aortic aneurysm42,43,44. This congenital cardiac malformation is reported to exist in 
the general population at a prevalence of 1-2%. In this subset of patients, one study 
found thoracic aortic dilation at a prevalence of 88% in those over the age of 80. It is 
known that BAVs can show an autosomal dominant inheritance in families, which is 
seen in approximately 9% of TAA cases 45. 
Davies et al were the first to show that bicuspid aortic valves are associated with an 
increased aortic aneurysm growth rate 46. Because the risk of TAA formation is so 
significant in these patients the latest TAA guidelines recommend intervening 
surgically earlier, when their aneurysms reach a size of 5.0cm. The pathogenesis 
remains a mystery. However, an aortic aneurysm associated with a BAV is 
histologically similar to that of Marfan patients chiefly; medial degeneration, 
increased metalloproteinase activity and decreased FBN-1 in the aortic wall. 
Combined this leads to increased aortic aneurysm growth rates with a propensity 
for rupture earlier than TAAs not associated with an inherited genetic condition 43. 
Of note, coarctation of the aorta is highly suggestive of BAV (up to 50% of patients). 
Originally, the pathogenesis was linked to the common embryological development 
of the aortic valve and the ascending aorta44. This observation suggests that 
pathological changes are not isolated to the proximal aorta and may well involve the 
arch and the descending aorta. 
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3.4.4 Vascular Ehlers-Danlos Syndrome 
Also referred to as Ehlers-Danlos (ED) syndrome type IV, is another rare autosomal 
dominant disorder affecting the COL3A1 gene 35. Typically, these patients have a 
distinctive facial appearance with an accompanying body habitus and a propensity 
to develop ecchymoses. It is described as a more serious form of ED syndrome in 
that blood vessels, particularly arterial vasculature, are prone to rupture. The 
syndrome causes a deficiency in the synthesis of type III collagen, the main 
component of connective tissue, the loss of which increases vessel fragility making 
surgical repair more difficult. These patients have a severely reduced life span 
approximated at 48 years. 
 
3.4.5 Loeys-Dietz Syndrome 
Loeys-Dietz (LD) syndrome is described as an autosomal dominant aortic aneurysm 
disorder with involvement of other systems 35,38. The classical triads of features are 
arterial tortuousity and aneurysms, hypertelorism and bifid uvula or cleft palate, or 
a uvula with a wide base and prominent ridge. Diagnosis is made on mutational 
analysis in TGFBR1 or TGFBR2, which are genes recently discovered as the primary 
defect in LD syndrome47. Unlike VD syndrome surgical intervention is not 
complicated by vessel fragility; thus these patients can be managed aggressively in 
respects to aneurysm treatment. The majority of these patients have aneurysms of 
the aortic root (98%), rupture of which is reported to occur at smaller diameters 
than other genetic syndromes, thus the bar is further lowered to a diameter of 4.4-
4.6cm in TAA as an indication for surgical repair6. 
 
                                                                
47 Pezzin i A, Del Zotto E, Gioss i A, Volonghi I, Costa P, Padovani A. Transforming growth factor β signaling 
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3.5 Risk Factors 
The Whitehall study identified two major risk factors in the development of thoracic 
aneurysms, namely smoking and hypertension48. Of the 18,403 participants in the 
prospective cohort study, 99 patients suffered aortic aneurysms.  
This extensive study is however subject to recall and measurement bias, as risk 
factors were assessed via questionnaire. Furthermore, the study was not 
particularly designed to look at TAAs. Smoking remains the highest modifiable risk 
factor for development of thoracic aneurysms in all studies29,30. Bonser et al 
evaluated TAA growth and used a univariate analysis to demonstrate; intramural 
thrombus, thrombus, previous stroke, smoking, and peripheral vascular disease as 
factors that statistically accelerate growth (p<0.05 in all cases)29. The study looked 
at 87 patients and used serial CT scans to identify aortic growth. It was limited by 
measurement bias, and referral bias, although this was improved by only one 
observer measuring aortic enlargement. 
Non-modifiable risk factors include age, which reflects the most common aetiology 
of medial degeneration discussed above, male gender, genetics, connective tissue 
disorders, and high BMI49.  The extensive database of TAA patients in Yale included 
data on patients totaling over 30001. Analysis of this database revealed a strong 
genetic link in approximately 20% of patients first degree relatives and was not 
associated with connective tissue genetic diseases, as noted previously. This striking 
observation has led to recommendations of earlier surgical intervention for 
aneurysm repair93. 
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Trimarchi et al devised a study of 613 patients with type B TAAs. After statistical 
analysis they observed a number of independent risk factors for death in those with 
an aortic diameter less than 5.5cm which included; hypotension/shock (p=0.001), 
acute kidney injury (p=0.14), mesenteric infarction/ischaemia (p=0.012), and 
periaortic haematoma (p=0.19). The largest risk factor for progression to death, 
rupture or dissection was aortic size discussed below. These risk factors, except for 
acute kidney injury, have not been replicated in other high quality studies, but this 
may be due to the design of these studies. 
Zierer et al used a multivariate analysis technique on 110 asymptomatic TAA 
patients undergoing elective TAA surgery. They identified predictors of late death 
as; thoracoabdominal aneurysms (p < 0.004), advanced age (p < 0.03), chronic renal 
failure (p < 0.03), and congestive heart failure (p < 0.001).  
This data is hindered with a small number of patients and the main aim of the study 
was quality of life and not assessment of risk factors. 
With the exception of connective tissue disorders, the pertinent risk factors which 
earlier active intervention is recommended are patients with bicuspid valves or 
familial TAA. Although other risk factors predispose to this condition, such as 
smoking, these factors have not been unified before to approximate risk 
stratification. Again this is because of small study numbers not being able to provide 
robust figures in risk. 
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3.6 Incidence of Thoracic & Thoracoabdominal Aortic 
Aneurysm in the UK 
The incidence of thoracic and thoracoabdominal aneurysms specifically within the 
UK is difficult to estimate. Several international population- based studies have 
estimated the incidence rate of thoracoabdominal aneurysms at around six new 
aneurysms per 100,000 person years50. In the UK, we may use Hospital Episode 
Statistics (Hospital episode statistics [HES] data, www. hesonline) to get an 
indication of activity within the English National Health Service (NHS) (population 
52 million) and National Statistics Service (www.ons.gov.uk) to get an indication of 
resulting mortality (England and Wales, population 55 million). HES ‘Diagnostic’ 
data suggest around 1000 admissions per year related to this disease (‘Thoracic’, 
‘Thoracoabdominal’, ‘with rupture’, ‘without rupture’). Cause of death data stated by 
Office of National Statistics suggest around 650 deaths per year (‘Thoracic Aortic 
Aneurysm’ [ICD 171.1/2] and ‘Thoracoabdominal Aortic Aneurysm’ [ICD 171.5/6], 
‘with rupture’ and ‘without rupture’). The data set suggests that in 2010 there were 
only nine deaths from ‘ruptured thoracoabdominal aneurysms’ nationally, clearly in 
gross error and likely reflecting diagnostic and coding errors. For comparison, this 
compares with 3593 deaths (2010) from abdominal aortic aneurysm with rupture 
(ICD 171.3). Although crude, these data help us understand the level of consumption 
of services within the NHS. 
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3.7 Clinical Presentation of Thoracic Aneurysms 
Most thoracic aneurysms are asymptomatic and are typically detected when imaging 
studies (chest x-rays, CT scans, MRI, etc) are being obtained for unrelated reasons. 
Intervention on this group of patients is not without caveats. The dilemma arises 
that asymptomatic patients are functionally able and clinically stable. However, the 
growth rate of an aneurysm dictates that this group of patients should undergo 
surgery to avert major complication and death. When aortic aneurysms reach larger 
sizes the symptoms are typically based on the location of the aneurysm6. A good 
percentage of aortic arch aneurysm patients are symptomatic (short of breath or 
chest pain) due to associated aortic valve dysfunction, heart failure, coronary 
disease or extreme size of aneurysm. These aneurysms can also result in a dull pain 
underneath the breastbone or radiating to the upper back.  However, when large, 
these aneurysms can compress both the esophagus and the airway resulting in 
difficulty swallowing and hoarseness.   
Descending thoracic aneurysms are mostly asymptomatic, but can occasionally 
cause back pain. In contrast, abdominal and thoracoabdominal aneurysms may 
cause a pulsating feeling in the upper abdomen. Abdominal and back pain may also 
be present if the aneurysm increases in size. Whereas, most of the symptoms of 
stable thoracic aneurysms are vague and non-specific, rupture or dissection of these 
aneurysms produces dramatic symptoms. A ripping sensation within the chest 
accompanied by severe pain in the back between the shoulder blades is the most 
typical complaint during thoracic aortic dissection or rupture. Dizziness, difficulty 
walking and speaking can all accompany this acute event. 
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3.8 Diagnosis and Imaging of Thoracic Aneurysms  
Suggestions of a thoracic aneurysm can frequently be inferred from routine chest X-
rays. However, thoracic aneurysms are most reliably diagnosed with a CT scan or 
MRI (Figure 3.8). Frequently, the diagnosis is made when one of these imaging 
studies is performed for symptoms unrelated to the aneurysm. Echocardiography is 
important for the evaluation of the aortic valve and also can be used to evaluate the 
size of the ascending aorta. 
3.9 The Role of Biomarkers 
The quest for the ideal biomarker to the detection and screening of aortic aneurysm 
and dissection continues. Trimarchi et al. summarized it at their best when they 
quoted “The utilization of biomarkers could lead to further improvements in 
diagnostic pathways in acute and chronic aortic diseases, highlighting potential 
targets for therapeutic intervention and establishing uniform, evidence-based 
follow-up programs.”51.  
Currently, several biomarkers are being investigated as suitors for prediction, risk 
stratification and prognostic evaluation in TAA patients which include; D-dimer, 
Plasmin, Fibrinogen, Matrix metalloproteinases, Cytokines, CD4 + CD28- cells, C-
reactive protein, Elastin peptide, Endothelin, Hepatocyte growth factor, 
Homocysteine, Ribonucleic acid signature. D-dimer has previously been identified 
as a potential biomarker in aortic dissection proving itself to have a sensitivity of 
99%. Its downfall though is that elevated d-dimers are highly non-specific, 
particularly in diseases of the chest. This critical point negates its usefulness as a sole 
biomarker. The development of RNA signatures is yielding significant interest. These 
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biomarkers measure RNA regulation related to aortic aneurysms and potentially 
could be useful in dissection and rupture prediction.  
So far, this RNA signature test, it has shown to be 80% accurate in determining 
whether a patient has an aneurysm, and potentially this may prove to be useful as a 
screening tool52.  
3.10 Medical Management  
3.10.1 The Role of Pharmaco-Therapeutics 
3.10.1.1 Beta Blockers 
Medical therapy of TAAs has recently received a lot of attention. Historically all 
patients were prescribed a beta blocker on diagnosis of TAA, and this is still the case 
today. The basis of this was based on two reasons; small clinical trials of Marfan 
syndrome patients, and anecdotal evidence that lower blood pressures in the aorta 
would relieve the outward tension of an aneurysm meaning it would be less likely to 
rupture.  
However, this belief has been challenged, firstly as Marfans patients make up a small 
proportion of TAA patients, secondly Marfans pathogenesis and degenerative TAA 
pathogenesis are two different entities and should be treated as such and thirdly 
recent evidence show limited benefit of beta blockers53. However, the current 
practice remains that once patients are diagnosed with an aneurysm of the thoracic 
aorta they tend to be placed on B-blockers. The 2010 guidelines on Thoracic aortic 
disease produced by The American College of Cardiology Foundation and The 
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American Heart Association Task Force, state that: All patients should be receiving 
beta blockers after surgery or medically managed aortic dissection6.  
For patients with thoracic aortic aneurysm, it is reasonable to reduce blood pressure 
with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers to the lowest point patients can tolerate without adverse effects. 
Beta blockers (β-blockers) are antagonists to sympathetic mediators for β-
adrenoreceptors. Once bound, β-blockers diminish calcium currents and downplay 
the sarcoplasmic reticulum pump within cardiac myocytes. The result of this is a 
reduced contractile force, which, in turn, leads to a decrease in heart rate, cardiac 
output, and a lower blood pressure54.  
It is imperative that these patients’ blood pressures are tightly regulated to maintain 
the surgical repair. The theory underpinning β-blocker therapy after TAA surgical 
repair is lower blood pressure produces less tension on the aorta, and subsequently, 
reduces the chances of the surgical repair failing. Evidence also suggests β-blocker 
therapy retards the diameter of aorta from expanding further; in a study comparing 
patients with Marfan’s syndrome, those taking β-blockers were contrasted against 
the control group who were not taking any treatment. Overall, researchers 
concluded β-blockers reduce aortic dilation a reflection of the 2010 guidelines55.   
Similarly, Genoni et al also conclude that prolonged β-blocker use halts the further 
expansion of the aneurysm56; the incidence of an increase of aortic diameter was 
12% amongst those taking β-blockers, compared to 40% in patients on other 
hypertensives. Furthermore, this adds weight to the decision to specifically name β-
blockers above other hypertensives in the guidelines.  
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A recent meta-analysis concluded that beta-blocker therapy had no clinical benefit 
in Marfan patients57. Six studies were included, of which 5 were non-randomized 
follow-up studies and 1 was a prospective randomized trial, and totalled 802 
patients. Using a random effects model, statistical significance was not reached for 
beta blocker therapy. The analysis is limited in that high quality randomized 
controlled trials are not available, furthermore, as it is standard practice to prescribe 
these patients beta blockers the control group in those not taking beta blockers is 
very small. 
 
3.10.1.2 Angiotensin Converting Enzyme Inhibitors 
Although ARBs and ACE inhibitors remain second-line choices for the treatment of 
hypertension in the absence of other compelling indications, drugs in these classes 
have been of particular interest as potential treatments for patients with Marfan 
syndrome (and Loeys-Dietz syndrome) because of their antagonism of TGF-β 
activity. In a signal study, mice heterozygous for a fibrillin-1 mutation (a model of 
Marfan syndrome) were treated with the ARB losartan and showed less elastin fiber 
fragmentation, less TGF-β signaling in aortic tissue, and slower aortic root growth 
rates than did placebo controls; the results in the losartan group were comparable 
to those of untreated wild-type mice and better than those of propranolol-treated 
mutant mice55. Investigators in Melbourne recently evaluated the effect of 
perindopril—an ACE inhibitor that effectively blocks angiotensin II receptors—in a 
small, randomized clinical trial56.  
Marfan patients who received a 24-week course of the study drug plus beta-blockers 
had less arterial stiffness, smaller aortic root diameters, and lower blood levels of 
TGF-β. MMP-2, and MMP-3 than patients receiving placebo plus beta-blockers; 
whether these short-term results will translate into long-term benefits is unknown 
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and will need to be investigated in larger clinical trials. The National Heart, Lung, 
and Blood Institute is sponsoring a presently ongoing trial of losartan versus 
atenolol for Marfan syndrome patients aged 6 months to 25 years. The trial, which 
has an expected enrolment of 604 subjects, is designed to determine whether 
losartan is superior lo atenolol in reducing aortic root size (Z-score adjusted to body 
surface area) at 36-month follow-up 58. However, recent evidence from Lacro et el. 
indicates that no benefit or superiority of losartan over the beta-blocker such as 
atenolol in respect to the rate of expansion of aortic-root dilatation in Marfan's 
syndrome patient population59. This study informs me that ARBs such as Losartan 
are as much effective as beta-blockers in the treatment of patients with Marfan's 
syndrome. A possible rhetorical idea would then emerge due to such interpretation 
to indicate that beta-blockers are an effective treatment option. This would happen 
to serve the thought mentioned in 2010 guidelines of the American College of 
Cardiology Foundation and the American Heart Association who recommended the 
use of beta-blockers, whereas the 2014 guidelines of the European Society of 
Cardiology did not 60. Multicentre large clinical trials need to resolve this much 
debated topic on the efficacy of ARBs or ACE inhibitors over the standard beta-
blockade therapy. This could result in significantly, shifting these Marfan patients’ 
away from almost inevitable, high-risk surgery and present a new shift in the 
paradigm. 
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CHAPTER FOUR 
 
4. ACUTE AORTIC DISSECTION 
4.1 Aetiology, Pathophysiology and Risks of Thoracic   
Acute Aortic Dissection 
Aortic dissection is more common in males with a peak incidence at 50–70 yr of age. 
Aortic dissection can result either from a tear in the intima and propagation of blood 
into the media or from intramural haematoma formation in the media followed by 
perforation of intima. An intimal tear can occur in the regions of the aorta that are 
subjected to the greatest stress and pressure fluctuations. Because mechanical stress 
in the aortic wall is proportional to intramural pressure and vessel diameter, 
hypertension and aortic aneurysm are known risk factors for dissections. Most 
aortic dissections occur with an initial transverse tear along the greater curvature of 
the aorta, usually within 10 cm of the aortic valve. The aortic root motion has a direct 
impact on the mechanical stresses acting on the aorta61. Data from the International 
Registry of Aortic Dissection (IRAD) 62 showed the following risk factors in acute 
aortic dissections: male sex, age, a history of hypertension or atherosclerosis, prior 
cardiac surgery including aortic valve surgery, a history of bicuspid aortic valve, or 
a history of Marfan syndrome. The younger patients were more likely to have Marfan 
syndrome, bicuspid aortic valve, Ehlers-Danlos syndrome, Loeys-Dietz syndrome 
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and a history prior cardiac surgery. The average age for aortic dissection was 63.1 
years. 65.3% of patients were male. 62.3% of the patients had type A dissection, 
72.1% had a history of hypertension, and 4.9% had Marfan syndrome.  
 
4.2 Clinical Presentation 
The clinical presentation of dissection patients may be diverse. It has been described 
that the pain is as stabbing, tearing, or ripping in nature63. However, the most 
common characteristic of acute dissection presentation is acute pain localized to the 
chest, abdomen, and back and sudden collapse. Analysis of the International Registry 
of Acute Dissection (IRAD), noted that severe chest pain is more common with type 
A dissection, whereas back pain and abdominal pain are more common in type B 
dissection62. The IRAD reported that 95.5% of all AAD patients presented with pain. 
However, in previous reports it was revealed that between 5 and 17% of all 
dissection patients present with painless acute aortic dissections. As expected, 
atypical presentation can lead to a delay in diagnosis, which is associated with higher 
mortality51. Immediate adequate medical treatment is essential and has to include 
optimal blood pressure control in order to reduce shear stress and limit the 
propagation of the dissection. Therefore, it is important to recognize these patients 
at the earliest possible stage62 .  
The true incidence in the population is probably even higher, as an atypical 
presentation will likely result in a higher risk of death prior to the diagnosis. Physical 
examination may reveal tachycardia accompanied by hypertension from anxiety and 
pain. Tachycardia and hypotension result from aortic rupture, pericardial 
tamponade, acute aortic valve regurgitation, or even acute myocardial ischaemia 
with involvement of the coronary ostia. Differential or absent pulses in the 
extremities and a diastolic murmur of aortic regurgitation may also be present. 
                                                                
63 Klompas M. Does this patient have an acute thoracic aortic dissection? JAMA. 2002;287:2262–72 
 61 
 
Syncope, stroke, and other neurological manifestations secondary to malperfusion 
syndrome may develop. A complete neurological examination is essential and 
findings should be documented. 
 
4.3 Diagnosis 
Accurate diagnosis of aortic dissection and a high index of suspicion are imperative 
especially in patients with predisposing risk factors such as hypertension, known 
and documented aneurysmal disease of the aorta, or a familial connective tissue 
disorders. However, not always we are presented with a full history and an all 
knowing patients of their medical status. This present a further challenge especially 
when patients are very moribund and their state of consciousness might not be 
pristine.  What compounds the aforementioned is the delay in diagnosis. 
Approximately 4.4 million patients who present annually to the US emergency 
departments for chest pain, only about 2,000 have acute aortic dissection and as a 
result correctly diagnosed aortic dissection is only in 15%–43% of patients in the 
initial presentation64, 65.  
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4.4 Imaging 
The choice for the diagnostic imaging depends on patient’s stability, local expertise, 
and availability. Its use should be to expedite the assertion of aortic dissection, 
identify the type/extent and locate the intimal tears. It should confirm the presence 
of true/false lumen and whether a thrombus is present, assess any aortic side branch 
involvement, detect any aortic regurgitation or coronary artery dissection to certain 
extent, and aid in the identification of the dissection aftermath i.e. any extravasation 
within the pericardium, mediastinum or hemithorax 66,67,68.  
Aortography has lost its place as the gold standard test due to a number of serious 
disadvantages, including the use of a heavy dose of IV contrast (1 mg/kg), the risks 
of an invasive procedure, and the extended time it takes to complete the procedure 
(up to 2+ hours).  
On the contrary, in 2002 IRAD reported69 that computed tomography angiography 
(CTA) is used in 63% of cases of suspected aortic dissection, followed 
transesophageal echocardiography (TEE) in 32%, aortography 4%, and magnetic 
resonance angiography (MRA) in 1%. Computed tomography angiography, TEE and 
MRA have similar pooled sensitivity (98%–100%) and specificity (95%–98%) 
although the pooled positive likelihood ratio appeared to be higher for MRA 
(positive likelihood ratio, 25.3; 95% confidence interval, 11.1–57.1) than for TEE 
(14.1; 6.0–33.2) or CTA (13.9; 4.2–46.0). CTA is widely available and relatively rapid, 
provides visualization of the entire aorta down to iliac arteries, and delineates the 
involvement of aortic side branches6369,.  
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The use of ECG-Gated CT offered the option instead of selecting scan data acquired 
in exactly the same phase of the cardiac cycle for each image as in standard ECG-
gated reconstruction techniques, the patient's ECG signal is used to omit scan data 
acquired during the systolic phase of highest cardiac motion. With this approach 
cardiac pulsation artefacts in CT studies of the aorta, of paracardiac lung segments, 
and of coronary bypass grafts can be effectively reduced. Again the culprit of CTA 
being the first definitive choice include the requirement that patients be transported 
to the CTA suite, the use of potentially nephrotoxic contrast, and the inability to 
assess aortic insufficiency. 
MRA is highly accurate and does not require the use of a contrast dye. It is, however, 
usually not available on an emergency basis and requires patients to be in MRA suite 
for an extended period of time. Other issues such as claustrophobia, the use of 
ventilator, and patient’s use of metal devices (pacemakers, aneurysmal clips) may 
further complicate its routine use69. 
TEE is a viable alternative in patients who are critically ill and/or hemodynamically 
unstable. The main advantages of a TEE include speed, good sensitivity and 
specificity, and the fact that it can be performed at the patient’s bedside in the ED. 
Its main limitations are lack of widespread expertise and subjective reporting which 
necessitates high level of expertise to avoid false positive reports. An aortic 
dissection is a tear in the inner layer of the aortic wall, which allows blood to enter 
into the wall of the aorta, creating a new passage for blood, known as the “false 
lumen.” Blood flow into the false lumen can cause several problems: It can rob 
crucial blood from the rest of the body, it can cause the dissection to spread and 
affect other arteries, and it can block blood flow in the true aortic channel (“true 
lumen”). These problems may cause decreased blood flow to vital organs. Aortic 
dissection also weakens the aortic wall and may lead to rupture, which may be fatal, 
or to formation of a balloon-like expansion of the aorta, known as an aneurysm. 
Aortic dissections are uncommon, yet they are highly lethal.  
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If untreated, an aortic dissection can be fatal within the first 24 to 48 hours. Several 
risk factors are associated with aortic dissections, such as high blood pressure 
(hypertension), genetic disorders affecting the blood vessel wall, atherosclerosis, 
cocaine use, and trauma.  
 
4.5 Management of Thoracic Acute Aortic Dissection 
Immediate management of aortic dissection includes stabilizing the patient with 
prompt attention to blood pressure reduction. Β-Blockers are the first drugs of 
choice because of their mechanism of lowering the rate of rise of ventricular force 
(dP/dt) and stress on the aorta. Intravenous agents are chosen for rapid onset. In 
many instances, multiple blood pressure agents are required. In patients in whom 
refractory hypertension exists, renovascular hypertension related to the dissection 
flap must be considered. All patients with acute aortic dissection should undergo 
multidisciplinary evaluation that includes cardiothoracic and/or vascular surgical 
consultation.  
Emergency surgery is recommended for acute type A dissection, in the International 
Registry of Acute Aortic Dissection, the mortality rate of patients undergoing surgery 
for type A dissection was 26% and for those treated medically was 58%. Patients 
with low-risk features have a significantly lower mortality rate than those with 
malperfusion, shock, or cardiac tamponade.  
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Surgical management of type A dissection involves excision of the intimal tear when 
possible, obliteration of entry into the false lumen proximally and distally, and 
interposition graft replacement of the ascending aorta. The aortic valve may need to 
be replaced, depending on the underlying pathology of the valve and aortic root70 .  
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CHAPTER FIVE 
 
5. RISK STRATIFICATION OF THORACIC AORTIC 
ANEURYSMS 
5.1 Introduction 
Risk stratification for the individual patient is a pertinent goal that has received 
much attention for many years. Historically this has been guided by personal clinical 
prowess and anecdotal evidence as noted by the Yale group. Retrospective analysis 
of data from large databases has shown insight into risk of rupture, dissection and 
death from absolute aortic size as mentioned above. This cumulated to the 5.5cm 
guideline as an operative indicator for asymptomatic TAA’s6. There are now more 
risk scores being developed that may be able to provide better insight into TAA 
complications and better guide clinical decisions.  
 
5.2 Seeking the Ideal Risk Prediction Model 
The Yale group were the first to publish data on relative aortic size in comparison to 
body surface area71. They retrospectively analysed data from 410 patients on their 
extensive TAA database. The study demonstrated a lower body surface area was 
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associated with a higher incidence of dissection, rupture and death. This data was 
extrapolated to make a measure of relative aortic size (ASI) and in this study ASI was 
a better predictor of negative outcomes than maximal aortic diameter. Statistical 
analysis was able to group patients into three stratified groups, according to aortic 
size index, that gave the patient a probability of rupture, dissection or death 
(p<0.00001).  Namely; low risk (ASI 2.75cm/m2) as less than 4%/year, moderate 
risk (ASI 2.75-4.24cm/m2) as approximately 8%/year and high risk (ASI 
<4.25cm/m2) as approximately 20%-25%/year. The data is consistent with the 
guidelines that surgery should be performed before an aneurysm is able to grow to 
6cm or greater.  
Furthermore, ASI proves to be a useful tool to guide patient decision regarding 
clinical decisions. The data provides a new insight in that it may be beneficial in a 
selected subgroup of patients, who have a small aortic aneurysm size, but with a high 
ASI, operative intervention maybe indicated before the aorta reaches 5.5cms as 
recommended in the guidelines.  
The author acknowledges that there are limitations to the data; measurement bias 
in so far as height and weight recorded in the emergency room is inaccurate, rupture 
rate is not accurately represented in all these patients as elective operative 
management eliminates the risk of rupture. Shimada et al used mathematical 
modelling to describe a formula that would predict thoracic aneurysm growth in 
their cohort of 88 patients 72. This formula used the difference between their initial 
diameter of their aneurysm, their current diameter, the time between the two 
measurements and a constant. Their formula derived an r value of 0.617, 
furthermore similar formulae from the Yale group, Mt Sinai and Osaka group applied 
to the data from this cohort of patient revealed very similar results. The authors 
concluded that because of this similarity TAA expansion is similar in different 
sample populations worldwide.  
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The study is limited is the small nature of the number of patients, and subject to 
measurement bias. It does not reliably predict TAA growth, but it can give a rough 
estimate for patients as to when they may likely be required to have surgery. 
5.3 Importance of Risk Prediction Models in Thoracic 
Aortic Aneurysms 
Risk prediction models can be used to provide important information to both 
patients and clinicians about the risks of surgery. They may even be used to decide 
between different treatment options. Risk prediction models also have a vital role to 
play in clinical governance analyses. Currently generic cardiac surgery risk 
prediction models are used for proximal aortic surgery.  
 
As these models were specifically developed for proximal aortic surgery they may 
be more accurate than generic models for informing patients and clinicians about 
the risks of in-hospital mortality following surgery on the aortic root, ascending 
aorta or aortic arch, and for risk-adjusting proximal aortic surgery outcomes 
analyses. 
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5.4 Developing a Thoracic Aortic Risk Prediction Model 
For the sake of this thesis, separate models for elective and non-elective surgery 
were developed as it has previously been demonstrated that cardiac surgery models 
that have been developed for both elective and non-elective surgery can perform 
poorly in emergency surgery.  
 
Although surgical activity in proximal aortic cases is relatively low compared to 
cardiac bypass graft or valvular surgery, the procedure itself carries a greater risk of 
mortality. Consequently, a number of studies have previously attempted to quantify 
the risks involved. Williams et al [18] presented risk factor results of proximal aortic 
surgery based on the Society of Thoracic Surgeons (STS) Dataset for both in-hospital 
mortality and mortality plus major morbidity, in overall and elective cohorts. The 
predictive power of their elective mortality model had an AUC of 0.77. As this study 
contained four separate models and was part of a wider review of North American 
outcomes an extended description of the model coefficients was not available.   
Other work by Huijskes [24] and Nishida [25] incorporate the widely used 
EuroSCORE and EuroSCORE II algorithms [26, 27, 28] in order to make comparisons 
with local models and to ascertain how the model performs in aortic surgery cohorts.  
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CHAPTER SIX 
 
6. BRAIN PROTECTION DURING OPEN THORACIC 
AORTIC SURGICAL REPAIR 
6.1 Historical Perspective of Deep Hypothermic 
Circulatory Arrest (DHCA)  
The first reported use of hypothermia as a therapeutic intervention dates to the 
Hippocratic era, from the Hippocratic School of Medicine, where it was described as 
a treatment for tetanus73. Hippocrates himself promoted the use of snow and ice 
packed around the injured soldier to promote healing74. In 1812, Dominique Larrey, 
surgeon to famous military leader Napoleon, used ice to alleviate injured soldiers’ 
pain during amputations75. Despite a history of well over two thousand years, 
hypothermia did not gain popularity until the 21st century. In modern medicine, 
mild therapeutic hypothermia is widely used post cardiac arrest with return of 
spontaneous circulation in an effort to reduce the incidence of neurological 
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damage76. DHCA is, however, reserved for aortic surgery and cerebrovascular 
surgery as a method of cerebral protection77.  
The birth of hypothermic cooling techniques for use in cardiac surgery began in 
earnest with the work of William Bigelow78. Today, Bigelow is famous for writing 
two books, including one called “Cold Hearts”. He is further recognized for his role 
in the development of the pacemaker. He was awarded the title of Officer of the 
Order of Canada, the second highest honor of merit awarded by the Queen to 
civilians, and he was inducted into the Canadian Medical Hall of Fame in 1997. 
In 1950, a research team in Toronto led by Bigelow published their two years’ work 
on oxygen uptake and expenditure in canines at temperatures considered 
hypothermic78.  
They hypothesized that a reduced body oxygen requirement could be achieved 
through a reduced metabolic drive secondary to hypothermia. This in turn would 
enable the heart to be excluded from circulation and allow the possibility of cardiac 
surgery. Their work was published before the invention of cardiopulmonary bypass 
by John Gibbons, who began clinical application of his heart-lung machine in 195279. 
Bigelow’s experiments encompassed 176 dogs, who were cooled with the by muscle 
relaxants to control homeostatic temperature regulation resulting in severe 
shivering, venesection as a method of reducing pressure within the venous system, 
and phrenic nerve stimulation to induce artificial respiration. Bigelow was able to 
successfully exclude the heart from circulation without arrest at a core temperature 
of 20˚C in 39 of his dogs. Of these 39, 51% of dogs were successfully revived.  
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Cardiac arrhythmias, particularly ventricular fibrillation, was the major hindrance 
in the dogs who were successfully revived78. 
In these early experiments, a common theme was to avoid ventricular fibrillation or 
at least to correct it as soon as it developed. We must remember this, as in the current 
era of cardiopulmonary bypass, we are immune to the impact of ventricular 
fibrillation, which is expected as part-and-parcel of deep hypothermia.  
Despite these promising advances, the team continued to search for better methods 
of cooling. They knew that a hibernating mammal, such as the groundhog, could 
survive a temperature of 3˚C. They wished to reduce the current limit of 20˚C 7880. 
The team performed further research on Macacus Rhesus monkeys, once again using 
cooling blankets, this time to below 20˚C. 11 of 12 monkeys cooled to temperatures 
between 16 to 19˚C survived between 15 to 24 minutes. Whereas in previous 
experiments on dogs, at which their respirations ceased around 24˚C, monkeys 
continued to respire at 8 per minute at 20˚C.  
Similarly, Bigelow et al. used groundhogs cooled below 5˚C (as in their natural 
hibernating state), operated and successfully revived 5 out of 6 of the animals81. 
A physiologist named Frank Gollan worked in the 1950s using hypothermia and an 
oxygenator of his own invention, and presented his work in 195581,82,83. Gollan made 
an important step in that his bubble oxygenator included a heat exchange device, 
whereby he could induce hypothermia as well as carryng out rewarming84. He was 
able to achieve measured core temperatures of 40C and published revival of the 
animals.  
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Despite this, his research was not widely recognized and was largely ignored 
amongst the surgeons at the American Association for Thoracic Surgery85. In 
Sweden, Juvenelle et al. were also coming to similar conclusions to Gollan—
specifically that the use of a pump-oxygenator and hypothermia of 12˚C would 
decrease oxygen requirements of the body to allow open cardiac operating times of 
up to 2 hours without adverse consequences86. However, Juvenelle’s method 
produced little in the way of long term survival85.  
The first successful human operation utilizing a period of hypothermia was 
performed in 1952 at the University of Minnesota by Dr. John F. Lewis87. Armed with 
knowledge of William Bigelow’s experiments on hypothermia, and his own 
extensive experiments involving several hundred canines, he was successful in 
closing a secundum atrial septal defect in a 5-year-old girl. For two hours he 
wrapped the anaesthetized patient in refrigerated blankets until her rectal 
temperature had fallen to below 28˚C. Lewis describes the operation in his landmark 
paper87. “The chest is opened with a transverse, sternal splitting incision through the 
4 interspaces, the heart is explored digitally through the right auricular appendage. 
Cardiac inflow and outflow are occluded and the right atrium is opened widely to 
allow repair. The left and right heart are filled with saline and atrium closed”. 
Following the operation, the patient was placed in hot water at 45˚C to increase her 
rectal temperature to 36˚C. This operation is heralded in cardiac history as the first 
ever successful operation within the open human heart under direct vision.  
Subsequently, Lewis used this technique on 29 more patients, with only three 
deaths88. Without cardiopulmonary bypass, hypothermia still carried an inherent 
risk of ventricular fibrillation, which remained a significant danger of hypothermia, 
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previously noted by Bigelow et al and Lewis et al who used cardiac massage, intra-
cardiac adrenalin and electrical shock successfully in over ninety percent of patients 
for restoration to normal sinus rhythm80,88. The success of Lewis’s operations gained 
worldwide medical recognition, and they represent a major milestone in cardiac 
surgical history. However, with the introduction of the cardiopulmonary bypass 
machine, the sole use of hypothermia as a technique to allow intra-cardiac 
operations was short lived, in view of the limited operating time this technique 
provided and the associated complications it carried. 
1953 came Henry Swan, who had repeated the work of Bigelow to investigate impact 
on the variables of pH, serum sodium, chloride, potassium, phosphorus, plasma 
protein and haematocrit under the influence of hypothermia, with particular 
interest in prevention of the well documented complication of ventricular 
fibrillation. On February 19th of the same year, Swan carried out open-heart surgery, 
a pulmonary valvulectomy, using hypothermia for the first time89,. Swan then 
applied these findings in a surgical setting, prior to the use of cardiopulmonary 
bypass, using 26-28˚C hypothermia on hundreds of patients, with a low mortality 
rate75. As such, Swan was considered to have the most surgical experience using 
hypothermia. 
The renowned surgeon Dr Denton Cooley employed hypothermia for cerebral 
protection during his first attempt at total resection and replacement of the aortic 
arch in 195590,91. The 49-year-old gentleman was suffering from a syphilitic 
aneurysm involving the arch and a further aneurysm affecting the descending aorta. 
Cooley used surface cooling to achieve 33˚C, and temporary shunts were placed to 
provide blood to the carotids and distal aorta. In this case, the patient went on to 
suffer a stroke and then death, although this was attributed to an 8-minute occlusion 
of the right carotid shunt. This case not only represented the first ever aortic arch 
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resection and replacement but exploited the use of hypothermia as an adjunct in 
aortic arch surgery, as it is still used today.  
Further, important developments in 1955 were introduced by Lillehei and Kirklin 
who used the pump-oxygenator for intra-cardiac surgery85. During their operations, 
it was noticed that body temperature would often cool spontaneously, as early 
oxygenators lacked heat exchangers. In this way it was noted that allowing 
spontaneous cooling alongside pump-oxygenators could produce better outcomes. 
Lillehei and Kirklin published their successful work, and their techniques became 
fashionable. 85 
Sealy et al. fronted this development throughout the late 1950s, and in 1959 and was 
the first to add a heat exchanger alongside a DeWall oxygenator85. This allowed rapid 
active cooling and rewarming to patients to a temperature 32˚C. They confirmed the 
compatibility of using hypothermia alongside oxygenator. He reported this 
technique for 95 patients in a variety of open cardiac surgeries including; tetralogy 
of fallot, compete transposition, valvular disease, septal defects, and reported a 
mortality rate of 17%85.  
From 1959 onwards, Charles Drew, a surgeon at the London Westminister Hospital, 
began developing his own methods for intracardiac surgery after disappointing 
results using other popularized methods85. Drew first used his technique, developed 
through experimentation on dogs, on a 1-year-old child with Down’s syndrome in 
congestive heart failure from an endocardial cushion defect, although the child later 
died after recovery.  
He successfully repaired his following two patients, who underwent VSD closure, 
and they recovered without complications in 195985. His technique involved a 
circulatory support system to cool patients to 15oC. His cynicism towards 
oxygenators led to using the patient’s own lungs for oxygenation. This technique was 
gradually advanced to children and adults across a career of 22 years, with varying 
degrees of success. But, eventually this technique lost ground.  
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Drew’s work represented a cardinal contribution to today’s knowledge of 
hypothermia, and this was recognised in 1961, when Drew was invited to present 
the renowned Hunterian lecture at the Royal College of Surgeons.  
In Siberia, Professor E. N. Meshalkin, who is credited as the pioneer of Soviet cardiac 
surgery, used hypothermia during the 1960s on a variety of patients. He was 
notorious for operating on congenital defects without cardiopulmonary bypass with 
only mild hypothermia77. It is documented that Prof. Meshalkin’s method of cooling 
was the utilization of the abundance of snow and ice available in Siberia for surface 
cooling92. 
Meanwhile, methods of cooling were being advanced by Delorme and Bruce via the 
insertion of a cannula into the femoral artery of canines, passing the blood through 
an extracorporeal coil immersed within an ice bath, and returning the cooled blood 
through the femoral vein93. They were both able to cool canines to 22 to 26oC 
without causing fibrillation, a dreaded complication of surface cooling (except in 1 
dog). Delorme concluded that, armed with this knowledge, operating on a bloodless 
field would become possible in cardiac surgery. However, arteriovenous cooling was 
subject to complications, including fistula formation and thrombosis. Furthermore, 
the technique required initiation before surgery.  
Mr. Donald Ross, well known for leading the team that performed the first cardiac 
transplant in the United Kingdom, is further credited with popularizing veno-venous 
cooling, a method he had devised in canine experimentation by cannulating the 
external jugular vein for blood drainage and providing return through the superior 
vena cava94.  
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He reported improved success using veno-venous cooling over surface cooling due 
to the greater control over the stages of cooling, preventing core temperatures to 
drop too low, or too rapid reducing the risk of cardiac irregularities. The recognized 
detrimental effect of ventricular fibrillation from rapid cooling was still a very real 
risk. Ross did not commence cooling until the chest was open, and thus able to 
observe the heart and deal with any irregularities.  
In 1959, Ross and Sir Russel Brock, from Guy’s Hospital London, declared “deep 
hypothermia by means of a heart lung bypass machine or a differential cooling 
technique holds promise of longer safe periods of safe intra cardiac surgery in the 
future”95. Following this pronouncement, there was a wave of experiments in the use 
of cardiopulmonary bypass with hypothermia.  
World renowned Dr Christiaan Neethling Barnard and Velva Schrire in 1963 were 
the first to use deep hypothermic circulatory arrest and cardiopulmonary bypass 
simultaneously, on two patients with aortic aneurysm involving the ascending aorta 
and arch. They cooled the patients to a temperature of approximately 10oC 
measured in the oesophagus77. They were successful in one of their patients. 
Following this, multiple renowned surgeons began reporting success with 
combinations of hypothermia and cardiopulmonary bypass, including Borst and 
Lilliehei.  
In 1975, Professor Randall Griepp published a series of four patient operations for 
aortic arch aneurysms using hypothermia via a combination of surface cooling and 
cardiopulmonary bypass96. He published successful resection of aneurysms in all 
four patients. Griepp et al. would later report (1991) the limitations of using 
                                                                
95 BROCK R, ROSS DN. Hypothermia. III. The clinical application of hypothermic techniques. Guys Hosp Rep. 
1955;104:99-113.  
96 Griepp RB. Cerebral protection during aortic arch surgery. J Thorac Cardiovasc Surg 2001;121:425-7. 
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hypothermic circulatory arrest alone for cerebral protection, noting a relationship 
between duration of hypothermic arrest and mortality9697,98,99. 
 These concerns were echoed by Haldenwang et al., who noted that temporary or 
permanent neurologic dysfunction incidence rose when HCA exceeded 40 minutes 
and mortality rates increased above 60 minutes of HCA100. It was this observation 
that led to the development of further techniques: antegrade cerebral perfusion 
(ACP) and retrograde cerebral perfusion (RCP), which are used in combination with 
DHCA today. 
 
6.2. Deep Hypothermic Circulatory Arrest (DHCA) 
DHCA has been in clinical practice for over 30 years and allows the surgeon to excise 
the distal clamp site, completely view the aortic anatomy in a bloodless field and 
perform a distal anastomosis without leaving any clamp-compromised tissue101102. 
The reasoning behind this technique is to reduce the brain’s activity and energy 
demand to a minimum. 
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There are two specific concerns about the use of DHCA: 
1) What temperature should be achieved before the extracorporeal circulation 
can be stopped? 
2) What is the anticipated ‘safe’ interval for a repair without neurological 
complications? 
Most clinicians consider 35-40 mins of HCA at 20 °C as relatively safe, but there is 
increasing evidence that the interval could be a lot shorter. The most common 
complications of this approach are post-ischemic hypothermia, impaired 
autoregulatory mechanisms, and the abolishment of the brain protective barriers 
manifested by the increase in the cerebrovascular resistance that is initiated during 
the rewarming part of the procedure. To counteract these untoward effects, 
reperfusion and rewarming are established gradually and slowly. Additionally, the 
gradient temperature between the perfusate temperature and the core temperature 
should never exceed 10 °C. The metabolic management during this crucial phase also 
plays a pivotal part, supplemented with pharmacological adjunct such as Mannitol, 
which aids in the prevention of cerebral oedema and increased intracranial 
pressure, and also act as a free radical scavenger103. 
The advantages of DHCA include: 
 A bloodless and motionless operative field; 
 Avoidance of clamping and manipulation of the aorta with reduced risk for 
brain embolism; 
 Simplicity and no need for additional perfusion equipment. 
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The disadvantages of DHCA include: 
 Limited safe time of circulatory arrest; 
 Prolonged cardiopulmonary bypass (CPB) time required to cool down and 
rewarm patients, which may result in an increased occurrence of pulmonary, 
renal, cardiac and endothelial dysfunction; 
 Reperfusion injury; 
 Clotting complications104 
Svensson et al. 102 reported in a series of 616 patients an overall stroke rate and early 
mortality rate of 7% and 10%, respectively (median DHCA time: 31 mins; range, 7-
120 mins).  
On univariate analysis, periods of circulatory arrest greater than 45 and 60 mins 
emerged as independent predictors of stroke and early mortality respectively. 
However, more recently, McCullogh et al. 105 demonstrated that the human cerebral 
metabolic rate is still 17% of baseline at 15 °C and that at this temperature the safe 
duration of circulatory arrest is no longer than 29 mins. Similarly, Reich et al.101, Di 
Eusanio et al.106 and Sakamoto et al. 107 have indicated that a duration of circulatory 
arrest of 25 mins is associated with an increased risk of transient neurological, 
memory and fine motor deficits. 
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For these reasons, the employment of DHCA seems to be rational only in patients 
requiring aortic arch repair with an anticipated duration of circulatory arrest 
shorter than 30 mins. 
 
6.3 Retrograde Cerebral Perfusion (RCP) 
The use of RCP was originally reported by Mills and Ochsner108 for the management 
of massive arterial air embolism during cardiopulmonary bypass in 1980. In 1982 
Lemole and colleagues109, described intermittent RCP as a method of facilitating 
intraluminal graft placement in the aorta. In 1990, Ueda and associates110 first 
described the routine use of continuous RCP in thoracic aortic surgery for the 
purpose of cerebral protection during the period of obligatory interruption of 
anterograde cerebral flow. 
There is compelling evidence that RCP may accomplish neuro-protection through 
providing cerebral metabolic support, expelling atheromatous and gaseous emboli 
from the cerebral vasculature, and maintaining cerebral hypothermia.  
The disadvantages in the use of RCP include cerebral oedema and the concern that 
very little of the perfusate actually reaches the brain to provide adequate 
neuroprotection. 
The Safi group from Houston reported on the concept of an “opening” pressure that 
was required to observe a reversal flow in the middle cerebral arteries. 31 mmHg 
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was required to open the venous capacitance vessels and overcome the jugular 
venous valves. This yielded acceptable results in terms of stroke111. 
The relationship between use of RCP and clinical outcome is also unclear. Some 
authors reported RCP duration to be a predictor of death and adverse neurological 
outcome112,113, whereas others did not114,115116. 
Current practice for RCP deployment is through a superior vena cava cannula with 
snaring of the caval cannula to prevent cardiac distention. The mode of application 
of RCP is uniformly accepted based on clinical observations, and anatomic and 
experimental data that support RCP with a pressurized entire venous system. Some 
centers limit the use of RCP to the prevention of neurologic injury in patients at high 
risk of embolic strokes. RCP could also be used in brief cycles to flush out the debris 
prior to the commencement of antegrade flow and reperfusion. 
In summary, based on human and laboratory investigations, RCP neuro-protective 
mechanisms still remain controversial. When compared to SACP, RCP seems to be 
less effective whilst still providing some adjunctive brain protection compared to 
DHCA alone, due to continued cerebral cooling via the veno-arterial and veno-
venous collateral circulations. 
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6.4 Selective Antegrade Cerebral Perfusion (SACP) 
The first attempt to repair the aortic arch relied on complex methods of antegrade 
cerebral perfusion. In 1957, DeBakey reported a successful resection of an aortic 
arch aneurysm using normothermic CPB and cannulation of both subclavian and 
carotid arteries by means of several pumps117. However, after early attempts, 
antegrade cerebral perfusion was abandoned due to unsatisfactory results and 
growing utilization of DHCA. SACP was then re-introduced by Frist et al.118, Bachet 
et al.119  and then popularized by Kazui et al.120 They employed two separate pump 
heads for cerebral and systemic circulations and, in an elegant experimental study, 
indicated optimal cerebral flow rate (10 mL/kg/min) and perfusion pressure (40-
70 mmHg) at 22 °C. 
SACP provides several advantages: (I) the circulatory arrest time can safely be 
extended up to 90 minutes allowing more complex aortic repairs to be performed, 
(II) moderate (nasopharyngeal, 25 °C) instead of profound hypothermia can be used 
with reduced coagulative and systemic complications. Criticisms against SACP 
include technical complexity, reduced surgical visibility, and manipulation of the 
aortic arch and arch vessels especially in cases of acute dissections or severely 
atherosclerotic aortic arch aneurysms106121,122. 
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Although many experimental animal and patient cohort studies have been 
performed with SACP, only three prospective randomized controlled trials have 
compared SACP with RCP. Okita and associates 114 studied a total of 60 patients (30 
with SACP and 30 with RCP) and found a decreased rate of total neurologic deficit in 
the SACP group (33% vs. 13%, P<0.05) but found no difference between groups in 
rates of death, stroke, or neurocognitive deficit. In an earlier report, Tanoue and 
colleagues122 used transcranial Doppler ultrasonography to verify cerebral blood 
flow in 32 patients (15 with RCP and 17 with SACP). This study found improved 
cerebral blood flow in the SACP group. Only 3 patients in the RCP group showed 
evidence of reversal of cerebral blood. This low incidence of identification of flow 
reversal can be attributed to the technique of RCP used in the study: the superior 
vena cava pressure was only 15 to 25 mmHg. In addition, the cerebral perfusion time 
was 71 minutes in the SACP group, but only 38 minutes in the RCP group (P=0.0047). 
No differences in clinical outcomes were noted. Recent studies with SACP have 
reported excellent clinical outcomes, but variations in technique make it difficult to 
determine if SACP alone was responsible. The limitations, in common with most of 
such clinical studies, included differences in cannulation, delivery of perfusate 
(unilateral vs. bilateral), amount of perfusate and temperature of perfusate. 
 
6.5  Neuromonitoring and Avoidance of Stroke 
Neurologic complications following aortic surgery impose a negative impact and 
burden on patients’ quality of life. Several mechanisms are implicated, including 
cerebral embolism, cerebral hypo-perfusion and inflammatory reactions. All of these 
mechanisms cause an imbalance between oxygen delivery and oxygen consumption 
in the brain. Neuromonitoring during aortic surgery may help to prevent injurious 
events or even detect them in a stage early enough to employ strategies to minimize 
secondary cerebral damage.  
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While there are many modalities that can be used to demonstrate specific or regional 
brain oxygen deprivation during aortic surgery, all of these modalities have 
limitations. 
Near infrared spectroscopy (NIRS) can be used to measure the cerebral tissue 
oxygen saturation of the bifrontal cortical regions.  
This method is non-invasive and works by emission of near infrared light and 
measurement of the absorption characteristics of oxy- and deoxyhemoglobin.  
Furthermore, transcranial Doppler (TCD) presents a non-invasive technique to 
monitor not only cerebral blood flow velocity, but also to detect cerebral emboli. 
Finally, epi-aortic echocardiography is an important tool to help avoid or minimise 
cerebral injury during cardiac and aortic surgery. Even though this technique does 
not monitor the brain directly, it can be considered as a neuromonitoring technique 
in the broader sense. 
Furthermore, the best manoeuvre to avoid stroke during complex aortic surgery is 
not only related to the sophisticated modality for neuromonitoring but also to the 
manoeuvres that are employed when a regional drop in oxygen is detected. This 
includes checking the patient’s head position to ensure that it is not rotated, 
increasing the PaCO2 to above 40 mmHg, increasing the mean arterial pressure to 
above 60 mmHg, increasing the pump flow to 2.5 L/m2/min, raising the haematocrit 
above 20%, lowering the central venous pressure below 10 mmHg, increasing the 
inspiratory oxygen concentration, and deepening anaesthesia123. In addition to this, 
scrupulous avoidance of manipulation of the diseased arch and cerebral vessels 
except during HCA is absolutely mandatory, as is careful, repeated aspiration of the 
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cerebral vessels after circulatory arrest and before institution of antegrade 
flow96,124. 
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CHAPTER SEVEN 
 
7. THE ROLE OF SURGERY IN THORACIC AORTIC 
ANEURYSM 
7.1 When Is Surgery Indicated? 
Once a thoracic aneurysm is diagnosed, routine, scheduled follow-up is necessary by 
an aortic specialist. Aneurysm size needs to be followed closely and surgery is 
warranted if there is rapid growth over a short period of time or if a critical size is 
reached. Follow-up typically includes CT scans or MRI's every 6-12 months. The 
ascending aorta grows at a rate of 0.10 cm per year and the descending aorta at a 
rate of 0.20 cm per year. Should an aneurysm increase in size by 0.4cm in any one 
year then surgery should be performed6. 
Decisions regarding surgery can be made if the risk of death, dissection or rupture 
is known for any particular aneurysm size. This risk can then be compared to the 
risk of surgery. The mortality for aortic arch surgery increases to 5-8% and the 
mortality for descending thoracic aneurysm surgery is 5.5%. Below is listed the 
yearly risk of complications based on aortic aneurysm size (Table 7.1) 
Given these statistics it is recommended that asymptomatic ascending aortic 
aneurysms be resected at a size of 5.0-5.5 cm.  If severe aortic insufficiency is present 
in the setting of a bicuspid valve, the ascending aorta should be resected when it is 
4.5 cm in diameter. Descending thoracic and aortic arch aneurysms typically are 
resected when they exceed 6.0 cm in diameter.  
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A patient with Marfan syndrome typically warrants earlier 
intervention.  Symptomatic aneurysms should be resected regardless of size6. 
 
7.2 Operative Techniques  
To allow an understanding of the extent of resection and reconstruction, we have 
defined the following terms: 
1) Hemiarch Surgery 
Hemiarch surgery or proximal arch surgery is performed as either a “simple” 
hemiarch or a “deep” hemiarch. In simple hemiarch surgery, under deep 
hypothermic circulatory arrest, the arch is resected in a line from the origin of the 
brachiocephalic artery to the apex of the underside of the arch opposite the left 
subclavian artery. In deep hemiarch surgery, the entire anterior and posterior wall 
of the arch is removed leaving an effective Carrel patch of arch vessels connected via 
a “bridge” of aorta to the descending thoracic aorta. In this study, these two groups 
have been amalgamated as historical records do not make this distinction. Simple 
open distal anastomosis under deep hypothermic circulatory arrest has been 
excluded. Patients undergoing simple open distal anastomosis for acute Type A 
repair (137 additional cases during this period) have been excluded. 
2) Total Arch Surgery 
We have defined total arch surgery as that occurring under deep hypothermic 
circulatory arrest and involving resection of the arch such that at least one of the 
great vessels requires reimplantation. Arch vessels were anastomosed either 
separately or as a Carrel patch. This simple definition was chosen to avoid 
subclassification of the myriad of permutations of aortic arch surgery. A number of 
patients who underwent total aortic arch replacement also underwent placement of 
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a conventional elephant trunk using an 8 cm graft in preparation for possible second 
stage procedures. In addition, in the latter half of the series, a number of patients 
underwent placement of a “frozen elephant trunk” using either an EVITA Open Plus 
Hybrid Stent Graft (Jotec, GmbH, Hechingen, Germany) or a Thoraflex device 
(Vascutek Terumo Thoraflex Hybrid Stent Graft; Vascutek, Renfrewshire, UK). These 
devices were only deployed in aneurysms in which there was no chronic dissection 
or evidence of connective tissue disorder. In addition, they were only deployed in 
patients who had proximal descending thoracic aneurysms with suitable distal 
landing zones. Our operative techniques have evolved through the study period as 
technology and experience have shaped our approach. Below is a general approach 
to our operations.  
It is relevant to say that between 1999 and 2007, operations were performed by all 
surgeons within the center, but principal activity was by a single subspecialized 
surgeon (Mr Abbas Rashid). After 2007, this same principal surgeon and 4 others 
subspecialized in aortic surgery (D.H., M.F., M.K., and A.O.) performed the operations. 
3) Conventional Elephant Trunk 
 
A conventional elephant trunk is defined as placement of a redundant extension of 
the arch graft into the descending thoracic aorta for use in subsequent second stage 
procedures. This may be placed proximal or distal to the left subclavian artery. 
Typically, these are no longer than 8cm in length. 
 
4) Prophylactic Elephant Trunks  
 
These are elephant trunks placed at the time of Stage I or Stage II but with no 
indication for an immediate subsequent stage. 
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5) Frozen Elephant Trunk 
Frozen elephant trunks are hybrid stent grafts which is this series were entirely 
Jotec E-Vita prostheses. They allow for endovascular stenting of distal 
arch/proximal descending thoracic aneurysms, with open deployment at the time of 
surgery on the aortic arch. The attached surgical graft allows for concurrent 
reconstruction of the aortic arch. 
 
6) Reverse Elephant Trunk 
Reverse elephant trunks are invaginated, redundant, surgical graft tissue placed at 
the time of construction of the proximal anastomosis at the level of the left 
subclavian artery during surgery on the descending thoracic aorta. This aide 
reconstruction of the arch during second stage operations through a median 
sternotomy. These are typically short and 3cm in length and may also be 
“prophylactic”. 
 
7.3 Mortality Following Surgery 
Operative mortality has drastically improved over the last century when thoracic 
aortic aneurysm repair was not survivable. Significant advances have been seen in 
Mortality following thoracic aortic aneurysm repair is dependent on many variables, 
the main ones being; extent and size of aneurysm, patient co-morbidities present, 
operation underdone on an elective or emergent basis, and recent evidence from the 
US showing better outcomes in centers who undergo higher volume of cases.  
The current 2010 guidelines for thoracic aortic disease describe death following 
composite valve graft as unusual and the risk is between 1 and 5%6. This risk is 
however center dependent.  
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Many centers have reported learning curves in all aspects of thoracic aortic surgery 
which improvements over time in terms of mortality, which adds to the argument 
that volume is an important factor in operative mortality125.  
In 2007, Kalkat et al from Birmingham, UK, interrogated the UK heart valve registry 
which contained data on 1962 patients undergoing first time composite valve graft 
replacement and report a 30-day mortality as 10.7%126. These results include 
patients operated on an emergency basis as with those with genetic conditions, 
which may explain the reported higher incidence of mortality compared to that of 
the 2010 guidelines.  
In consideration of patients with genetic conditions, Karck et al from Germany, 
describe postoperative mortality in Marfan patients as high as 6.8% in those 
undergoing composite valve grafts in a retrospective group of 119 patients (Figure 
7.3a)127. A further paper in 2010 by Bernhradt et al describes a 30 day mortality in 
Marfans patients undergoing composite graft replacement as 0%, however this rose 
to 10% at follow up. Patel et al also describe a 10% mortality following Bentall 
procedure in Marfan patients at 8 year follow up128. Other papers describing other 
genetic syndromes, such as Loeys-Dietz, and composite graft replacement report 
series too small to draw any relevant conclusions129. BAV and ascending aorta repair 
is now a commonly recognized procedure. El Khoury et al report no hospital 
mortality following repair of a regurgitant bicuspid aortic valve with aortic root 
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replacement130. A BAV does not significantly increase the risk of mortality following 
operation compared to those with a tricuspid valve.  
Aortic arch operations carry a pre-requisite of cerebral protection due to the nature 
of the procedure. This opens patients to higher risk of mortality, relating to reduced 
cerebral perfusion, time of operation, cardiopulmonary bypass time, aortic cross 
clamp times and periods of deep hypothermic circulatory arrest.  
The 2010 thoracic aortic guidelines quote a 2 to 6% risk of death in patients 
undergoing these types of operations. Leshnower et al report their center 
experience between 2004 and 2009 encompassing 412 patients and report and 
operative mortality of 7.0%, this included patients undergoing emergency 
operations131.  
The Mayo clinic reports 9 years of results from 2001 to 2010 of 209 patients and 
report a procedure specific mortality of 5.5% and 1.0% in total arch and hemiarch 
procedures respectively256.  Furthermore, the same paper describes how even over 
9 years they have seen decreases in rates of mortality from the first half of their 
study period compared to their second half (7.9% vs 4.5% respectively). Other 
centers have reported similar decreases in mortality over short spans of time 
including Mount Sinai132,133.  
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Gega et al from Yale published results in 2007 using deep hypothermic circulatory 
arrest as the sole means of cerebral protection134. In their study of 394 patients over 
10 years they report a mortality rate of 3.6% in elective cases.  
Such rapid advancements in aortic arch surgery have led to different techniques 
being used by different centers worldwide. This adds a further variable that should 
be considered when studying mortality rates.  Although mortality rates vary 
worldwide, in general mortality rates reported are in the single digits, particularly 
so in elective repair and modern day aortic arch surgery is performed with low risk 
of mortality.  
Thoracoabdominal aortic aneurysm surgery represents the most challenging 
operation that can be undertaken on the aorta. The 2010 guidelines describe an 
approximate mortality of 10% in patients undergoing type II thoracoabdominal 
repair, again this is center dependent and furthermore this is recognized in the 
guidelines. Wong et al, describe 305 patients undergoing TAAA repair of which 
operative survival following elective repair is 6.2% (Figure 7.3b)135. In 2007, Coseli 
et al report their entire open thoracoabdominal aneurysm repair encompassing a 
total of 2286 patients and report 30-day survival rate of 95.0% 136. Coseli et al have 
also reported their experience of TAAA surgery in patients with Marfans syndrome, 
which totally 50 patients between 1986 and 1996. 30-day survival in these patients 
was 96%. Cambria et al from Havard, performed 337 operations on the 
thoracoabdominal aorta, and reported operative mortality of 8.3% 137. This 
mortality rate included patients undergoing operations in a non-elective setting and 
all types of TAAA repair. Endovascular interventions are becoming ever popular in 
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TAAA repair, particularly as hybrid techniques are being developed. However, these 
are still very much in their infancy. Although there are some published literatures 
on long term data it still represents an area that is currently under close 
investigation.  
Survival rates still rank highly in TAA research, as it should in all diseases as we 
strive to improve patient care. The majority of survival rates in TAA are subdivided 
according to; TAA size or growth, type of aneurysm, location of aneurysm, and ASI138.  
A paper published by Clouse et al statistically showed that over the past 15 years 
(from 1998) the prognosis of patients diagnosed with TAA has improved139. This 
retrospective review used 133 patients who were with a diagnosis of degenerative 
TAA from 1980 to 1994 were compared against a similar cohort of patients from 
1951-1980. Overall 5-year survival improved from 19% to 56% in the two different 
time points. The median survival time was 6.6 years with the most common cause of 
death cited as rupture of the thoracic aneurysm accounting for 30%, other causes 
included cardiac events (25%), pulmonary causes (15%), cancer (10%), stroke 
(4%), other (16%). This study was performed in 1998 and included a small number 
of patients over many years. This report is subject to reporting and measurement 
bias. Trimarchi et al studied 613 patients with type B TAA only revealing an in 
hospital mortality rate of 6.6% and 23.0% for TAA’s or less than 5.5cm and greater 
than 5.5cms respectively (p<0.001).  
This study looks only at patients with type B TAA, and is subjected to measurement 
bias. These figure further enforce the surgical indications of 5.5cm in TAAs.  
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Zierer et al140 retrospectively analysed 110 asymptomatic patients who underwent 
elective TAA repair. Overall survival at 2 and 4 years was 79% and 70% respectively. 
This study included all types of TAA’s and did not differentiate between them. It is 
worth mentioning that this study is the first of its kind to look at quality of life and 
functional status following thoracic aneurysm operations. Age and procedure did 
not significantly impede return to normal function (p>0.59 and p>0.18 respectively). 
Older patients (greater than 70 years) had an improved psychological quality of life. 
Thus the authors concluded that age should not be a determinant factor alone to 
perform elective TAA surgery.  
The Yale TAA database is likely to hold the largest sets of data on these specific 
subsets of patients2. They analysed 1600 patients, which included a total of 3000 
images. They were then able to provide statistical analysis to give calculations of 
death based entirely on aortic size. The yearly risk for aortic size; 3.5cm – 3.9cm is 
5.9%, 4.0 – 5.0cm is 4.6%, 5.0 – 6.0cm 4.8%, and greater than 6cm as 10.8%. This 
correlates with previous studies mentioned above that mortality increases with 
increasing aortic aneurysm size. The Yale group used their new stratification system 
based on aortic size index to further divide patients into groups to relate a mortality 
risk to. Five-year survival in patients with; the highest ASI was 44.4%, compared to 
a low ASI was 94.7% (p<0.0001). These figures are likely to be skewed as it included 
patients who underwent operative repair. 
Davies et al used the data from 721 to show a 5-year survival for patients with TAA 
not operated on as 54%2. Furthermore, in this cohort of patients TAA with a size 
greater than 6cm gave a yearly mortality rate of 11.8%. They found that elective 
surgery to prevent TAA’s reaching the critical 6cm point restored patient survival 
rate to near normal.  
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The authors strongly advocate the need for regular monitoring in TAA patients, 
stress that TAA is a lethal disease and increasing size is strongly related to increased 
morbidity and mortality.   
Although there is a tendency to report mid-term and late out comes amongst the 
endovascular aortic arch repair; there remain a subtlety in these report on the re-
intervention rate. It’s the case that endovascular procedures, patients need to be 
fully informed that they will require a lifetime of careful follow-up and that in those 
patients who have a life expectancy of more than 5 to 10 years; it is likely they will 
require multiple repeat procedures. Indeed, in an independent audit of stented 
patients in France, 45% of patients had an event in the first year, excluding deaths. 
There is no doubt that future work is needed to identify TEVAR candidates unlikely 
to benefit from repair. 
 
7.4 Aortic Intervention in the UK 
Current intervention on thoracic and thoracoabdominal aneurysms within the UK is 
not well documented. It is performed by cardiac surgeons, vascular surgeons, 
interventional radiologists and a few cardiologists and varies by region and local 
historically based arrangements. There is no single regulatory body and no single 
registry. Data are stored by the Society for Cardiothoracic Surgery, the Vascular 
Society and Commercial Companies including the UK Registry for Thoracic Stent 
Grafts. In addition, some registries are pan-European making it difficult to extract 
UK-specific data. Although these figures also include intervention on ascending and 
arch thoracic aortic aneurysms they give an interesting representation of the total 
activity and distribution of thoracic aortic activity with centres in England (Figure 
7.4).  
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For open surgical approaches, data from St Mary’s published in 1995141 and 1999 142 
have influenced approaches within the UK. Results in this study suggested very poor 
outcomes from an open approach. However, these data should be judged in their 
historical context with no or little use of perfusion, cell salvage or clotting products. 
More contemporary results presented by Thoracic Aortic Aneurysm Service at the 
Liverpool Aortic Symposium (2011) (www.aorticaneurysm) suggest results 
comparable with any international institution are achievable within the UK.  
In a series of 80 elective open repairs (60% Extent I and II [left subclavian to either 
visceral vessels or aortic bifurcation]), 30-day mortality was 6.25% and in-hospital 
mortality was 11.2%, with a permanent paraplegia rate of 2.5%. Interestingly, 
within Scotland, the National Services Advisory Group nominated the Royal 
Infirmary of Edinburgh the sole national provider of thoracoabdominal aortic 
aneurysm intervention in April 2001 (www.nsd.scot.nhs.uk). The group has 
published outcomes for Type IV (abdominal) and what they describe as supra- 
coeliac aneurysms, via a totally abdominal approach with a 30-day mortality of 6% 
(3/53). Their Government Review in 2007 (www.nsd. scot.nhs.uk) does suggest a 
practice dominated by this group of patients (Extent IV, 60%), with patients 
undergoing Extent II repairs (left subclavian to aortic bifurcation) only 14%, 
respectively.  
This together with the lack of provision for cardiopulmonary bypass presumably 
reflects the lack of involvement of cardiac surgical services. Certainly, their 
outcomes for this particular extent are comparable with any international centre. 
However, the poor early outcomes from open surgery in the UK undoubtedly have 
driven attempts at total endovascular solutions and hybrid approaches reflecting 
some inter- national practices.  
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Results from the Royal Liverpool University Hospital suggest acceptable early 
results from Extent II branched stent grafting143  and  other less complex pathologies 
published from London144,145. However, UK Commissioners have increasingly 
questioned the clinical and cost- effectiveness of endovascular approaches as inter- 
national studies have shown mixed outcomes from this approach. Certainly, in our 
Institution, we are required to request funding for endovascular approaches on a 
case-by-case basis but require no such scrutiny for open surgical intervention. 
Hybrid approaches with staged extra-anatomical bypass and endovascular stenting 
have been trialed in an attempt to reduce morbidity, mortality and cost146,147.  
However, results have also been mixed and this approach has not provided the 
expected solution. The Society of Cardiothoracic Surgeons has published limited 
data on out- comes from intervention on the descending thoracic aorta and 
thoracoabdominal aneurysms; however, the data are rudimentary and few 
conclusions can be drawn. 148 
 
7.5 Open Aortic Arch Aneurysm Surgery in the UK 
Within the United Kingdom thoracic aortic surgery is performed to some degree by 
all cardiac surgery units and this is principally open intervention. It is difficult to get 
an accurate picture of the activity, extent of service and outcomes from published 
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date which in the case of cardiac surgery is the Society for cardiothoracic surgeons’ 
Blue book (www.scts.org).  
Very few cardiac centres have high volume activity and outcomes and even fewer 
have published their results, with the noticeable exceptions of Birmingham and 
Bristol. Undoubtedly, this has given an impression that open aortic arch surgery is 
not widely available and comes at high risk of stroke and death.  
In order to circumvent this issue and offer treatment options for this group of 
patients there has been much innovation in endovascular technology principally 
driven by Vascular Surgery and Interventional Radiology. Within the Northwest the 
thoracic aortic aneurysm service at the Liverpool Heart and Chest Hospital (LHCH) 
has increasingly specialized in thoracic and thoracoabdominal intervention. This 
service has not been formally commissioned but has been supported by the LHCH 
NHS Trust Board with the appointment of 4 cardiac surgeons with a specialized 
interest in thoracic aortic surgery. 
Bristol published an analysis of their results for ascending/arch surgery in 2004149. 
The objective of the work was to compare outcomes within the unit between a single 
high volume operator and a group of other more general operators performing 
aortic surgery on a more ad hoc basis. The study had a high percentage of 
urgent/emergency cases. Although there was no mortality difference between the 
two groups there was a significant difference in morbidity. A detailed breakdown of 
the extent of arch surgery is not available but we know 291 patients underwent 
surgery on the ascending aorta/aortic arch. Overall mortality was 12.5%; 10.8% in 
high volume group and 13.9% in low volume group. Only 16.9% of cases by the 
higher volume surgeon and 5.4% in the lower surgeons group were labelled as 
involving the aortic arch. Neurological complications were noted in 7.7% and 7.8% 
in the two groups respectively. 
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 100 
 
A second paper by the Bristol group150 compared surgery on the ascending aorta +/- 
arch examining the impact of redo operations. The overall mortality was 13.8% 
(4/29) versus 12.4% (33/267) for primary operations.  Mortality in redo elective 
surgery was 5.9% versus 25% for emergencies. However, this was a mixed group of 
patients with only 49% elective and 55% of redo patients requiring circulatory 
arrest. Only 10% of first time and 14% of repeat procedures were labelled as arch 
replacements. Neurological complications were seen in 7% of first time procedures 
and 7% of repeat procedures.  
In a third analysis of the Bristol data set151 this group looked at the influence of 
coronary artery bypass surgery on surgery of the ascending aorta/arch. Of the 296 
patients analysed, addition of CABG to this group changed the mortality from 11% 
to 21.4%. However, again this is a heterogeneous group with a high proportion of 
emergencies and only 10.2% involving arch surgery in the “no CABG” group and 
11.9% in the “added CABG” group. 
Within the context of two randomized controlled trials investigating methods of 
neuro-protection during deep hypothermic circulatory arrest, the Birmingham 
group have documented their mortality and morbidity outcomes for open aortic 
arch surgery. In a study by Harrington et al152 looking at neuropsychometric 
outcomes from deep hypothermic circulatory arrest with and without retrograde 
cerebral protection in patients undergoing hemiarch and total arch replacement 
there were 2 deaths in 38 (5.25) and one permanent stroke.  
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A second study by Harrington et al 153 examined the effect of selective anterograde 
cerebral perfusion on brain metabolic deficit during deep hypothermic circulatory 
arrest and aortic arch surgery. 42 patients underwent aortic arch surgery with 3 
deaths (7.1%). Two patients experience stroke and 6 had transient neurological 
deficit. Certainly the publication of detailed open outcomes in the UK has been 
limited by heterogeneity of datasets and limited by the context of randomized trials.  
There is a lack of published data on a large consecutive group of patients, principally 
undergoing arch surgery, with detailed information on extent of resection, outcomes 
and survival. The Society for Cardiothoracic Surgeons four yearly publication of 
outcomes (“Blue book”) does not document in sufficient detail outcomes from aortic 
arch surgery.  
 
7.6 Endovascular Intervention in the UK 
Both the St Mary’s unit and the St George’s unit in London have published outcomes 
for endovascular intervention on the aortic arch. Holt et al 154 from St George’s group, 
published on outcomes of the endovascular management of aortic arch aneurysm, in 
particular focusing on the management of the left subclavian artery. The series 
involved non-fenestrated grafts and extra-anatomic reconstruction. Over an 8-year 
period, 78 patients were treated. Overall mortality and stroke rate was 14.3% and 
14.3% for emergency treatment versus 4% and 2% for elective patients. Three 
patients (3.85%) sustained paraplegia. Re-intervention was required in 9 of 68 
patients (13%) with 1 year of follow-up. Long term survival data and re-intervention 
rates are missing.  
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Antoniou et al 155 from Nick Cheshire’s group at St Mary’s have published a series of 
33 patients over 6 years who underwent similar hybrid repair of arch aneurysms 
with endovascular intervention and extra-anatomic bypass.  
Elective 30-day mortality was given as 13% and 35% for elective and 
urgent/emergency respectively. However, when divided into complete arch repair 
verses partial arch the 30-day mortality was 44% versus 13% (P<0.046). When this 
was further subdivided into just elective patients the 30-day mortality was 29% 
versus 6% (P<0.144). Late endoleak rate was 35%. Stroke rate was 12% and 
paraplegia rate was 6%. Certainly endovascular intervention on the aortic arch is in 
its infancy but with acceptable outcomes. Undoubtedly, outcomes will improve 
further with current innovations in fenestrated and branched stent grafts. However, 
as with most comparisons of stent versus surgery for thoracic aortic intervention, 
the patient groups are not comparable and interpretation of superiority is not 
possible. Certainly in our practice, endovascular intervention on the aortic arch is 
limited to those too old and frail for surgery and blunt traumatic aortic rupture.  
 
7.7 Open Aortic Arch Surgery Vs Endovascular Repair 
To date, there has been no prospective, randomized trial that has compared open 
aortic arch surgical repair versus endovascular stenting approaches. The current 
published reports are not without significant limitations due to essentially the 
ambiguity and lack of consensus of the understanding of the natural history of aortic 
arch disease. In a recent review by Abraha et al156 they found no published or 
unpublished evidence to assess the efficacy of TEVAR over conventional aortic 
surgical repair. The authors concluded that there is a need to carry out a quality 
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randomized control trail to assess TEVAR and open repair. The trials should have 
adequate follow up and be enough to evaluate the durability of endovascular 
treatment in terms of endoleak rate, re-intervention rate, open-conversion rate, and 
rupture-free survival. In addition to clinically relevant outcomes including early and 
late mortality, major complications, and hospital and intensive care unit stay must 
be considered.  Despite the aforementioned, studies by Orandi et al and by Walsh et 
al suggested that endovascular techniques are considered safer and less invasive 
with mortality and morbidity that are similar to conventional open aortic surgical 
repair. Orandi et al157 found that among a total of 1030 patients who underwent 
open TAA repair and 267 who underwent TEVAR, there was no significant difference 
in mortality between open aortic repair and TEVAR. They also added that although 
open repair patients were more likely to have cardiac, respiratory, and hemorrhagic 
complications, patients undergoing TEVAR were more likely to be discharged to 
home and had a decreased length of hospital stay. On the other hand, Walsh et al158 
based their conclusion on series of comparative studies that solely looked at stent 
grafting to the descending aortic aneurysm without any reference to the ascending 
and aortic arch aneurysms and the surgical management of this entity.  
The Gore TAG trial compared the TAG endograft patients (n=140) with standard 
open surgical controls (n=94) with enrollment from September of 1999 to May of 
2001159. At 5 years, aneurysm-related mortality was lower for TAG patients at 2.8% 
compared with open controls at 11.7% (P=0 .008). No differences in all-cause 
mortality were noted, with 68% of TAG patients and 67% of open controls surviving 
to 5 years (P=0.43). Major adverse events at 5 years were significantly reduced in 
the TAG group; 57.9% vs 78.7% (P=0.001). Endoleaks in the TAG group decreased 
from 8.1% at 1 month to 4.3% at 5 years. Five TAG patients have undergone major 
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aneurysm-related re-interventions at 5 years (3.6%), including one arch aneurysm 
repair for type1 endoleak and migration, one open conversion and five endovascular 
procedures for endoleaks in three patients. At 5 years, there have been no ruptures, 
one migration, no collapse, and 20 instances of fracture in 19 patients, all before the 
revision of the TAG graft. A study by Goodney et al looked at survival among the open 
aortic arch repair and endovascular groups160. Their conclusion was that although 
perioperative mortality is lower with TEVAR, Medicare patients selected for TEVAR 
have worse long-term survival than patients selected for open repair. The results of 
this observational study suggest that higher-risk patients are being offered TEVAR 
and that some do not benefit on the basis of long-term survival. Evolution of surgical 
techniques and perioperative care has significantly improved morbidity and 
mortality rates for patients undergoing aortic arch surgery and acute aortic 
dissections cohort161. Whereas early surgical series reported mortality rates that 
would be prohibitive today, recent studies have published rates largely in single 
figures 1,2,3,4. A number of studies have also published rudimentary survival data 
demonstrating a beneficial effect of surgery compared to estimated natural history 
of patients with aortic arch aneurysms 8,9,13.  
The objectives of this study were to:  
1) Report, compare, and analyse our morbidity and mortality outcomes for 
hemiarch and total aortic arch surgery;  
2) Examine the survival benefit of hemiarch and total aortic arch surgery 
compared to age- and sex-matched controls;  
3) Define factors which influence survival in these two groups and, in 
particular, identify those that are modifiable and potentially actionable and  
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4) Compare outcomes within the unit between high volume operators and a 
group of other more general operators performing aortic surgery on a more 
ad hoc basis.  
This is clearly reflected under the general term of subspecialisation in aortic surgery.  
 
7.8 Long Term  
The rapid and evolving nature of thoracic aortic surgery means long term survival is 
hard to assess. Many centres have reported “learning curves” that show even over a 
ten-year period their mortality rates can be reduced by half. Such advancements are 
not limited to the surgery itself but also to anaesthetic, pre and post-operative 
management of these patients.   
Higgins et al analysed a database containing data on all adult patients who had 
undergone thoracic aortic aneurysm repair in British Columbia which totalled 1960 
patients (Figure 7.8a) 162. Long-term survival was 77.7%, 59.6%, and 44.7% at 5, 10, 
and 15 years, respectively. Survival in the first half of the study was significantly less 
compared to the second half of the study 74.3% (95% CI, 70.6-77.7) versus 60.4% 
(95% CI, 56.6-63.9) respectively. Crawford et al report a similar experience of 605 
patients in 1986 and report a 5-year survival of 60% 163. 
Mount Sinai published long term data in 2010 after aortic arch replacement in 206 
patients between 1999 and 2009 (Figure 7.8b)164. Bischoff et al describe at 6 years, 
75% of patients were still alive, compared with 92% in a matched New York State 
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control population (P < .001). In Japan, Minakawa et al analyzed data from 122 
patients who underwent total aortic arch replacement.  
Overall long-term survival was 80.4% at 5 years and 58.9% at 10 years. Estrera et al 
have published results in 2002 relating to long term survival in aortic arch 
patients165, with long term survival rates 72% at 5 years and 71% at 10 years after 
surgery.  
Cambria et al from Havard Medical School reported their 15-year experience of 337 
TAAA repairs survival rates at 2 and 5 years were 81.2 +/- 3% and 67.2 +/- 5%, 
which in their study is comparable to routine aortic abdominal repair. Fehrenbacher 
et al reviewed 343 patients in their center undergoing TAAA repair or descending 
aortic aneurysm repair and report The 1, 5, and 10-year survival rates were 90%, 
69%, and 54%, respectively. Kouchokos et al looked at survival following TAAA 
using hypothermic circulatory arrest in 243 patients between 1986 and 2012166. 
They reported a 5-year survival rate of 55%.  
Long term survival is hard to assess particularly considering many centers report 
significant reductions in mortality in as short a time as ten years. This can be 
attributed to major advances made in this subspecialty, as well as improved 
anaesthetic, pre and post-operative management.  
The wealth of techniques and devices available for use also add to variables that can 
potentially affect long term survival. However, the amount of data available to assess 
best practice is still in its infancy. It is because of this; thoracic aortic surgery is a 
rapidly advancing subspecialty which is exciting to see what developments are made 
in the near future.  
 
                                                                
165 Estrera AL, Miller CC 3rd, Huynh TT, Porat EE, Safi HJ. Replacement of the ascending and transverse aortic 
arch: determinants of long-term survival. Ann Thorac Surg. 2002;74:1058-64 
166 Kouchoukos NT, Kulik A, Castner CF. Outcomes after thoracoabdominal aortic aneurysm repair using 
hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2013;145:S139-41 
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7.9 Reoperation 
All operations carried out on the thoracic aorta carry a risk of reoperation. It is 
thought that this risk is reduced with the use of beta blockers. Theoretically, with 
reduction of the heart rate the blood pressure is subsequently reduced and in turn 
relieves the pressure that the repair is subjected to from the heart. Beta blockers are 
also thought to reduce the expansion rate of thoracic aortic aneurysms before 
operation; however, the use of beta blockers before and after operation is highly 
debated. To date though, the 2010 guidelines still recommend the use of beta 
blockers lifelong following diagnosis of aneurysm6.  
It is well described that reoperation is significantly increased in patients with Marfan 
syndrome. Geisbuesch et al describe that almost half of the Marfan’s patients who 
undergo surgical repair will require reoperation167. This is well described in centers 
that deal with high volumes of patients and come across a higher number of Marfan 
patients168. In comparison, Osslen et al report analysis of the Swedish national 
healthcare register of patients with thoracic aortic disease, incorporating over 
14000 patients169. In this paper, Osslen describes a reoperation rate of 7.8%.  
However, survival following reoperation in all aetiologies can be described as low. 
The 2010 guidelines describe the risk of death following reoperation as between 2 
and 6%. This is also described in a similar report on Marfan patients by Geisbuesch 
who describe reoperative hospital mortality between 0 to 1.6%167.  
Although more common in Marfan patients’ reoperation is considered a procedure 
that when undertaken electively can be done with a low mortality rate.   
                                                                
167 Geisbuesch S, Schray D, Bischoff MS, Lin HM, Di Luozzo G, Griepp RB. Frequency of reoperations in patients 
with Marfan syndrome. Ann Thorac Surg. 2012;93:1496-501 
168 Lombardi JV, Carpenter JP, Pochettino A, Sonnad SS, Bavaria JE. Thoracoabdominal aortic aneurysm repair 
after prior aortic surgery. J Vasc Surg. 2003;38:1185-90 
169 Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing 
prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 
cases from 1987 to 2002. Circulation. 2006. 12;114:2611-8 
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Modern day thoracic aortic aneurysm surgery is a relatively new specialty, but has 
roots deeply embedded in history. Mortality rates have remained high until the 
advent of specialty has progressed at a rapid rate. In general, mortality is higher in 
patients with a larger extent of aneurysm and those associated with a genetic 
syndrome. However, TAA surgery can be carried out on an elective basis with 
excellent results, in terms of post-operative mortality and reoperation. It is of vital 
importance to understand how operation affects TAAs so we can confer this 
knowledge to the patient and to be able to improve on our current results. Genetic 
syndromes represent a rare subset of patients who suffer from aortic aneurysms and 
they represent an area of medicine for which there remains many unanswered 
questions. Undoubtedly, considering the pace of discoveries and developments 
within this specialty in such a short amount of time, we will see research become 
more focused towards a personalized approach. 
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CHAPTER EIGHT 
8. THE COMPARATOR: WHAT WOULD HAPPEN TO 
PATIENTS IN THE ABSENCE OF SURGERY? 
8.1 A Perspective on the Natural History and Survival in 
Non-Operated Thoracic Aortic Patients 
8.1.1 Introduction 
Thoracic aortic aneurysm (TAA) represents an important component of vascular 
disease due to the particularly lethal nature of this disease138. It is widely accepted 
that without intervention, medical or surgical, TAA carries a poor prognosis. The 
bleak long-term prognosis of TAA underpins the critical importance of 
understanding precisely the natural history of the disease. Such understanding is 
crucial to making precise diagnostic, management, and prevention plans. 
Furthermore, such understanding is imperative, as it needs to be imparted on 
patients, allowing them to make a well-informed decision and provide consent 
regarding their management plan. Knowledge of the natural history is critical when 
planning elective surgery in order to weigh the significant risk of major surgery 
against the risk of aneurysm progression. This is particularly pertinent considering 
that, after surgical aneurysm repair, survival rates comparable to that of a matched 
general population can be achieved50. 
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8.1.2 Methods 
8.1.2.1 Literature Search Strategy 
Electronic searches were performed on PubMed and Cochrane databases with no 
limits placed on dates. Search terms included natural history, thoracic aortic 
aneurysms, aneurysm size, risk factors, survival rates, medical therapy, aneurysm 
growth, dissection, rupture, and mortality. Search terms were charted to MeSH 
terms and combined using Boolean operations, and also used as key words.  
Papers were selected on the basis of title and abstract. The reference lists of selected 
papers were reviewed to identify any relevant papers that might be suitable for 
inclusion in the study. 
 
8.1.2.2 Selection Criteria 
Research papers were not excluded based on study design except for case reports. 
Comments, opinions, or editorials were not included in our selection, so as to 
provide an unbiased view. Papers were selected based on providing primary end 
points of death, rupture, or dissection and/or information regarding aortic 
aneurysm growth. Papers were not excluded based on patient population age.  
 
8.1.3 Survival 
There is unarguable evidence that a diagnosis of TAA carries with it a dismal 
prognosis. This is well described by Crawford 170in an observational study of 
                                                                
170 Crawford S, Denatale R. Thoracoabdominal aortic aneurysm: observations regarding the natural course of 
the disease. Journal of vascular surgery1. 1986;3:578–82. 
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unoperated thoraco-abdominal aneurysm patients published in 1986. This 
observation has since been repeated in much larger cohorts that also include TAAs 
of the ascending and descending portions of the aorta. This is visibly demonstrated 
in Figure 8.1.3, a Kaplan-Meier plot displaying the starkly poor 10-year survival in a 
group of 170 patients from 1984 to 1993 [144], which compares TAAs, thoraco-
abdominal aneurysms, and abdominal aortic aneurysms. A report of 107 patients 
with TAAs attending the Mayo Clinic between 1945 and 1955 describes 1- and 5-
year survival rates of 87% and 50%, respectively145. It is pertinent to consider that 
these observations were reported more than 5 decades ago, and advances in 
conservative management may have improved prognosis, although even this is 
currently debated. The advent of large databases, specifically designed for thoracic 
aortic aneurysms, has allowed for more recent estimates of survival.  
 
Coady et al 78 report overall survival in 230 patients at 1 and 5 years from diagnosis 
to be 85% and 64% respectively, during the period 1985 to 1996. To date, this 
database has now recruited 721 patients and reports that 5-year survival in 
medically treated patients is approximately 66%. 
 
8.1.4 Size of Aneurysm 
TAA size is currently utilized as the primary marker for surgical indication in 
asymptomatic patients. The Yale group was amongst the first to provide evidence-
based data supporting aortic size as a predictor of rupture and mortality171. Their 
initial work encompassed clinical and radiological data of 370 patients with TAAs 
from 1985 to 1997.  
                                                                
171 Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the appropriate size 
criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg. 1997;113:476–91 
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This produced a striking graph depicting how survival significantly decreases over 
time with increasing aortic aneurysm diameter (Figure 8.1.4a.) please note that 
small aneurysms take years to produce mortality: this is a virulent but indolent 
disease. Furthermore, the incidence of rupture and dissection as a function of initial 
aneurysm size increases with greater aneurysm diameter (Figure 8.1.4b.).  
Figure 8.1.4b. Cumulative Incidence of Rupture and/or Dissection displayed as a 
function of initial aortic size.  
 
From Davies et al. 
Statistical analysis reveals odds of rupture or dissection to be 8.84 times greater for 
an aneurysm of 6-6.9 than that of an aneurysm of 4.0-4.9 cm. This paper 
demonstrates how aneurysm size significantly relates to probability of rupture, 
dissection, and death. These data have since been the foundation of current 
recommended guidelines for surgical intervention based on size, and these 
evidence-based paradigms are used internationally6  Other groups as well have 
published results pertaining to aneurysm size, morbidity, and mortality which show 
similar results, strengthening the evidence in favour of using size as a predictor of 
 113 
 
rupture or dissection172,173 . Perko et al.173 report a 5-fold increase in cumulative 
hazard of rupture in aneurysms greater than 6 cm compared to those below this 
threshold, and a 66% probability of rupture.  
Further analysis of size, from the Yale group, reveals a statistically significant 
increase in the incidence of rupture, mortality, and dissection with increasing size.2 
Certainly, there is powerful evidence that initial measured aortic size accurately 
predicts prognosis with regard to mortality, rupture, and dissection. Furthermore, 
documented analysis shows these risks increase with increasing aortic size, and 
maximal risk is realized in aneurysms > 6 cm. Analysis from the Yale database in 
2002, that includes data prospectively collected from 1600 patients, demonstrates 
that even in aneurysms categorized to the smallest diameter (3.5 cm-3.9 cm) have a 
yearly risk of rupture, dissection, or death of 7.2% (Figure 8.1.4c.)174  the majority 
representing dissection rather than rupture. Rupture is reported at a 0% rate in 
aortic sizes of 3.5-4.0 cm. 
However, size as a model of prediction of the natural history is not perfect. It could 
be argued that information derived from large groups and data sets do not 
accurately predict the behaviour of the individual patients. The ideal would be a 
move toward a personalized medical model, however to achieve this, the complete 
understanding of the natural history of the disease is a necessity. 
 
  
                                                                
172 Joyce JW, Fairbairn JF, Kincaid OW, Juergens JL. Aneurysms of the Thoracic Aorta: A Clinical Study with 
Special Reference to Prognosis. Circulation. 1964;29: 176–81. 
173 Perko MJ, Nørgaard M, Herzog TM, Olsen PS, Schroeder TV, Pettersson G. Unoperated aortic aneurysm: A 
survey of 170 patients. Ann Thorac Surg. 1995;59:1204–9 
174 Elefteriades JA. Natural History of Thoracic Aortic Aneurysms : Indications for Surgery, and Surgical 
Versus Nonsurgical Risks. Ann Thorac Surg. 2002;74:S1877–80 
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8.1.5 Location 
The thoracic aorta is a complicated structure that has been shown in mechanical ex 
vivo modelling to display different characteristics on both a macro- and microscopic 
level in different anatomical locations along the aorta 175,176.  
Clinically, aneurysms located in the ascending, descending and thoraco-abdominal 
aorta vary in terms of prevalence, management, and prognosis. Elfeteriades 
differentiates two different diseases, separated at the ligamentum arteriosum33.  
Ascending aortic aneurysms are rarely calcified, almost never contain thrombus, and 
are not as strongly correlated with traditional arteriosclerotic risk factors. On the 
other hand, descending and thoracoabdominal aneurysms are almost invariably 
calcified, contain generous thrombus, and correlate well with traditional 
arteriosclerotic risk factors.  
It is recognized that descending aneurysms are less prevalent than ascending 
aneurysms, but are associated with a poorer prognosis, starkly demonstrated in 
Figure 8.1.5a. 171. The Yale group report 5-year survival in ascending and descending 
aneurysms as 77% and 39% respectively, in a cohort of 153 patients. In this study 
the prevalence of ascending and descending aortic aneurysms were 64% and 24% 
respectively. Other groups report similar figures and a similar difference in survival 
amongst ascending and descending aortic aneurysms 177. The postulated reasons 
why descending aneurysms are more deadly than ascending aneurysms are 
speculative and not conclusively proven.  
 
                                                                
175 Haskett D, Johnson G, Zhou A, Utzinger U, Vande Geest J. Microstructural and biomechanical alterations of 
the human aorta as a function of age and location. Biomech Model Mechanobiol. 2010;9(6):725–36. 
176 Koullias G, Modak R, Tranquilli M, Korkolis DP, Barash P, Elefteriades JA. Mechanical deterioration 
underlies malignant behavior of aneurysmal human ascending aorta. J Thorac Cardiovasc Surg. 2005;130:677–
83.  
177 Clouse WD, Hallett JW, Schaff H V, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved Prognosis of Thoracic 
Aortic Aneurysms. JAMA. 1998;280:1926–9. 
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A further critical observation of aneurysm location regards the mean aortic diameter 
for rupture.  Coady et al report significantly different probabilities in the 
complications from aneurysms with similar aortic sizes, in the ascending and 
descending aorta171 . They describe these sizes where the risk dramatically increases 
as “hinge points”, which are 6 cm and 7 cm in the ascending and descending aorta 
respectively (Figures 8.1.5b and 8.1.5c). This observation has influenced recent 
aortic aneurysm surgical guidelines in so far that it is recommended to operate on 
ascending and descending aneurysms at different sizes6.  
Thus, location of an aortic aneurysm plays a decisive role in the natural history of 
the disease. There is a significant difference in the prognosis of ascending and 
descending aortic aneurysms. Furthermore, the ascending aorta has a susceptibility 
to rupture at smaller diameters in comparison to the descending aorta. However, it 
is pertinent to consider aortic arch involvement, which has not yet been discussed.  
Involvement of the arch is not uncommon in TAA disease, and considering its added 
complexity, it is natural to question whether aortic arch involvement can influence 
the natural history of the disease. This is a question that has not been thoroughly 
investigated, and our future research will address this.  
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8.1.6 Growth Rate 
TAAs growth rate is an important factor to consider in the natural history of the 
disease. Graph 3 demonstrates that with increasing aortic size, the risk of rupture, 
dissection or death is increased. Accurate predictions of aneurysm growth would 
significantly add to the surgeon’s armamentarium to predict the opportune time for 
surgical intervention. Such ability would enhance decision making, which is 
currently based on current indications of aneurysm size6. 
Calculation of growth rate exhibits controversy in the aortic world178. In particular, 
many studies ignore the fact that measurements vary about a mean, and that specific 
aortic measurements may be lower than a prior measurement in the same patient. 
To discard such measurements leads to an erroneously high calculated rate of 
growth. Accordingly, some experts argue that such measurements not be discarded. 
Such issues contribute to much varied reported aneurysm growth rates in different 
centre,238.  
Bonser et al described a mean aneurysm expansion rate of 1.43 mm/year31. This 
expansion rate was significantly different by anatomical location of the aneurysm 
and aneurysm size. The ascending aorta experienced the lowest expansion rate, with 
the highest rate of expansion observed in the mid-portion of the descending. In all 
segments, increasing aortic size was associated with increasing rate of aneurysm 
expansion. Aneurysm growth was not affected by presence of a dissection in this 
study.  
 
 
                                                                
178 Rizzo JA, Coady MA, Elefteriades JA. Procedures for estimating growth rates in thoracic aortic aneurysms. 
Journal of clinical epidemiology. 1998;51:747–54.  
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Nishimura et al in Japan, observed in a case series of 82 TAAs, aneurysms of the arch 
grew at the faster rate than any other location (0.56cm/year, n = 34)179. Other 
quoted rates of aneurysm growth vary between 0.07 to 2.0cm per year, but on 
average are about 1mm per year.178 
 TAA growth rate is often described as indolent, and thus it is recommended that 
asymptomatic TAA that have yet to reach the appropriate size for intervention be 
imaged yearly (or even less frequently). However, it is generally accepted that rapid 
expansion of TAAs is a criterion for surgical intervention. Clinical practice tells us 
that these patients are likely to suffer an acute aortic dissection or rupture, although 
documented evidence behind this is limited though180. 
  
                                                                
179 Hirose Y, Hamada S, Takamiya M, Imakita S, Naito H, Nishimura T. Aortic aneurysms: growth rates 
measured with CT. Radiology. 1992;185:249–52.  
180 Gallo A, Davies RR, Coe MP, Elefteriades JA, Coady MA. Indications, timing, and prognosis of operative 
repair of aortic dissections. Semin Thorac Cardiovasc Surg. 2005;17:224–35.  
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CHAPTER NINE 
 
9. NATIONAL TARIFF REIMBURSEMENT IN 
THORACIC AND THORACOABDOMINAL AORTIC 
ANEURYSM SURGERY 
9.1 Introduction 
Currently thoracic aortic surgery is performed on patients in a few large 
cardiothoracic centres within the UK. The outcomes for patients are improving as 
the skills/competencies within the MDT’s at these centres increases. There is 
however a significant financial risk associated with delivery of this service and that 
relates to the national tariff reimbursing this activity, in that the HRGs are not 
adequately supporting the current range of surgical procedures involved in aortic 
surgery. 
Since the formation of the current set of HRGs, aortic surgical procedures and 
techniques have developed significantly, allowing interventionists (cardiac 
surgeons, vascular surgeons and interventional radiologists) to perform a larger 
variety of operations on the aortic root, ascending thoracic aorta, aortic arch, 
descending thoracic aorta and abdominal aorta and their combinations. These 
operations are currently being performed as either elective or emergency 
procedures, and include replacement of a part of the aorta or a combination of both.  
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Consequently, in large cardiothoracic centres, aortic surgery has become a 
subspecialisation within cardiac surgery requiring interventionists and other staff 
to dedicate the majority, or all, of their time to this sub-speciality, in order to deal 
with the increasing complexity of the procedures.  
9.2 Developing a Homogeneous Coding of Procedures 
OPCS developed a coding system to classify interventions and procedures in health 
care. In UK health care, OPCS Classification of Interventions and Procedures (OPCS-
4) is a procedural classification for the coding of operations, procedures and 
interventions performed during in-patient stays, day case surgery and some out-
patient attendances in the National Health Service (NHS). Responsibility for revision 
and maintenance is currently with NHS Connecting for Health (NHS CFH). Though 
the code structure is different, as a code set, OPCS-4 is comparable to the American 
Medical Association's Current Procedural Terminology. This coding system is 
generally understood by clinicians and the HRGs are developed around OPCS codes. 
On the other hand, quality demand and advances in technology were growing 
requiring additional expenditure.  In addition to the above, global financial crunch 
in 2008 has forced DoH to freeze NHS funding at the levels of 2010 necessitating the 
NHS to find 20 billion pounds recurrently in order to fund expansion and 
development. Suddenly every provider realized that they had to do more for less. 
Traditional financial information and management techniques were not providing 
enough information to effectively understand and manage the behavioural pattern 
of costs.  Monitor that was established in 2004 to authorize and regulate NHS 
foundation trusts, recommended as part of their process of awarding foundation 
status to implement service line reporting (SLR). It is broadly accepted that clinical 
engagement is essential to deliver a healthcare change programmed at all stages 
from developing the vision through to the implementation and embedding of a 
policy13. 
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9.3 Current Issues of Reimbursement 
The complexity of aortic surgery and the current level of clinical expertise required 
to manage this complexity have outstripped the scope of the existing HRGs assigned 
to the area.  
Two particular aspects of complex thoracic aortic surgery which characterise the 
involvement of cardiac surgeons, and underpins their ability to intervene on 
previously inoperable disease, is that of: perfusionists and cardiopulmonary bypass. 
This is not reflected in the tariff of “vascular surgery” performed by vascular 
surgeons without bypass; 
More recently the introduction of highly skilled technicians to support the use of 
Spinal drains /monitoring in the intra and post-operative stages following complex 
thoracic aortic surgery  
New HRGs need to be developed to appropriately reflect the specialist developments 
in this area of cardiothoracic surgery. The revision should also reflect the procedure 
times as well as the perioperative and post-operative needs of the patients. Neither 
of these issues are reflected in existing tariff adding to the significant financial risk 
in those centres delivering the service. The current reimbursement supports 1 
session in the theatre complex, these procedures take much longer. 
One particular aspect of complex thoracic aortic surgery which characterises the 
involvement of cardiac surgeons, and underpins their ability to intervene on 
previously inoperable disease, is that of perfusionists and cardiopulmonary bypass.  
This is not reflected in the tariff of “vascular surgery” performed by vascular 
surgeons without bypass.  A new HRGs need to be created that appropriately reflect 
the specialist developments in this area of cardiothoracic surgery as well as the 
extended length of the procedures and the need to support these patients  
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peri-operatively. The attached table 9.3 highlights the current difficulty within the 
existing HRG structure.  The structure needs to be modified to both reflect the 
specialist nature of the work being done and also to allow for the financial 
reimbursement of these new complex procedures. This paper is the collaborative 
work of the three hospitals that comprise 2 of the UK’s specialist centres currently 
performing the specialist thoracic and thoracic-abdominal aortic surgical 
procedures - Liverpool Heart and Chest Hospital NHS FT and Royal Brompton and 
Harefield NHS FT. We have reviewed and compared the coding of these procedures 
in both Trusts (as presented in the table 9.3), and conducted analysis of HRGs, 
procedure costs and income. 
 
9.4 Proposition of Reimbursement 
Our main observation as evident from table 9.3 is that at present HRGs do not 
capture or reflect the complexity of the specialist aortic surgery (or the pre and post-
operative care), where often multiple surgical procedures occur within one single 
case / episode. Consequently, we would like to propose firstly that the current HRGs 
are split into separate bandings that cover groups of procedures of differing 
complexity; and secondly that some new HRGs are created to cover some of the more 
specialist procedures that do not readily fit within these bandings.  
We also would like to share with the NHS Information Authority team some 
additional observations and suggestions which might help development and fine-
tuning of those HRGs: 
1. We believe that in the next 3-5 years there will be: 
a. Growth in hybrid and endovascular procedures, particularly involving aortic 
arch: this currently is not set up as a separate OPCS group of codes. This will 
require procedures to be carried out in a hybrid theatre environment; 
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b. Increase in stenting of the thoracic aorta: this will require more expensive 
surgical set up (again the hybrid theatre) plus more sophisticated higher value 
devices and stents. This procedure will lead to shorter lengths of stay, and will 
enable a wider range of patients to be operated upon. Again the OPCS codes have 
not been developed for this likely growth area. 
 
2. In addition to the standard list of comorbidities and complications leading to 
increased medical dependency, longer recovery and higher complexity which 
applies to cardiac surgical procedures, specialist aortic surgery has additional 
significant complications that need to be taken account of as HRG modifiers.  
 
3. The main additional complications include: stroke, paraplegia (particularly when 
operating on the descending thoracic aorta), damage to the recurrent laryngeal 
nerve, damage to the lungs (resulting in the need for prolonged ventilation), renal 
impairment, infections (more commonly in the lungs). 
Any of the above complications, as well as the standard complications and 
comorbidities affecting the HRGs in cardiac surgery, will have a very significant 
effect on the complexity of the procedure, speed of recovery and the degree of the 
medical dependency. We believe therefore that each of the HRGs for specialist aortic 
surgery needs to reflect these significant comorbidities and complications.  
Many of the aortic surgical procedures need to be performed with full circulatory 
arrest and body cooling - both will increase the complexity and the duration of the 
surgery. 
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4. For many but not for all of the procedures the theatre time was a good indicator 
of complexity of the procedure, recovery time and the overall cost. The longest 
average theatre times were for the following groups of procedures:  
 Other aortic aneurism procedures (proposed Group C)- 20 hours of theatre 
time per elective patient and 23 hours per emergency procedure on average; 
 Aortic surgery plus other simultaneous procedures such as CABG, MVR, TVR 
etc. (group D) – 15 hours of the theatre time; 
 Root plus AAo+ AVR, hemiarch, total arch, or and ET (Group B2) – 11 hours; 
5. In addition to the theatre time as described above the other indicators of the 
complexity of the procedure and the total cost were: lengths of stay on the ward, 
involvement of second surgeon/anaesthetist.  
The cost of valves is also currently not separately reimbursed so any procedure 
requiring a valve has a higher degree of mismatch between the procedure cost and 
income. 
6. The TAAA (thoracoabdominal aortic aneurysm) is a very complex group of 
patients. They are either managed medically with drugs, use of complex 
endovascular stents of with surgery. The surgical procedure is either done on left 
heart bypass or on cardiopulmonary bypass and circulatory arrest.  They could be 
divided into 2 main groups in terms of extent of their aneurism: either isolated 
thoracic aortic aneurysms or thoracoabominal aortic aneurysms. 
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9.5 Reflection of 2012/2013 Tariff to Existing Cost 
Analysis for Aortic Arch Surgery  
Table 9.5 shows a breakdown of the cost per aortic arch surgery based on tariff 
obtained from the department of health 2012/2013. The table is split in between 
revenue and actual cost, per procedure (hemi arch and total arch). The total median 
revenue for hemi arch is £26,035 whereas for total arch is £27,246. The actual 
median cost per hemi arch is £24,152, and for total arch is £32,515. It is observed 
the median loss and surplus per case were as follow, for hemi arch there is a surplus 
of £1883 where as there is a median loss for total arch of £5269.  
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Table 9.5. Cost Analysis for Aortic Arch Surgery Based On 2012/2013 Tariff 
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CHAPTER TEN 
 
10. VOLUME OUTCOME RELATIONSHIP AND SUB-
SPECIALIZATION IN THORACIC AORTIC ANEURYSM 
AND DISSECTION SURGERY 
10.1 Volume-Outcome Relationships in Thoracic Aortic 
Surgery 
It is generally anticipated that in undertaking any activity the greater the level of 
experience/practice that any individual has access to then the better the 
performance and hence the outcome of the service being performed. In the clinical 
context this volume outcome relationship is a longitudinal process where an 
increase in the volume of a particular procedure performed by a surgeon is 
anticipated to lead to improved patient outcomes (mortality, hospital length of stay 
and survival)181. This is referred to as subspecialised practice and ability to perform 
caseload of interventions that are highly specific-procedure to one organ system.  
In order for subspecialisation to be effective, utilising procedure-specific resources 
must be applicable. This study provided an insight into the specificity of procedure 
volume–outcome associations and its inverse effect in a service that deliver aortic 
                                                                
181 Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume 
on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 
2002;131:6-15 
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aneurysm surgery. It certainly suggests that the benefits of high volume are 
restricted to the specific procedure for specific disease and not for the generality of 
cardiac surgical interventions. There exist different structural components of 
service delivery and care that contributed to this mechanism to be most effective 
and efficiently executed. The most effective component is the uniformity of the 
surgical techniques among the team. The aortic team at Liverpool Heart and Chest 
Hospital efficiently perform aortic aneurysm surgical repair declaring not only 
unique surgical skills but also the application and methods of such skills that have 
been transformed and passed on from trainer to apprentice over multitude of case 
work.  
Hence, the examined effect was proven to be effective and is translated in the 
improvement of clinical outcomes among the examined group performing elective 
and non-elective aortic aneurysm repair.  
Surgical outcomes are increasingly being scrutinised through national audit and 
publication of unadjusted practice and surgical intervention. The volume outcome 
relationship is not unique to aortic surgery and has been the centre of debate and 
discussion amongst other disciplines including arterial and hepato-pancreato-
biliary surgery, have focused on the relation between hospital annual workload 
(volume) and outcome182. Their reported results show that units doing a higher 
volume of work produce significantly better outcomes. This association must be 
acknowledged when services are commissioned, and complex surgery should not be 
performed in low volume centres. However, the aforementioned is not applicable for 
aortic surgery in the UK since there isn’t one centralised centre that only perform 
complex aortic surgery. This point brings us to the current climate of operating on 
aortic aneurysm in the UK, which doesn’t follow selective referral and surely is a mix 
and match between “practice makes perfect” and low volume centres.  
                                                                
182 Boudourakis LD, Wang TS, Roman SA, Desai R, Sosa JA. Evolution of the surgeon-volume, patient-outcome 
relationship. Ann Surg. 2009 Jul;250(1):159-65 
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The low volume centres are often unable to provide evidence of improved outcomes 
not only due to their low case volume but also due to consequent lack of statistical 
power that could potentially provide meaningful analysis.  
Therefore, not only are low volume centres associated with a worse outcome, but 
the appropriateness of performing high risk surgery in such centres is questionable 
because outcomes cannot be assessed in terms of safety,183,184,185. 
Analyses of national data have an important role in planning the delivery of services 
and in comparing peers. Local data must be used to understand individual unit 
outcomes, identify areas for improvement, quality assurance and guide local 
commissioning.  
This has been the initiative followed by the aortic service at Liverpool Heart & Chest 
Hospital. The essence of aortic subspecialisation was a pair between local expertise 
and interest of individual surgeons who wanted to perform aortic surgery. Needless 
to say, the divergent results of poor aortic surgery outcomes were at the centre that 
evoked subspecialisation and mandated the change in the trend of surgical delivery 
at LHCH. The analyses of aortic local data revealed to be of interest to healthcare 
commissioners that supported the scheme of rearrangement of services.  
Aortic aneurysm surgery remains a priority at local institutions but not at national 
levels. National data unfortunately doesn’t follow pursuit and clinical input a high 
enough standard to provide evidence to facilitate service reconfiguration nationally 
is still controversial.  
 
                                                                
183 Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major 
cancer surgery. JAMA 1998;280:1747-1751 
184 Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals: 
estimating potentially avoidable deaths. JAMA 2000;283:1159-1166 
185 Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and 
methodologic critique of the literature. Ann Intern Med 2002;137:511-520 
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The initiative to improve aortic outcomes in elective and non-elective work drove 
the aortic team at Liverpool Heart and Chest to rearrange the service because it 
warranted immediate attention.  This was followed by investigation on how to 
change and rearrange the service promptly.  
 
10.2 Subspecialisation, Centralization and Concentration 
of Aortic Expertise in the UK 
Since the 70s of last century, surgical specialties such as Urology, ENT, and 
orthopaedics have followed pursuit of subspecialty and came off the general surgery 
rooster. This has led to restructure of training programs and final speciality exit 
exams that met the development of alternative tracks or pathways to provide earlier 
or increased exposure to subspecialties.  In current climate there is certainly an 
interest and place for specialization in the different disciplines of surgical practice.  
This serves well the increasing and demanding well-informed public interest that 
frequently seeks advanced and specialized care for their healthcare.  In many 
healthcare systems and in particular in surgery, sub-specialty and subspecialisation 
has developed and evolved from the generality of surgery. For instance, vascular 
surgery that has been widely practiced amongst general surgery has been recently 
devolved from this non-yielding linkage and is now considered as a standalone 
speciality.  
This similarly was the case demonstrated in cardiothoracic surgery and hepato-
pancreatobiliary surgery. Due to the increase in hospital workload and surgeons’ 
case mix of volume and the need to report outcomes, many specialities are seeking 
to centralize their service and care provision. Hence, many healthcare systems have 
embraced a move to specialization in surgical practice and regionalization of 
complex services. Not to forget the patient choice policy that utterly relies on the 
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patient having the freedom of choice of care provider and access to the public 
reporting of outcome data for surgical procedures. In this context, quality became an 
important barometer of service measurable outcomes which in turn is imperative to 
concentrate the expertise of experts in a complex and regional centres.  
The volume and outcome relationship has not been supported by evidence 
extensively in thoracic aortic aneurysm repair. Hence, further research is required 
to define the correlation and existing nature of this relationship. There is no clear 
cut evidence to suggest that certain volume of cases is required for subspecialisation 
to be attained. Many factors have been shown to underlie the relationship between 
volume and outcome in a subspecialised unit. Such could be attributed to specialised 
anaesthetists, along with advanced intensive care facilities, that would support the 
transformation of service not only around the surgeon but also to other disciplines. 
The UK is quite different to USA and Europe with training in Cardiac Surgery 
unlinked to Vascular Surgery. Vascular surgery is a separate specialty with its roots 
in General Surgery with significant involvement in interventional radiology. Thus, 
training and service provision have influenced the development of services for 
intervention on the   thoracoabdominal   aorta.   
Effectively, this has led to a dependence on collaboration between specialties with a 
reliance on cardiac surgeons to provide adjuncts such as cardiopulmonary bypass 
and on vascular surgeons and radiologists to provide guide wire skills and endo- 
vascular options. In some centres, collaboration has flourished to the benefit of 
patients; however, in other centres treatment has been concentrated to one form of 
intervention such as surgery or endovascular approaches. The benefits of this 
arrangement are in the fact that skills are highly developed in respective specialties 
and where collaboration occurs the treatment options are impressive and outcomes 
are comparable with any international centre.  
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There is good evidence from the literature on the relationship between hospital 
volume and mortality risk for many surgical procedures including heart valve 
replacement and aortic root replacement. Recently published data from the US 
Nationwide Inpatient Sample has confirmed that this is also true of acute type A 
aortic dissection.  Hence, the evidence indicates that complex operations performed 
by specialized, high-volume surgeons have better outcome.   
In terms of resource utilisation two contradictory influences affect total hospital 
costs.  If subspecialisation reduces in-hospital mortality, the average length of stay 
could easily increase, since a patient who dies in hospital has their stay curtailed 
while a patient who is sent home does so only when they have a sufficient recovery 
in hospital. On the other hand, higher quality surgery and a reduction in adverse 
events could mean that patients recover more quickly and avoid the very long ICU 
and ward stays that result from complications. The same is also true for the costs of 
the surgeries themselves; a successful surgery may take longer than one in which 
the patient dies before it is completed, but a more experienced surgeon may 
complete the surgery with fewer complications and in less time than one who is less 
skilled186. 
 
10.3 Existing Outcomes and Volume Effect Nationally 
Within the United Kingdom, few cardiac centres have established high volume 
activity in aortic arch and acute type A dissection surgery and even fewer have 
published their outcomes.  
Currently two formally published historical series of open repair exist from 
Birmingham and Bristol aortic services.  
                                                                
186 An Economic Analysis of Aortic Surgery- University of York 
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No meaningful data on open aortic arch repair has been published in The Society for 
Cardiothoracic Surgeons “Blue book” (National Adult Cardiac Surgical Database 
Report).  
The lack of nationwide service provision for open intervention and perceived high 
risk nature of this surgery has led to regional centres developing local endovascular 
strategies to treat these patients principally led by Vascular Surgeons and 
Interventional Radiologists. Several groups have published UK outcomes for 
endovascular intervention on the arch however activity is limited. 
 
10.4 UK Data on Aortic Arch Intervention 
Several sources of data exist, some from pier reviewed journals and some from less 
reliable sources such as government statistics (HES and ONS) and from national 
societies and registries (Society for Cardiothoracic Surgeons and The Vascular 
Society).  
 
10.5 Existing Outcomes and Volume Effect Internationally  
Thoracic aortic aneurysm is a fatal condition with dire prognosis unless surgical 
intervention is performed. Open aneurysm repair has traditionally been associated 
with high operative morbidity and mortality Table 10.5. The International Registry 
of Acute Dissection (IRAD) has published outcomes from multiple centres 
worldwide with an average mortality of 25.1% in 2005187.  
                                                                
187 Tsai TT, Evangelista A, Nienaber C, Sechtem U, Fattori R, Myrmel T, Llovet A, Cooper JV, Fang J, Isselbacher 
E, Eagle KA. Long-term survival in patients presenting with type A aortic dissection: insights from the 
International Registry of Acute Aortic Dissection (IRAD). Circulation 2005; 112:534-535 
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European registries in the United Kingdom and Germany have published operative 
mortalities of 23.1% and 17% respectively188.  
A recent publication from Mount Sinai Medical Centre, using the Nationwide 
Inpatient Sample database of 24,777 patients between 1998 and 2008, showed 
average operative mortality of 21.6%189. Further analysis of this data set 
demonstrated mortality was related to surgeon volume (odd ratio 1.78) and centre 
volume.  
Anderson et al. from the Duke Group published their results pertaining to the impact 
model of multi-disciplinary team approach190. They reported operative mortality 
before multi-disciplinary implementation was 33.9% and was statistically 
equivalent to the expected operative mortality rate of 26.0% (observed-to-expected 
mortality ratio 1.30; p = 0.54). Operative mortality after multi-disciplinary 
implementation fell to 2.8% and was statistically improved compared with the 
expected operative mortality rate of 18.2% (observed-to-expected mortality ratio 
0.15; p = 0.005). Clearly, the United States has established aortic supercentres, which 
have demonstrated clear improvements in the short-term and long-term outcomes 
after surgery on the thoracic aorta. This model of care does not exist in the United 
Kingdom. 
In aortic dissection, 3 patients with acute Type A aortic dissection are diagnosed out 
of every 1,000 emergency department patients presenting with acute back, chest, or 
abdominal pain6. Mortality in untreated patients is estimated at more than 1% per 
hour after onset of symptoms, whereas 30-day survival for appropriately treated 
and early diagnosed patients approaches 80%.  
                                                                
188 Conzelmann LO, Krüger T, Hoffmann I, Rylski B, Easo J, Oezkur M, Kallenbach K, Dapunt O, Karck M, 
Weigang E; Teilnehmenden GERAADA-Zentren. [German Registry for Acute Aortic Dissection Type A 
(GERAADA): initial results]. Herz. 2011 Sep;36(6):513-24 
189 Chikwe J, Cavallaro P, Itagaki S, Seigerman M, Diluozzo G, Adams DH. National outcomes in acute aortic 
dissection: influence of surgeon and institutional volume on operative mortality. Ann Thorac Surg. 2013 
May;95(5):1563-9 
190 Andersen ND, Ganapathi AM, Hanna JM, Williams JB, Gaca JG, Hughes GC. Outcomes of acute type a 
dissection repair before and after implementation of a multidisciplinary thoracic aortic surgery program. J Am 
Coll Cardiol. 2014 May 6;63(17):1796-803 
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The International Registry for Acute Dissection and the Society for Cardiothoracic 
Surgery still publish mortality rates of 26.6% and 25% respectively. The timely 
diagnosis and rapid surgical management of acute Type A aortic dissection are of 
paramount importance for better outcomes and survival. Once diagnosed the key to 
a successful outcome is rapid referral to a cardiac surgery centre and immediate 
surgical intervention. Surgical outcomes are highly variable from centre to centre 
(Table 10.5).  
A significant amount of literature exists relating outcome to volume of activity by 
surgeon and hospital in the related specialty of Vascular Surgery. Outcomes from the 
USA show a very clear relationship between activity and outcome from abdominal 
aortic aneurysm repair and this has led to a major review in the UK and 
rearrangement of services to address these issues and improve outcomes. Bristol 
published an analysis of their results for ascending/arch surgery in 2004. Although 
there was no mortality difference between the two groups there was a significant 
difference in morbidity. 
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CHAPTER ELEVEN 
 
11.  METHODS 
11.1 Ethics in Research 
The Hippocratic oath that clinicians take and build on their code of conduct and 
practice is centered around "First of all, do no harm". This reflects the certain degree 
of norm that allows us to distinguish between the acceptable and the non-acceptable 
which very much coincide with the bylaws of a civil society. The society we serve 
expect an unremitted honesty and confidentiality that bounds the very things that 
we do to the norms accepted by the social welfare of the society and the community 
at large. As such, the development and adherence to the social norms in clinical 
practice is not very different from ethical application on the research front. The 
latter provides a degree of clinical knowledge to be attained that will reciprocate its 
benefit in clinical settings. Accepting to conduct research on clinical grounds and 
providing an ethical approval allows the clinical researcher to avoid commitments 
of error, fabricating, falsifying, or misrepresenting research data interpretability of 
results and perception of proper judgments. Clinical research often involves 
interactivity, cooperation and coordination amongst different researchers of various 
disciplines.  This collaborative work is centered on mutual trust, accountability and 
mutual respect. It’s from these fundamental understanding guidelines reflecting 
authorship, copyright and patenting policies, data sharing policies, and 
confidentiality rules exist in peer review process to protect the intellectual property 
of the research team, individuals and the institution.  
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Liverpool Heart & Chest Hospital, collects important data and demographics about 
patients for the purposes of governance and research output. This is done through 
rigorous steps that the trust maintains including: Accessing health records and 
personal information, Patient confidentiality, Data Protection Act 1998 and 
Caldecott Principles - the principles covering the safe handling of patient identifiable 
information. These steps are overseen by Information Governance to provide and 
reciprocate safe healthcare provision for patients and for provider in equal manner. 
 
For this particular research, I have attained local institutional approval from 
governing committee that scrutinized the application process maintaining that 
patients’ identifiers information is not to be disclosed and confidentiality not to be 
breached. Strictly speaking, the committee commission its decisions according to the 
Caldecott Principles in that the review process of my research data acquisition 
application was to ensure that patient-identifiable information was only shared for 
justified purposes and that only the minimum necessary information was used. The 
Committee also advised on actions to minimize risks to confidentiality. Hence, upon 
a stringent process the aortic data from a wide range of cardiac database was filtered 
that supported the foundation of analysis this thesis was built on. 
 
11.2 Research Bias 
Its endurably valid to state that this thesis is built around the motion of validity of 
the construct and in this case the impact model that the aortic service represent 
not only in aortic surgery nationally but also in the domain of public health sector. 
The motion of validity of the construct provided me as a researcher with available 
resources in a utilitarian manner to conduct an analysis on aortic surgery 
performance knowingly that I belong to that aortic surgery team and service.  
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The performance bias is rather applicable, however, researchers are fallible. We do 
the mistakes and learn from the very experience of that mistake but also we 
provide the solution knowingly that there is no paradigm solution to the 
elimination of error and bias.  In that sense, considerable consideration was needed 
to be able to draw the focus of my intention to analyze a team and their results in a 
rather objective and not subjective manner. This dwells on the facts that as a sceptic 
who genuinely understand the process of skepticism, I have given this step a 
personal and clinical strategy so that its addressed adequately.   
 
The realization of the aforementioned limitation in this thesis enforced the 
commitment and detachment from the aortic service and team. This required 
intense concentration and efforts so that my research attitude and approach 
remain open non-framed in intellectuality and concept. 
 
This helped in allowing me to attain a degree of foreclosure and to source out 
measures to prevent imminent favoritism that will falsify prudent judgment. These 
measures included obsolete detachment from oneself as part of the service and the 
willingness to look at the influences that might cause hind-sight representation of 
the quality of data and reports. A very exact approach was to present the data at 
various national and international platforms allowing for a degree of criticism in 
addition to being rounded by self-criticism in a constructive manner.  
 
For this thesis to qualify as not built on cognitive bias, the utilization of critical 
thinking was paramount.  This confined certain elements that were required in the 
analysis and avoided the prospect of cognitive flaws. Hence, this step aimed to 
promote a sense of logic reasoning and empiricism. I always apply such tactics in 
the field of surgery and I refer for them as prediction and definitive diagnosis. The 
elements of definitive diagnosis are concentrated on utilization of multiple 
resources available that will help in drawing up judgement and conclusion and aim 
to avoid prediction in most settings.   
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Applying such concept in dealing with the confounding bias of me as a researcher 
belonging to a team to be researched allowed for the analysis to be made in 
conjunction with approaches such as positivism and avoiding the effect of the 
interpretivist. As a positivist, the data were compiled, validated thoroughly and 
analyzed using appropriate scientific methodology. This was done avoiding the 
bias of the interpretivist who happens to be in this case the surgeon and the team. 
Having been equipped with this fundamental evaluation allowed the biases to be 
controlled yielding the following thesis. 
 
11.3 Liverpool Heart & Chest Cardiac Database  
The cardiac database at Liverpool Heart and Chest Hospital is used to collect data for 
every cardiac surgical operation performed; pre-operative data is collected about 
the clinical condition of the patient (demographics such as age, gender, Body Mass 
Index, etc along with potential risk factors such as diabetes, renal insufficiency, 
previous cardiac operations, etc), the operation itself (details such as bypass 
strategy, time on bypass, aortic cross-clamp time, graft or valve details and so on), 
and post-operative outcomes (including mortality, morbidity, critical care 
information and any reoperation information). 
 
The cardiac database is recognised as being an integral component of delivering high 
quality clinical information to the trust; it has been specifically designed along with 
input from cardiac consultants to facilitate the process of data entry and data 
reporting. Cardiac data is used within the hospital for measuring and managing 
cardiac surgical performance at a unit and an individual consultant level (using risk 
adjusted models which typically assess expected levels of mortality based on the 
EuroSCORE risk model 1, 2).  
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Liverpool Heart and Chest Hospital participate in the UK National Adult Cardiac 
Surgery Audit via the National Institute for Cardiovascular Outcomes Research 
(NICOR: http://www.ucl.ac.uk/nicor). The aim of this audit is to collect information 
about all major heart operations carried out in the UK and through that to improve 
the quality of patient care. The audit allows appropriate comparison of clinical 
performance with national and international standards, and provides useful data on 
changing trends within the specialty. 
 
11.4 Liverpool Heart and Chest Aortic Database 
Validation 
The initial phase of my thesis mandated that I validate and verify the entry of 
variables into the database. To enhance this method, I followed the literature on the 
validation of database and its appropriate application. Below are the steps that I 
used to validate and verify the aortic arch and acute type A dissection: 
1) Character checks: to ascertain that characters are present across all the data 
set and fields. When a missing record is identified, I utilized the case notes of 
that particular patient to verify and record the missing field. When the case 
notes happened to be off-site i.e. stored in secured storage place, I would 
request the case notes to be delivered back to the hospital for validation. In 
order to facilitate this process, the request case notes were ordered in 
batches. Request were made to Health Record Department at LHCH.  
2) Cardinality & Format: This would allow me to ascertain a valid number of 
related records. Unfortunately, some of the historical data that goes as far as 
1998, contained missing cardinal notes on patient hospital number and 
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identifiers. To overcome this step, I crossed check their other identifiers (date 
of birth, address, hospital admission and discharge and consultant in charge) 
with other possible databases. This would then flag out the patient and the 
patient would then be given an appropriate identifier. Format of entered data 
is also checked and formatted data are all placed in a specified format 
(template) to allow accurate analysis and avoidance of missing data. 
3) Consistency:  This was utilized to ensure data in different fields corresponds 
with patient clinical data, demographics ad characteristic. Incorporated in 
this check was the cross-system consistency check that enabled me to 
compares data in different systems and databases to ensure it is consistent, 
present and usable for analytical basis.  
4) Quality: The data quality is universal and in essence, all relevant clinical data 
were collected prospectively and entered into our local hospital database 
from which, periodically, core datasets were validated and submitted to The 
Society for Cardiothoracic Surgery (UK). In brief, for each operation, a dataset 
was collected that included relevant demographics, indicators of disease 
severity, acuity, comorbidities, and procedural details, along with all relevant 
in-hospital outcomes. Outcomes evaluated for the purposes of this study 
include neurological and renal complications, postoperative ventilation 
times, and both in-hospital and follow-up mortality. This section also 
included spelling and grammar check to look for spelling and grammatical 
errors that could refrain and limit the analysis and its accuracy. 
5) Logic check was also followed to attain a logical input in data entered that 
should correspond with the surgical intervention on patient. This would 
allow to avert duplication and conflicting data.  
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11.5 National Institute of Cardiovascular Outcomes 
Research Database 
Prospectively collected data were extracted from the National Institute for 
Cardiovascular Outcomes Research (NICOR) National Adult Cardiac Surgery Audit 
(NACSA) registry (version 4.1.2) on 20th November 2014 for all adult cardiac 
surgery procedures performed in the UK. As described elsewhere, reproducible 
cleaning algorithms were applied to the database191. Briefly, duplicate records and 
non-adult cardiac surgery entries [including transcatheter aortic valve 
implantations (TAVIs)] were removed, transcriptional discrepancies harmonised 
and clinical and temporal conflicts and extreme values corrected or removed. Data 
summaries are returned regularly to each unit for local validation as part of the 
NACSA in the UK. 
 
11.6 Variables Documented and Definitions 
11.6.1 Variables 
Preoperative variables 
a) Current smoker: Smoking within six weeks of the operation. 
b) Diabetes: Diagnosis of diet, tablet or insulin controlled diabetes. 
                                                                
191 Hickey GL, Grant SW, Cosgriff R, Dimarakis I, Pagano D, Kappetein AP et al. Clinical registries: governance, 
management, analysis and applications.  Eur J Cardiothorac Surg 2013;44:605–14 
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c) Hypercholesterolemia: Diagnosed with cholesterol over 5.0 mmol/L or on 
drug treatment. 
d) Hypertension: Diagnosed with hypertension (blood pressure > 139/89 
mmHg) or on antihypertensive treatment. 
e) Cerebrovascular disease: The presence of carotid artery disease, chronic 
neurological injury, or a history of transient ischemic attack (TIA) or 
cerebrovascular accident (CVA). 
f) Respiratory disease: Diagnosed with a respiratory disease (i.e., asthma, 
emphysema, bronchiectasis, chronic obstructive pulmonary disease), on 
treatment (i.e., inhalers) or impaired pulmonary function tests. 
g) Peripheral vascular disease: Diagnosed with peripheral vascular disease on 
the basis of symptoms (claudication), previous intervention, or evidence of 
stenotic disease. 
h) Renal dysfunction: The definition of renal failure has changed over time. Over 
the last 3 years we have recorded eGFR (estimated glomerular filtration rate) 
as well as the presence of established renal failure and dialysis. An eGFR < 89 
mL/min/1.73 m2 is considered as renal dysfunction (Chronic Kidney 
Disease). Prior to this, we recorded renal dysfunction as a creatinine value 
greater than 200 μmol/L and as established renal failure with dialysis. 
i) Previous cardiac surgery: Previous sternotomy for any reason. 
 
Postoperative variables 
 Intubation time (hours): Presence of endotracheal tube with supported 
respiratory effort. 
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 Intensive Therapy Unit (ITU) stay (days): Care within our Critical Care Area 
which includes 1:1 nursing care as “intensive care” or 2:1 nursing as “high 
dependency care.” 
 Postoperative stay (days): Number of days within the hospital setting from the 
day after surgery. 
 Acute renal failure: Postoperative requirement for hemofiltration. 
 Deep sternal wound infection: This is defined as wound dehiscence to the 
sternal plate with a positive wound culture. It excludes simple superficial 
wound infections and aseptic mechanical dehiscence. 
 Reexploration for bleeding: This is defined as resternotomy and exploration 
in the acute postoperative period for bleeding and/or evidence of 
tamponade. 
All stroke: 
 CVA, diagnosed clinically or on imaging. 
 TIA, diagnosed as clinical evidence of neurological impairment with return of 
function within 24 hours. 
 Confusion: Acute confusional state diagnosed clinically. 
 
11.6.2 Surgical Definitions 
1) Incisions. All elective operations were performed through a midline and full 
sternotomy. In a very small number of emergencies we used either a 
clamshellor lateral extension to a sternotomy incision. 
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2) Cannulation options. A myriad of cannulation techniques were used 
depending on the anatomy, pathology and available imaging. 
3) Arterial cannulation. Arterial cannulation of either the ascending aorta, arch 
of the aorta, femoral artery, or axillary arteries was performed. In a limited 
number of emergency operations, the left ventricular apex was cannulated. 
All cannulations via the axillary artery were through an anastomosed 8 mm 
graft. 
4) Venous cannulation. Venous drainage was achieved via the right atrial 
appendage, bicaval cannulation, main pulmonary artery, or femoral vein. 
5) Venting. Venting of the heart was performed either through the right superior 
pulmonary vein, main pulmonary artery, or left ventricle (LV) apex via a mini 
left thoracotomy. 
6) Conduct of cardiopulmonary bypass. Cardiopulmonary bypass was initiated 
following full heparinization (300 U/kg) to an activated clotting time > 450, 
and during active cooling, alpha stat was maintained. Warming was 
commenced ensuring no excessive differential between peripheral and core 
temperatures. 
7) Cardioplegia. Intermittent cold blood cardioplegia was administered 
anterogradely at induction and retrogradely during maintenance. 
Anterograde cardioplegia was supplemented into the right coronary system 
throughout cases where possible. A “hot shot” of warm blood cardioplegia 
was administered prior to reflow. 
8) Monitoring. It is our practice to monitor a radial and femoral arterial trace as 
well as central venous cannulation and central venous pressure. A 
nasopharyngeal and bladder/rectal catheter are used to monitor 
temperature. Near infrared spectroscopy (NIRS) was employed beginning in 
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2008. Transeosophageal echocardiography is routinely utilized unless 
contraindicated. 
9) Brain protection. Our approach to neuroprotection is centered around deep 
hypothermic circulatory arrest; however, adjuncts include CO2 flooding of 
operative field, packing of head in ice, phenobarbitone prior to circulatory 
arrest, and supplementary cerebral perfusion as indicated below: 
 Anterograde cerebral perfusion. This is administered in total arch 
surgery. Cold blood is administered via the head and neck vessels 
directly or via clamping of the brachiocephalic artery and perfusing 
the axillary artery. The left subclavian artery is temporarily occluded 
or may be perfused if NIRS is suboptimal. Target flows of 10 
mL/kg/min are used; however, this is modified according to perfusion 
pressure (target mean, 50-60 mm Hg) and NIRS response. 
 Retrograde cerebral perfusion. This technique is used for simple 
hemiarch surgery or acute pathologies where tissue quality of arch 
vessels may be poor. The superior vena cava (SVC) is cannulated with 
a 15 French cannula and a small clamp placed between SVC and right 
atrial appendage. Flow is commenced at 10 mL/kg/min aiming for a 
central venous pressure (CVP) between 25 and 50 mm Hg and an 
acceptable NIRS reading. 
10) Temperature: Our core (urinary or rectal) target temperatures for 
hemiarch and total arch surgery have evolved over the time of the study. 
During early periods, target temperature for all procedures was less than 
18°C (deep hypothermia). Currently, our typical target for an elective 
hemiarch is 25°C (moderate hypothermia), elective total arch is 20°C 
(moderate hypothermia), and for emergency cases, 20°C. Rewarming was 
aided with external warmers. 
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11.7 Costing Definitions 
1. Cost driver: Cost drivers are the structural determinants of the cost of an 
activity, reflecting any linkages or interrelationships that affect it; therefore, 
we could assume that the cost drivers determine the cost behaviour within 
the activities, reflecting the links that these have with other activities and 
relationships that affect them.  
 
2. Cost pool: A cost pool is a group of individual costs that is allocated to cost 
objectives (like patient episode) using a single cost driver. For example, 
building rent, utilities cost, and janitorial services may be in the same cost 
pool because all are allocated on the basis of square meters of space occupied.  
 
3. Tracing: Direct tracing requires that, by physical observations, a cost can 
easily and accurately be related to a cost object. 
 
 
11.8  Costing Methodology  
11.8.1 Estimation of Costs for Pre-SLR Period Patients 
Although data on clinical outcomes were available for all cases between 1999 and 
the present day, only on the more recent cases could resource use be identified 
through PLICS, because SLR data was available for only from 2009. Costs for the 
cases prior to 2009 were estimated.  
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The method of cost estimation was as follows. Firstly, some preliminary analyses 
were undertaken to determine the most significant drivers of cost. This required the 
collaboration of both clinicians and members of the finance department to 
determine which aspects of the treatment and perioperative care drive cost. Factors 
like Cutting time (the length of time in surgery), intensive care unit (ICU) length of 
stay, and ward length of stay were found to be the major drivers of cost. Cost lines 
which are impacted by these factors are considered as relevant costs for this study. 
Cost lines like cost of valves and high cost antibiotic drugs will remain the same on 
either side of sub specialisation (when inflation adjusted) and hence are considered 
irrelevant costs for this study. All cost analysis in this study is based only on the 
relevant costs. Although the cardiac database at LHCH is invaluable for analysis of 
clinical outcomes, this prospectively collected data was not designed to support 
economic analysis. Hence we added costs to the available time values found in the 
cardiac database for each episode based on the current rates derived from PLICS 
from 2009 when the PLICS data is readily available. This process ensured all rates in 
this study are inflation adjusted. 
Costs of primary and secondary measures as defined above will be sought and 
compared for the two groups.  Using PLICS cost data from Liverpool Heart and Chest 
Hospital's service line reporting (SLR) system, enabling detailed micro-costing that 
is far superior to the use of NHS reference costs. SLR allows the trust to analyze cost 
and profitability at patient level of each service it provides rather than just overall 
profitability. Costs of resources that can be directly attributed to particular patient 
episode are ‘traced’, that is, they are allocated to the episode without any treatment 
or manipulation. Such costs include the likes of prostheses and consumables.  
The use of consumables dispensing and supply tracking technologies assigns costs 
on the fly and allows precise tracing of resource use to the patient and episode on 
which they were used.  
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This applies to drugs, and in surgery, where surgical consumables, valves, 
prostheses, anaesthetic drugs etc. are all automatically attributed to the patient and 
procedure as they are used. Staff time is allocated with reference to employment 
contracts and the proportion of the time that is to be dedicated to each duty. That is, 
the cost of a particular surgeon for a given procedure is a function of his salary, the 
proportion of his contract he is to operate, and the time the procedure takes. 
Similarly, the ward costs of clinician can be allocated in the same way. These costs 
are then allocated based on the observed values of time for each patient episode. 
Indirect costs such as utilities and trust overheads are allocated/absorbed – 
although some of them are not directly attributable to any particular episode 
/service lines, they are divided up and shared amongst all episodes. 
 
11.8.2 Estimation of Costs for Aortic Arch Aneurysm and Acute 
Type A Dissection Patients 
The method of cost estimation is as follows. Firstly, some preliminary analyses will 
be undertaken to determine the most significant drivers of cost. Factors like cutting 
time (the length of time in surgery), intensive care unit (ICU) length of stay, and ward 
length of stay were previously found from parallel and confounding research to be 
the major drivers of cost. Cost lines which are impacted by these factors are 
considered as relevant costs for this study. Relevant cost is the cost which is 
impacted by the quality of service provided per unit of time spent in the theatre, 
critical care and ward. Actual data of times spent in these three areas recorded and 
the current rates per unit of time is applied on all cases to arrive at the comparable 
cost adjusted for inflation.  
All cost analysis in this study is based only on the relevant costs. Although the cardiac 
database at LHCH is invaluable for analysis of clinical outcomes, this prospectively 
collected data was not designed to support economic analysis.  
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Hence we added costs to the available time values found in the cardiac database for 
each episode based on the current rates derived from PLICS from 2009 when the 
PLICS data is readily available.   
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CHAPTER TWELVE 
 
12. RESULTS 
12.1 Development and Validation of Elective and non-
Elective Risk Prediction Models for in-Hospital Mortality in 
Proximal Aortic Surgery Using the National Institute for 
Cardiovascular Outcomes Research (NICOR) Database 
The number of patients undergoing aortic surgery has increased greatly since the 
1990’s192. As the discipline has developed from a subsection of cardiovascular 
surgery to an established speciality with many individualised techniques and 
treatment models 193,194,195, there has naturally been a corresponding focus on 
clinical outcomes in both the overall patient group and within the individualised 
                                                                
192 Czerny M, Bachet J, Bavaria J, Bonser RS,  Borger MA, De Paulis R et al. The future of aortic surgery in 
Europe European Journal of Cardio-Thoracic Surgery. 2013; 43; 226–230 
193 Borst HG, Heinemann MK, Stone CD. Surgical Treatment of Aortic Dissection, 1st edn. Churchill 
Livingstone, 1995 
194 Bachet J, Guilmet D, Goudot B, Termignon JL, Teodori G, Dreyfus G et al. Cold cerebroplegia. A new 
technique of cerebral protection during operations on the transverse aortic arch. J Thorac Cardiovasc Surg 
1991; 102 : 85–93 
195 Dubost C. The first successful resection of an aneurysm of the abdominal aorta followed by re-
establishment of continuity using a preserved human arterial graft. Ann Vasc Surg 1986; 1 : 147–49. 
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pathologies and treatments that are available. Several recent publications continue 
to demonstrate this important approach to surgical quality196,197,198,199.  
Meanwhile, the application of statistical models to produce risk adjusted outcomes 
has become an established practice in many healthcare disciplines200201202203, 
especially cardiac surgery.  These models are typically used to inform patients, to 
give clinical assurance and to allow benchmark comparisons between institutions. 
Several risk adjustment models have been published which would allow risk 
prediction in certain types of aortic patient, or in patients undergoing vascular 
surgery204,205,206,207,208,209,210. 
                                                                
196 Hughes GC, Zhao Y, Rankin JS, Scarborough JE, O'Brien S, Bavaria JE, et al. Effects of institutional volumes 
on operative outcomes for aortic root replacement in North America. J Thorac Cardiovasc Surg. 2013 
Jan;145(1):166-70 
197 Chikwe J, Cavallaro P, Itagaki S, Seigerman M, Diluozzo G, Adams DH. National outcomes in acute aortic 
dissection: influence of surgeon and institutional volume on operative mortality. 
Ann Thorac Surg. 2013 May;95(5):1563-9 
198 Kilic A, Tang R, Whitson BA, Sirak JH, Sai-Sudhakar CB, Crestanello J, Higgins RS. Outcomes in the current 
surgical era following operative repair of acute Type A aortic dissection in the elderly: a single-institutional 
experience. Interact Cardiovasc Thorac Surg. 2013 Jul;17(1):104-9 
199 Canaud L, Karthikesalingam A, Jackson D, Cresswell L, Cliff M, Markar SS, et al Clinical outcomes of single 
versus staged hybrid repair for thoracoabdominal aortic aneurysm. J Vasc Surg. 2013 Nov;58(5):1192-200 
200 Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, et al A risk model for secondary cytoreductive 
surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012  
Feb;19(2):597-604 
201 Teguh DN, Levendag PC, Ghidey W, van Montfort K, Kwa SL. Risk model and nomogram for dysphagia and 
xerostomia prediction in head and neck cancer patients treated by radiotherapy and/or chemotherapy. 
Dysphagia. 2013 Sep;28(3):388-94 
202 Shahian DM, Edwards FH The Society of Thoracic Surgeons 2008 Cardiac Surgery Risk Models: 
Introduction.  Ann Thorac Surg 2009;88:1 
203 Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac 
operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999 Jul;16(1):9-13 
204 Mehta RH, Suzuki T, Hagan PG, Bossone E, Gilon D, Llovet A, et al. Predicting death in Patients with Acute 
Type A Aortic Dissection. Circulation. 2002 Jan 15;105(2):200-6 
205 Giles KA, Schermerhorn ML, O'Malley AJ, Cotterill P, Jhaveri A, Pomposelli FB, et al Risk prediction for 
perioperative mortality of endovascular vs open repair of abdominal aortic aneurysms using the Medicare 
population. J Vasc Surg. 2009 Aug;50(2):256-62. 
206 Choke E, Lee K, McCarthy M, Nasim A, Naylor AR, Bown M, et al. Risk models for mortality following 
elective open and endovascular abdominal aortic aneurysm repair: a single institution experience. Eur J Vasc 
Endovasc Surg. 2012 Dec;44(6):549-54 
207 Grant SW, Hickey GL, Grayson AD, Mitchell DC, McCollum CN. National risk prediction model for elective 
abdominal aortic aneurysm repair. Br J Surg. 2013 Apr;100(5):645-53 
208 Bala Ramanan B, Gupta PK, Sundaram A, Gupta H, Johanning JM, Lynch TG, et al Development of a risk 
index for prediction of mortality after open aortic aneurysm repair Journal of Vascular Surgery; 2013; 58(4); 
871–878 
209 Williams JB, Peterson ED, Zhao Y, O’Brien SM, Andersen ND, Miller DC, Chen EP, Hughes GC  Contemporary 
results for proximal aortic replacement in North America. J Am Coll Cardiol. (2012) 60:1156–1162 
210 Kunihara T, Aicher D, Asano M, Takahashi H, Heimann D, Sata F & Schäfers HJ Risk factors for prophylactic 
proximal aortic replacement in the current era. Clinical Research in Cardiology (2014), 103(6), 431-440 
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We conducted a retrospective analysis of aortic surgery data submitted to the 
National Institute for Cardiovascular Outcomes Research (NICOR) National Adult 
Cardiac Surgery Audit (NACSA) database by all cardiac centres in the UK. The 
primary aim of the study was to develop and validate a risk prediction model for 
post-operative mortality following open surgery on the proximal aorta (i.e. root, 
ascending or arch aortic segments). 
 
12.1.1 NICOR Database.  
For this study, records were included that met the following criteria: operation on 
one or more of the root, ascending or arch aortic segments that were performed in 
England and Wales between 1 April 2007 and 31 March 2013. As only non-
identifiable patient data were used for this research, formal ethical approval was not 
required. This project was approved by the NICOR research board.  
 
12.1.2 Study and Outcome Variables 
For each operation, data are recorded on patient characteristics, comorbidities, 
surgical team, intraoperative factors and postoperative outcomes. For this study, we 
extracted data on patient age at the time of operation (years), gender, body mass 
index [BMI, defined as weight (kg) / height2 (m2)], Canadian Cardiovascular Society 
(CCS) angina class, dyspnoea (New York Heart Association grade), recent myocardial 
infarction (defined as within 90 days of surgery), history of cardiac procedures, 
diabetes (diet- or insulin controlled), smoking status, history of hypertension, serum 
creatinine >200 μmol/l, history of renal dysfunction, history of pulmonary disease, 
history of neurological dysfunction, extracardiac arteriopathy, preoperative heart 
rhythm (classified for the purposes of this study as sinus rhythm or non-sinus 
rhythm. Non-sinus rhythm includes: atrial fibrillation, atrial flutter, complete heart 
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block, presence of a pacing device, ventricular fibrillation, ventricular tachycardia or 
any other abnormal rhythm), left ventricular ejection fraction (classified as <30, 30–
50 and >50%), use of preoperative IV nitrates, IV inotropes prior to anaesthesia, 
preoperative ventilation, pre-operative cardiogenic shock, operative urgency, 
concomitant CABG and valve procedures. Further details of variable definitions are 
available at http://www.ucl.ac.uk/nicor/audits/adultcardiac/datasets.  
Missing data were assumed to be absent for categorical variables or replaced with 
the mean value for continuous variables. Ejection fraction was the categorical 
variable with the highest incidence of missing data (3.5%). The proportions of 
missing data for continuous variables were: age, 0%; BMI, 3.6%; cardiopulmonary 
bypass time, 2.3%; and aortic cross clamp time = 2.9%. The outcome for this study 
was in-hospital mortality, defined as death due to any cause during admission to the 
operating hospital for cardiac surgery.  
Records were excluded from the analysis if in-hospital mortality status was missing.  
Data on cause of death were unavailable. 
 
12.1.3 Developing the Model 
Continuous variables were dichotomised where appropriate; a left ventricular 
ejection fraction of >50% was categorised as good, 30-50% was categorised as 
moderate and <30% was categorised as poor. Age at operation, body mass index 
(BMI) and operative times were retained as continuous variables. Pre-operative 
heart rhythm was dichotomised into sinus rhythm (normal) and non-sinus rhythm 
as detailed above. Similarly, the pathology of the aortic segments was dichotomised 
into aneurysmal or normal pathologies and other pathologies which included: 
chronic dissection, acute dissection, trauma, coarctation, penetrating atheromatous 
ulcer, pseudoaneurysm, intramural haematoma and “other” pathology. Ordinal 
variables were dichotomised as follows: NYHA category, which classifies heart 
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failure, was grouped into no or mild symptoms (Class I and II) and moderate or 
severe symptoms (Class III and IV) and the CCS angina grade into stable (Class I to 
III) and unstable (Class IV). The data were split into an elective group and a non-
elective group. The non-elective group included urgent, emergency and salvage 
surgery. Separate multiple logistic regression models were fitted for elective and 
non-elective surgery using the backwards elimination procedure for variable 
selection; all preoperative patient variables listed above were offered to the analysis.  
 
12.1.4 Assessing Model Performance 
Model performance was assessed using bootstrap methodology, the complete 
datasets were sampled from repeatedly and the final multivariate logistic regression 
model was refit 100 times. Model performance summary statistics were calculated 
for each iteration with the average across all the bootstrapped samples then 
calculated. Model calibration was assessed in three ways. Firstly, a Hosmer-
Lemeshow goodness-of-fit test where the overall differences between the observed 
mortality rate and the mortality rate predicted by the risk model are evaluated using 
a 2 test211.  
The second method involved visual inspection of a calibration plot. The calibration 
plot shows the mean predicted probability of outcome against the observed 
proportion of outcomes for ten equally sized groups based on the ranked predicted 
risks calculated by the models. Thirdly, the datasets were divided into three groups 
based on their predicted risk of in-hospital death (low, medium and high risk). For 
each group the observed mortality rate was compared with the mortality rate 
predicted by the risk model and goodness-of-fit was evaluated using a 2 test. Model 
discrimination was evaluated by calculating the ROC curve, which is summarised by 
                                                                
211 Hosmer D, Lemeshow S. Applied Logistic Regression.  John Wiley: New York, 1989 
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the area under the curve (AUC)212. In all cases, P < 0.05 was considered significant. 
All statistical analyses were carried out using SAS software for Windows, version 9.3 
(SAS Institute Inc., Cary, NC, USA).  
 
12.1.5 Patient Characteristics 
In total 8641 records were identified as meeting the study criteria. Two records 
were missing in-hospital mortality status and were excluded, leaving 8639 records 
for analysis. Over the six year study period 44 hospitals contributed data. The largest 
contribution from a single centre was 638 cases and the smallest contribution from 
a single centre was two. A summary of patient characteristics is shown in Table 
12.1.5. There were 775 in-hospital deaths giving an in-hospital mortality rate of 
8.97% (95% CI = 8.35% to 9.63%). There were 5463 elective patients identified with 
250 deaths (4.6% (95% CI = 4.0% to 5.2%)) and 3176 non-elective patients with 525 
deaths (16.5% (95% CI = 15.3% to 17.9%)). 
 
12.1.6 Univariable and Multivariable Analyses 
Risk factors for in-hospital mortality based on univariate analysis are shown in 
Tables 12.1.5 and 12.1.6a. The final risk prediction models with estimated model 
coefficients, odds ratios, approximate 95% CI, corresponding P values, and the 
model equation itself are shown in Tables 12.1.6b and 12.1.6c. 
  
                                                                
212 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) 
curve. Radiology 1982; 143: 29–36 
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12.1.7 Overall Performance of the Risk Models 
Both models demonstrated good calibration according to the Hosmer–Lemeshow χ2 
(elective model P = 0.427 and non-elective model P = 0.616. The calibration plots for 
both models are shown in Figure 12.1.7. and demonstrated good calibration for both 
models. The low, medium and high risk group assessments also supported the 
assumption of satisfactory calibration for both models as shown in Table 12.1.7. The 
AUC for the elective model was 0.805 (95% CI: 0.802 to 0.807), for the non-elective 
model the AUC was 0.761 (95% CI: 0.761 to 0.765) with bias-corrected values 
calculated using the bootstrap method of 0.795 and 0.756, respectively, indicating 
good discrimination 
The risk models share five common risk factors: age, additional CABG surgery, poor 
ejection fraction, preoperative arrhythmia and previous cardiac surgery. These 
factors will be familiar to healthcare professionals involved in the care of patients 
with cardiac disease and are well represented in previously developed risk models 
213,214,215,21624, 26, 27, 28. It is no surprise that older, sicker patients with more 
complicated presentation are at an increased risk of in-hospital mortality. Among 
the elective cohort, the remaining factors of lung disease, female gender, NYHA class, 
current smoker, neurological disease, triple vessel disease, surgery on the aortic 
arch and more complicated pathologies are similarly understandable contributors 
to increased patient risk. Within the non-elective model: renal disease, peripheral 
vascular disease, cardiogenic shock and increasingly critical presenting priority are 
all intuitively reasonable inclusions. 
  
                                                                
213 Huijskes RV, Wesselink RM, Noyez L, Rosseel PM, Klok T, van Straten BH, Nesselaarg A and  Tijssen JG. 
Predictive models for thoracic aorta surgery. Is the Euroscore the optimal risk model in the Netherlands? 
Interactive cardiovascular and thoracic surgery 4(6) (2005): 538-542. 
214 Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR and Lockowandt U. Euroscore II. 
European Journal of Cardio-Thoracic Surgery 41 (2012) 1–12 
215 Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E et al. Risk factors and outcome in 
European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J 
Cardiothorac Surg 1999;15:816–22; discussion 22–3 
216 Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac 
operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9–13. 
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12.2 National Outcomes in Acute Type A Dissection 
This section aims to report the national UK outcomes in the operated ATAD patients’ 
population and explore the relationship between adjusted in-hospital mortality for 
ATAD repair and case volume at both a hospital and surgeon level. 
 
12.2.1 NICOR Database 
For this section, records were included that corresponded to the following criteria: 
operation on one or more of the root, ascending or arch aortic segments with a 
recorded pathology of Acute Dissection that were performed in England and Wales 
between 1st April 2007 and 31st March 2013. Records missing responsible 
consultant cardiac surgeon data (recorded in the form of General Medical Council 
registration number) or vital status at discharge were excluded. 
 
12.2.2 Study and Outcome Variables 
For each operation, data are recorded on patient characteristics, comorbidities, 
surgical team, intraoperative factors and postoperative outcomes. For this study, 
we extracted data on patient age at the time of operation (years), gender, body 
mass index [BMI, defined as weight (kg) / height2 (m2)], Canadian Cardiovascular 
Society (CCS) angina class, dyspnoea (dichotomised as New York Heart Association 
(NYHA) grade < III and NYHA grade ≥ III), recent myocardial infarction (defined as 
within 90 days of surgery), history of major cardiac surgery, diabetes (diet- or 
insulin controlled), smoking status, history of hypertension, serum creatinine >200 
μmol/l, history of renal dysfunction, history of pulmonary disease, history of 
neurological dysfunction, extracardiac arteriopathy, preoperative heart rhythm, 
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left ventricular ejection fraction (classified as <30, 30–50 and >50%), use of 
preoperative IV nitrates, IV inotropes prior to anaesthesia, preoperative 
ventilation, pre-operative cardiogenic shock, operative urgency, concomitant CABG 
and valve procedures, cardiopulmonary bypass time, aortic cross-clamp time and 
circulatory arrest time. Operative times were dichotomised using the third quartile 
as an upper boundary, rounded to the nearest five minutes. Administrative data 
were also extracted including: patient admission, procedure and discharge dates, 
responsible consultant cardiac surgeon and anonymised hospital identifier.  
The outcome for this study was in-hospital mortality, defined as death due to any 
cause during admission to the base hospital for cardiac surgery. Follow-up data up 
until the point of discharge was collected by the NACSA clinical registry system. Data 
on cause of death were unavailable.  
 
12.2.3 Statistical Analysis 
Categorical and dichotomous variables are summarized as absolute number and 
percentage. Non-normally distributed continuous data are summarized as median 
and inter-quartile range (IQR). The univariate associations of each variable to in-
hospital mortality are reported as odds ratios with 95% confidence intervals (CIs) 
along with their respective p-values. Due to the relatively low number of missing 
data items for the majority of the variables, missing data was assumed not to be 
present for binary variables and imputed with the mean value for continuous 
variables before calculations were performed. Where categorical comparisons are 
made, the chi-squared test was used to obtain p-values. Scatterplots were generated 
to assess the relationship between observed in-hospital mortality and volume, and 
locally weighted scatterplot smoothing (LOWESS) curves for visual inspection were 
included.  
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12.2.4 Characteristics of the Study Population 
1632 patients were identified from the NACSA database as having an aortic 
dissection during the time period. After excluding patients who had surgery on the 
descending and thoracoabdominal segments of the aorta, and records that lacked 
discharge or responsible clinician data, a total of 1386 patients were included in the 
study. These patients were admitted to 33 different hospitals throughout England 
and Wales and were under the care of by 218 different consultant cardiac surgeons. 
During this time period, the mean number of acute dissection operations performed 
by a hospital was 42, with 21 out of 33 (63.6%) performing fewer than 40 
operations. The minimum hospital activity was 8 and the maximum activity was 103. 
The average number of operations performed by a surgeon was 6.4, with 171 of 218 
surgeons (78.4%) performing fewer than 10 operations. The minimum surgeon 
activity was 1 (34 (15.6%) of surgeons performed a single acute dissection 
operation) and the maximum activity was 32.  
The median age of the patient cohort was 63 (Q1 = 52, Q3 = 72), 446 (32.2%) were 
female, 1362 (98.3%) of patients were recorded as being non-elective priority, with 
97 (7.0%) being salvage operations. 463 (33.4%) underwent a procedure that 
involved the aortic root segment, 1202 (86.7%) the ascending aorta segment and 
176 (12.7%) the aortic arch segment. 569 (41.1%) had a concomitant cardiac valve 
operation and 181 (13.1%) a concomitant CABG. The median cardiopulmonary 
bypass time was 197 (Q1 = 152, Q3 = 257) minutes.  Patient pre-operative and 
operative characteristics are shown in Tables 12.2.4a and 12.2.4b. 
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12.2.5 Univariate Predictors of in-Hospital Mortality by Patient-
Level Factors and Clinical Factors 
Unadjusted associations between patient-level characteristics and in-hospital 
mortality from univariate logistic regression analyses are shown in Tables 12.2.4a 
and 12.2.4b. The following pre-operative characteristics were found to be associated 
with in-hospital mortality: age, NYHA class ≥ III, previous MI, recent MI, previous 
cardiac surgery, preoperative creatinine > 200 μmol/L, history of renal dysfunction, 
peripheral vascular disease, pre-operative non-sinus heart rhythm, impaired left 
ventricular ejection fraction, pre-operative IV inotropes, pre-operative ventilation 
and pre-operative cardiogenic shock. The following operative characteristics were 
found to be similarly associated with in-hospital mortality: salvage operation, 
concomitant CABG operation, cardiopulmonary bypass time, circulatory arrest time 
and operating consultant having fewer than 10 acute dissections in the dataset. 
 
12.2.6 Patient Outcomes 
In-hospital mortality occurred in 246 (17.7%) patients and 165 (11.9%) suffered a 
post-operative stroke. 7 (0.5%) patients suffered paraparesis and 3 (0.2%) 
paraplegia. 198 (14.3%) patients required post-operative dialysis. 236 (17.0%) 
required a return to theatre during their hospital stay with the majority of these 
being for bleeding (n=198; 14.3%). Outcome data is presented in Table 12.2.6. 
Figure 12.2.6a. and 12.2.6b show the relationship between acute dissection volume 
and in-hospital mortality for hospitals and consultant cardiac surgeons, respectively.  
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12.2.7 Medium Term Survival 
Along with in-hospital mortality, survival rates at 90 days, 1 year and 3 years are 
shown in Table 12.2.7. Responsible consultant activity is categorised into 3 groups: 
1 to 9 operations, 10 to 19 operations and >20 operations over the study period. In-
hospital mortality rates in the lower activity group are 20.2% vs. 13.2% in the higher 
activity group and similarly at 3 years the mortality rate is 29.2% vs. 21.2%. 
Associated p-values suggest that this difference has some statistical significance at 
0.049 and 0.047, respectively. 
Table 12.2.7. Survival rates by consultant activity 
    
Overall 
(n=1386) 
  
1 - 9 
procedures 
(n=699) 
10 - 19 
procedures 
(n=536) 
20 or more 
procedures 
(n=151) 
In-hospital mortality 
  
246 (17.8) 
  
141 (20.2) 
 
85 (15.9) 
 
20 (13.2) 
 
90 day mortality 
  
286 (20.6) 
  
160 (22.9) 
 
102 (19.0) 
 
24 (15.9) 
 
1 year mortality 
  
332 (24.0) 
  
182 (26.0) 
 
121 (22.6) 
 29 (19.2) 
3 year mortality   368 (26.6)   204 (29.2) 132 (24.6) 32 (21.2) 
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12.3 Is the Volume-Outcome Relationship Cost-Effective 
and Can It be a Template of Quality Improvement in Acute 
Type A Aortic Dissection and Aortic Arch Surgery. 
In 2007, a specialised aortic service line was established at our institution in 
response to perceived poor outcomes from acute Type A aortic dissection repair. 
Prior to the change all elective and emergency aortic surgery were performed by 13 
general cardiac surgeons. Following the specialised team formation the majority of 
elective aortic surgery and all emergency aortic surgery were performed by 4 aortic 
surgeons. The primary aim was to reduce operative mortality and associated 
morbidity and consequently to improve long term survival. In addition to improving 
quality of outcomes, our aim was to assess whether such primary goals were 
mirrored with cost-effectiveness arm.  
 
12.3.1 Study Population 
We identified 135 patients who underwent emergency surgery for acute Type A 
aortic dissection and 232 patients who underwent aortic arch surgery at our 
institution between October 1998 and August 2012. Patients were divided into two 
groups based on the time period in which they were operated. Prior to August 31st 
2007 Acute Type A aortic dissection repair (ATADR) and aortic arch surgery was 
performed by 13 surgeons on a general cardiac on call rota. Subsequent to this date, 
a specialist aortic on call rota was established with 4 aortic consultants. These 
surgeons performed the majority of the elective and all non-elective thoracic aortic 
surgery. 
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12.3.2 Data Collection 
All study data were prospectively entered into an electronic database by the 
operating surgeon during the study period. The database was validated 
retrospectively by case notes review. Outcomes evaluated for the purposes of this 
study included key quality markers as defined by STS (www.sts.org) for coronary 
surgery: in-hospital mortality, stroke, re-exploration for bleeding, sternal wound 
infections, renal failure and prolonged ventilation times.   
 
12.3.3 Survival Data 
Follow up survival was derived by linking patient records to a national spine via the 
Demographics Batch Service (DBS). Records were linked using National Health 
Service number, name, and date of birth, gender and postcode. The DBS returns a 
variety of patient demographics, including date of death. 
 
12.3.4 Costing Methodology 
12.3.4.1 Service Level Reporting & Patient Level Costing Information 
System 
We utilize and employs Patient Level Costing Information System (PLICS) and 
Service Level Reporting (SLR) systems, enabling detailed micro-costing. SLR allows 
the hospital to analyze cost and profitability at a patient level of each service it 
provides rather than just overall profitability. Costs of resources can be directly 
attributed to particular patient episodes. The use of sophisticated consumables 
dispensing and supply tracking technologies assigns costs and allows precise tracing 
of resource use to the patient and episode on which they were used.  
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Staff time is allocated with reference to employment contracts and the proportion of 
the time that is to be dedicated to each duty. That is, the cost of a particular surgeon 
for a given procedure is a function of his salary, the proportion of his contract he is 
to operate, and the time the procedure takes. Similarly, the ward costs of clinician 
can be allocated in a similar way.  These costs are then allocated based on the 
observed values of time for each patient episode. Indirect costs such as utilities and 
hospital overheads are allocated/absorbed – although some of them are not directly 
attributable to any particular episode /service lines, they are divided up and shared 
amongst all episodes. 
 
12.3.4.2 Estimation of Costs for pre-SLR Period Patients 
Data on clinical outcomes was available for all cases between 1999 and the present 
day. Resource use identified through PLICS was only obtainable from 2009 due to 
availability of SLR data from 2009. Costs for the cases prior to 2009 were estimated. 
The method of cost estimation was as follows. Firstly, preliminary analyses were 
undertaken to determine the most significant drivers of cost. This required the 
collaborative involvement of clinicians and members of the finance department to 
agree which treatment and perioperative processes drive cost. Factors included, 
“cutting time” (the length of time in surgery), intensive care unit (ICU) length of stay, 
and ward length of stay were found to be the major drivers of cost. These variables 
were considered the “cost drivers” accounting for approximately 80% of the true 
cost. Cost lines such as involving consumables will remain the same on either side of 
sub specialisation time line, adjusted for inflation and hence are considered 
irrelevant costs for this study. 
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12.3.5 Statistical Analysis 
Due to non-normal distributions (tested using the Shapiro-Wilk test), continuous 
variables are shown as median with 25th and 75th percentiles and comparisons were 
made with Wilcoxon rank-sum tests. Categorical variables are shown as a 
percentage and comparisons were made with chi-squared tests or Fisher’s exact 
tests as appropriate. Patients from the pre-specialisation era were propensity-
matched with unique post-specialisation patients. To do this, logistic regression was 
used to develop a propensity score.  
The propensity score was constructed using all the pre-operative variables listed in 
Table 12.3.5. In all cases a p-value less than 0.05 was considered significant. All 
statistical analyses were performed with SAS for Windows Version 9.2 (SAS, Cary, 
NC). 
 
12.3.6 Patient Characteristics  
Patient preoperative and operative characteristics for ATAD and aortic arch surgery 
are shown in Table 12.3.5 and table 12.3.6 respectively. In the unmatched groups of 
ATAD, there was a higher incidence of hypertension and cerebrovascular disease in 
the pre-subspecialisation era (both p=0.01). For the aortic arch group NYHA class III 
and above and respiratory disease was significantly higher but was not evident post 
match. For both aortic arch surgery and ATAD the operative variables, 
cardiopulmonary bypass and aortic cross clamp time were all significantly increased 
in the post- subspecialisation era (p=0.002, p<0.001 and p=0.001, respectively). The 
propensity-matched analysis provided 51 patients from the post-subspecialisation 
era successfully matched to 51 who were operated on pre-subspecialisation.  
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The patient characteristics of the propensity matched groups are also in Table 12.3.5 
and table 12.3.6, showing both groups were well matched with respect to major 
preoperative characteristics such as age, gender, left ventricular function and 
comorbidities such as: diabetes, peripheral vascular disease, respiratory and renal 
dysfunction. Previous cardiac surgery and BMI were also well matched. 
 
12.3.7 Patient Outcomes 
There was no difference in the extent of procedures performed pre and post-
subspecialisation after matching. However, operative times, cardiopulmonary 
bypass times and aortic cross clamp times were significantly longer in the post–
subspecialisation cohort after matching in ATAD patients however this was only true 
of aortic cross clamp time in the Arch Surgery group.  
Patient outcomes are shown in Table 12.3.7a. and 12.3.7b. for ATAD and aortic arch 
respectively. Patients who underwent repair of acute Type A aortic dissection in the 
post-subspecialisation era were less likely to suffer in-hospital mortality in both the 
matched and unmatched groups (p=0.001 and p=0.007, respectively). Fourteen 
(17.5%) patients suffered a post-operative permanent stroke in the pre-
subspecialisation cohort, compared to only five (9.6%) patient’s post-
subspecialisation (p=0.21). In the aortic arch surgery group, the significant 
outcomes from the post-match were; renal failure, prolonged ventilation and 
composite outcome (mortality, stroke, prolonged ventilation or renal failure) (Table 
12.3.7b.).  
Re-operation for bleeding was performed in 10 (13%) patients in pre-
subspecialisation compared to 5(9.6) patients in post-subspecialisation (p=0.58) for 
ATAD. Intensive care unit and hospital length of stay were different between the 2 
groups in ATAD however, when aligned using propensity matching there was no 
statistical significance.
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Table 12.3.7a. Patient Outcomes in Acute Aortic Dissection 
  
Before Match   After Match 
Pre-
Subspecialisation 
Post-
Subspecialisation P value 
 
Pre-
Subspecialisation 
Post-
Subspecialisation P value 
(n=80) (n=55)   (n=51) (n=51) 
ITU stay (days) 4 (2, 7) 5 (2, 15) 0.06  5 (2, 8) 5 (2, 15) 0.07 
Post-operative stay (days) 12 (7, 19) 13 (10, 28) 0.26  12.5 (7, 23) 13 (10, 27) 0.27 
Re-exploration for bleeding 10 (12.5) 5 (9.1) 0.54  6 (11.8) 5 (9.8) 0.75 
Prolonged ventilation 
(> 48 hours) 
26 (32.5) 5 (9.1) 0.002  17 (33.3) 5 (9.8) 0.004 
Renal failure 21 (26.3) 6 (10.9) 0.03  16 (31.4) 6 (11.8) 0.02 
Stroke 14 (17.5) 5 (9.1) 0.17  7 (13.7) 5 (9.8) 0.54 
In-hospital mortality 27 (33.8) 5 (9.1) 0.001   16 (31.4) 5 (9.8) 0.007 
 
Continuous data shown as median (25th to 75th percentile), comparisons made with Wilcoxon rank sum tests;  
Categorical data shown as percentage (number), comparisons made with Chi-square tests and Fishers exact tests as appropriate 
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Table 12.3.7b. Patient Outcomes in Aortic Arch Repair 
  
Before Match   After Match 
Pre-
Subspecialisation 
Post-
Subspecialisation P value 
 
Pre-
Subspecialisation 
Post-
Subspecialisation P value 
(n=73) (n=159)   (n=71) (n=71) 
ITU stay (days) 3 (2, 5) 3 (1, 6) 0.29  3 (2, 5) 3 (1, 5) 0.28 
Post-operative stay (days) 11 (9, 16) 10 (7, 16.5) 0.04  11 (9, 18) 10 (7, 15) 0.14 
Re-exploration for bleeding 7 (9.6) 7 (4.4) 0.14  7 (9.9) 5 (7.0) 0.55 
Prolonged ventilation (> 48 hours) 14 (19.2) 9 (5.7) 0.001  13 (18.3) 3 (4.2) 0.008 
Renal failure 11 (15.1) 3 (1.9) <0.001  11 (15.5) 2 (2.8) 0.009 
Stroke 6 (8.2) 5 (3.1) 0.10  6 (8.5) 1 (1.4) 0.12 
In-hospital mortality 6 (8.2) 8 (5.0) 0.38  6 (8.5) 1 (1.4) 0.12 
Composite outcome  
(Mortality, Stroke, Prolonged ventilation 
or Renal failure) 
18 (24.7) 22 (13.8) 0.043   17 (23.9) 6 (8.5) 0.01 
 
Continuous data shown as median (25th to 75th percentile), comparisons made with Wilcoxon rank sum tests;  
Categorical data shown as percentage (number), comparisons made with Chi-square tests and Fishers exact tests as appropriate 
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12.3.8 Survival 
Mid-term survival is shown in Figure 12.3.8a. and Figure12.3.8b. We found a 
significant improvement in 5-year survival for the pre and post-subspecialisation in 
both matched and unmatched patients (p=0.002 and p=0.01, Log-Rank test). 
 
12.3.9 Cost Drivers 
Table 12.3.9a. displays the median (IQR) comparisons of relevant costs were 
£28,784 (£21,431, £44,381) pre-subspecialisation compared to £31,648 (£20,184, 
£47,882) in a matched group of patient’s post-subspecialisation, p=0.70 for ATAD. 
In addition, Table 12.3.9b. displays the median (IQR) comparisons of relevant costs 
for aortic arch surgery cost. This reveals that cost comparison between the two 
groups was non-significant and cost neutral. The improvement in the outcomes and 
survival between the two groups was cost effective.  
The average cost per patient in the post–subspecialisation era has not varied 
significantly. With no notable change in resource cost resulting from the change in 
the clinical re-organization, it is perhaps reasonable to deduce that the introduction 
of subspecialisation was cost neutral to the hospital.  
The improvement in clinical outcomes would seem to have two separate effects on 
costs. The effect of reduced mortality is, “ceteris paribus”, an increase in length of 
stay and therefore an increase in costs. However, also present is the effect of a 
reduction in adverse events and other complications, which works to reduce length 
of stay by improving recovery time. Another consequence is that where mortality is 
not avoided, it may be postponed, thereby increasing the average length of stay.
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Table 12.3.9a. Patient Cost in Acute Aortic Dissection (currency shown as £ sterling) 
  
Before Match   After Match 
Pre-Subspecialisation Post-Subspecialisation P 
value 
 Pre-Subspecialisation Post-Subspecialisation 
P value 
(n=80) (n=55)   (n=51) (n=51) 
Cost Drivers        
     Critical Care 8185 (3727, 13863) 9235 (4180, 24475.5) 0.19  8185 (3274, 14630) 8020 (4180, 25236) 0.25 
     Theatre costs 6762 (4713, 9207) 6932.5 (5705, 9234) 0.27  7450 (5272, 9241) 7037 (5751, 9234) 0.75 
     Ward costs 2103 (1176, 3490.5) 2101.5 (1611, 4323.5) 0.34  1911 (1176, 3675) 2058 (1584, 3829) 0.42 
        
Other Costs        
     Pathology 785 (366, 1334.5) 809.5 (418, 1881) 0.29  785 (314, 1463) 748 (418, 1881) 0.22 
     Medical Staffing 2332.5 (1474.5, 3289) 2660 (1850, 3369) 0.62  2689 (1625, 3372) 2710 (1927, 3369) 0.71 
     Other Clinical Supplies & 
     service 
4460 (2295.5, 10949) 4043 (2579.5, 10767) 0.48  8404 (2409, 11642) 4109 (2561, 11642) 0.10 
     Other Diagnostics 149 (86, 224) 168 (109, 227.5) 0.57  144 (88, 243) 163 (108, 224) 0.56 
     Pharmacy services 198 (104, 305.5) 234 (151.5, 413.5) 0.21  195 (104, 324) 216 (142, 387) 0.38 
     Therapies 390 (224.5, 584.5) 426.5 (261, 870) 0.46  377 (232, 667) 404 (239, 841) 0.45 
        
Total relevant costs 
26428 (19152.5, 
40873.5) 
31131 (20273, 47882) 0.22   28784 (21431, 44381) 31648 (20184, 47882) 0.70 
 
Continuous data shown as median (25th to 75th percentile), comparisons made with Wilcoxon rank sum tests;  
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Table 12.3.9b. Patient Cost in Aortic Arch Repair (currency shown as £ sterling) 
  
Before Match   After Match 
Pre-Subspecialisation Post-Subspecialisation P 
value 
 Pre-Subspecialisation Post-Subspecialisation P 
value (n=73) (n=159)   (n=71) (n=71) 
Cost Drivers        
     Critical Care 3531 (2354, 5885) 3531 (1839, 7520) 0.99  3531 (2354, 5885) 3531 (1968, 8239) 0.85 
     Theatre costs 5996 (5358, 7120) 6556 (5034, 8226) 0.17  5996 (5358, 7120) 6554 (4855, 7691) 0.49 
     Ward costs 2769 (2130, 3834) 2343 (1704, 3834) 0.04  2769 (2130, 3834) 2537 (1917, 4473) 0.38 
        
Other Costs        
     Pathology 416 (338, 624) 391 (260, 641) 0.17  416 (338, 624) 380 (260, 588) 0.09 
     Medical Staffing 1948 (1740, 2313) 2129 (1661, 2534) 0.27  1948 (1740, 2313) 2146 (1749, 2513) 0.25 
     Other Clinical Supplies 
     & service 
2841 (2539, 3374) 3106 (2394, 3622) 0.42  2841 (2539, 3374) 3110 (2471, 3671) 0.41 
     Pharmacy services 208 (169, 312) 192 (130, 324) 0.15  208 (169, 312) 196 (130, 351) 0.55 
     Therapies 240 (195, 360) 207 (135, 409) 0.08  240 (195, 360) 248 (150, 482) 0.99 
        
Total relevant costs 18812 (15896, 22666) 19579 (15495, 26017) 0.46   18812 (15804, 23422) 19579 (15504, 26640) 0.49 
 
Continuous data shown as median (25th to 75th percentile), comparisons made with Wilcoxon rank sum tests;  
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12.4 Contemporary Hospital Outcomes and Survival 
Following Open Aortic Arch Surgery in a Specialized UK 
Thoracic Aortic Centre 
As a marker for comparison between open arch surgery and the endovascular 
approach the aim of this section is not to draw bench-marking among LHCH and 
those around the country, however, it’s to illustrate our experience and practice in 
addition to documenting our outcomes in terms of mortality, postoperative 
morbidity and survival.  It’s also our aim to demonstrate that provided the expertise 
and the available resources open repair aortic arch surgery outcomes in the UK 
could be of international standards. 
 
12.4.1 Study Population 
This study looked at all patients who had undergone aortic arch surgery under deep 
hypothermic circulatory arrest with the aid of cardiopulmonary bypass.  
All study data were entered into an electronic database by the operating surgeon, 
prospectively during the period of the study (June 1999 - November 2012). The 
database was validated retrospectively by a case notes review.  
 
12.4.2 Data Collections and Outcomes 
Methods of data collection and definitions have been published previously. In brief, 
each operation had a dataset collected that included relevant demographics, 
indicators of heart disease severity, acuity, comorbidities and procedural details 
along with all relevant in-hospital outcomes. Outcomes evaluated for the purposes 
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of this study included in-hospital reoperations, sternal wound infections, 
neurological and renal complications, post-operative ventilation times and in-
hospital mortality.  In-hospital outcomes and survival were stratified by elective and 
non-elective total arch replacement (TAAR) and elective and non-elective hemiarch 
replacement (HAAR), (Figure 11.5). Receiver operating characteristic (ROC) analysis 
was also performed to establish a suitable age cut-off for elective follow up survival, 
which is also presented. Follow up survival was derived by linking patient records 
to a national spine via the Demographics Batch Service (DBS). Records were linked 
using National Health Service number, name, and date of birth, gender and postcode. 
The DBS returns a variety of patient demographics, including date of death. 
 
12.4.3 Statistical Analysis 
Continuous data are shown as median (inter-quartile range), comparisons are made 
using Wilcoxon’s Signed Rank tests and students t-tests as appropriate. Categorical 
variables are shown as frequency and percentage, comparisons are made with chi-
squared tests and Fisher‘s exact tests as appropriate. Follow-up mortality rates are 
presented using the Kaplan-Meier method.  In all cases a p-value less than 0.05 was 
considered significant. All statistical analyses were performed with SAS for 
Windows Version 9.2 (SAS, Cary, NC). 
 
12.4.4 Patient Characteristics 
Of the 276 patients analysed (Figure 12.4.4.), 110 (39.9%) underwent TAAR and 166 
(60.1%) underwent HAAR. 35 (31.8%) of the TAAR and 26 (15.7%) of the HAAR 
operations were performed non-electively. Patients were mostly male (60.1%) and 
had a median age of 61.2 (range, 16.7 to 87.3) years. Patient characteristics, co-
morbidities and aortic aetiologies are collected in Table 12.4.4. Notable differences 
between the elective and non-elective TAAR groups include; a higher proportion of 
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current smokers and patients with a left ventricular ejection fraction between 30% 
and 50% in the non-elective group (9.3% vs. 28.6%; p=0.009 and 8.0% vs. 22.9%; 
p=0.06, respectively), together with a higher proportion of patients with respiratory 
disease in the elective group (40.0% vs. 14.3%; p=0.007) and a higher proportion of 
patients having undergone previous cardiac surgery (32.0% vs. 14.3%; p=0.0495). 
In the HAAR procedures, non-elective patients were more likely to suffer from renal 
dysfunction and peripheral vascular disease (2.1% vs. 19.2%; p=0.003 and 4.3% vs. 
15.4%; p=0.052, respectively), while elective patients were more likely to suffer 
from hypercholesterolaemia (55.0% vs. 19.2%; p=0.001). 
 
12.4.5 Operative Procedures 
Repair of the ascending aorta was the most common concomitant procedure (Table 
12.4.5a), it was performed respectively in 97.3% and 94.3% of elective and non-
elective TAAR, and in 99.3% and 100% of elective and non-elective HAAR. Operative 
times were typically observed to be shorter in the elective groups (also Table 
12.4.5b), time on cardiopulmonary bypass for non-elective patients saw a significant 
increase in both the TAAR and HAAR cohorts (358 minutes (IQR, 272 to 435) vs. 398 
minutes (IQR, 338 to 479); p=0.006 and 299 minutes (IQR, 256 to 341) vs. 340 
minutes (IQR, 283 to 440); p=0.004, respectively). In the HAAR cohort, median 
circulatory arrest times were significantly lower in elective patients compared to 
non-elective (29 minutes (IQR, 23 to 36) vs. 46 minutes (IQR, 26 to 66); p<0.001).
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Table 12.4.5a Operative Variables and Times 
Variable 
Total Arch Replacement   Hemi-Arch Replacement 
Elective  Non-elective  
p-value 
 Elective  Non-elective  
p-value 
(n=75) (n=35)   (n=140) (n=26) 
Concurrent procedures        
    Aortic valve replacement 49 (65.3) 21 (60.0) 0.59  112 (87.1) 21 (80.8) 0.37 
    Aortic root 43 (57.3) 20 (57.1) 0.99  104 (74.3) 18 (69.2) 0.59 
    Ascending 73 (97.3) 33 (94.3) 0.59  139 (99.3) 26 (100) >0.99 
    Other concomitant procedure 10 (13.3) 5 (14.3) >0.99  29 (20.7) 5 (19.2) 0.86 
Operative times        
    Circulatory arrest 71 (56, 99) 88 (62, 120) 0.11  29 (23, 36) 46 (26, 66) <0.001 
    Cardiopulmonary bypass 358 (272, 435) 398 (338, 479) 0.006  299 (256, 341) 340 (283, 440) 0.004 
    Aortic crossclamp 205.5 (135, 267) 219 (157, 305) 0.35   174 (138, 207) 190.5 (149, 209) 0.25 
 
Categorical variables shown as n (%), comparisons made with chi-squared and Fisher’s exact tests as appropriate;  
Continuous variables shown as median (25th percentile, 75th percentile), comparisons made with Wilcoxon’s Signed Rank test and t-tests as 
appropriate 
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A conventional elephant trunk (ET) procedure was performed in 49.3% and 37.1% 
of elective and non-elective TAAR procedures respectively. ET activity and 
outcomes, including frozen and reverse procedures, are shown in Table 12.4.5b. 
 
Table 12.4.5b Elephant Trunk (ET) Post-Operative Complications 
Variable 
Total Arch Replacement 
Elective  Non-elective  
p-value 
(n=75) (n=35) 
Conventional ET 37 (49.3) 13 (37.1) 0.23 
    Stroke 2/37 (5.4) 1/13 (7.7) >0.99 
    In-hospital mortality 4/37 (10.8) 1/13 (7.7) >0.99 
    30 day mortality 3/37 (8.1) 1/13 (7.7) >0.99 
    
Frozen ET 7 (9.3) 5 (14.3) 0.52 
    Stroke 0/7 (0) 0/5 (0) - 
    In-hospital mortality 0/7 (0) 1/5 (20.0) 0.42 
    30 day mortality 0/7 (0) 1/5 (20.0) 0.42 
    
Reverse ET (2nd stage) 2 (2.7) 0 (0) >0.99 
    Stroke 0/2 (0) 0 (0) - 
    In-hospital mortality 0/2 (0) 0 (0) - 
    30 day mortality 0/2 (0) 0 (0) - 
 
Categorical variables shown as n (%), comparisons made with chi-squared and Fisher’s exact 
tests as appropriate 
 
12.4.6 Outcomes  
In the TAAR group, in-hospital mortality occurred in 6.7% of elective patients and 
25.7% of non-elective patients (p=0.01). In the HAAR group, in-hospital mortality 
occurred in 2.1% of elective patients and 19.2% of non-elective patients (p=0.003). 
Post-operative stroke occurred in 4.0% of elective TAAR’s and 14.3% of non-elective 
(p=0.11), 2.9% of elective HAAR’s suffered a stroke compared with 11.5% non-
elective (p=0.08), as shown in Table 12.4.6. 
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Median intubation times were significantly shorter in elective TAAR patients when 
compared to non-electives (16 hours (IQR, 12 to 38) vs. 27.5 hours (IQR, 16 to 99.5); 
p=0.045). Median ITU stay was significantly longer in non-elective HAAR patients 
when compared to electives (4 days (IQR, 3 to 13.5) vs. 2 days (IQR, 1 to 4); p=0.001). 
Significantly higher rates of postoperative bleeding requiring reoperation were seen 
in non-elective HAAR patients when compared to electives (19.2% vs. 4.3%; 
p=0.015). Similar postoperative rates of acute renal failure were seen when 
comparing priority in the TAAR group (6.7% vs. 22.9%; p=0.02). Figure 12.4.6a. and 
Figure 12.4.6b. respectively show the 5-year survival for TAAR stratified by priority 
and, in the elective group only, age <65 or >=65. After an early divergence, the 
survival curves based on priority reintersect and ultimately result in no significant 
difference (p=0.69).  
 
Elective survival based on age, however, does result in significantly poorer outcomes 
in the older group (p=0.006). Figure 12.4.6c and Figure 12.4.6d. similarly show the 
5-year survival for HAAR stratified by priority and, in the elective group only, age 
<65 or >=65.  
In this cohort, the non-elective group have consistently poorer survival over 5 years 
than the elective group (p=0.03). But in contrast to the TAAR cohort, elective 
survival based on age does not result in any significant difference (p=0.16). In our 
conventional ET subcategory, 5 patients died in-hospital; 4 (10.8%) were elective 
and 1 (7.7%) was non-elective (p>0.99).  
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12.4.7 Paraplegia Rate 
No patients sustained paraplegia or paraparesis. 
 
12.4.8 Our Hospital Outcome 
This is the first UK publication of detailed outcomes and survival from a series of 
contemporary patients undergoing aortic arch surgery in a specialized thoracic 
aortic centre. Acute aortic dissection patients have been excluded from this series 
unless documentation of a formal hemiarch or total arch surgery took place. 
Typically, these patients have a simple open distal anastomosis under circulatory 
arrest. 
 
12.4.9 Hemiarch versus total Arch 
Median age of elective patients was not significantly different at 64.3 (53.7, 71.9) versus 64.5 
(46.4, 71.0) respectively. Elective hospital mortality is very acceptable at 1.5% and 7.5% 
respectively for hemiarch and total arch surgery. Similarly stroke rate was 3% versus 4.5% 
in elective patients. A high proportion of both groups underwent concomitant procedures 
on the aortic valve, root and ascending aorta. Not unsurprisingly, the need for arch vessel 
reimplantation results in longer periods on cardiopulmonary bypass and deep hypothermic 
circulatory arrest with consequent higher morbidity and mortality. 
 
12.4.10 Elective versus Non-Elective 
Non-elective surgery was associated with much high mortality and morbidity. Mortality and 
stroke rate for total arch as an urgent/emergency were 31% and 17.2 % respectively. For 
hemiarch these were 20% and 12% respectively. This reflects the nature of emergency work 
with acute Type A dissection, leaking aneurysms, pseudoaneurysms and endocarditis. 
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12.4.11 Elephant Trunk Procedures 
More than 50% of our elective and non-elective patients undergoing total arch replacement 
underwent some form of elephant trunk procedure. A proportion (43.1%) of these were 
“prophylactic” and simply placed to aid possible further surgery on the thoracoabdominal 
aorta. Others (31.4%) were placed with the intention of a planned second stage intervention 
on the descending thoracic aorta allowing guaranteed placement of a proximal clamp and 
left heart bypass rather than cardiopulmonary bypass. Mean delay between first and second 
stages was 12.4 months. 
 
12.5 Influences on Early and Medium-Term Survival 
Following Surgical Repair of the Aortic Arch 
Surgery to replace the proximal or total aortic arch has become relatively 
commonplace, with many examples of international centers publishing excellent 
morbidity and mortality outcomes in large series254256217,,218 compared with the 
very early series96. Underpinning these patient outcomes are a host of 
improvements in surgery, anaesthesia, nursing, perfusion, and intensive care, all 
well described by Coselli and LeMaire 219in Aortic Arch Surgery: Principles, Strategies 
and Outcomes. This success with clinical morbidity and mortality outcomes has 
allowed the development of more sophisticated quality measures of the “process” 
and “structure” of care delivered by institutions published in the form of guidelines 
on performing and reporting of thoracic aortic surgery 220.  
                                                                
217 Estrera AL, Miller CC 3rd, Lee TY, Shah P, Safi HJ. Ascending and transverse aortic arch repair. Circulation. 
2008; 118:S160–S166 
218 Ma WG, Zhu JM, Zheng J, Liu YM, Ziganshin BA, Elefteriades JA, et al.. Sun's procedure for complex aortic 
arch repair: total arch replacement using a tetrafurcate graft and stented elephant trunk implantation. Ann 
Cardiothorac Surg 2013; 2:642–648.  
219 Coselli JS, LeMaire SA. Aortic arch surgery: principles, strategies and outcomes, Ed 1. London: Blackwell 
Publishing Ltd, 2008. 
220 Svensson LG, Adams DH, Bonow RO, Kouchoukos NT, Craig Miller D, O'Gara PT, et al.. Aortic valve and 
ascending aorta guidelines for management and quality measures. Ann Thorac Surg. 2013; 95:1–66. 
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However, reporting of contemporary survival following aortic arch surgery, and the 
factors which influence it, remains limited 165,221.  
This work has three aims: 1) report, compare and analyse our morbidity and 
mortality outcomes for hemiarch and total aortic arch surgery; 2) examine the 
survival benefit of hemiarch and total aortic arch surgery compared to age- and sex-
matched controls; and 3) define factors which influence survival in these two groups 
and, in particular, identify those that are modifiable and potentially actionable. 
 
12.5.1 Patient Population and Data 
We performed a retrospective study on 287 consecutive patients who underwent 
aortic arch surgery at Liverpool Heart and Chest Hospital between June 15, 1999 and 
December 31, 2012. All relevant clinical data were collected prospectively and 
entered into a local hospital database from which, periodically, core datasets were 
validated and submitted to The Society for Cardiothoracic Surgery (UK). In brief, for 
each operation, a dataset was collected that included relevant demographics, 
indicators of disease severity, acuity, comorbidities, and procedural details, along 
with all relevant in-hospital outcomes. Outcomes evaluated for the purposes of this 
study include in-hospital reoperations for bleeding, sternal wound infections, 
neurological and renal complications, postoperative ventilation times, and both in-
hospital and follow-up mortality. 
 
 
 
                                                                
221 Patel HJ, Deeb GM. Open aortic arch reconstruction. Ann Cardiothorac Surg. 2013; 2:181–183. doi: 
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12.5.2 Preoperative and Postoperative Criteria 
Indications for surgery. Indications for isolated elective aortic aneurysm surgery 
were: aneurysmal size greater than 5.5 cm in nonconnective tissue disorders, size 
greater than 4.5 cm with connective tissue disorders. Attributable symptoms were 
an indication for surgery. Other indications were acute aortic syndromes, infection, 
fistula, and pseudoaneurysms. In patients in whom the principal indication for 
surgery was severe disease in the aortic valve, mitral valve, or tricuspid valve and/or 
coronaries, the threshold for intervention on the aorta was lowered to 4.0-4.5 cm. 
Similarly, when the primary indication for surgery was the aorta, the threshold for 
cardiac intervention was lowered; i.e., moderate aortic valve disease, one and two 
vessel or proximal left anterior descending coronary artery disease. Nonelective 
surgery was performed based on the presence of acute aortic syndrome or 
decompensation of nonaortic cardiac-related factors such as aortic valve disease and 
pulmonary oedema or coronary disease with recent non-ST elevation myocardial 
infarction. We currently adhere to the American Heart Association Guidelines11 on 
indications for aortic surgery which, although presented in 2009, broadly reflected 
our practice prior to publication. 
Patient follow-Up. To establish follow-up vital status, patient records were linked to 
the national Personal Demographic Service (PDS). Patients were matched to the PDS 
(http://systems.hscic.gov.uk/demographics/pds) based on National Health Service 
number, patient name and date of birth, gender, and postcode.  
12.5.3 Indications for Surgery 
 Indications for isolated elective aortic aneurysm surgery were: aneurysmal size 
greater than 5.5 cm in nonconnective tissue disorders, size greater than 4.5 cm with 
connective tissue disorders. Attributable symptoms were an indication for surgery. 
Other indications were acute aortic syndromes, infection, fistula, and 
pseudoaneurysms.  
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In patients in whom the principal indication for surgery was severe disease in the 
aortic valve, mitral valve, or tricuspid valve and/or coronaries, the threshold for 
intervention on the aorta was lowered to 4.0-4.5 cm.  
Similarly, when the primary indication for surgery was the aorta, the threshold for 
cardiac intervention was lowered; i.e., moderate aortic valve disease, one and two 
vessel or proximal left anterior descending coronary artery disease. Non-elective 
surgery was performed based on the presence of acute aortic syndrome or 
decompensation of non-aortic cardiac-related factors such as aortic valve disease 
and pulmonary oedema or coronary disease with recent non-ST elevation 
myocardial infarction. We currently adhere to the American Heart Association 
Guidelines6 on indications for aortic surgery which, although presented in 2009, 
broadly reflected our practice prior to publication. 
 
12.5.4 Patient Follow-Up  
To establish follow-up vital status, patient records were linked to the national 
Personal Demographic Service (PDS). Patients were matched to the PDS 
(http://systems.hscic.gov.uk/demographics/pds) based on National Health Service 
number, patient name and date of birth, gender, and postcode. 
 
12.5.5 Statistical Methods 
Continuous data that are not normally distributed are reported as median 
(25th percentile, 75th percentile) with Wilcoxon's signed rank test used for 
comparisons. Categorical variables are shown as frequency and percentage, while 
comparisons are made with chi-square (χ2) tests and Fisher‘s exact tests as 
appropriate.  
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Follow-up mortality rates are presented using the Kaplan-Meier method222 and 
comparisons are made using the log-rank test. Cox proportional hazards analysis 
with forward stepwise selection of covariates was used to calculate adjusted hazard 
ratios (HRs). Limits for entry to and removal from the model were set at P < 0.10 
and P > 0.05, respectively. In all cases a p-value less than 0.05 was considered 
significant. All statistical analyses were performed with SAS for Windows Version 
9.2 (SAS Institute, Cary, NC, USA). 
 
12.5.6 Demographic Data 
Within the study period we performed a total of 1240 operations on thoracic aortic 
aneurysms, of which 287 involved the aortic arch and circulatory arrest and were 
included in this study. Preoperative patient characteristics, including comorbidities 
and disease etiology, are presented in Table 12.5.6a, along with operative data. “All 
AAR” (all aortic arch Aneurysms, n = 287) is presented in column 1, followed by a 
spilt of “Elective HAAR” (elective hemi-aortic arch resection) and “Elective TAAR” 
(elective total aortic arch resection). Nonelective patients undergoing HAAR (n = 30) 
and TAAR (n = 36) are described in Table 12.5.6b. 
 
12.5.7 Comorbidities 
Of 287 patients included in the present study, 115 (40.1%) of patients were female. 
Median age was 63.7 years. A total of 76 (26.5%) patients had a New York Heart 
Association (NYHA) class ≥ III, 100 (34.8%) suffered from respiratory disease, and 
48 (16.7%) had undergone a surgical cardiac procedure in the past. There were no 
major differences in comorbidity as defined between elective hemiarch and total 
                                                                
222 Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 
53:547–581. 
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aortic arch patients apart from a slightly higher incidence of peripheral vascular 
disease in the elective total arch group (P < 0.03). Also, previous cardiac surgery was 
more common in the elective TAAR group (30.9%) versus the elective HAAR group 
(10%, P < 0.001). In the non-elective cohort, all variables were similar apart from a 
significantly higher incidence of current smoking in the TAAR group (33.3%) versus 
the HAAR group (6.7%, P < 0.008). 
 
12.5.8 Aetiology 
A total of 147 (51.2%) patients had simple age-related degenerative disease in which 
we also included atherosclerotic aneurysms and bicuspid valve syndrome-related 
aneurysms. Of these, 138 (48.1%) were non-degenerative disease including such 
diagnoses as Marfan syndrome, Ehlers-Danlos syndrome, Loeys-Dietz syndrome, 
infection, inflammation, and pseudoaneurysms. Two patients had iatrogenic disease. 
Aetiology was poorly specified in our database, principally because it is often 
uncertain, and in 13.6%, aetiology was not recorded. There was no significant 
difference between the TAAR and HAAR elective groups. 
12.5.9 Concomitant Procedures 
A high proportion of patients required intervention on the aortic valve (76.7%), and 
this was significantly different between the two elective groups (HAAR, 87.1%; 
TAAR, 64.2%, P < 0.001). This was typically associated with aortic root replacement 
in the two groups together (76.7%), although this was not statistically different 
between the two elective groups (Table 12.5.6a). A similar trend was observed in 
the non-elective cohort (Table 12.5.6b). Coronary artery bypass graft (CABG) was 
required in 16% of the entire group, and this was not significantly different between 
elective HAAR and TAAR. 
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12.5.10 Preoperative Outcomes 
Non-normally distributed variables are shown as median (interquartile range); thus, 
time on cardiopulmonary bypass was 330 (272, 394) min (for completeness, the 
mean ± standard deviation (SD) was 337.5 ± 98.9 min). Similarly, time for circulatory 
arrest was 38 (24, 68; 50 ± 38.5) min. Cardiopulmonary bypass time and circulatory 
arrest time were significantly longer in the TAAR group than in the HAAR group for 
both elective and non-elective cohorts. 
 
12.5.11 In-Hospital and Survival Outcomes 
Median (interquartile range; mean ± SD) stay in intensive care was 3 (2, 6; 6.4 ± 10.7) 
days, while overall postoperative length of stay in hospital was 11 (8, 17; 15.2 ± 15.4) 
days. A total of 35 (12.2%) patients remained on mechanically assisted ventilation 
for more than 48 hours, 21 (7.3%) suffered acute renal failure, 18 (6.3%) patients 
required a re-exploration for bleeding, 16 (5.6%) patients suffered a stroke [CVA = 
13 (4.5%), TIA = 3 (1.1%)], 19 (6.6%) patients experienced postoperative confusion, 
and there was 1 (0.7%) deep sternal wound infection. A total of 23 (8.0%) patients 
died in-hospital, and survival at 1, 3 and 5 years was 87.5%, 80.8%, and 79.1%, 
respectively. The mean (+/- standard error) survival period was 3.9 (0.12) years. 
When looking at elective HAAR versus TAAR, the ITU length of stay was significantly 
longer in the latter group; however, key outcomes such as mortality, stroke, acute 
renal failure, prolonged ventilation, re-intubation, and re-exploration for bleeding 
did not reach statistical significance. In-hospital mortality in HAAR and TAAR was 
significantly and dramatically higher in non-elective groups versus elective groups 
(Tables 12.5.11a and 12.5.11b)  
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In-hospital mortality, 30-day mortality, and 1 year and 5-year survival were not 
different between elective HAAR and TAAR groups. 
We matched the 287 patients by age and gender to the UK population life tables 
available from the United Kingdom Office of National Statistics 
(http://www.ons.gov.uk/). The resulting Kaplan-Meier chart comparing survival is 
shown in Figure 12.5.11. The median follow-up period for aortic arch patients was 
2.8 years. 11.9a and 11.9b how sex- and age- matched survival broken down into 
elective HAAR and TAAR. 
 
12.5.12 Univariate and Multivariate Analysis 
Table 12.5.12a shows the univariate analysis of risk factors for overall survival. Nine 
perioperative factors were identified to be statistically significant: age at operation 
≥ 65 years (P = 0.007), angina class IV (P = 0.005), NYHA class ≥ III (P = 0.002), 
diabetes (P = 0.038), respiratory disease (P = 0.02), peripheral vascular disease (P < 
0.001), preoperative renal dysfunction (defined as patients with a functioning renal 
transplant and patients with acute or chronic renal failure or insufficiency; P < 
0.001), concurrent CABG operation (P = 0.029), circulatory arrest time > 100 min 
(P = 0.001), and cardiopulmonary bypass time > 450 minutes (P < 0.001).  
Multivariate analysis of patient risk factors revealed 5 variables independently 
associated with overall follow-up survival (Table 12.5.12b): renal dysfunction [HR = 
3.11; 95% confidence interval (CI) = 1.44 to 6.73; P < 0.001], NYHA class ≥ III (HR = 
2.25; 95% CI = 1.38 to 3.67; P = 0.002), circulatory arrest time > 100 min (HR = 2.92; 
95% CI = 1.57 to 5.43; P = 0.001), peripheral vascular disease (HR = 2.44; 95% CI = 
1.25 to 4.74; P = 0.004), and concomitant CABG operation (HR = 2.14; 95% CI = 1.20 
to 3.80; P = 0.008) (Table 12.5.12b). The c-statistic for the Cox model was 0.72, 
indicating an acceptable level of discrimination. 
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12.5.13 Elephant Trunk Procedures 
A total of 117 patients of the entire cohort (81 electives and 36 non-elective) 
included either a conventional or frozen elephant trunk. Table 12.5.13 shows 
selected and important clinical outcomes from these procedures. No patients 
suffered paraplegia following these procedures. 
 
12.5.14 Characteristics of the Cohort 
The median age of our patients was 63.7 years with 40.1% being female. Apart from 
previous cardiac surgery, there were no significant differences in comorbidities 
between those patients undergoing elective hemiarch and total aortic arch surgery 
(Table 12.5.6a). In the non-elective patients, current smoking was significantly more 
common in the total aortic arch group (6.7% versus 33.3%, P < 0.008; Table 12.5.6b). 
Of significant interest in our cohort was the presence of symptoms in the form of 
breathlessness (NYHA class ≥ III). Typically, thoracic aortic aneurysms have been 
thought of as largely asymptomatic. This feature of our cohort is multifactorial.  
The most likely cause is the high incidence of aortic valve disease with 76.7% of our 
entire cohort undergoing aortic valve surgery. In addition to that, 16% underwent 
concomitant coronary artery bypass grafting, thus ischemic heart disease had been 
a likely additional cause of symptoms. Two other characteristics important in 
conferring symptoms are the left ventricular dysfunction (ejection fraction < 50% in 
20.2%) and the incidence of respiratory disease (34.8%). Current smoking was 
documented in 13.6% of the entire group. These data confirm that a good proportion 
of our patients underwent surgery on both symptomatic and prognostic grounds.  
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This feature is contrary to common dogma that thoracic aortic aneurysm patients 
are largely asymptomatic, although this is likely true absent the additional factors 
enumerated above. 
The entire cohort of patients (287) undergoing some form of aortic arch surgery 
under deep hypothermic circulatory arrest had an in-hospital mortality of 8% and 
stroke rate of 5.6%. Other key outcome measures were prolonged ventilation 
(12.2%), acute renal failure (7.3%), re-exploration for bleeding (6.3%), and deep 
sternal wound infection (0.4%). Stroke rate in the entire group was 5.6% with an 
additional 1.1% suffering TIA and 6.6% confusion. 
Our institution has developed a “Quality Outcomes Framework” (QOF), broadly 
based on Society of Thoracic Surgeons (STS) Quality Performance Measures in 
cardiac surgery (www.sts.org/quality), for internal reporting of annualized data 
from aortic arch surgery. Unlike the STS measures, which include indicators of 
process, structure, and outcome, our QOF concentrates on outcomes, annualized, 
and is presented as a “Statistical Process Control Chart” (Appendices). These include 
in-hospital mortality, 30-day mortality and 1-year mortality, stroke, re-exploration, 
postoperative renal failure, and prolonged ventilation. This mechanism allows us to 
monitor the stability of our outcomes annually and investigate and modify processes 
when deviation is observed. These data are presented in Appendices and not only 
demonstrate our increasing annual activity over time but also the relative stability 
of outcomes with little influence of the change in service provision from 2007 (see 
Methods). Stability of outcomes, particularly major morbidity and mortality, is an 
important platform for interpreting our survival data and the influences on it. 
An interesting aspect of our outcomes is seen when the elective hemiarch and total 
arch cohorts are examined separately. There were no significant differences in our 
QOF measures of in-hospital mortality, 30-day mortality, 1-year mortality, 
prolonged ventilation, acute renal failure, re-exploration bleeding, or stroke (Table 
12.5.15). Even more surprising, although the absolute differences in these two 
groups within the nonelective cohort were significantly different (Table 12.5.11b), 
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the relative difference between hemiarch and total arch were nonsignificant. This 
has informed our consent process and operative strategies. It gives assurance that 
organ protection strategies are sufficiently robust to allow resection of the total arch 
where indicated, at the price of a small but nonsignificantly higher morbidity and 
mortality. 
 
12.5.15 Survival Outcomes 
12.5.15.1 Age- and Sex-Matched Survival 
Our data as an entirety show that survival following some form of aortic arch 
surgery, under hypothermic circulatory arrest, matched to age and sex of the UK 
population (Fig. 19), is parallel beyond 2 years with a disparity of approximately 
20%. The reasons underlying this effect at 2 years are seen in Figure 12.5.15a and 
Figure 12.5.15b. These figures demonstrate survival in hemiarch and total aortic 
arch groups matched by age and sex. While the hemiarch group survival is fairly flat 
and parallel with controls, separated by 10%, the survival in total aortic arch 
patients is somewhat different, albeit on an expanded Y-axis.  
Survival in the total aortic arch group drops off quickly over the first 24 months to 
approximately 70% and then remains fairly flat out to 5 years. In absolute terms, the 
5-year survival of 70% is comparable with other published series,221,238; however, 
the shape of the survival curve for this subset of patients of ours is unusual. The Safi 
group165,217 reported a 72% and 71% survival at 5 and 10 years, respectively, from 
1991 to 2001. A separate report from the Mount Sinai group described long-term 
survival in 206 aortic arch patients, reporting a 6-year survival rate of 75%. In a large 
study of 721 patients followed over 17 years, Patel et al.221  reported survival at 5 
years to be 80%, with 10 and 12-year survival of 65% and 51%, respectively.  
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Our captured follow-up data systems do not allow us to easily determine the cause 
of this early attrition in our total arch cohort. Future enquiry will focus on causes of 
early death in this group and act as a focus of effort to identify modifiable risk factors. 
For the present, these data allow us to better inform the consent process. 
 
12.5.15.2 Univariate and Multivariate Analysis of Survival 
Univariate analysis of the entire cohort found significant relationships between 
survival and age (65 years), NYHA class ≥ III, diabetes, respiratory disease, 
peripheral vascular disease, renal dysfunction, concomitant CABG, circulatory arrest 
time (> 100 min) and cardiopulmonary bypass (> 450 min). Multivariate analysis 
demonstrated that independent factors associated with survival were renal 
dysfunction (HR 3.11), NYHA class ≥ III (HR 2.25), circulatory arrest time (> 100 min; 
HR 2.92), peripheral vascular disease (HR 2.44), and concomitant CABG (HR 2.14). 
Safi's group165,217 identified increasing age, chronic obstructive pulmonary disease, 
concurrent unoperated aneurysm, arch involvement, pump time, concurrent aortic 
valve replacement, and postoperative renal failure to negatively affect survival 
following aortic arch repair. Interestingly, Crawford's group, of which Safi was a part, 
published a similar paper on influences on survival in 1989 223, showing 
independent predictors of follow-up survival were: aneurysm symptoms, 
preoperative angina, extent of proximal replacement, associated residual distal 
aneurysm, balloon pump, renal dysfunction, cardiac dysfunction, and stroke. Several 
predictors of late mortality identified by Patel et al. 221 included increasing age, 
preoperative renal function, history of CABG or descending aortic replacement, 
prolonged circulatory arrest time, and postoperative tracheostomy. 
                                                                
223Crawford ES, Svensson LG, Coselli JS, Safi HJ, Hess KR. Surgical treatment of aneurysm and/or dissection of 
the ascending aorta, transverse aortic arch and ascending aorta and transverse arch. Factors influencing 
survival in 717 patients. J Thorac Cardiovasc Surg. 1989; 98:659–673. 
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12.5.15.3 Independent Influences on Survival 
 NYHA class ≥ III.  
The finding of NYHA class ≥ III+ as an independent risk factor for survival (HR 2.25, 
P < 0.002) is most likely a surrogate marker for a multitude of pathologies 
underlying this symptom—a composite variable—which independently are not 
significant. These include aortic valve disease, ischemic heart disease, impaired left 
ventricular function, and respiratory disease. By far, the largest proportion of 
patients, however, required aortic valve replacement, but this did not come out as 
an independently significant variable with respect to survival. A recent study 
examining NYHA class at the time of aortic valve repair (AVR) for severe aortic 
stenosis224 demonstrated that patients with NYHA III–IV had significantly impaired 
short- and long-term survival compared to those with NYHA I–II, even with 
preserved left ventricular function. Ischemic heart disease, ventricular dysfunction, 
and respiratory compromise might all be expected to negatively impact prognosis 
independent of aortic disease. A study by Leavitt et al. 2006225 has shown that in 
patients who have undergone CABG, survival over 10 years is significantly impaired 
in those patients with a diagnosis of COPD. Similarly, survival has been shown to be 
impacted by ischemic heart disease and ventricular dysfunction226.  
Unlike most series, a good proportion of our patients were symptomatic from 
concomitant disease rather than aneurysm per se, and these data suggest that earlier 
intervention before development of symptoms is appropriate. Interestingly, 
                                                                
224 Piérard S, de Meester C, Seldrum S, Pasquet A, Gerber B, Vancraeynest D, et al.. Impact of preoperative 
symptoms on postoperative survival in severe aortic stenosis: implications for the timing of surgery. Ann 
Thorac Surg. 2014; 97:803–809 
225 Leavitt BJ, Ross CS, Spence B, Surgenor SD, Olmstead EM, Clough RA, et al.. Long term survival of patients 
with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery. Circulation. 2006; 
114:1430–1434 
226 Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, et al.. Long-term survival of 
medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994; 90:2645–
2657. 
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Crawford's original series223 did demonstrated the presence of symptoms in the 
form of angina as an independent variable in long-term survival following aortic 
arch surgery.  
Preoperative investigation and aggressive optimization of causes of breathlessness 
may represent an opportunity to improve not only perioperative morbidity and 
mortality, but also longer-term survival in these patients. 
 Postoperative renal dysfunction.  
Preoperative renal impairment has the highest hazard ratio in our multivariate 
model (3.11, P < 0.0001) of risk factors for follow-up survival. A recent study 227 in 
which a large cohort of patients undergoing cardiac surgery, including aortic 
surgery, were examined for a relationship between renal impairment and survival 
showed that, preoperative renal dysfunction is a predictor of long-term mortality in 
cardiac surgery patients. Indeed, in a large series of aortic patients presented by 
Patel et al.221, preoperative renal impairment was an independent predictor of 
survival. In the original Crawford series223, renal dysfunction was a significant 
variable. Interestingly, Estrera et al217, in 2002, found postoperative renal failure but 
not preoperative renal impairment as a risk factor for follow-up survival. Certainly, 
Loef et al 228, in 2005, drew a similar conclusion in a large series of patients 
undergoing cardiac surgery: immediate postoperative renal function deterioration 
in cardiac surgical patients predicts in-hospital mortality and long-term survival (HR 
1.83). While postoperative renal failure and its relationship to survival are, of course, 
interesting, this points us to providing excellent preoperative and postoperative 
care. Preoperative renal impairment and its relationship to survival offer us an 
opportunity to modify and improve the health status of the patient with a view to 
improving long-term survival.  
                                                                
227 Dhanani J, Mullany DV, Fraser JF. Effect of preoperative renal function on long-term survival after cardiac 
surgery. J Thorac Cardiovasc Surg. 2013; 146:90–95. 
228 Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G, et al.. Immediate postoperative renal 
function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am 
Soc Nephrol. 2005; 16:195–200 
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Taken together, evidence suggests that meticulous attention to modifying or 
maintaining renal function in the perioperative period is crucial to long-term 
survival. 
 Circulatory arrest time > 100 min.  
Intuitively, prolonged periods of circulatory arrest will cause significant 
physiological distress. Indeed, numerous studies have discussed durations of 
circulatory arrest as significant predictors of death and morbidity such as stroke, 
many of these summarized in systematic reviews229230. Such morbidity will of course 
have consequences for survival. While prolonged circulatory arrest times may 
simply reflect complex anatomy and pathologies such as acute Type A dissection, 
chronic Type A dissection or infective processes, these times are also determined by 
the orchestration of the operation in terms of early distal body perfusion, use of 
various branched configurations for arch vessels, or the Carrel patch technique. The 
definition of the circulatory arrest time is also important in understanding and 
interpreting studies. In this study, we have taken circulatory arrest time as the time 
taken to re-establish distal body perfusion. In the case of hemiarch, this definition is 
easily understood as completion of the anastomosis is the point of return of distal 
body perfusion and cerebral perfusion. When total arch with Carrel patch is 
employed, again, the definition is easily understood as completion of the distal 
anastomosis and patch is the point at which distal and cerebral perfusion is 
established. However, in total arch replacement, when separate branches were 
employed, distal perfusion was re-established on completion of the distal 
anastomosis. Each head vessel was then anastomosed sequentially with ongoing 
anterograde cerebral perfusion, and in these cases, the circulatory arrest time was 
less than the “assisted cerebral perfusion time” by the duration of time it took to re-
anastomose 1-3 cerebral vessels. In terms of modifiable risk factors, the more 
                                                                
229 Ziganshin BA, Elefteriades JA. Deep hypothermic circulatory arrest. Ann Cardiothorac Surg. 2013; 2:303–
315. 
230 Tian DH, Wan B, Bannon PG, Misfield M, Lemaire SA, Kazui T, et al.. A meta-analysis of deep hypothermic 
circulatory arrest alone versus with adjunctive selective anterograde cerebral perfusion. Ann Cardiothorac 
Surg. 2013; 2:261–270 
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frequent use of individual branches as opposed to a Carrel patch has allowed us to 
reduce our circulatory arrest times, although we have yet to see this translate into 
survival benefit. We have not yet acquired an easy, safe, and reproducible 
mechanism to establish distal perfusion during construction of the distal 
anastomosis, but this would effectively reduce circulatory arrest time further, as 
defined in our series. 
 Peripheral vascular disease.  
With the exception of one small study of 62 patients, which revealed that peripheral 
vascular disease was significantly associated with transient neurological 
dysfunction following arch surgery231, little has been published. This may be because 
of the small number of patients with peripheral vascular disease in other studies, 
and even with our patient cohort, only 7.3% were found to have peripheral vascular 
disease. Clearly, atherosclerotic burden might be expected to influence follow-up 
survival. A study by Kurra et al 232 studied computed tomography imaging data on 
862 patients undergoing cardiac surgeries and quantified a “plaque burden score.” 
They concluded that the extent of thoracic atheroma burden is independently 
associated with increased long-term mortality in patients following cardiothoracic 
surgery. This again provides opportunity to modify survival by careful investigation 
and treatment of peripheral vascular disease both preoperatively and 
postoperatively. 
 Concomitant CABG operation.  
In our study, 16% of patients underwent concomitant CABG. A number of previous 
studies have described outcomes from concomitant CABG and aortic surgery. As far 
                                                                
231 Matalanis G, Hata M, Buxton BF. A retrospective comparative study of deep hypothermic circulatory arrest, 
retrograde and anterograde cerebral perfusion in aortic arch surgery. Ann Thorac Cardiovasc Surg. 2003; 
9:174–179. 
232 Kurra V, Lieber ML, Sola S, Kalahasti V, Hammer D, Gimple S, et al.. Extent of thoracic aortic atheroma 
burden and long-term mortality after cardiothoracic surgery: a computed tomography study. JACC Cardiovasc 
Imaging. 2010; 3:1020–1029 
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back as 2002, Hitoshi Yokoyama233 summarized the outcomes of 6 studies between 
1989 and 2001 demonstrating higher operative mortality and morbidity from 
concomitant CABG. Our study demonstrates that concomitant CABG is not associated 
with higher operative mortality but is associated with worse postoperative follow-
up survival, with a hazard ratio of 2.14 (P < 0.008). There is a wealth of data from 
numerous studies demonstrating that concomitant CABG at the time of AVR is 
negatively associated with survival 233,234, and data from the Bristol group235 have 
reported reduced 3-year survival in patients undergoing concomitant CABG at the 
time of ascending/arch surgery. Coronary grafting at the time of aortic arch surgery 
is required for symptomatic reasons and to aid myocardial protection at the time of 
surgery; it does not, however, appear to be associated with prognostic benefit. On 
the face of it, this does not appear to be a modifiable risk factor coming into surgery. 
Managing Perioperative Risk Factors for Long-term Survival— “Primary and 
Secondary Prophylaxis” 
Good long-term survival does not just happen. Careful attention is required to 
modifiable risk factors preoperatively, and the best possible pre- and postoperative 
care is crucial. Care for these patients should not end on discharge from hospital. 
Lifelong follow-up and attention to ongoing secondary prophylaxis is important.  
                                                                
233 De Waard GA, Jansen EK, de Mulder M, Vonk AB, Umans VA. Long term outcomes of isolated aortic valve 
replacement and concomitant AVR and coronary artery bypass grafting. Neth Heart J. 2012; 20:110–117. 
234 Jones JM, Lovell D, Cran GW, Macgowan SW. Impact of coronary artery bypass grafting on survival after 
aortic valve replacement. Interact Cardiovasc Thorac Surg. 2006; 5:327–330. 
235 Narayan P, Rogers CA, Caputo M, Angelini GD, Bryan AJ. Influence of concomitant coronary bypass graft on 
outcome of surgery of the ascending aorta/arch. Heart. 2007; 93:232–237 
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CHAPTER THIRTEEN 
 
13. DISCUSSION 
13.1 The LHCH Experience of Sub-Specialisation 
Liverpool Heart and Chest Hospital (LHCH) is the only cardiothoracic stand-alone 
centre in the UK with independent trust status. The hospital covers a population of 
2.8 million, performing approximately 1800 cardiac and thoracic surgical procedure 
a year of which 180 cases are elective and non-elective thoracic and 
thoracoabdominal aortic aneurysm repairs. Despite the high volume of general and 
conventional cardiac surgery that is being performed by 10 surgeons on general 
cardiac rota, it was felt that the hospital mortality for acute Type A aortic dissection 
was excessive at around 30%. Hence, in 2007, LHCH became the first in the UK to 
implement a subspecialised twenty-four hour on-call rota for acute Type A aortic 
dissection. The primary objective was to reduce morbidity and mortality of this dire 
operation to an acceptable national and international level. Hence, the trust 
underwent and approved a radical rearrangement to try and achieve the 
aforementioned.  The aortic team was formed and which more or less were 
performing the highest volume of procedures relating to elective and non-elective 
aortic aneurysm surgery. The team which currently comprises of four aortic 
surgeons performs solely all non-elective and elective procedures. In addition, the 
surgical team is supported by dedicated anaesthetists and nursing staff. Subsequent 
to this re-organisation within the service delivered by LHCH, the mortality and 
morbidity for both elective and non-elective complex aortic surgery has dramatically 
improved. Pertaining to the scope of this study, we have clearly presented in our 
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results the significant reduction in mortality after acute Type A aortic dissection 
falling from 33.8% to 9.6% after implementation of the specialised rota. We also 
demonstrated the same effect to aortic arch aneurysm surgery cohort and as such 
we demonstrated that the mortality and morbidity following aortic arch aneurysm 
repair is equivalent to international level and is below the national average. The 
subspecialisation model improved the 5 years’ actuarial survival of effected patients 
and that truly relates to the effectiveness arm of this subspecialised and high volume 
service and centre.  
Subsequently, this improvement I results and outcomes observed in our elective and 
non-elective surgery paved the way for the aortic aneurysm service and team to 
accept higher volume of referral from the region and from the country at large.  
Putting this concept into perspective, one would deduce that concentration of 
expertise and volume to the appropriate surgeons who provide a well-rounded 
service perform increasing more work and complex aortic cases than the rest of 
cardiac surgeons within the same centre have the tendency to support the linearity 
seen with volume versus outcomes. The volume trends increased with time as one 
would expect with increasingly better outcomes.  
No wonder the expertise of the team and the establishment of better outcome 
emerged from not only volume, referral and skills but also due to a very subtle fact 
that the three surgeons were all trained by one senior surgeon. Aortic arch 
operations were preformed among three aortic surgeons who were all trained by a 
principle surgeon who had transferred his skills to the subspecialised team as of 
2005. Interestingly, while the extent of surgical intervention did not change between 
the two eras (before and after subspecialisation), the time spent in surgery noted as 
cutting time was prolonged. Certainly, the cardiopulmonary bypass times and cross 
clamp times were significantly prolonged in equally acute type A dissection repair 
and elective aortic arch surgery. The reason behind this paradoxical observation is 
suspected due to the adoption and evolution of skills to initiate a robust and reliable 
prophylactic techniques, such as routine buttressing of suture lines, developed 
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during elective aortic cases and also applied to the emergency situation. This 
operative techniques development aims to minimise bleeding and malperfusion. 
Bleeding being the commonest reason why patients are returned to theatre for re-
exploration and for targeting the actual cause. This take back approach although it’s 
aimed at saving the patient’s lives, it comes at a monetary cost.  Which is why the 
aortic team at Liverpool Heart and Chest Hospital adopted a very rigid protocol for 
haemostasis by adding two double layers to avert bleeding and hence the increment 
in cost as seen in the pre and post subspecialised era.  While this added cost as 
reflected by increased theatre time, clearly it is a very reliable approach and is cost-
effective in the sense that such approach led to improvement in surgical outcomes 
and overall survival as elaborated in the sections above. 
The only published paper on standardization of care for aortic dissection comes 
from Minneapolis (11), where a regional protocol was instituted in August 2005. 
This began with the suspicion of the diagnosis in community hospitals where a single 
telephone call activated the protocol, leading to operation by one of 4 specialist 
cardiovascular surgeons. The group demonstrated significantly reduced times from 
diagnosis to surgery but no significant reduction in mortality rates so far.   A clear 
issue in comparing studies is the different patient groups. Typically, young, low risk 
patients are thought to be referred for surgery, with older higher risk patients 
undergoing endovascular treatment. We would suggest all patients undergoing total 
arch/proximal descending aortic intervention to be discussed at a truly multi-
disciplinary meeting with cardiac surgeons, vascular surgeons, interventional 
radiologists and intensivists. Ideally, patients should be assessed and treated on the 
basis of their pathology and fitness for intervention at a national level rather than 
availability and success of local services.  
Arguably, prospective randomised trials have never been performed in acute aortic 
dissection, and realistically are not likely due to their ethical controversies. As such 
reporting of aneurysm surgery experience from each and every centre worldwide is 
a form of accepted evidence based medicine.  
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We acknowledge the fact that current reported results in the literature might be due 
to better developments in anaesthetic agents and drugs employed, the 
understanding of brain protection and perfusion techniques over the last few years. 
However, all of the aforementioned could be grouped as adjuncts to the fact the 
practice does make perfect and more volume reflects better outcomes. This will be 
discussed in details in the section below. 
 
13.2 Factors Underlying Improved Clinical Outcomes 
There are multiple factors that ought to be highlighted in this context that 
collectively attributed to the overall success of the working model of 
subspecialisation.  Of these aspects are the following: 
1. Volume: The major contributing factor amongst other is the large number of 
volume of case load that was initiated following the concept of subspecialisation 
at Liverpool Heart & Chest Hospital. The analysis has identified a significant 
improvement in clinical outcomes resulting from the introduction of a sub-
specialised aortic surgical team. As we demonstrated, the increase in volumes, 
with published evidence on relationship between the hospital volume of 
procedures and outcomes for elective and non-elective surgeries is the most 
forward concept to explain the rearrangement in service and reduction in 
mortality and morbidity. It relevant to mention that the team non-aortic elective 
and non-elective work remained within national standards for mortality and 
morbidity. This is clearly reflected in the CUSSUM curves that the team of non-
aortic conventional work is regularly audited and the quality of the service 
provision is not compromised. This rearrangement of service that complies with 
standard of care and better service provision didn’t come at the stake of more 
concentrated and conventional work is being directed to other consultants hence 
creating a pseudo-subspecialisation to the rest of the cardiac surgeons on the 
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rota. This was a divisional and strategic operational move that ultimately 
concentrated the expertise from one end to aortic aneurysm service provision 
without alteration of normal conventional cardiac work load.  
2. Multidisciplinary Team Process: Other related factor is the strong 
multidisciplinary team (MDT) processes in cardiothoracic surgery practice in the 
UK that has a strong tradition with involvement in MDTs particularly in lung 
cancer surgery and oesophageal cancer surgery. In addition, new European 
Guidelines on the management of ischaemic heart disease place the MDT at the 
heart of decision-making236. Liverpool has a strong MDT process ensuring 
intervention is personalized to patients depending on pathology and co-
morbidities. Key to this is preoperative assessment by anaesthetics/intensivists 
and their inclusion in the whole perioperative process. On the opposite end, the 
only international guidelines on thoracic and thoracoabdominal aortic aneurysm 
intervention published by the American Heart Association make no mention of 
involvement of an MDT in managing cases.  
3. Quality Outcomes Framework: Our institution has developed a “Quality 
Outcomes Framework” (QOF), broadly based on Society of Thoracic Surgeons 
(STS) Quality Performance Measures in cardiac surgery (www.sts.org/quality), 
for internal reporting of annualized data from aortic arch surgery. Unlike the STS 
measures, which include indicators of process, structure, and outcome, our QOF 
concentrates on outcomes, annualized, and is presented as a “Statistical Process 
Control Chart” (Appendices). These include in-hospital mortality, 30-day 
mortality and 1-year mortality, stroke, re-exploration, postoperative renal 
failure, and prolonged ventilation. This mechanism allows us to monitor the 
stability of our outcomes annually and investigate and modify processes when 
deviation is observed. These data are presented in Appendices and not only 
demonstrate our increasing annual activity over time but also the relative 
stability of outcomes with little influence of the change in service provision from 
                                                                
236 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the 
management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 
Oct;34(38):2949-3003 
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2007.  Stability of outcomes, particularly major morbidity and mortality, is an 
important platform for interpreting our survival data and the influences on it. 
4. Subspecialised Clinical Disciplines and other Allied Teams:  The advent of 
the subspecialised aortic team that jointly perform aortic work-loads on complex 
thoracic and thoracoabdominal aortic aneurysm cases, advertently had to be met 
with the surge of anaesthetic expertise, clinical radiology, perfusion innovation 
and implementation and most importantly the efforts made from allied health 
professionals to implement protocols and intensive surgical care structure. 
Although this thesis can’t support the aforementioned in terms of robust data 
and analysis seen from different disciplines, it’s the overall presupposition of all 
these services that worked together in a coherent and homogenous team effort 
that inadvertently supported the subspecialised team and concept.  
5. Innovation in Thoracic Aortic Aneurysm Surgery: Its inconceivable that the 
model of subspecialisation revealed out to be an impact model which allowed for 
the morbidity and mortality figures to be restored to and beyond national and 
international levels. Yet, this not only was accomplished through rearrangement 
in the service and the development of specialised area and clinical settings that 
supported this rearrangement but also due the fundamental fact that innovation 
and evolution of device technology, anaesthetic agents, perfusion techniques, 
brain protection methods, neuromonitoring advancement and post-operative 
monitoring techniques all contributed to this impact model. Hence, all the 
aforementioned co-existed to supplement the advancement of the aortic surgery 
team and impact the model of subspecialisation. Also, this moves in conjunction 
with the uniformity on the surgical and technical skills. The intricacy of this 
uniform surgical practices and skills see applied amongst different surgeon who 
perform aortic complex procedures using same skills and abilities explains why 
such impact model is attained. The primary senior surgeon who aided in the 
development of this team passed on his skills that were transferred amongst the 
team.   Hence, its inarguably correct that the uniformity of the skills executed in 
between the surgeons and that was transcribed from their predecessor would 
undoubtedly correlate to the improvement in quality outcomes as conveyed 
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thought in this thesis.  
13.3 Subspecialisation Enhances Cost-Effectiveness 
The increase of referral of elective and non-elective workload to the specialised 
aortic team contributed to enhancing the improvement seen on outcomes level and 
influenced the survival of our patient cohort. One could argue that the operative 
characteristic has been prolonged in a sense due to extra haemostatic control intra-
operatively that impacted the reoperation and re-exploration rate for bleeding in a 
positive sense.  
Yet, if more time is being spent in theatre while surgeons take extra care in making 
sure that re-exploration is minimised to subliminal levels that afford the patient 
better outcomes and the surgeons’ better results. The cost of theatre time increased 
as it’s a mere reflection of the length of operation and due to the fact that more of the 
subspecialised team patients surviving longer, one would expect that the post-
operative lengths of stay, both on the ward and on the ICU to increase significantly 
as a consequence. However, the analysis revealed that the cost between the two 
group before and after the subspecialisation remained to be neutral and no 
meaningful cost incurrence occurred. This leads us to say that the subspecialisation 
certainly led to improvement in outcomes and survival benefits were enhanced. This 
was accomplished at cost neutral effect between the two groups. This will lead us to 
conclude that subspecialisation has certainly been demonstrated to be an important 
factor in enhancement of cost-effectiveness.   
There have been significant clinical and economic benefits as a resultant to a 
dedicated sub-specialised surgical service and team in aortic surgery at Liverpool 
Heart & Chest Hospital. It would be superb if such cost-effective model could be 
transferred to other organisations with the National Health Service. It’s 
demonstrated across the country that other specialities such as the hepatobialiary 
and pancreatic surgery benefited profoundly from developing a subspecialised and 
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concentrated services. This is also true for vascular service throughout the UK and 
their establishment of new era of vascular breed through their instrumental training 
system that was initiated in 2011.  Hence, reaping the benefits from similar 
centralization and reorganisation of their service and expertise in cardiothoracic 
and in particular aortic surgery will certainly follow pursuit.  
However, the overall centralisation that was viewed at LHCH affected positively 
other service delivery by attaining improvements in parallel reorganization of 
associated services, such as interventional radiology and specialist critical care. 
Radiology at LHCH offer and due to wide range of expertise and experience the 
ability to aid in diagnostic measures and resources. This surely would require some 
degree of scale measurement in terms of costing and manpower. Yet, it’s my insight 
that such reorganisation in manpower and parallel and allied speciality will all fall 
under one umbrella of being cos-effective and overall will provide patient with 
better quality of care provision.   
 
13.4 Standardization and Centralization of Thoracic 
Aortic Aneurysm 
The aim and strong rationale of subspecialisation and centralization is to provide 
centres with a large and reaching catchment areas that has a reciprocal effect on the 
subspecialised unit. It allows more robust referral to influx and hence will maintain 
an adequate voluminous exposure. Essentially, thoracic aortic aneurysm service is 
in much need of such approach and a national policy and mandate that would 
support such programs across the UK.  Hence, this will provide a sustained and 
increasing in volume to concentrated expertise that will allow the possibility to 
address dire surgical diseases and avert associated complications.  
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It will then reciprocate this arrangement that will ultimately reduce mortality and 
improve long term survival following aortic surgery.   
The advent of technological superiority in aiding the diagnosis and surgical planning 
of aortic surgery and the understanding of the natural history resulted in 
personalised and targeted therapies and surgical procedures to be done on wider 
range of the affected population. This allowed for such cost-effective diagnostic tests 
to be distributed to a smaller number of regional centres to attempt on operating on 
such patients’ cohort. Hence this has titrated the inexistence of specialist centres and 
diverted a large number of patients to be operated at local low- volume institutions.  
The development of standardization subspecialisation requires a comprehensive 
assessment of the current status in aortic surgery in the UK.   
This thesis illustrated this from the wider literature review. The aforementioned, 
should it be a mandate and a national policy would irrevocably prevent unnecessary 
death related event due to lack of available resources, expertise at the centre or 
hospital that provide237. This initiative has ultimately to be mandated as a 
governance policy in the NHS and to be commissioned to supra-regional centres or 
hospitals with intent to treat the wide array of aortic pathologies and established 
framework of referral and robust mechanism to refer patients.  
The quality and measured outcomes from such national reorganisation that was 
demonstrated at a smaller scale in this thesis i.e. at LHCH provides a platform for 
such transfer of quality and expert skills to other much need population across the 
region and the country. This will impact the utilisation of resources and direct it to 
the much needed and debilitated patients. It will allow an analysis to be made on 
large scale nationally to attain a better understanding albeit on cost and outcome 
measures.  
                                                                
237 CIS Meadows, W Rattenberry, C Waldmann. Centralisation of specialist critical care services, JICS 
2011;12:2, 
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However, centralisation and subspecialised service has its own at a drawback; this 
includes displacement of families and relatives, together with increased travel times 
and costs to meet with a specialist.  This is not easy to quantify and is beyond the 
scope of this thesis but surely will need to be considered. The emphasis of 
importance of concentration of experts in a suitably subspecialised and central 
service might be met in the public eye and media perception as negative. This could 
be attributed to loss of local services. However, the ‘hub and spoke’ model of 
specialist service delivery is characterised by close links between regional   referring 
hospitals and specialist centres and is exemplified by percutaneous coronary 
intervention networks238,239.  
The introduction of such a network for cardiac surgery in Italy had a positive effect 
on patients’ outcomes, with a 22% reduction in hospital mortality rates240.  
 
13.5 Is the LHCH Subspecialized Model Generalizable 
throughout the NHS?  
A key to answering this question is in deciding whether we believe there is evidence 
that intervention can alter the natural history of this disease process to provide 
either symptomatic or prognostic benefit. As suggested earlier, the international 
literature does document particularly poor survival for patients managed medically 
and improved significantly following intervention. There are no data published on 
survival with and without intervention in the UK; however, published   survival   in   
our   own   group   of postoperative aortic patients in Liverpool compares favourably 
                                                                
238 De Maria E, Ricci S, Capelli S et al. Feasibility of transradial approach in a hub and spoke cath lab network. 
Minerva Cardioangiol 2010;58:11-15 
239 Morgan KP, Leahy MG, Butts JN, Beatt KJ. The cost-effectiveness of primary angioplasty compared to 
thrombolysis in the real world: one year results from West London. Eurointervention 2010;6:596-603 
240 Nobilio L, Fortuna D, Vizioli M et al. Impact of regionalisation of cardiac surgery in Emilia-Romagna, Italy. J 
Epidemiol Community Health 2004; 58:97-102 
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with published survival for medically treated patients. At present, it is necessary to 
accept that international data on clinical effectiveness of intervention on thoracic 
and thoracoabdominal aneurysms may be extrapolated to the English NHS; 
however, this is the subject of a recent call by the UK National Institute for Health 
Research. Having drawn the tentative conclusion that survival following 
intervention in the UK is improved is there sufficient volume to underpin acceptable 
outcomes. This is uncertain, however, the Liverpool model, which predominantly 
accepts patients from The North West (population 7 million), has an annual activity 
of between 150 and 180 shared between four surgeons.  
Providing this model can be duplicated it would suggest that in a population of over 
50 million in England there is roughly sufficient volume for 4 – 5 centres. 
Interestingly, NHS Scotland, with a population of around five million, commissioned 
the Vascular Surgery Unit at the Royal Infirmary of Edinburgh to perform 25 
interventions per year on the thoracoabdominal aorta from April 2001 
(www.nsd.scot.nhs.uk). In their government review in 2007 their service was 
deemed clinically robust and offered value for money. These figures are comparable 
with the population in the North West and the activity through Liverpool.  
Based on this, we believe there is sufficient international evidence for intervention, 
sufficient UK volume and proof that acceptable outcomes can be achieved in the UK 
NHS framework. 
Generalizability of this subspecialised model could potentially be achievable. 
Accepting the change and limitations of surgical ability are amongst the factors that 
might tip sub-speciality in thoracic aortic aneurysm as a favourable and sensible 
trend. This was the bottom element that rerouted surgical expertise in aneurysm 
repair at LHCH. This initiative further led to a local generalizability of a consensus 
that was made in harmony between a group of skilful individuals, the managers and 
local commissioners. Yet, such change was met by another challenge that is the 
opportunity cost if surgeons are moved away from other therapeutic areas.  
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To divert this, surgeons were being as effective as needed in other conventional 
surgeries. Their results were also audited and quality monitored.  
Hence, opportunity cost and service provision was balanced and overall welfare gain 
and quality outcomes were set and met. We feel however, that the development of 
standard surgical techniques and the regular performance of these on a weekly basis 
as well as the increased number of cases per surgeon are the major contributing 
factors to the improvement in results. This might stand out as a challenge to other 
centres.  
We acknowledge that this model of care might not be appropriate to every trust and 
that ours is one of the largest cardiothoracic units in the country. It may however, be 
regionally applied in order to provide consistent subspecialist out of hours, year 
round cover. If such model could be disseminated to other service providers across 
generality across the wide service in the NHS might be achieved with limited 
modification.  
Overall, the patients’ needs and expectation are constantly changing and the need 
for specialised and cost effective model with new treatment and technological 
advancement is the future of the NHS. This would be viable in a financial constraint 
environment that aimed at delivering safe options and world class service.  
This thesis has demonstrated that given the significant clinical and economic 
benefits of a subspecialised team can result in quality service and outcomes. The fact 
that such improved surgical outcomes can be achieved with little or no change in 
resource use suggests that sub-specialisation holds the potential to be a highly cost-
effective structure of surgical care.  
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CHAPTER FOURTEEN 
 
14. CONCLUSION 
Subspecialisation in aortic aneurysm surgery has been demonstrated as an impact 
model that certainly seems to function within the framework of NHS. Crucial to this 
service provision is the team approach and the volume of cases referred. Yet, a very 
important contributing factor manifesting is the inclusive and comprehensive 
multidisciplinary team (MDT) discussion on every patient.  
We demonstrated that simple changes in service provision has led to a significant 
improvement in outcome and survival amongst our elective and non-elective case 
mix. The contemporary aortic outcomes accomplished are directly related to the 
increasing volume of cases being operated on at LHCH. This volume outcome 
relationship has been well established in literature and has been at the centre of 
attention in many speciality including vascular speciality that underwent rigorous 
steps to re-align the provision of services in the UK. This has provided ample of 
lessons to be learned from and how a speciality has moved to effectively be 
centralised and subspecialized at national scale.   
The development of a robust referral system and the increasing of volume of aortic 
cases has allowed us to produce an initiative to hospital managers and 
commissioners. The initiative that rearrangement in the way we offer aortic service 
is crucial to attempt to reduce morbidity and mortality from dissection and non-
dissection work load. This has led to the establishment of a UK first specialised 
service with a dedicated 24 hours’ acute aortic service. The subspecialisation 
initiative stood ground not only due to our commitment to offer better service but 
due to factors that the team has standardized in between them. Such factors are 
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attributable to the fact that the aortic surgeons were all trained by one principle 
surgeon whose skills has been passed on. Other factors include the uniformity in the 
surgical techniques and additional higher number of cases per surgeon per year 
were amongst the major contributing factors to the improvement in results.  
The outlined results that were demonstrated between the before and after 
subspecialisation rota are sufficient evidence that indicate quality improvement that 
impacted patient outcomes, survival benefit at cost neutral implications.  
The introduction of subspecialisation was expected to have direct impact on cost 
distribution in our division.  Although the introduction of a separate aortic on call 
rota resulted in some change in how surgeons were remunerated, this was merely 
to reflect the change in their on call case load.  Surgeons on the aortic team would 
see their on call case load go up as a result of all aortic cases being directed their 
way. To reflect this, the on call premium they are paid above their basic salary was 
increased. However, this increase in on call caseload for the newly created aortic 
team naturally coincided with an equal and opposite reduction for the non-aortic 
surgeons. Hence, the change was once again achieved at cost neutral level. The 
average cost per patient in the post subspecialisation has not varied significantly as 
seen in our analysis and with no notable change in resource cost resulting from the 
change in the clinical re-organization, it is perhaps reasonable to deduce that the 
introduction of subspecialisation was cost neutral to the hospital as well. The 
improvement of our patients’ cohort outcomes had two separate effects on cost 
implication. The effect of reduced mortality is, “ceteris paribus”, an increase in length 
of stay and therefore an increase in costs. However, also present is the effect of a 
reduction in adverse events and other complications, which works to reduce length 
of stay by improving recovery time. 
The idea of producing aortic supercentre that follows pursuit the model seen in the 
United States could not be achievable at the NHS service level due to multitude of 
factors at the centre of which is cost and the fact that aortic subspecialisation model 
has been floated in the United Kingdom so that the highest quality of preoperative 
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evaluation, operative management, and follow-up can be provided patients. Yet we 
look at our experience and results in the elective and non-elective open thoracic 
aortic surgery and can deduce that at our regional unit including patient 
demographics, in- hospital results such as mortality and postoperative outcomes, as 
well as survival are equivalent to worldwide published results.  
It’s undeniable that a surplus of other relevant changes had to be implemented to 
support our concept of subspecialisation and to help in the consistency of the volume 
of our cases and such changes occurred at other similar speciality including 
anaesthesia and operative perfusion scientist. We have specialised aortic 
anaesthetist and perfusionist that assist in every case albeit on thoracic and 
thoracoabdominal cases. This increased in volume has mirrored our results and 
their expertise has also been well concentrated. This is in addition to our well-
resourced critical care area whose staff are well trained to delineate critical phases 
in the post-operative management of our aortic patient that certainly influenced our 
patient outcome and longevity of their survival. Another major contributing factor 
that supported the subspecialisation of our aortic service is the multidisciplinary 
team meeting that allowed cases to be openly discussed and for the best intervention 
and case management to be achieved. The eventuality of the improvement of our 
results culminated in our dedicated aortic clinics and we at LHCH are amongst the 
top hospitals in the world to follow-up our patients and screen for their aneurysm 
changes and intercept any change that require immediate attention and surgical 
intervention that potentially avert the patient futile outcomes. In a nutshell, all the 
aforementioned factors contributed significantly to subspecialised initiative that 
evolved rapidly and allowed for our results to be superior to national published 
aortic outcomes and survival.  
We believe there is sufficient volume and evidence of adequate outcomes for the UK 
to offer a comprehensive service for intervention on thoracic aortic aneurysms. 
Indeed, the UK has several facets of service provision that would allow for 
development of an internationally unique and effective system.   
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However, we suggest there is a need for a review of service provision by all 
stakeholders and a rationalization of services. A comprehensive and inclusive MDT 
must be central to the process.    
 
  
 212 
 
AREAS FOR FUTURE RESEARCH 
This thesis opens a significant number of areas for future research. Such areas can 
be categorized in broad terms as “clinical research”, and 'economic/health policy 
research'. Throughout this study we demonstrated the current evidence that 
thoracic aortic aneurysm service at LHCH became an evolving subspecialty. A case 
for a national strategy with a few designated regional centres in a system analogous 
to provide aortic specialism has to be mandated. The cluster of specialism should be 
related to the expertise offered, hence, each patient should be matched to 
appropriate treatment regimens and adequately consented. Each centre should be 
subject to regular audit to ensure adequate activity monitoring and outcomes. All 
national centres should commit to regular bench-marking exercises, exchange of 
processes, audit and provide training.  
In the UK, thoracic aortic surgery remains a part of cardiothoracic surgery in general, 
rather than an independent sub-specialty. Proposals for the centralization or 
subspecialisation of aortic aneurysm surgery as a subspecialty is underway. We 
acknowledge that our model of care may not be appropriate to every trust and that 
ours is one of the largest cardiothoracic units in the country. It may however, be 
regionally applied in order to provide consistent subspecialist out of hours, year 
round cover. We have demonstrated that simple changes in service provision can 
lead to significant improvement in outcome for this lethal condition. 
  
 213 
 
REFERENCES 
1. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and 
uncertainties. J Am Coll Cardiol. 2010; 55:841–857. 
2. Davies RR, Kaple RK, Mandapati D, Gallo A, Botta DM Jr, Elefteriades JA, et al.. Natural history of 
ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg. 
2007; 83:1338–1344 
3. Kuzmik GA, Feldman M, Tranquilli M, Rizzo JA, Johnson M, Elefteriades JA. Concurrent intracranial 
and thoracic aortic aneurysms. J Am Coll Cardiol. 2010; 105:417–420 
4. Hornick M, Moomiaie R, Mojibian H, Ziganshin B, Almuwaqqat Z, Lee ES, et al.. ‘Bovine' aortic arch -a 
marker for thoracic aortic disease. Cardiology. 2012; 123:116–124.  
5. lbornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al.. Familial thoracic aortic 
aneurysms and dissections–incidence, modes of inheritance, and phenotypic patterns. Ann Thorac 
Surg. 2006; 82:1400–1405.  
6. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and 
Management of Patients With Thoracic Aortic Disease. Circulation. 2010;121:e266-e369 
7. Henry Gray (1821–1865).  Anatomy of the Human Body. 
8. DeBakey M. A surgical perspective. Ann. Surg. 1991;213:499–531 
9. Cooley DA. Aortic Aneurysm Operations : Past, Present, and Future. Ann Thorac Surg 1999;67:1959– 
10. Tuffier T. Intervention chirurgicale directe pour un anevrisme de la crosse de I’aorte: ligature du sac. 
Press Med. 1902;10:267 
11. Moore C, Murchison C. On a new method of procuring the consolidation of Fibrin in certain incurable 
Aneurisms with the Report of a case in which an Aneurism of the ascending Aorta was treated by the 
insertion of Wire. Med Chir Trans. 1864; 47:129–49. 
12. Borrie J, Griffin SG. Twenty-seven cases of syphilitic aneurysms of the thoracic aorta and it branches. 
Thorax. 1950; 5:293–324. 
13. Harrison PW, Chandy J. A Subclavain Aneurysm Cured by Cellophane Fibrosis Three Years Ago. Ann. 
Surg. 1941;118:478–81 
14. Coselli JS, Green SY. A brief history of aortic surgery: insight into distal aortic repair. J Thorac 
Cardiovasc Surg. AATS; 2013;145:S123–5 
15. Dake M, Miller D, Semba C, Mitchel l R, Walker P, Liddell R. Transluminal placement of endovascular 
stent-grafts for the treatment of descending thoracic aortic aneurysms. NEJM 1994;331:1792–34 
16. Young R, Ostertag H. Incidence etiology and risk of rupture of aoritc aneursyms. An autopsy study. 
Dtsh Med Wschr. 1987;112(1253-6). 
17. Kunz R. Aneurysms in 35,380 autopsies. Schweiz Med Wochenschr. 1980;110:142–8. 
18. Bonser RS, Pagano D, Lewis ME, Rooney SJ, Guest P, Davies P, et al. Clinical and patho-anatomical 
factors affecting expansion of thoracic aortic aneurysms. Heart [Internet]. 2000 Sep;84(3):277–83. 
19. Patel HJ, Deeb GM. Ascending and arch aorta: pathology, natural history, and treatment. Circulation. 
2008;118:188–95 
20. Coady M a, Davies RR, Roberts M, Goldstein LJ, Rogalski MJ, Rizzo J a, et al. Familial patterns of 
thoracic aortic aneurysms. Arch Surg. 1999;134:361–7. 
21. Agarwal P, Chughtai A, Matzinger FR, Kazerooni EA. Multidetector CT of Thoracic Aortic Aneurysms. 
RG. 2009;29:537–53. 
22. Elefteriades JA, Farkas E a. Thoracic Aortic Aneurysm Clinically Pertinent Controversies and 
Uncertainties. J Am Coll Cadiol. 2010;55(9):841–57. 
23. De Backer J. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype. 
Verh K Acad Geneeskd Belg. 2009;71:335–71 
24. Cury M, Zeidan F, Lobato A. Aortic disease in the young: genetic aneurysm syndromes, connective 
tissue disorders, and familial aortic aneurysms and dissections. Int J Vasc Med. 2013;2013:267215 
25. Halme T, Savunen T, Aho H, Vihersaari T, Penttinen R. Elastin and collagen in the aortic wall: changes 
in the Marfan syndrome and annuloaortic ectasia. Exp Mol Pathol. 1985;43:1–12. 
26. Loeys B, Dietz H, Braverman A, Callewaert B, De Backer J, Devereux R, et al. revised Ghent nosology 
for the Marfan syndrome. J Med Genet. 2010;47:476–85. 
27. Van Karnebeek CD, Naeff MS, Mulder BJ, Hennekam RC, Offringa M. Natural history of cardiovascular 
manifestations in Marfan syndrome. Arch. Dis. Childh.. 2001;84:129–37 
28. Glower DD. Indications for ascending aortic replacement size alone is not enough. Journal of the 
American College of Cardiology. 2011;58:585–6. 
 214 
 
29. Brooke BS, Habashi J, Judge D, Patel N, Loeys B, Dietz III H. Angiotensin II Blockade and Aortic-Root 
Dilation in Marfan’s Syndrome. NEJM. 2008;358:2787–95. 
30. Cook JR, Nistala H, Ramirez F. Drug-Based Therapies for Vascular Disease in Marfan Syndrome : From 
Mouse Models to Human Patients. Mount Sinai Journal of Medicine. 2010;77:366–73 
31. Della Corte A, Bancone C, Quarto C, Dialetto G, Covino FE, Scardone M, et al. Predictors of ascending 
aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. European journal 
of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 
2007;31:397–404 
32. Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic valve: 
pathophysiology, molecular biology, and clinical implications. Circulation [Internet]. 2009;119:880–
90 
33. Fedak PWM. Clinical and Pathophysiological Implications of a Bicuspid Aortic Valve. Circulation . 
2002;106:900–4 
34. Loscalzo M, Goh D, Loeys B. Familial thoracic aortic dilation and bicommissural aortic valve: a 
prospective analysis of natural history and inheritance. Am J Med Genet A. 2007;143:1960–7 
35. Davies R, Kaple R, Mandapat i D, Gallo A, Botta D, Elefteriades J, et al. Natural history of ascending 
aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg. 
2007;83:1338–44. 
36. Pezzin i A, Del Zotto E, Gioss i A, Volonghi I, Costa P, Padovani A. Transforming growth factor β 
signaling perturbation in the Loeys-Dietz syndrome. Curr Med Chem. 2012;19:454–60. 
37. Strachan D. Predictors of death from aortic aneurysm among middle-aged men: The Whitehall study. 
BJS. 2005;78:401–4. 
38. Elefteriades JA. Focused Review Thoracic Aortic Aneurysm : Current Approach to Surgical Timing. 
ACC 2002;1458(02):82–8 
39. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. 
Surgery 1982;92:1103 – 8 
40. Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspectives from the International 
Registry of Acute Aortic Dissection (IRAD). Eur J Vasc Endovasc Surg. 2009 Feb;37(2):149-59 
41. Wang Y, Barbacioru CC, Shiffman D, Balasubramanian S, Iakoubova O, Tranquilli M, et al. Gene 
expression signature in peripheral blood detects thoracic aortic aneurysm. PLoS ONE. 2007;2:e1050 
42. Andrew S. Chun, John A. Elefteriades, Sandip K. Mukherjee. Do Beta-Blockers Really Work for 
Prevention of Aortic Aneurysms? Time for Reassessment.  AORTA, Vol.1, Issue 1 
43. Levick JR. An Introduction to Cardiovascular Physiology. Fifth ed: Hodder Arnold, 2010 
44. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-
term β- adrenergic blockade in Marfan's syndrome. New England Journal of Medicine 
1994;330(19):1335-41 
45. Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M. Chronic β-blocker therapy improves outcome 
and reduces treatment costs in chronic type B aortic dissection. European Journal of Cardio-thoracic 
Surgery 2001;19 (5):606-10 
46. Thakur V, Rankin KN, Hartling L, Mackie AS. A systematic review of the pharmacological management 
of aortic root dilation in Marfan syndrome. Cardiol Young. 2013 Aug;23(4):568-81 
47. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a 
mouse model of Marfan syndrome. Science. 2006;312:117–21 
48. The division of Cardiac Surgery at St. Luke's - Roosevelt Hospital. http://www.slrctsurgery.com/114 
Diagnosis and management of aortic dissection. Contin Educ Anaesth Crit Care Pain (2009) 9 (1): 14-
18. 
49. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL et al. The International 
Registry ofAcute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 
16;283(7):897-903 
50. Klompas M. Does this patient have an acute thoracic aortic dissection? JAMA. 2002;287:2262–72 
51. Trimarchi S, Jonker FHW, Hutchison S, Isselbacher EM, Pape L a, Patel HJ, et al. Descending aortic 
diameter of 5.5 cm or greater is not an accurate predictor of acute type B aortic dissection. J Thorac 
Cardiovasc Surg. 2001;142:e101–7 
52. Mészáros I, Mórocz J, Szlávi J, Schmidt J, Tornóci L, Nagy L, et al.. Epidemiology and clinicopathology 
of aortic dissection. Chest. 2000; 117:1271–1278 
53. Imamura H, Sekiguchi Y, Iwashita T, Dohgomori H, Mochizuki K, Aizawa K, et al.. Painless acute aortic 
dissection. Diagnostic, prognostic and clinical implications. Circ J. 2011; 75:59–66 
54. Braverman AC. Acute aortic dissection: clinician update. Circulation. 2010 Jul 13;122(2):184-8 
55. Bashir, Mohamad; Fok, Matthew; Hammoud, Ibrahim; Rimmer, Lara; Shaw, Matthew; Field, Mark; 
Harrington, Debbie; Kuduvalli, Manoj; Oo, Aung. AORTA, Volume 1, Number 3, August 2013 , pp. 182-
189(8) 
 215 
 
56. Nallamothu BK, Mehta RH, Saint S, Eagle KA. Syncope in aortic dissection: diagnostic, prognostic, and 
clinical implications. J Am Coll Cardiol 2002; 39:241A.  
 
57. McCaig LF, Nawar EW. National Hospital Ambulatory Medical Care Survey: 2004 emergency 
department summary. Adv Data. 2006; 372:1–29.Sullivan PR, Wolfson AB, Leckey RD, et al. Diagnosis 
of acute thoracic aortic dissection in the emergency department. Am J Emerg Med. 2000;18:46–50 
58. Elefteriades J. Thoracic aortic Aneurysms: Reading the enemies playbook. Curr Probl Cardiol. 2008 
May;33(5):203-77. 
59. Shimada I, Rooney SJ, Pagano D, Farneti PA, Guest PJ, Bonser RS, et al. Prediction of Thoracic Aortic 
Aneurysm Expansion : Validation of Formulae Describing Growth. Ann Thorac Surg. 1999;67:1968–
70 
60. Adams F. The Genuine Works of Hippocrates. New York: William Wood. 1929 
61. Lloyd G (editor), Chadwick J (trans), Mann N. Hippocratic Writings. London Penguin Books. 1983;223. 
62. Naef a P. The mid-century revolution in thoracic and cardiovascular surgery: part 4. Interact 
CardioVasc Thorac Surg. 2004;3:535-541 
63. Mikkelsen M, Christie J, Abella B, Kerlin M, Fuchs B, Schweickert W. American Heart Association’s Get 
With the Guidelines- Resuscitation Investigators. Use of therapeutic hypothermia after in-hospital 
cardiac arrest. Critical Care Med. 2013;41:1385–95 
64. Chau KH, Friedman T, Tranquilli M, Elefteriades JA. Deep hypothermic circulatory arrest effectively 
preserves neurocognitive function. Ann Thorac Surg. 2013;96:1553-9 
65. Bigelow WG, Callaghan IJC, Hoppst JA. General hypothermia for experimental intracardiac surgery. 
Ann Surg. 1950;531–7 
66. Stoney WS. Evolution of cardiopulmonary bypass. Circulation. 2009 ;119:2844–53 
67. Bigelow WG, Mcbirnie JE. Further experiences with hypothermia for intracardiac surgery in monkeys 
and groundhogs. Annals of surgery. 1953;137:361–5 
68. Clark L, Gollan F, Gupta V. The oxygenation of blood by gas dispersion. Science. 1950; 111:85-87. 
69. Clark Lc, Gupta Vb, Gollan F. Dispersion Oxygenation For Effecting Survival Of Dogs Breathing Pure 
Nitrogen For Prolonged Periods. Proc Soc Exp Biol Med. 1950;74:268-71 
70. Gollan F, Clark Lc Jr, Gupta Vb. The Prevention Of Acute Anoxic Anoxia By Means Of Dispersion 
Oxygenation Of Blood. Am J Med Sci. 1951;222:76-81 
71. Gollan F, Blos P, Schuman H. Studies On Hypothermia By Means Of Pump-Oxygenator. Am J Physiol. 
1952;171:331-4 
72. Dobell a R, Bailey JS. Charles Drew and the origins of deep hypothermic circulatory arrest. The Annals 
of thoracic surgery. 1997;63:1193–9. 
73. Juvenelle A, Lind J, Wegelius C. Quelques possibilites offertes par l’hypothermie generale profonde 
provoquee (Une etude experimentale chez le chien). Presse Med. 1952;60:973–978 
74. Lewis Fj, Taufic M. Closure Of Atrial Septal Defects With The Aid Of Hypothermia; Experimental 
Accomplishments And The Report Of One Successful Case. Surgery. 1953;33:52-9 
75. Lewis Fj, Taufic M, Varco Rl, Niazi S. The Surgical Anatomy Of Atrial Septal Defects: Experiences With 
Repair Under Direct Vision. Ann Surg. 1955;142:401-15 
76. Swan H, Zeavin I, Holmes Jh, Montgomery V. Cessation of Circulation in General Hypothermia. I. 
Physiologic Changes and Their Control. Ann Surg. 1953;138:360-7 
77. Cooley DA. Milestones in the Treatment of Aortic Aneurysm. Tex Heart Inst J. 2005; 32: 130–134. 
78. Cooley D, Mahaffey D, Bakey M. Total excision of the aortic arch for aneurysm. Surg Gynecol Obstet. 
1955; 101:667–72. 
79. Karaskov A, Litasova E, Vlasov Y. A documentary on the life and work of Eugenij Nikolaevich 
Meshalkin. Circ Pathol Cardiac Surg. 1999;4-11 
80. 1 Bruce C. Discussion on the application of hypothermia to surgical procedures. Royal Society of 
Medicine. 1956; 49:345–54. 
81. Ross D. Report of a heart transplantation operation. Am J Cardiol. 1968; 
82. BROCK R, ROSS DN. Hypothermia. III. The clinical application of hypothermic techniques. Guys Hosp 
Rep. 1955;104:99-113.  
83. Griepp RB. Cerebral protection during aortic arch surgery. J Thorac Cardiovasc Surg 2001;121:425-7. 
84. ROSS DN. Venous cooling: a new method of cooling the blood-stream. Lancet. 1954;266:1108-9 
85. Barnard CN, Schrire V. The surgical treatment of Acquired aneurysm of the thoracic aorta. 
Thorax.1963;18:101-15 
86. Griepp RB, Ergin MA, Lansman SL, Galla JD, Pogo G. The physiology of hypothermic circulatory arrest. 
Semin Thorac Cardiovasc Surg. 1991;3:188-93 
87. Haldenwang PL, Bechtel M, Moustafine V, Buchwald D, Wippermann J, Wahlers T, Strauch JT. State of 
the art in neuroprotection during acute type A aortic dissection repair. Perfusion. 2012 
Mar;27(2):119-26 
 216 
 
88. Reich DL, Uysal S, Sliwinski M, et al. Neuropsychologic outcome after deep hypothermic circulatory 
arrest in adults. J Thorac Cardiovasc Surg 1999;117:156-63 
89. Svensson LG, Crawford ES, Hess KR, et al. Deep hypothermia with circulatory arrest. Determinants of 
stroke and early mortality in 656 patients. J Thorac Cardiovasc Surg 1993;106:19-28; discussion 28-
31. 
90. Hagl C, Khaladj N, Karck M, et al. Hypothermic circulatory arrest during ascending and aortic arch 
surgery: the theoretical impact of different cerebral perfusion techniques and other methods of 
cerebral protection. Eur J Cardiothorac Surg 2003;24:371-8 
91. Di Bartolomeo R, Pilato E, Pacini D, et al. Cerebral protection during surgery of the aortic arch. 
MMCTS 2011;2010:004457 
92. McCullough JN, Zhang N, Reich DL, et al. Cerebral metabolic suppression during hypothermic 
circulatory arrest in humans. Ann Thorac Surg 1999;67:1895-9; discussion 1919-21 
93. Di Eusanio M, Wesselink RM, Morshuis WJ, et al. Deep hypothermic circulatory arrest and antegrade 
selective cerebral perfusion during ascending aorta-hemiarch replacement: a retrospective 
comparative study. J Thorac Cardiovasc Surg 2003;125:849-54 
94. Sakamoto T, Zurakowski D, Duebener LF, et al. Combination of alpha-stat strategy and hemodilution 
exacerbates neurologic injury in a survival piglet model with deep hypothermic circulatory arrest. 
Ann Thorac Surg 2002;73:180-9; discussion 189-90  
95. Mills NL, Ochsner JL. Massive air embolism during cardiopulmonary bypass. Causes, prevention, and 
management. J Thorac Cardiovasc Surg 1980;80:708-17 
96. Lemole GM, Strong MD, Spagna PM, et al. Improved results for dissecting aneurysms. Intraluminal 
sutureless prosthesis. J Thorac Cardiovasc Surg 1982;83:249- 
97. Ueda Y, Miki S, Kusuhara K, et al. Surgical treatment of aneurysm or dissection involving the 
ascending aorta and aortic arch, utilizing circulatory arrest and retrograde cerebral perfusion. J 
Cardiovasc Surg (Torino) 1990;31:553-8 
98. Lee TY, Safi HJ, Estrera AL. Cerebral perfusion in aortic arch surgery: antegrade, retrograde, or both? 
Tex Heart Inst J 2011;38:674-7. 
99. Sasaguri S, Yamamoto S, Hosoda Y. What is the safe time limit for retrograde cerebral perfusion with 
hypothermic circulatory arrest in aortic surgery? J Cardiovasc Surg (Torino) 1996;37:441-4. 
100. Deeb GM, Williams DM, Quint LE, et al. Risk analysis for aortic surgery using hypothermic circulatory 
arrest with retrograde cerebral perfusion. Ann Thorac Surg 1999;67:1883-6; discussion 1891-4. 
101. Okita Y, Takamoto S, Ando M, et al. Mortality and cerebral outcome in patients who underwent aortic 
arch operations using deep hypothermic circulatory arrest with retrograde cerebral perfusion: no 
relation of early death, stroke, and delirium to the duration of circulatory arrest. J Thorac Cardiovasc 
Surg 1998;115:129-38 
102. Wong CH, Bonser RS. Does retrograde cerebral perfusion affect risk factors for stroke and mortality 
after hypothermic circulatory arrest? Ann Thorac Surg 1999;67:1900-3; discussion 1919-21 
103. Ueda Y, Okita Y, Aomi S, et al. Retrograde cerebral perfusion for aortic arch surgery: analysis of risk 
factors. Ann Thorac Surg 1999;67:1879-82; discussion 1891-4. 
104. DeBakey M, Crawford ES, Cooley DA, et al. Successful resection of fusiform aneurysm of aortic arch 
with replacement by homograft. Surg Gynecol Obstet 1957;105:657-64 
105. Frist WH, Baldwin JC, Starnes VA, et al. A reconsideration of cerebral perfusion in aortic arch 
replacement. Ann Thorac Surg 1986;42:273-81 
106. Bachet J, Guilmet D, Goudot B, et al. Cold cerebroplegia. A new technique of cerebral protection during 
operations on the transverse aortic arch. J Thorac Cardiovasc Surg 1991;102:85-93; discussion 93-4 
107. Kazui T, Inoue N, Yamada O, et al. Selective cerebral perfusion during operation for aneurysms of the 
aortic arch: a reassessment. Ann Thorac Surg 1992;53:109-14 
108. Okita Y, Minatoya K, Tagusari O, et al. Prospective comparative study of brain protection in total 
aortic arch replacement: deep hypothermic circulatory arrest with retrograde cerebral perfusion or 
selective antegrade cerebral perfusion. Ann Thorac Surg 2001;72:72-9 
109. Tanoue Y, Tominaga R, Ochiai Y, et al. Comparative study of retrograde and selective cerebral 
perfusion with transcranial Doppler. Ann Thorac Surg 1999;67:672-5 
110. Murkin JM, Adams SJ, Novick RJ, et al. Monitoring brain oxygen saturation during coronary bypass 
surgery: a randomized, prospective study. Anesth Analg 2007;104:51-8 
111. Hagl C, Ergin MA, Galla JD, et al. Neurologic outcome after ascending aorta-aortic arch operations: 
effect of brain protection technique in high-risk patients. J Thorac Cardiovasc Surg 2001;121:1107-21 
112. Gazoni LM, Speir AM, Kron IL, Fonner E, Crosby IK. Elective thoracic aortic aneurysm surgery: better 
outcomes from high-volume centers. J Am Coll Surg. 2010;210:855-9 
113. Kalkat MS, Edwards MB, Taylor KM, Bonser RS. Composite aortic valve graft replacement: mortality 
outcomes in a national registry. Circulation. 2007. 11;116:I301-6 
 217 
 
114. Karck M, Kallenbach K, Hagl C, Rhein C, Leyh R, Haverich A. Aortic root surgery in Marfan syndrome: 
Comparison of aortic valve-sparing reimplantation versus composite grafting. J Thorac Cardiovasc 
Surg. 2004;127:391-8 
115. Patel ND, Weiss ES, Alejo DE, Nwakanma LU, Williams JA, Dietz HC, Spevak PJ, Gott VL, Vricella LA, 
Cameron DE. Aortic root operations for Marfan syndrome: a comparison of the Bentall and valve-
sparing procedures. Ann Thorac Surg. 2008;85:2003-10 
116. Williams JA, Loeys BL, Nwakanma LU, Dietz HC, Spevak PJ, Patel ND, François K, DeBacker J, Gott VL, 
Vricella LA, Cameron DE. Early surgical experience with Loeys-Dietz: a new syndrome of aggressive 
thoracic aortic aneurysm disease. Ann Thorac Surg. 2007;83:S757-63 
117. El Khoury G, Vanoverschelde JL, Glineur D, Pierard F, Verhelst RR, Rubay J, Funken JC, Watremez C, 
Astarci P, Lacroix V, Poncelet A, Noirhomme P. Repair of bicuspid aortic valves in patients with aortic 
regurgitation. Circulation. 2006.4;114:I610-6 
118. Leshnower BG, Myung RJ, Kilgo PD, Vassiliades TA, Vega JD, Thourani VH, Puskas JD, Guyton RA, Chen 
EP. Moderate hypothermia and unilateral selective antegrade cerebral perfusion: a contemporary 
cerebral protection strategy for aortic arch surgery. Ann Thorac Surg. 2010;90:547-54 
119. K. Minatoya, H. Ogino, H. Matsuda, H. Sasaki, H. Tanaka, J. Kobayashi et al. Is conventional aortic arch 
surgery justifiable in octogenarians? J Thorac Cardiovasc Surg, 2010;139:641–645 
120. Strauch JT, Spielvogel D, Lauten A, Galla JD, Lansman SL, McMurtry K, et al. Technical advances in total 
aortic arch replacement. Ann Thorac Surg. 2004;77:581-89 
121. Gega A, Rizzo JA, Johnson MH, Tranquilli M, Farkas EA, Elefteriades JA. Straight deep hypothermic 
arrest: experience in 394 patients supports its effectiveness as a sole means of brain preservation. 
Ann Thorac Surg. 2007;84:759-66 
122. Wong DR, Parenti JL, Green SY, Chowdhary V, Liao JM, Zarda S, Huh J, LeMaire SA, Coselli JS. Open 
repair of thoracoabdominal aortic aneurysm in the modern surgical era: contemporary outcomes in 
509 patients. J Am Coll Surg. 2011;212:569-79 
123. Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal aortic aneurysms. 
Ann Thorac Surg. 2007;83:S862-4 
124. Cambria RP, Clouse WD, Davison JK, Dunn PF, Corey M, Dorer D. Thoracoabdominal aneurysm repair: 
results with 337 operations performed over a 15-year interval. Ann Surg. 2002;236:471-9 
125. B Patterson, P Holt, C Nienaber - Journal of Vascular …, 2013 - elsevier-usairforce.com Journal of 
Vascular Surgery, Volume 57, Issue 5, Pages 1449, May 2013, Authors:B. Patterson; P. Holt; C. 
Nienaber 
126. Improved Prognosis of Thoracic Aortic Aneurysms. A Population-Based Study William Darrin Clouse, 
MD; John W. Hallett, Jr, MD; Hartzell V. Schaff, MD; Michelle M. Gayari, BS; Duane M. Ilstrup, MS; L. 
Joseph Melton III, MD. JAMA. 1998; 280(22):1926-1929. doi:10.1001/jama.280.22.1926 
127. Zierer A, Melby SJ, Lubahn JG, Sicard G a, Damiano RJ, Moon MR. Elective surgery for thoracic aortic 
aneurysms: late functional status and quality of life. Ann Thorac Surg [Internet] 2006 [cited 2013 Mar 
12];82(2):573–8 
128. Gilling-Smith G, Worswick L, Knight P, Wolfe J, Mansfield. Surgical repair of thoracoabdominal aortic 
aneurysm: 10 years’ experience. Br J Surg 1995;82:624 –  
129. Bradbury A, Bulstrode N, Gilling-Smith G, Stansby G, Mansfield A, Wolfe J. Repair of ruptured 
thoracoabdominal aortic aneurysm is worthwhile in selected cases. Eur J Vasc Endovasc Surg 
1999;17:160 – 5 
130. Scurr J, McWilliams RG. Aorta and Great Vessels: Fenestrated Aortic Stent Grafts. Semin intervent 
radiol. 2007;24:211-220 
131. Thompson M, Avaz S, Cheshire N, et al. Early results of endovascular treatment of the thoracic aorta 
using the valiant endograft. Cardiovasc Intervent Radiol 2007;30:1130 – 8 
132. Clough R, Mani K, Lyons O, et al. Endovascular treatment of acute aortic syndrome. J Vasc Surg 2011 
133. Choong A, Clough R, Bicknell C, et al. Recent advances in thoraco-abdominal aortic aneurysm repair. 
The Surgeon Royal College of Surgeons Edinburgh and Ireland 2010;8:28 – 38 
134. Biasi L, Ali T, Loosemore T, Morgan R, Loftus I, Thompson M. Hybrid repair of complex 
thoracoabdominal aortic aneurysms using applied endovascular strategies combined with visceral 
and renal revascularisation. J Thoracic Cardiovasc Surg 2009;138:1331 – 8 
135. The Fifth National Adult Cardiac Surgical Database Report 2003. The Society of Cardiothoracic 
Surgery in Great Britain and Ireland. Dendrite Clinical Systems Ltd 
136. Early and midterm outcome of surgery of the ascending aorta/arch: is there a relationship with 
caseload?. / Narayan, P; Caputo, M; Rogers, CA; Alwair, H; Mahesh, B; Angelini, GD; Bryan, AJ. 
European Journal of Cardiothoracic Surgery, Vol. 25, 05.2004, p. 676 - 682 
137. Ascending aorta or arch surgery: is previous cardiac surgery a risk factor? Narayan, P; Rogers, CA; 
Caputo, M; Angelini, GD; Bryan, AJ. Asian Cardiovascular and Thoracic Annals, Vol. 14 (1), 02.2006, p. 
14 - 19 
 218 
 
138. Influence of concomitant coronary artery bypass graft on outcome of surgery of the ascending 
aorta/arch. Narayan, P., Rogers, C. A., Caputo, M., Angelini, G. & Bryan, A. J. Feb 2007 Heart. 93(2), p. 
232 - 237 6 p 
139. Selective antgegrade cerebral perfusion attenuates brain metabolic deficit in aortic arch surgery: a 
prospective randomized trial, Circulation 14/9/2004. Harrington, Deborah | Walker, Anne | 
Kaukuntla, Hemanth | Bracewell, Robert | Clutton-Brock, Thomas | Faroqui, Muzaffar | Bonser, Robert 
| Pagano, Domenic 
140. Non-neurological morbidity and profound hypothermia in aortic surgery, The Annals of thoracic 
surgery 1/1/2003. Harrington, Deborah | Rooney, SJ | Lilley, JP | Bonser, Robert 
141. Holt PJ, Karthikesalingam A, Patterson BO, Ghatwary T, Hinchliffe RJ, Loftus IM, Thompson MM. Aortic 
rupture and sac expansion after endovascular repair of abdominal aortic aneurysm. Br J Surg. 2012 
Dec;99(12):1657-64 
142. Hybrid Repair of the Aortic Arch in Patients with Extensive Aortic Disease European Journal of 
Vascular & Endovascular Surgery Volume 40, Issue 6 , Pages 715-721, December 2010 
143. Abraha I, Romagnoli C, Montedori A, Cirocchi R. Thoracic stent graft versus surgery for thoracic 
aneurysm. Cochrane Database Syst Rev. 2013 Sep11;9:CD006796 
144. Orandi BJ, Dimick JB, Deeb GM, Patel HJ, Upchurch GR Jr. A population-based analysis ofendovascular 
versus open thoracic aortic aneurysm repair. J Vasc Surg. 2009 May;49(5):1112-6 
145. Walsh SR, Tang TY, Sadat U, Naik J, Gaunt ME, Boyle JR, Hayes PD, Varty K.Endovascular stenting 
versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative 
results. J Vasc Surg. 2008.May;47(5):1094-1098 
146. Makaroun MS, Dillavou ED, Kee ST, Sicard G, Chaikof E, Bavaria J, Williams D,Cambria RP, Mitchell RS. 
Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the 
GORE TAG thoracic endoprosthesis. J Vasc Surg. 2005 Jan;41(1):1-9 
147. Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC, Cronenwett JL, Stone DH. Survival after 
open versus endovascular thoracic aortic aneurysm repair in an observational study of the Medicare 
population. Circulation. 2011 Dec 13;124(24):2661-9 
148. BioMed Research International Volume 2014 (2014), Article ID 736298, 10 pages 
149. Higgins J, Lee MK, Co C, Janusz MT. Long-term outcomes after thoracic aortic surgery: A population-
based study. J Thorac Cardiovasc Surg. 2013. pii: S0022-5223(13)00805-2 
150. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, et al. Thoracoabdominal aortic 
aneurysms: preoperative and intraoperative factors determining immediate and long-term results of 
operations in 605 patients. J Vasc Surg. 1986;3:389-40 
151. Bischoff M, Brenner R, Scheumann J, Bodian CA, Griepp R, Lansman S, et al. Long-term outcome after 
aortic arch replacement with a trifurcated graft. J Thorac Cardiovasc Surg. 2010;140;s86-91 
152. Estrera AL, Miller CC 3rd, Huynh TT, Porat EE, Safi HJ. Replacement of the ascending and transverse 
aortic arch: determinants of long-term survival. Ann Thorac Surg. 2002;74:1058-64 
153. Kouchoukos NT, Kulik A, Castner CF. Outcomes after thoracoabdominal aortic aneurysm repair using 
hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2013;145:S139-41 
154. Geisbuesch S, Schray D, Bischoff MS, Lin HM, Di Luozzo G, Griepp RB. Frequency of reoperations in 
patients with Marfan syndrome. Ann Thorac Surg. 2012;93:1496-501 
155. Lombardi JV, Carpenter JP, Pochettino A, Sonnad SS, Bavaria JE. Thoracoabdominal aortic aneurysm 
repair after prior aortic surgery. J Vasc Surg. 2003;38:1185-90 
156. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing 
prevalence and improved outcomes reported in a nationwide population-based study of more than 
14,000 cases from 1987 to 2002. Circulation. 2006. 12;114:2611-8 
157. Crawford S, Denatale R. Thoracoabdominal aortic aneurysm: observations regarding the natural 
course of the disease. Journal of vascular surgery1. 1986;3:578–82. 
158. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the appropriate size 
criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg. 1997;113:476–91 
159. Joyce JW, Fairbairn JF, Kincaid OW, Juergens JL. Aneurysms of the Thoracic Aorta: A Clinical Study 
with Special Reference to Prognosis. Circulation. 1964;29: 176–81. 
160. Perko MJ, Nørgaard M, Herzog TM, Olsen PS, Schroeder TV, Pettersson G. Unoperated aortic 
aneurysm: A survey of 170 patients. Ann Thorac Surg. 1995;59:1204–9 
161. Elefteriades JA. Natural History of Thoracic Aortic Aneurysms : Indications for Surgery, and Surgical 
Versus Nonsurgical Risks. Ann Thorac Surg. 2002;74:S1877–80 
162. Haskett D, Johnson G, Zhou A, Utzinger U, Vande Geest J. Microstructural and biomechanical 
alterations of the human aorta as a function of age and location. Biomech Model Mechanobiol. 
2010;9(6):725–36. 
 219 
 
163. Koullias G, Modak R, Tranquilli M, Korkolis DP, Barash P, Elefteriades JA. Mechanical deterioration 
underlies malignant behavior of aneurysmal human ascending aorta. J Thorac Cardiovasc Surg. 
2005;130:677–83.  
164. Clouse WD, Hallett JW, Schaff H V, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved Prognosis of 
Thoracic Aortic Aneurysms. JAMA. 1998;280:1926–9. 
165. Rizzo JA, Coady MA, Elefteriades JA. Procedures for estimating growth rates in thoracic aortic 
aneurysms. Journal of clinical epidemiology. 1998;51:747–54.  
166. Hirose Y, Hamada S, Takamiya M, Imakita S, Naito H, Nishimura T. Aortic aneurysms: growth rates 
measured with CT. Radiology. 1992;185:249–52.  
167. Gallo A, Davies RR, Coe MP, Elefteriades JA, Coady MA. Indications, timing, and prognosis of operative 
repair of aortic dissections. Semin Thorac Cardiovasc Surg. 2005;17:224–35.  
168. 1 Haycox, A., & Noble, E. (2003). What is health economics? Hayward Group. Retrieved 04/06/2015, 
from http://www.isciii.es/htdocs/pdf/WhatisHealthEcon.pdf. 
169. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 
170. Economic evaluation and health care. What does it mean? BMJ. Sep 11, 1993; 307(6905): 670–673. 
171. The American Economic Review, UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE 
Vol.3 , Number 5 
172. Gateway reference: 9006/11400; Doh-NHS Costing Publications 
173. Transparency and accountability: using better data to drive performance in the NHS. The Health and 
Social Care Information Centre 
174.   Kaplan, Robert S. and Bruns, W. Accounting and Management: A Field Study Perspective (Harvard 
Business School Press, 1987) 
175. Sapp, Richard, David Crawford and Steven Rebishcke.  Journal of Bank Cost and Management 
Accounting (Volume 3, Number 2), 1990 
176. Journal of Bank Cost and Management Accounting (Volume 4, Number 1), 1991 
177. Drucker Peter F.Management Challenges of the 21st Century. New York: Harper Business, 1999. 
178. Kuzmik G a, Sang AX, Elefteriades J a. Natural history of thoracic aortic aneurysms. Journal of vascular 
surgery [Internet]. Elsevier Inc.; 2012 Aug [cited 2013 Jun 2];56(2):565–71.  
179. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon 
volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with 
cancer. Surgery 2002;131:6-15 
180. Boudourakis LD, Wang TS, Roman SA, Desai R, Sosa JA. Evolution of the surgeon-volume, patient-
outcome relationship. Ann Surg. 2009 Jul;250(1):159-65 
181. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for 
major cancer surgery. JAMA 1998;280:1747-1751 
182. Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals: 
estimating potentially avoidable deaths. JAMA 2000;283:1159-1166 
183. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and 
methodologic critique of the literature. Ann Intern Med 2002;137:511-520 
184. An Economic Analysis of Aortic Surgery- University of York 
185. Tsai TT, Evangelista A, Nienaber C, Sechtem U, Fattori R, Myrmel T, Llovet A, Cooper JV, Fang J, 
Isselbacher E, Eagle KA. Long-term survival in patients presenting with type A aortic dissection: 
insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2005; 112:534-
535 
186. Conzelmann LO, Krüger T, Hoffmann I, Rylski B, Easo J, Oezkur M, Kallenbach K, Dapunt O, Karck M, 
Weigang E; Teilnehmenden GERAADA-Zentren. [German Registry for Acute Aortic Dissection Type A 
(GERAADA): initial results]. Herz. 2011 Sep;36(6):513-24 
187. Chikwe J, Cavallaro P, Itagaki S, Seigerman M, Diluozzo G, Adams DH. National outcomes in acute 
aortic dissection: influence of surgeon and institutional volume on operative mortality. Ann Thorac 
Surg. 2013 May;95(5):1563-9 
188. Andersen ND, Ganapathi AM, Hanna JM, Williams JB, Gaca JG, Hughes GC. Outcomes of acute type a 
dissection repair before and after implementation of a multidisciplinary thoracic aortic surgery 
program. J Am Coll Cardiol. 2014 May 6;63(17):1796-803 
189. Hickey GL, Grant SW, Cosgriff R, Dimarakis I, Pagano D, Kappetein AP et al. Clinical registries: 
governance, management, analysis and applications.  Eur J Cardiothorac Surg 2013;44:605–14 
190. Czerny M, Bachet J, Bavaria J, Bonser RS,  Borger MA, De Paulis R et al. The future of aortic surgery in 
Europe European Journal of Cardio-Thoracic Surgery. 2013; 43; 226–230 
191. Borst HG, Heinemann MK, Stone CD. Surgical Treatment of Aortic Dissection, 1st edn. Churchill 
Livingstone, 1995 
 220 
 
192. Bachet J, Guilmet D, Goudot B, Termignon JL, Teodori G, Dreyfus G et al. Cold cerebroplegia. A new 
technique of cerebral protection during operations on the transverse aortic arch. J Thorac Cardiovasc 
Surg 1991; 102 : 85–93 
193. Dubost C. The first successful resection of an aneurysm of the abdominal aorta followed by re-
establishment of continuity using a preserved human arterial graft. Ann Vasc Surg 1986; 1 : 147–49. 
194. Hughes GC, Zhao Y, Rankin JS, Scarborough JE, O'Brien S, Bavaria JE, et al. Effects of institutional 
volumes on operative outcomes for aortic root replacement in North America. J Thorac Cardiovasc 
Surg. 2013 Jan;145(1):166-70 
195. Chikwe J, Cavallaro P, Itagaki S, Seigerman M, Diluozzo G, Adams DH. National outcomes in acute 
aortic dissection: influence of surgeon and institutional volume on operative mortality. Ann Thorac 
Surg. 2013 May;95(5):1563-9 
196. Kilic A, Tang R, Whitson BA, Sirak JH, Sai-Sudhakar CB, Crestanello J, Higgins RS. Outcomes in the 
current surgical era following operative repair of acute Type A aortic dissection in the elderly: a 
single-institutional experience. Interact Cardiovasc Thorac Surg. 2013 Jul;17(1):104-9 
197. Canaud L, Karthikesalingam A, Jackson D, Cresswell L, Cliff M, Markar SS, et al Clinical outcomes of 
single versus staged hybrid repair for thoracoabdominal aortic aneurysm. J Vasc Surg. 2013 
Nov;58(5):1192-200 
198. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, et al A risk model for secondary cytoreductive 
surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg 
Oncol. 2012  Feb;19(2):597-604 
199. Teguh DN, Levendag PC, Ghidey W, van Montfort K, Kwa SL. Risk model and nomogram for dysphagia 
and xerostomia prediction in head and neck cancer patients treated by radiotherapy and/or 
chemotherapy. Dysphagia. 2013 Sep;28(3):388-94 
200. Shahian DM, Edwards FH The Society of Thoracic Surgeons 2008 Cardiac Surgery Risk Models: 
Introduction.  Ann Thorac Surg 2009;88:1 
201. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac 
operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999 Jul;16(1):9-13 
202. Mehta RH, Suzuki T, Hagan PG, Bossone E, Gilon D, Llovet A, et al. Predicting death in Patients with 
Acute Type A Aortic Dissection. Circulation. 2002 Jan 15;105(2):200-6 
203. Giles KA, Schermerhorn ML, O'Malley AJ, Cotterill P, Jhaveri A, Pomposelli FB, et al Risk prediction for 
perioperative mortality of endovascular vs open repair of abdominal aortic aneurysms using the 
Medicare population. J Vasc Surg. 2009 Aug;50(2):256-62. 
204. Choke E, Lee K, McCarthy M, Nasim A, Naylor AR, Bown M, et al. Risk models for mortality following 
elective open and endovascular abdominal aortic aneurysm repair: a single institution experience. 
Eur J Vasc Endovasc Surg. 2012 Dec;44(6):549-54 
205. Grant SW, Hickey GL, Grayson AD, Mitchell DC, McCollum CN. National risk prediction model for 
elective abdominal aortic aneurysm repair. Br J Surg. 2013 Apr;100(5):645-53 
206. Bala Ramanan B, Gupta PK, Sundaram A, Gupta H, Johanning JM, Lynch TG, et al Development of a risk 
index for prediction of mortality after open aortic aneurysm repair Journal of Vascular Surgery; 2013; 
58(4); 871–878 
207. Williams JB, Peterson ED, Zhao Y, O’Brien SM, Andersen ND, Miller DC, Chen EP, Hughes GC  
Contemporary results for proximal aortic replacement in North America. J Am Coll Cardiol. (2012) 
60:1156–1162 
208. Kunihara T, Aicher D, Asano M, Takahashi H, Heimann D, Sata F & Schäfers HJ Risk factors for 
prophylactic proximal aortic replacement in the current era. Clinical Research in Cardiology 
(2014), 103(6), 431-440 
209. Hosmer D, Lemeshow S. Applied Logistic Regression.  John Wiley: New York, 1989 
210. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) 
curve. Radiology 1982; 143: 29–36 
211. Huijskes RV, Wesselink RM, Noyez L, Rosseel PM, Klok T, van Straten BH, Nesselaarg A and  Tijssen JG. 
Predictive models for thoracic aorta surgery. Is the Euroscore the optimal risk model in the 
Netherlands? Interactive cardiovascular and thoracic surgery 4(6) (2005): 538-542. 
212. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR and Lockowandt U. Euroscore II. 
European Journal of Cardio-Thoracic Surgery 41 (2012) 1–12 
213. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E et al. Risk factors and outcome 
in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. 
Eur J Cardiothorac Surg 1999;15:816–22; discussion 22–3 
214. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac 
operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9–13. 
215. Estrera AL, Miller CC 3rd, Lee TY, Shah P, Safi HJ. Ascending and transverse aortic arch 
repair. Circulation. 2008; 118:S160–S166 
 221 
 
216. Ma WG, Zhu JM, Zheng J, Liu YM, Ziganshin BA, Elefteriades JA, et al.. Sun's procedure for complex 
aortic arch repair: total arch replacement using a tetrafurcate graft and stented elephant trunk 
implantation. Ann Cardiothorac Surg 2013; 2:642–648.  
217. Coselli JS, LeMaire SA. Aortic arch surgery: principles, strategies and outcomes, Ed 1. London: 
Blackwell Publishing Ltd, 2008. 
218. Svensson LG, Adams DH, Bonow RO, Kouchoukos NT, Craig Miller D, O'Gara PT, et al.. Aortic valve and 
ascending aorta guidelines for management and quality measures. Ann Thorac Surg. 2013; 95:1–66. 
219. Patel HJ, Deeb GM. Open aortic arch reconstruction. Ann Cardiothorac Surg. 2013; 2:181–183. doi: 
220. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 
53:547–581. 
221. Crawford ES, Svensson LG, Coselli JS, Safi HJ, Hess KR. Surgical treatment of aneurysm and/or 
dissection of the ascending aorta, transverse aortic arch and ascending aorta and transverse arch. 
Factors influencing survival in 717 patients. J Thorac Cardiovasc Surg. 1989; 98:659–673. 
222. Piérard S, de Meester C, Seldrum S, Pasquet A, Gerber B, Vancraeynest D, et al.. Impact of preoperative 
symptoms on postoperative survival in severe aortic stenosis: implications for the timing of 
surgery. Ann Thorac Surg. 2014; 97:803–809 
223. Leavitt BJ, Ross CS, Spence B, Surgenor SD, Olmstead EM, Clough RA, et al.. Long term survival of 
patients with chronic obstructive pulmonary disease undergoing coronary artery bypass 
surgery. Circulation. 2006; 114:1430–1434 
224. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, et al.. Long-term survival of 
medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994; 
90:2645–2657. 
225. Dhanani J, Mullany DV, Fraser JF. Effect of preoperative renal function on long-term survival after 
cardiac surgery. J Thorac Cardiovasc Surg. 2013; 146:90–95. 
226. Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G, et al.. Immediate postoperative renal 
function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term 
survival. J Am Soc Nephrol. 2005; 16:195–200 
227. Ziganshin BA, Elefteriades JA. Deep hypothermic circulatory arrest. Ann Cardiothorac Surg. 2013; 
2:303–315. 
228. Tian DH, Wan B, Bannon PG, Misfield M, Lemaire SA, Kazui T, et al.. A meta-analysis of deep 
hypothermic circulatory arrest alone versus with adjunctive selective anterograde cerebral 
perfusion. Ann Cardiothorac Surg. 2013; 2:261–270 
229. Matalanis G, Hata M, Buxton BF. A retrospective comparative study of deep hypothermic circulatory 
arrest, retrograde and anterograde cerebral perfusion in aortic arch surgery. Ann Thorac Cardiovasc 
Surg. 2003; 9:174–179. 
230. Kurra V, Lieber ML, Sola S, Kalahasti V, Hammer D, Gimple S, et al.. Extent of thoracic aortic atheroma 
burden and long-term mortality after cardiothoracic surgery: a computed tomography study. JACC 
Cardiovasc Imaging. 2010; 3:1020–1029 
231. De Waard GA, Jansen EK, de Mulder M, Vonk AB, Umans VA. Long term outcomes of isolated aortic 
valve replacement and concomitant AVR and coronary artery bypass grafting. Neth Heart J. 2012; 
20:110–117. 
232. Jones JM, Lovell D, Cran GW, Macgowan SW. Impact of coronary artery bypass grafting on survival 
after aortic valve replacement. Interact Cardiovasc Thorac Surg. 2006; 5:327–330. 
233. Narayan P, Rogers CA, Caputo M, Angelini GD, Bryan AJ. Influence of concomitant coronary bypass 
graft on outcome of surgery of the ascending aorta/arch. Heart. 2007; 93:232–237 
234. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the 
management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 
2013 Oct;34(38):2949-3003 
235. CIS Meadows, W Rattenberry, C Waldmann. Centralisation of specialist critical care services, JICS 
2011;12:2, 
236. De Maria E, Ricci S, Capelli S et al. Feasibility of transradial approach in a hub and spoke cath lab 
network. Minerva Cardioangiol 2010;58:11-15 
237. Morgan KP, Leahy MG, Butts JN, Beatt KJ. The cost-effectiveness of primary angioplasty compared to 
thrombolysis in the real world: one year results from West London. Eurointervention 2010;6:596-
603 
238. Nobilio L, Fortuna D, Vizioli M et al. Impact of regionalisation of cardiac surgery in Emilia-Romagna, 
Italy. J Epidemiol Community Health 2004; 58:97-102 
222 
 
 
 
 
APPENDICES
223 
 
 
 
 
TABLES
 224 
 
Table 7.1. The Yearly Risk of Aortic Rupture, Dissection and Death 
Correlated to Aortic Aneurysm Size 
 
(Taken from Division of Cardiothoracic surgery at St. Roosevelt Aneurysm 
Centre. USA) 
      Aortic size   
Yearly Risk > 3.5cm >4.0cm >5.0 cm > 6.0cm 
          
Rupture 0.0% 0.3% 1.7% 3.6% 
Dissection 2.2% 1.5% 2.5% 3.7% 
Death 5.9% 4.6% 4.8% 10.8% 
          
Any of the above 7.2% 5.3% 6.5% 14.1% 
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Table 9.1. Table Displaying the Common Economic Methods Utilised Particular in Health Ecomonics 
Method Outcome measure Application/interpretation 
Cost-minimisation 
analysis 
Evidence is available that outcomes for competing 
therapies are equivalent 
Given the evidence of output equivalence (and only 
when such evidence is available), the cheapest therapy 
is preferred 
Cost-effectiveness 
analysis 
Health benefits are measured in natural units, reflecting 
a dominant common therapeutic goal for competing 
therapies 
How much more does it cost (incremental cost) to 
achieve an additional unit (incremental effectiveness) 
of the common therapeutic good (incremental cost- 
effectiveness ratio)? 
Cost–utility 
analysis 
In the absence of a common therapeutic goal, outcome 
is measured through the effect of any intervention on 
mortality (quantity of life) and morbidity (quality  of 
life) 
The quality-adjusted life-year measures the number of 
additional life years weighted by the quality of life 
(value) of the health state experienced in each year 
Cost–benefit 
analysis 
Both costs and benefits are measured in  the same unit 
– money – with the financial value of the costs being 
compared with the financial value of the benefits 
An intervention should be undertaken if the (financial) 
value of the benefits exceeds the (financial) value of the 
costs.  If only one intervention can be funded, choose the 
activity with the highest excess financial benefit over 
costs 
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Table 9.3. Thoracic and thoraco-abdominal aortic surgery OPCS 4 Procedures and HRGs analysis (1 of 4) 
 
  
Operations 
Relative 
Clinical 
complexity 
Emergency Coding- Liverpool 
Emergency Coding - 
Royal Brompton 
Elective Codes- Liverpool 
Elective Codes- Royal 
Brompton 
 Proposed HRG 
groupings 
AAo Simple L181 EA20Z/EA22Z L181 EA20Z/EA22Z L191 EA20Z/EA22Z L191 EA20Z/EA22Z Group A1, 
modify if 
complications 
AAo+AVR Simple L181 + K263  EA20Z/EA22Z 
L181 + K263  
EA20Z/EA22Z 
L191 + K263  
EA20Z/EA22Z 
L191 + K263  
EA20Z/EA22Z 
AAo+hemiarch Complex 
L181+L188 +Z34.2 
EA20Z/EA22Z 
L181+L188 +Z34.2 
EA20Z/EA22Z 
L191+L198 +Z34.2 
EA20Z/EA22Z 
L191+L198 +Z34.2 
EA20Z/EA22Z 
 
 
Group A2, 
higher risk of 
significant 
complications, 
so need to 
modify HRG is 
complications 
AAo+AVR+hemiarch Complex 
L181 +L188 +Z34.2+ K263 
EA20Z/EA22Z 
L181 +L188 +Z34.2+ K263 
EA20Z/EA22Z 
L191+L198 +Z34.2 + K263 
EA20Z/EA22Z 
L191+L198 +Z34.2 + K263 
EA20Z/EA22Z 
AAo+total arch Complex 
L181 + L188 + Z342 
EA20Z/EA22Z 
L181 + L188 + Z342 
EA20Z/EA22Z 
L191 + L198 + Z342 
EA20Z/EA22Z 
L191 + L198 + Z342 
EA20Z/EA22Z 
AAo+total arch 
+AVR 
Complex 
L181 + L188 + Z342 + K263  
EA20Z/EA22Z 
L181 + L188 + Z342 + 
K263  EA20Z/EA22Z 
L191 + L198 + Z342 + 
K263  EA20Z/EA22Z 
L191 + L198 + Z342 + 
K263  EA20Z/EA22Z 
AAo+total arch +ET Complex 
L181 + L188 + L761+ Z342-  
EA20Z/EA22Z 
L181 + L188 + L761+ 
Z342-  EA20Z/EA22Z 
L191 + L198 + L761+Z342-  
EA20Z/EA22Z 
L191 + L198 + L761+Z342- 
EA20Z/EA22Z 
AAo+total 
arch+ET+AVR 
Complex 
L181 + L188 +  L761+Z342 + 
K263 EA20Z/EA22Z 
L181 + L188 +  L761+Z342 
+ K263 EA20Z/EA22Z 
L191 + L198 + 
L761+.K263+Z342  
EA20Z/EA22Z 
L191 + L198 + 
L761+.K263+Z342 
EA20Z/EA22Z 
Root 
Simple/ 
Complex 
K334 Mechanical / K335 
Tissue / K33.3 homograft, 
EA20Z/EA22Z 
K334 Mechanical / K335 
Tissue / K33.3 
homograft, EA20Z/EA22Z 
K334 Mechanical / K335 
Tissue / K33.3 homograft  
EA20Z/EA22Z 
K334 Mechanical / K335 
Tissue / K33.3 homograft  
EA20Z/EA22Z  
 
Group B1, 
modify if 
complications 
Root+AVR 
Simple/ 
Complex 
K334 Mechanical / K335 
Tissue / K33.3 homograft + 
K263 EA20Z/EA22Z 
K334 Mechanical / K335 
Tissue / K33.3 homograft 
+ K263 EA20Z/EA22Z 
K334 Mechanical / K335 
Tissue / K33.3 homograft 
+ K263  EA20Z/EA22Z 
K334 Mechanical / K335 
Tissue / K33.3 homograft 
+ K263  EA20Z/EA22Z 
Root+ AAo 
Simple/ 
Complex 
L181+ K334 Mechanical / 
K335 Tissue, EA20Z/EA22Z 
L181+ K334 Mechanical / 
K335 Tissue, 
EA20Z/EA22Z 
L191+ K334 Mechanical / 
K335 Tissue EA20Z/EA22Z 
L191+ K334 Mechanical / 
K335 Tissue EA20Z/EA22Z 
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Table 9.3. Thoracic and thoraco-abdominal aortic surgery OPCS 4 Procedures and HRGs analysis (2 of 4) 
 
 
  
Operations 
Relative 
Clinical 
complexity 
Emergency Coding- 
Liverpool 
Emergency Coding - Royal 
Brompton 
Elective Codes- Liverpool 
Elective Codes- Royal 
Brompton 
 Proposed HRG 
groupings 
Root 
+AAo+AVR 
Major 
complex 
L181 + K334 Mechanical / 
K335 Tissue  + K263,  
EA20Z/EA22Z 
L181 + K334 Mechanical / 
K335 Tissue  + K263,  
EA20Z/EA22Z 
L191 + K334 Mechanical / 
K335 Tissue  + K263 
EA20Z/EA22Z 
L191 + K334 Mechanical / 
K335 Tissue  + K263 
EA20Z/EA22Z 
 
 
Group B2, 
modify if 
complications 
 
 
 
 
 
 
 
Group B2, 
modify if 
complications 
Root 
+AAo+hemia
rch 
Major 
complex 
L181 + K334 Mechanical / 
K335 Tissue+L188 +Z34.2,  
EA20Z/EA22Z 
L181 + K334 Mechanical / 
K335 Tissue+L188 +Z34.2,  
EA20Z/EA22Z 
L191 +  K334 Mechanical / 
K335 Tissue + L198 + Z34.2 
EA20Z/EA22Z 
L191 +  K334 Mechanical / 
K335 Tissue + L198 + Z34.2 
EA20Z/EA22Z 
Root 
+AVR+AAo+
hemiarch 
Major 
complex 
L181 +  K334 Mechanical / 
K335 Tissue +L188 +Z34.2+ 
K263 , EA20Z/EA22Z 
L181 +  K334 Mechanical / 
K335 Tissue +L188 +Z34.2+ 
K263 , EA20Z/EA22Z 
L191 +  K334 Mechanical / 
K335 Tissue +L198 +Z34.2+ 
K263 EA20Z/EA22Z  
L191 +  K334 Mechanical / 
K335 Tissue +L198 +Z34.2+ 
K263 EA20Z/EA22Z  
Root+AAo+t
otal arch 
Major 
complex 
L181 + L188 +Z342 + K334 
Mechanical / K335 Tissue, 
EA20Z/EA22Z 
L181 + L188 +Z342 + K334 
Mechanical / K335 Tissue, 
EA20Z/EA22Z 
L191 + L198 +  Z342 + 
K334 Mechanical / K335 
Tissue  EA20Z/EA22Z 
L191 + L198 +  Z342 + K334 
Mechanical / K335 Tissue  
EA20Z/EA22Z 
Root+AVR+ 
AAo+total 
arch 
Major 
complex 
L181 + L188+Z34.2 + K334 
Mechanical / K335 Tissue 
+  K263   EA20Z/EA22Z 
L181 + L188+Z34.2 + K334 
Mechanical / K335 Tissue 
+  K263   EA20Z/EA22Z 
L191 + L198 + Z342 + K334 
Mechanical / K335 Tissue 
+  K263 EA20Z/EA22Z 
L191 + L198 + Z342 + K334 
Mechanical / K335 Tissue +  
K263 EA20Z/EA22Z 
Root+AAo + 
total arch + 
ET 
Major 
complex 
L181 + L188+ L761+Z34.2 + 
K334 Mechanical / K335 
Tissue  EA20Z/EA22Z 
L181 + L188+ L761+Z34.2 + 
K334 Mechanical / K335 
Tissue  EA20Z/EA22Z 
L191 + L198 + L761 + Z34.2 
+ K334 Mechanical / K335 
Tissue EA20Z/EA22Z 
L191 + L198 + L761 + Z34.2 + 
K334 Mechanical / K335 
Tissue EA20Z/EA22Z 
Root+AVR+A
Ao + total 
arch + ET 
Major 
complex 
L181 + L188 + L761+Z34.2 
+ K334 Mechanical / K335 
Tissue +  K263  
EA20Z/EA22Z 
L181 + L188 + L761+Z34.2 
+ K334 Mechanical / K335 
Tissue +  K263 
EA20Z/EA22Z 
L191 + L198 + L761 + Z34.2 
+ K334 Mechanical / K335 
Tissue +  K263 
EA20Z/EA22Z 
L191 + L198 + L761 + Z34.2 + 
K334 Mechanical / K335 
Tissue +  K263 EA20Z/EA22Z 
Isolated arch Complex L188 QZ01A/QZ01B  L188 + Z342QZ01A/QZ01B  L198 + Z342QZ01A/QZ01B  L198 QZ01A/QZ01B  
Group C 1, 
 Modify if 
complications 
Frozen 
elephant 
trunk 
Complex L188 + L27/L28  L198 + L27/L28  
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Table 9.3. Thoracic and thoraco-abdominal aortic surgery OPCS 4 Procedures and HRGs analysis (3 of 4) 
 
Operations 
Relative 
Clinical 
complexity 
Emergency Coding- 
Liverpool 
Emergency Coding - Royal 
Brompton 
Elective Codes- Liverpool 
Elective Codes- Royal 
Brompton 
 Proposed HRG 
groupings 
Aortic 
surgery as 
above+ 
other 
(CABG, 
MVR, TVR) 
Complex 
K401 - K469 (CABG) 
EA14Z/EA16Z 
K401 - K469 (CABG) 
EA14Z/EA16Z 
K401 - K469 (CABG) 
EA14Z/EA16Z 
K401 - K469 (CABG) 
EA14Z/EA16Z 
 
Group D1, 
modify if 
complications 
 Complex 
K251 - K259 (Mitral Valve) 
EA17Z/EA19Z 
K251 - K259 (Mitral Valve) 
EA17Z/EA19Z 
K251 - K259 (Mitral Valve)  
EA17Z/EA19Z 
K251 - K259 (Mitral Valve)  
EA17Z/EA19Z 
 Complex 
K271 - K279 (Tricuspid 
Valve) EA17Z/EA19Z 
K271 - K279 (Tricuspid 
Valve) EA17Z/EA19Z 
K271 - K279 (Tricuspid 
Valve) EA17Z/EA19Z 
K271 - K279 (Tricuspid Valve) 
EA17Z/EA19Z 
 Complex 
K281 - K289 (Pulmonary 
Valve) EA17Z/EA19Z 
K281 - K289 (Pulmonary 
Valve) EA17Z/EA19Z 
K281 - K289 (Pulmonary 
Valve) EA17Z/EA19Z 
K281 - K289 (Pulmonary 
Valve) EA17Z/EA19Z 
 Complex 
K301 - K309 Revision of 
Repair of  Valve  
EA20Z/EA22Z 
K301 - K309 Revision of 
Repair of  Valve  
EA20Z/EA22Z 
K301 - K309 Revision of 
Repair of  Valve 
EA20Z/EA22Z 
K301 - K309 Revision of Repair 
of  Valve EA20Z/EA22Z 
Group D2, 
modify if 
complex 
 Complex 
K341 - K343 Annuloplasty  
EA17Z/EA19Z 
K341 - K343 Annuloplasty  
EA17Z/EA19Z 
K341 - K343 Annuloplasty  
EA17Z/EA19Z 
K341 - K343 Annuloplasty  
EA17Z/EA19Z 
Redo  
Depends on the previous 
procedure  
Depends on the previous 
procedure  
Depends on the previous 
procedure  
Depends on the previous 
procedure  
Modify due to 
increased 
complexity 
and higher risk 
of 
complications 
Other Aortic 
Aneurysm 
Procedures 
Complex 
L183, L184, L185, L186 
QZ01A/QZ01B 
L183, L184, L185, L186 
QZ01A/QZ01B 
L193, L194, L195, L196  
QZ01A/QZ01B 
L193, L194, L195, L196  
QZ01A/QZ01B 
Group C, 
modify if 
complications 
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Table 9.3. Thoracic and thoraco-abdominal aortic surgery OPCS 4 Procedures and HRGs analysis (4 of 4) 
 
 
Operations 
Relative 
Clinical 
complexity 
Emergency Coding- 
Liverpool 
Emergency Coding - Royal 
Brompton 
Elective Codes- Liverpool 
Elective Codes- Royal 
Brompton 
 Proposed HRG 
groupings 
Other Aortic 
Bypass 
Procedures 
Complex 
L201 - L209  EA20Z/EA22Z, 
L20.3 to L20.9 = 
QZ01A/QZ01B) 
L201 - L209 (L20.1&L20.2 = 
EA20Z/EA22Z, L20.3 to 
L20.9 = QZ01A/QZ01B) 
L21.1 - L219  ( 
EA20Z/EA22Z, L20.2 to 
L20.9 = QZ01A/QZ01B) 
L21.1 - L219  (L21.1= 
EA20Z/EA22Z, L20.2 to L20.9 = 
QZ01A/QZ01B) 
Group D, 
modify if 
complications 
Isolated 
DTA(Thoracic 
aortic 
dissection) 
Medical 
management 
Simple 
L201 - L209  EA20Z/EA22Z, 
L20.3 to L20.9 = 
QZ01A/QZ01B) 
L201 - L209 (L20.1&L20.2 = 
EA20Z/EA22Z, L20.3 to 
L20.9 = QZ01A/QZ01B) 
L21.1 - L219  ( 
EA20Z/EA22Z, L20.2 to 
L20.9 = QZ01A/QZ01B) 
L21.1 - L219  (L21.1= 
EA20Z/EA22Z, L20.2 to L20.9 = 
QZ01A/QZ01B) 
Group E 1, 
modify if 
complications 
Isolated 
DTA(Thoracic 
aortic 
dissection) 
Surgical 
management 
Complex 
L201 - L209  EA20Z/EA22Z, 
L20.3 to L20.9 = 
QZ01A/QZ01B) 
L201 - L209 (L20.1&L20.2 = 
EA20Z/EA22Z, L20.3 to 
L20.9 = QZ01A/QZ01B) 
L21.1 - L219  ( 
EA20Z/EA22Z, L20.2 to 
L20.9 = QZ01A/QZ01B) 
L21.1 - L219  (L21.1= 
EA20Z/EA22Z, L20.2 to L20.9 = 
QZ01A/QZ01B) 
Group E2, 
modify if 
complications 
TAAA (thoraco 
abdominal 
aortic 
aneurysm)  
Major 
complex 
L181 / L182 + L185 
EA20Z/EA22Z or 
QZ01A/QZ01B 
L181 / L182 + L185 
EA20Z/EA22Z or 
QZ01A/QZ01B 
L191 / L192 + L195 
EA20Z/EA22Z or 
QZ01A/QZ01B 
L191 / L192 + L195 
EA20Z/EA22Z or 
QZ01A/QZ01B 
Group F, 
modify if 
complications 
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Table 10.5. Outcomes following aortic arch surgery and cerebral 
protection method used since 1997 to current date in the published 
literature (1 of 2) 
Author Year Site Method Mortality References 
Hayashi 1997 Arch SCP 24% (137) (241) 
Sadahiro 1997 Ascending/ 
arch 
SCP 10% (91) (242) 
Ohkita 1998 Arch HCA+RCP 9% (129)  
Crawford 1998 Ascending/ 
arch 
HCA 7% (596)  
Ehrlich 2000 Ascending/ 
arch 
HCA 9% (311) (243) 
Yamashiro 2001 Arch SCP 20% (25)  
Czerny 2003 Ascending/ 
arch 
HCA 11.6% (369) (244) 
Ueda 2003 Arch SCP 12% (103) (245) 
Griepp 2004 Arch HCA/SCP/T 14% (150) (246) 
Elefteriades 2007 Ascending/ 
arch 
HCA/SCP 3% (360) (247) 
Minatoya 2006 Arch SACP 2.3% (271) (248) 
                                                                
241 Tabayashi K, Ohmi M, Togo T, Miura M, Yokoyama H, Akimoto H, Murata S, Ohsaka K, Mohri H. 
Aortic arch aneurysm repair using selective cerebral perfusion. Ann Thorac Surg. 1994 
May;57(5):1305-10 
242 Uchida N, Watanabe S, Shinozaki S, Niibori K, Sadahiro M, Ohmi M, Tabayashi K.[Early and late 
results of replacement of the ascending aorta and/or aortic arch using selective cerebral perfusion]. 
Nihon Kyobu Geka Gakkai Zasshi. 1997 Aug;45(8):1076-83 
243 Ehrlich MP, Ergin MA, McCullough JN, Lansman SL, Galla JD, Bodian CA, Apaydin AZ, Griepp RB. 
Predictors of adverse outcome and transient neurological dysfunction after ascending aorta/hemiarch 
replacement. Ann Thorac Surg. 2000 Jun;69(6):1755-63 
244 Czerny M, Fleck T, Zimpfer D, Dworschak M, Hofmann W, Hutschala D, Dunkler D, Ehrlich M, 
Wolner E, Grabenwoger M. Risk factors of mortality and permanent neurologic injury in patients 
undergoing ascending aortic and arch repair. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1296-301 
245 Ueda T, Shimizu H, Hashizume K, Koizumi K, Mori M, Shin H, Yozu R. Mortality and morbidity after 
total arch replacement using a branched arch graft with selective antegrade cerebral perfusion. Ann 
Thorac Surg. 2003;76(6):1951-6 
246 Strauch JT, Spielvogel D, Lauten A, Lansman SL, McMurtry K, Bodian CA, Griepp RB. Axillary artery 
cannulation: routine use in ascending aorta and aortic arch replacement. Ann Thorac Surg. 2004 
Jul;78(1):103-8 
247 Achneck HE, Rizzo JA, Tranquilli M, Elefteriades JA. Safety of thoracic aortic surgery in the present 
era. Ann Thorac Surg. 2007 Oct;84(4):1180-5  
248 Minatoya K, Ogino H, Matsuda H, Sasaki H, Yagihara T, Kitamura S. Surgical management of distal 
arch aneurysm: another approach with improved results. Ann Thorac Surg. 2006 Apr;81(4):1353-6 
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Table 10.5. Outcomes and cerebral protection method used since 1997 to 
current date in the literature (2 of 2) 
 
Author Year Site Method Mortality References 
Sundt 2008 Arch SCP 2.9% (347) (249) 
Minatoya 2010 Arch HCA 7.9% (114) (250) 
Bischoff 2010 Arch  7% (50) (251) 
Kulik 2011 Arch  6% (67) (252) 
Zierer 2011 Arch UACP/HCA 4% (44) (253) 
LeMaire 2011 Arch  2% (200) (254) 
Misfeld 2012 Arch UACP/BACP/HCA 11% (636) (255) 
Thomas 2012 Arch/DTA UACP/BACP/HCA 8% (20) (256) 
Iba 2013 Arch  6% (67) (257) 
Urbanski 2013 Arch HCA/SCP 7% (50) (258) 
HCA: hypothermic circulatory arrest, tRCP: retrograde cerebral perfusion, T: Trifurcated Graft 
 
                                                                
249 Sundt TM 3rd, Orszulak TA, Cook DJ, Schaff HV. Improving results of open arch replacement. Ann 
Thorac Surg. 2008 Sep;86(3):787-96 
250 Minatoya K, Ogino H, Matsuda H, Sasaki H, Tanaka H, Kobayashi J, Yagihara T, Kitamura S. Is 
conventional aortic arch surgery justifiable in octogenarians? J Thorac Cardiovasc Surg. 2010 
Mar;139(3):641-5. 
251 Bischoff MS, Brenner RM, Scheumann J, et al. Long term outcome after aortic arch replacement 
with a trifurcated graft. (2010) J Thorac Cardiovac Surgery;140(6 Suppl):S71-76 
252 Kulik A, Castner CF, Kouchoukos NT. Outcomes after total aortic arch repair withright axillary artery 
cnannulation and a presewn multibranched graft. (2011). Ann Thorac Surg;92:889-97 
253 Zierer A, Detho F, Dzemali O, Aybek T, Moritz A, Bakhtiary F. Antegrade cerebral perfusion with 
mild hypothermia for aortic arch replacement: single-center experience in 245 consecutive patients. 
Ann Thorac Surg. 2011 Jun;91(6):1868-73 
254 LeMaire SA, Price MD, Parenti JL, et al. Early outcomes after total aortic arch replacement by using 
the Y-graft technique. (2011) Ann Thorac Surg;91:700-708 
255 Misfeld M, Leontyev S, Borger MA, Gindensperger O, Lehmann S, Legare JF, Mohr FW. What is 
the best strategy for brain protection in patients undergoing aortic arch surgery? A single center 
experience of 636 patients. Ann Thorac Surg. 2012 May;93(5):1502-8 
256 Thomas M, Li Z, Cook DJ, Greason KL, Sundt TM. Contemporary results of open aortic arch surgery. J Thorac Cardiovasc Surg. 2012 Oct;144(4):838-44 
257 Iba Y, Minatoya K, Matsuda H, et al. Contemporary open aortic arch repair with selective cerebral 
perfusion in the era of endovascular aortic repair. (2013) J Thorac Cardiovasc Surg; 145:S72-77 
258 Urbanski PP, Raad M, Lenos A, Bougioukakis P, Zacher M, Diegeler A. Open aortic arch 
replacement in the era of endovascular techniques. Eur J Cardiothorac Surg. 2013 Feb 20. [Epub 
ahead of print] PubMed PMID: 23425674. 
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Table 12.1.5. Patient characteristics and univariable analysis of risk 
factors for in-hospital mortality after proximal aortic surgery in the UK  
    
No. of 
patients* 
Odds ratio (95% CI) 
for in-hospital mortality 
P value 
Age (years) < 70 5723 (66.3) Reference  
 ≥ 70 2916 (33.8) 1.98 (1.70, 2.29) <0.001 
 Continuous 64 (51, 73) 1.03 (1.02, 1.03) <0.001 
Gender Male 5784 (67.0) Reference  
 Female 2855 (33.0) 1.06 (0.91, 1.24) 0.48 
Admission type NHS patient 8269 (95.7) Reference  
 Private patient 370 (4.3) 0.39 (0.23, 0.67) <0.001 
BMI <30 6460 (74.8) Reference  
 ≥ 30 2179 (25.2) 0.90 (0.76, 1.07) 0.24 
 Continuous 26.9 (24.1, 30.1) 1.00 (0.98, 1.01) 0.57 
Angina CCS class I to III 8232 (95.3) Reference  
 IV 407 (4.7) 2.56 (1.98, 3.32) <0.001 
New York Heart Association (NYHA) class < III 6014 (69.6) Reference  
 ≥ III 2625 (30.4) 1.80 (1.55, 2.09) <0.001 
Previous myocardial infarction No 7978 (92.3) Reference  
 Yes 661 (7.7) 2.36 (1.91, 2.93) <0.001 
Myocardial infarction within last 90 days No 8344 (96.6) Reference  
 Yes 295 (3.4) 2.97 (2.23, 3.96) <0.001 
Previous angioplasty No 8363 (96.8) Reference  
 Yes 276 (3.2) 1.65 (1.16, 2.35) 0.005 
Previous cardiac surgery No 7419 (85.9) Reference  
 Yes 1220 (14.1) 2.80 (2.37, 3.32) <0.001 
Diabetes No 8042 (93.1) Reference  
 Yes 597 (6.9) 1.46 (1.13, 1.88) 0.004 
Current smoker No 7671 (88.8) Reference  
 Yes 968 (11.2) 1.10 (0.88, 1.39) 0.39 
Hypertension No 3335 (38.6) Reference  
 Yes 5304 (61.4) 1.50 (1.27, 1.75) <0.001 
Creatinine > 200 µmol / L No 8386 (97.1) Reference  
 Yes 253 (2.9) 3.82 (2.86, 5.11) <0.001 
History of renal impairment No 8471 (98.1) Reference  
 Yes 168 (1.9) 2.96 (2.04, 4.30) <0.001 
Pulmonary disease No 7624 (88.3) Reference  
 Yes 1015 (11.8) 1.35 (1.09, 1.66) 0.005 
History of neurological disease No 7913 (91.6) Reference  
 Yes 726 (8.4) 2.04 (1.65, 2.53) <0.001 
Neurological dysfunction No 8297 (96.0) Reference  
 Yes 342 (4.0) 2.36 (1.77, 3.13) <0.001 
Peripheral vascular disease No 7268 (84.1) Reference  
 Yes 1371 (15.9) 1.79 (1.51, 2.14) <0.001 
Preoperative non-sinus rhythm No 7604 (88.0) Reference  
 Yes 1035 (12.0) 2.14 (1.77, 2.57) <0.001 
Triple vessel disease No 8244 (95.4) Reference  
 Yes 395 (4.6) 2.62 (2.02, 3.40) <0.001 
Left main stem disease No 8472 (98.1) Reference  
 Yes 167 (1.9) 1.99 (1.31, 3.03) 0.001 
Left ventricular ejection fraction 30%-50% No 6933 (80.3) Reference  
 Yes 1706 (19.7) 1.78 (1.49, 2.12) <0.001 
Left ventricular ejection fraction <30% No 8251 (95.5) Reference  
 Yes 388 (4.5) 3.50 (2.69, 4.55) <0.001 
Presence of IV nitrates No 8171 (94.6) Reference  
 Yes 468 (5.4) 2.60 (2.04, 3.32) <0.001 
Presence of IV inotropes No 8404 (97.3) Reference  
 Yes 235 (2.7) 6.09 (4.61, 8.04) <0.001 
Cardiogenic shock No 8253 (95.5) Reference  
 Yes 386 (4.5) 6.32 (5.05, 7.90) <0.001 
Preoperative ventilation No 8472 (98.1) Reference  
  Yes 167 (1.9) 6.08 (4.39, 8.42) <0.001 
     
*With percentages in parentheses; non-normallly distributed continuous data are presented as median (IQR)  
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Table 12.1.6a. Operative factors and univariable analysis of risk factors for 
in-hospital mortality after proximal aortic surgery from the NICOR database 
in the UK 
    
No. of 
patients* 
Odds ratio (95% CI) 
for in-hospital mortality 
P value 
Operative details     
Priority Elective 5461 (63.2) Reference  
 Urgent 1412 (16.3) 2.52 (2.04, 3.11) <0.001 
 Emergency 1615 (18.7) 4.76 (3.98, 5.69) <0.001 
 Salvage 149 (1.7) 20.03 (14.18, 28.29) <0.001 
 MISSING 2 (0.02)   
Concomitant procedures No CABG operation 7000 (81.0) Reference  
 CABG operation 1639 (19.0) 2.10 (1.79, 2.47) <0.001 
 No Valve operation 2642 (30.6) Reference  
 Valve operation 5997 (69.4) 0.59 (0.50, 0.68) <0.001 
 No Other operation 5841 (67.6) Reference  
 Other operation 2798 (32.4) 1.02 (0.87, 1.19) 0.47 
Aortic pathology     
Aneurysm No 3604 (41.7) Reference  
 Yes 5035 (58.3) 0.27 (0.23, 0.32) <0.001 
Chronic dissection No 8299 (96.1) Reference  
 Yes 340 (3.9) 1.37 (0.98, 1.93) 0.07 
Acute dissection No 7071 (81.9) Reference  
 Yes 1568 (18.2) 3.02 (2.58, 3.54) <0.001 
Trauma No 8603 (99.6) Reference  
 Yes 36 (0.4) 3.94 (1.9, 8.21) <0.001 
Coarctation No 8636 (99.97) Reference  
 Yes 3 (0.03) 5.09 (0.46, 56.14) 0.18 
Penetrating 
Atheromatous Ulcer No 8599 (99.5) Reference  
 Yes 40 (0.5) 2.97 (1.41, 6.26) 0.004 
Pseudoaneurysm No 8592 (99.5) Reference  
 Yes 47 (0.5) 2.77 (1.37, 5.59) 0.005 
Intramural haematoma No 8611 (99.7) Reference  
 Yes 28 (0.3) 1.70 (0.59, 4.90) 0.33 
Other No 7161 (82.9) Reference  
 Yes 1478 (17.1) 1.51 (1.26, 1.80) <0.001 
Aortic segment     
Root No 4354 (50.4) Reference  
 Yes 4285 (49.6) 0.89 (0.76, 1.03) 0.11 
Ascending No 2214 (25.7) Reference  
 Yes 6425 (74.4) 0.90 (0.76, 1.06) 0.22 
Arch No 7801 (90.3) Reference  
  Yes 838 (9.7) 1.72 (1.39, 2.13) 0.004 
     
*With percentages in parentheses; non-normally distributed continuous data are presented as median (IQR)  
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Table 12.1.6b. Final multivariable logistic regression model for risk prediction in elective patients. Data taken from the 
NICOR database. 
Parameter Odds Ratio 95% CI Co-efficient P 
Intercept - - -6.6707 <0.001 
Age at operation (years) 1.04 1.02, 1.05 0.0345 <0.001 
Female gender 1.49 1.13, 1.98 0.4002 0.005 
NYHA class > 2 1.45 1.10, 1.92 0.3721 0.009 
Previous cardiac surgery 4.10 2.97, 5.67 1.4118 <0.001 
Current smoker 1.61 1.04, 2.48 0.475 0.032 
Pulmonary disease 1.50 1.07, 2.12 0.4081 0.02 
History of neurological disease 2.12 1.46, 3.08 0.7518 <0.001 
Preoperative non-sinus rhythm 1.61 1.15, 2.26 0.4765 0.006 
Triple vessel disease 2.29 1.49, 3.52 0.8296 <0.001 
Left ventricular ejection fraction < 30% 2.46 1.43, 4.25 0.9011 0.001 
Concomitant CABG operation 2.29 1.68, 3.13 0.8275 <0.001 
Surgery on the arch segment of the aorta 2.39 1.68, 3.41 0.8719 <0.001 
Aortic pathology other than 'Aneurysm' 1.86 1.28, 2.70 0.619 0.001 
 
Calculation of predicted risk using patient data and logistic regression coefficients: odds of in-hospital death = exp(-6.6707+[0.0345*age (continuous in years)]+ 
[0.4002*Female gender]+ [0.3721*NYHA Class > 2]+[1.4118*Previous cardiac surgery]+[0.475*Current smoker]+[0.4081*History of pulmonary 
disease]+[0.7518*History of neurological disease]+[0.4765*Non sinus rhythm]+[0.8296*Triple vessel disease]+[0.9011*Left ventricular ejection fraction < 
30%]+[0.8275*Concomitant CABG operation]+[0.8719*Surgery on the arch segment of the aorta]+[0.619*Aortic pathology other than 'Aneurysm'])  
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Table 12.1.6c. Final multivariable logistic regression model for risk prediction in non-elective patients 
Parameter Odds Ratio 95% CI Co-efficient P 
Intercept - - -4.666 <0.001 
Age at operation (years) 1.03 1.02, 1.03 0.0251 <0.001 
Previous cardiac surgery 3.86 2.99, 4.98 1.3506 <0.001 
Creatinine > 200 µmol / L 1.73 1.21, 2.48 0.5483 0.003 
Peripheral vascular disease 1.43 1.11, 1.83 0.3548 0.005 
Preoperative non-sinus rhythm 1.74 1.32, 2.31 0.5563 <0.001 
Left ventricular ejection fraction < 30% 1.52 1.06, 2.19 0.4187 0.024 
Cardiogenic shock 1.87 1.42, 2.48 0.6265 <0.001 
Emergency priority 2.77 2.17, 3.53 1.0186 <0.001 
Salvage priority 9.90 6.46, 15.18 2.2928 <0.001 
Concomitant CABG operation 2.17 1.69, 2.79 0.7739 <0.001 
 
Calculation of predicted risk using patient data and logistic regression coefficients: odds of in-hospital death = exp(-4.666+[0.0251*age (continuous in 
years)]+[1.3506*Previous cardiac surgery]+[0.5483*Creatinine > 200 µmol / L]+[0.3548*Peripheral vascular disease]+[0.5563*Non sinus rhythm]+[0.4187*Left 
ventricular ejection fraction < 30%]+[0.6265*Cardiogenic shock]+[1.0186*Emergency priority]+[2.2928*Salvage priority]+[0.7739*Concomitant CABG operation]) 
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Table 12.1.7. Risk group assessment demonstrating good calibration of the risk prediction model ultising NICOR data  
Risk Group n Score Range Observed mortality Predicted mortality P 
Elective cohort      
Low 4047 0%-5%  1.75 2.01 0.398 
Medium 624 5%-8% 7.69 6.29 0.331 
High 792 >8% 16.54 16.36 0.923 
      
Non-elective cohort      
Low 1547 0%-12%  6.33 7.09 0.401 
Medium 823 12%-20% 15.8 15.14 0.713 
High 806 >20% 36.85 36.13 0.764 
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Table 12.2.4a. Patient characteristics showing univariate odds ratios for 
in-hospital mortality 
  
All Type A Acute 
Dissections  
(n=1386) 
Missing 
Data 
Odds ratio  
(95% CI) 
p-value 
Age at operation (years) 63 (52, 72) 0 (0) 1.02 (1.01, 1.03) <0.001 
Female gender 446 (32.2) 0 (0) 0.91 (0.68, 1.23) 0.53 
Body mass index (kg/m2) 26.3 (23.8, 29.4) 48 (3.5) 1.01 (0.98, 1.04) 0.55 
Angina class IV 215 (15.5) 17 (1.2) 1.37 (0.96, 1.96) 0.09 
NYHA class ≥ III 360 (26.0) 23 (1.7) 1.45 (1.07, 1.95) 0.02 
Previous Q-wave MI 140 (10.1) 13 (0.9) 2.37 (1.61, 3.49) <0.001 
Recent MI (within 90 days) 71 (5.1) 10 (0.7) 3.28 (1.99, 5.39) <0.001 
Previous PCI 45 (3.3) 39 (2.8) 1.17 (0.55, 2.45) 0.69 
Previous cardiac surgery 85 (6.1) 97 (7.0) 1.68 (1.01, 2.79) 0.04 
Diabetes (diet or insulin controlled) 63 (4.6) 11 (0.8) 1.48 (0.81, 2.69) 0.20 
Current smoker 246 (17.8) 53 (3.8) 0.88 (0.61, 1.28) 0.50 
History of hypertension 964 (69.6) 8 (0.6) 1.15 (0.85, 1.56) 0.37 
Creatinine > 200 μmol/L 72 (5.2) 111 (8.0) 1.99 (1.18, 3.38) 0.01 
History of renal dysfunction 33 (2.4) 60 (4.3) 2.73 (1.33, 5.63) 0.006 
History of pulmonary disease 152 (11.0) 9 (0.7) 1.00 (0.64, 1.56) >0.99 
History of neurological disease 145 (10.5) 19 (1.4) 1.01 (0.65, 1.59) 0.95 
History of neurological dysfunction 103 (7.4) 15 (1.1) 1.28 (0.79, 2.10) 0.32 
Peripheral vascular disease 283 (20.4) 16 (1.2) 1.48 (1.07, 2.04) 0.02 
Non-sinus heart rhythm 126 (9.1) 92 (6.6) 2.00 (1.32, 3.03) 0.001 
Triple vessel disease 30 (2.2) 324 (23.4) 1.16 (0.47, 2.88) 0.74 
Left ventricular ejection fraction 
30% - 50% 267 (19.3) 23 (1.7) 1.45 (1.04, 2.03) 0.03 
Left ventricular ejection fraction 
<30% 47 (3.4) 23 (1.7) 3.96 (2.17, 7.22) <0.001 
Intravenous nitrates or any heparin  190 (13.7) 6 (0.4) 1.01 (0.68, 1.51) 0.95 
Intravenous inotropes prior to 
anaesthesia 100 (7.2) 8 (0.6) 3.33 (2.17, 5.12) <0.001 
Pre-operative ventilation 81 (5.8) 6 (0.4) 2.97 (1.85, 4.76) <0.001 
Pre-operative cardiogenic shock 235 (17.0) 13 (0.9) 2.76 (2.00, 3.79) <0.001 
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Table 12.2.4b. Operative characteristics showing univariate odds ratios for in-hospital mortality 
  
All Type A Acute 
Dissections  
(n=1386) 
Missing Data OR (95% CI) p-value 
Elective operation 24 (1.7) 0 (0) 2.21 (0.90, 5.41) 0.08 
Urgent operation 189 (13.6) 0 (0) 0.74 (0.47, 1.19) 0.21 
Emergency operation 1076 (77.6) 0 (0)  1 (referent category) - 
Salvage operation 97 (7.0) 0 (0) 5.05 (3.28, 7.76) <0.001 
Root segment 463 (33.4) 0 (0) 1.13 (0.84, 1.51) 0.38 
Ascending segment 1202 (86.7) 0 (0)  1 (referent category) - 
Arch segment 176 (12.7) 0 (0) 1.20 (0.80, 1.78) 0.38 
Concomitant CABG 181 (13.1) 27 (2.0) 2.72 (1.92, 3.84) <0.001 
Concomitant Valve 569 (41.1) 26 (1.9) 0.96 (0.73, 1.27) 0.78 
Concomitant Other cardiac procedure 428 (30.9) 31 (2.2) 1.08 (0.99, 1.18) 0.08 
Cardiopulmonary bypass time > 260 mins 324 (24.1) 39 (2.8) 2.04 (1.51, 2.75) <0.001 
Aortic cross clamp time > 145 mins 329 (24.5) 45 (3.2) 1.10 (0.80, 1.52) 0.55 
Circulatory arrest time > 35 mins 252 (24.0) 335 (24.2) 1.55 (1.11, 2.16) 0.01 
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Table 12.2.6. Post-operative outcomes from NICOR in all patients under going Type A Acute Dissection Surgery in the 
UK. A separate column for missing data is provided  
  
All Type A Acute Dissections  
(n=1386) 
Missing Data 
In-hospital mortality 246 (17.8) 0 (0) 
All stroke 165 (11.9) 169 (12.2) 
    TIA 57 (4.1) 169 (12.2) 
    CVA 108 (7.8) 169 (12.2) 
Paraparesis 7 (0.5) 169 (12.2) 
Paraplegia 3 (0.2) 169 (12.2) 
Post-operative dialysis 198 (14.3) 156 (11.3) 
Return to theatre (RTT) 236 (17.0) 74 (5.3) 
    RTT for bleeding 198 (14.3) 74 (5.3) 
    RTT for valvular problems 4 (0.3) 74 (5.3) 
    RTT for graft problems 3 (0.2) 74 (5.3) 
    RTT for other cardiac problems 33 (2.4) 74 (5.3) 
    RTT for other sternal resuturing 11 (0.8) 74 (5.3) 
    RTT for deep sternal wound infection 3 (0.2) 74 (5.3) 
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Table 12.3.5. Patients Demographics of LHCH patients pre and post match (1of 2) 
(Continued…) 
  
  
Before Match   After Match 
Pre-Subspecialisation Post-Subspecialisation 
P value 
 Pre-Subspecialisation Post-Subspecialisation 
P value 
(n=80) (n=55)   (n=51) (n=51) 
Pre-operative         
    Age at operation (years) 62.8 (53.3, 67.9) 58.4 (52.5, 72.5) 0.69  62.1 (53.3, 68.7) 58.5 (52.5, 72.6) 0.72 
    Body mass index (kg/m2) 27.0 (24.3, 29.3) 26.7 (23.6, 31.6) 0.66  27.5 (24.6, 29.4) 26.6 (23.6, 31.2) 0.76 
    Female gender  24 (30.0) 23 (41.8) 0.16  15 (28.9) 21 (40.4) 0.22 
    Angina class IV  8 (10.0) 6 (10.9) 0.86  7 (13.5) 6 (11.5) 0.77 
    Previous myocardial infarction 4 (5.0) 1 (1.8) 0.65  1 (1.9) 1 (1.9) >0.99 
    Myocardial infarction within the last 30 days 2 (2.5) 1 (1.8) >0.99  0 (0) 1 (1.9) >0.99 
    NYHA class ≥ III 12 (15.0) 6 (10.9) 0.49  6 (11.5) 6 (11.5) >0.99 
    Current smoker  23 (28.8) 11 (20.0) 0.25  14 (26.9) 10 (19.2) 0.35 
    Diabetes  1 (1.3) 3 (5.5) 0.30  1 (1.9) 3 (5.8) 0.62 
    Hypercholesterolaemia  16 (20.0) 14 (25.5) 0.45  11 (21.2) 13 (25.0) 0.64 
    Hypertension  56 (70.0) 27 (49.1) 0.01  34 (65.4) 27 (51.9) 0.16 
    Respiratory disease * 16 (20.0) 9 (16.4) 0.59  10 (19.2) 9 (17.3) 0.80 
    Cerebrovascular disease  9 (11.3) 0 (0) 0.01  0 (0) 0 (0) - 
    Peripheral vascular disease  7 (8.8) 2 (3.6) 0.31  6 (11.5) 2 (3.9) 0.27 
    Renal dysfunction † 9 (11.3) 12 (21.8) 0.10  7 (13.5) 12 (23.1) 0.20 
    Left ventricular ejection fraction <30%  3 (3.8) 1 (1.8) 0.65  1 (1.9) 1 (1.9) >0.99 
    Logistic EuroSCORE 19.1 (12.2, 31.0) 22.5 (9.2, 32.1) 0.90  18.4 (12.2, 29.2) 22.8 (11.7, 32.8) 0.46 
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Table 12.3.5. Patients Demographics (2 o 2) 
 
 
Continuous data shown as median (25th to 75th percentile), comparisons made with Wilcoxon rank sum tests;  
Categorical data shown as percentage (number), comparisons made with Chi-square tests and Fishers exact tests as appropriate 
* Respiratory disease defined as patient having FEV1<75, asthma, emphysema, chronic obstructive airway disease or being on respiratory medications 
† Renal dysfunction includes patients with a functioning renal transplant and patients with acute or chronic renal failure or insufficiency 
  
Before Match   After Match 
Pre-Subspecialisation Post-Subspecialisation 
P value 
 Pre-Subspecialisation Post-Subspecialisation P 
value (n=80) (n=55)   (n=51) (n=51) 
Operative        
    Prior surgery  3 (3.8) 1 (1.8) 0.65  2 (3.9) 1 (1.9) >0.99 
    Cutting time 480 (420, 610) 583 (520, 675) 0.002  510 (421, 617) 598.5 (502.5, 682.5) 0.038 
    Cardiopulmonary bypass time 291 (240.5, 353) 345 (305, 425) <0.001  303.5 (261, 353) 342.5 (305, 425) 0.01 
    Aortic crossclamp time 145 (119, 194) 204 (147, 258) 0.001   151.5 (112.5, 201) 203 (142, 258) 0.004 
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Table 12.3.6. Patients Demographics Aortic Arch before and after matching for both pre and post subspecialisation(1 of 2) 
 
 
 
 
 
 
 
 
 
  
  
Before Match   After Match 
Pre-
Subspecialisation 
Post-
Subspecialisation 
P 
value 
 
Pre-
Subspecialisation 
Post-
Subspecialisation P value 
(n=73) (n=159)   (n=71) (n=71) 
Pre-operative         
    Age at operation (years) 62.2 (52.4, 69.8) 63.1 (48.9, 71.5) 0.95  62.1 (52.1, 69.7) 64.9 (54.9, 74.5) 0.07 
    Body mass index (kg/m2) 26.2 (23.7, 29.7) 26.9 (23.9, 30.0) 0.57  26.2 (23.5, 29.7) 27.1 (23.8, 29.4) 0.57 
    Female gender  34 (46.6) 61 (38.4) 0.24  32 (45.1) 33 (46.5) 0.87 
    Angina class IV  1 (1.4) 1 (0.6) 0.53  1 (1.4) 1 (1.4) >0.99 
    Previous myocardial infarction 0 (0) 4 (2.5) 0.31  0 (0) 2 (2.8) 0.50 
    Myocardial infarction within 
    the last 30 days 
0 (0) 0 (0) -  0 (0) 0 (0) - 
    NYHA class ≥ III 28 (38.4) 33 (20.8) 0.005  26 (36.6) 26 (36.6) >0.99 
    Current smoker  8 (11.0) 24 (15.1) 0.40  8 (11.3) 11 (15.5) 0.46 
    Diabetes  2 (2.7) 8 (5.0) 0.73  2 (2.8) 3 (4.2) >0.99 
    Hypercholesterolaemia  29 (39.7) 70 (44.0) 0.54  29 (40.9) 35 (49.3) 0.31 
    Hypertension  41 (56.2) 77 (48.4) 0.27  40 (56.3) 36 (50.7) 0.50 
    Respiratory disease * 34 (46.6) 43 (27.0) 0.003  32 (45.1) 31 (43.7) 0.87 
    Cerebrovascular disease  9 (12.3) 9 (5.7) 0.08  9 (12.7) 6 (8.5) 0.41 
    Peripheral vascular disease  3 (4.1) 11 (6.9) 0.56  3 (4.2) 2 (2.8) >0.99 
    Renal dysfunction † 3 (4.1) 10 (6.3) 0.76  3 (4.2) 3 (4.2) >0.99 
    Left ventricular ejection 
    fraction <30%  
1 (1.4) 3 (1.9) >0.99  1 (1.4) 2 (2.8) >0.99 
    Logistic EuroSCORE 17.4 (10.0, 24.8) 11.7 (6.2, 23.6) 0.009  16.8 (9.6, 24.8) 13.8 (7.2, 24.9) 0.30 
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Table 12.3.6. Patients Demographics Aortic Arch before and after matching for both pre and post subspecialisation (2 of 2) 
 
 
 
 
 
 
 
 
 
 
 
 
Continuous data shown as median (25th to 75th percentile), comparisons made with Wilcoxon rank sum tests;  
Categorical data shown as percentage (number), comparisons made with Chi-square tests and Fishers exact tests as appropriate 
* Respiratory disease defined as patient having FEV1<75, asthma, emphysema, chronic obstructive airway disease or being on respiratory medications 
† Renal dysfunction includes patients with a functioning renal transplant and patients with acute or chronic renal failure or insufficiency 
  
Before Match   After Match 
Pre-
Subspecialisation 
Post-
Subspecialisation 
P 
value 
 
Pre-
Subspecialisation 
Post-
Subspecialisation P value 
(n=73) (n=159)   (n=71) (n=71) 
Operative         
    Non-elective 11 (15.1) 43 (27.0) 0.045  11 (15.5) 12 (16.9) 0.820 
    Prior surgery  10 (13.7) 32 (20.1) 0.24  10 (14.1) 10 (14.1) >0.99 
    Cutting time 400 (358, 475) 437 (371, 491) 0.24  400 (358, 475) 416 (359, 467) 0.99 
    Cardiopulmonary bypass time 289 (230, 341) 335 (275, 409) 0.001  289 (230, 341) 308 (269, 369) 0.06 
    Aortic crossclamp time 157 (119, 205) 185 (145, 239) 0.004   157 (119, 199) 183 (138, 239) 0.045 
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Table 12.4.4. Patient Demographics for total and hemi arch replacement at LHCH in both elective and non elective surgeries 
Variable 
Total Arch Replacement   Hemi-Arch Replacement 
Elective (n=75) Non-elective (n=35) p-value  Elective (n=140) Non-elective (n=26) p-value 
Age at operation (years) 64.5 (46.4, 71.0) 60.0 (52.1, 69.0) 0.59  64.3 (53.7, 71.9) 60.6 (52.7, 74.3) 0.54 
Female gender 37 (49.3) 16 (45.7) 0.72  48 (34.3) 9 (34.6) 0.95 
Comorbidities        
    Body mass index (kg/m2) 26.0 (23.1, 30.0) 26.6 (23.8, 29.1) 0.96  27.5 (24.9, 30.4) 27.8 (24.7, 31.7) 0.57 
    Angina class IV 2 (2.7) 1 (2.9) >0.99  3 (2.1) 2 (7.7) 0.17 
    Previous Q-wave MI 4 (5.3) 0 (0) 0.30  5 (3.6) 2 (7.7) 0.30 
    Left ventricular ejection fraction 30% - 50% 6 (8.0) 8 (22.9) 0.06  27 (20.0) 9 (34.6) 0.10 
    Left ventricular ejection fraction <30% 2 (2.7) 0 (0) >0.99  3 (2.1) 1 (3.9) 0.50 
    NYHA class ≥ III 20 (26.7) 7 (20.0) 0.45  41 (29.3) 8 (30.8) 0.88 
    Current smoker 7 (9.3) 10 (28.6) 0.009  19 (13.6) 2 (7.7) 0.53 
    Diabetes 4 (5.3) 2 (5.7) >0.99  8 (5.7) 2 (7.7) 0.66 
    Hypercholesterolaemia 32 (42.7) 13 (37.1) 0.58  77 (55.0) 5 (19.2) <0.001 
    Hypertension 43 (57.3) 20 (57.1) 0.99  76 (54.3) 14 (53.9) 0.97 
    Cerebrovascular disease 5 (6.7) 2 (5.7) >0.99  12 (8.6) 2 (7.7) >0.99 
    Respiratory disease 30 (40.0) 5 (14.3) 0.007  50 (35.7) 9 (34.6) 0.91 
    Peripheral vascular disease 10 (13.3) 1 (2.9) 0.17  6 (4.3) 4 (15.4) 0.052 
    Renal dysfunction 3 (4.0) 5 (14.3) 0.11  3 (2.1) 5 (19.2) 0.003 
    Previous cardiac surgery 24 (32.0) 5 (14.3) 0.0495  14 (10.0) 3 (11.5) 0.73 
Aetiology        
    Degenerative 42 (56.0) 18 (51.4) 0.65  74 (52.9) 13 (50.0) 0.79 
    Non-Degenerative 33 (44.0) 16 (45.7) 0.87  65 (46.4) 13 (50.0) 0.74 
    Other 0 (0) 1 (2.9) 0.32   1 (0.7) 0 (0) >0.99 
 
Categorical variables shown as n (%), comparisons made with chi-squared and Fisher’s exact tests as appropriate;  
Continuous variables shown as median (25th percentile, 75th percentile), comparisons made with Wilcoxon’s Signed Rank test and t-tests as appropriate 
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Table 12.4.6. Post-Operative Complications And Length Of Stay 
Complication 
Total Arch Replacement   Hemi-Arch Replacement 
Elective  Non-elective  
p-value 
 Elective  Non-elective  
p-value 
(n=67) (n=29)   (n=133) (n=25) 
Intubation time (hours) 16 (11, 38) 44 (18, 120) 0.03  16 (11, 23) 10 (9, 20) 0.33 
ITU stay (days) 3 (2, 7) 5 (2, 10) 0.17  2 (1, 4) 4 (3, 15) 0.002 
Post-operative stay (days) 11 (9, 20) 12 (9, 20) 0.77  10 (7, 14) 11.5 (7.5, 19.5) 0.25 
Re-intubation 7 (10.5) 2 (6.9) 0.72  6 (4.5) 4 (16.0) 0.053 
Prolonged ventilation (> 48h) 11 (16.4) 7 (24.1) 0.37  12 (9.0) 3 (12.0) 0.71 
Acute renal failure 5 (7.5) 7 (24.1) 0.04  6 (4.5) 2 (8.0) 0.61 
Deep sternal wound infection 3 (4.5) 0 (0) 0.55  2 (1.5) 0 (0) >0.99 
Re-exploration for bleeding 4 (6.0) 3 (10.3) 0.43  6 (4.5) 5 (20.0) 0.02 
Stroke 3 (4.5) 5 (17.2) 0.052  4 (3.0) 3 (12.0) 0.08 
Local readmission within 30 days 3 (4.5) 3 (10.3) 0.36  9 (6.8) 1 (4.0) >0.99 
In-hospital mortality 5 (7.5) 9 (31.0) 0.005   2 (1.5) 5 (20.0) 0.001 
 
Categorical variables shown as n (%), comparisons made with chi-squared and Fisher’s exact tests as appropriate;  
Continuous variables shown as median (25th percentile, 75th percentile), comparisons made with Wilcoxon’s Signed Rank test and t-tests as appropriate 
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Table 12.5.6a. Aortic Arch Characteristics and Activity 
Variables 
  All AAR   Elective HAAR Elective TAAR 
p-value 
 (n=287)  (n=140) (n=81) 
Age at operation (years)  63.7 (52.4, 71.5)  64.3 (53.7, 71.9) 65.3 (46.6, 72.1) 0.25 
Female gender  115 (40.1)  48 (34.3) 40 (49.4) 0.03 
Comorbidities       
    Body mass index (kg/m2)  26.9 (24.3, 30.1)  27.5 (24.9, 30.4) 26.0 (23.2, 29.3) 0.03 
    Left ventricular ejection 
    fraction < 50% 
 58 (20.2) 
 
31 (22.1) 9 (11.1) 
0.04 
    NYHA class ≥ III  76 (26.5)  41 (29.3) 20 (24.7) 0.46 
    Current smoker  39 (13.6)  16 (11.4) 9 (11.1) 0.94 
    Diabetes  16 (5.6)  8 (5.7) 4 (4.9) >0.99 
    Hypercholesterolemia  133 (46.3)  77 (55.0) 36 (44.4) 0.13 
    Hypertension  159 (55.4)  76 (54.3) 47 (58.0) 0.59 
    Cerebrovascular disease  23 (8.0)  12 (8.6) 6 (7.4) 0.76 
    Respiratory disease  100 (34.8)  52 (37.1) 34 (42.0) 0.48 
    Peripheral vascular disease  21 (7.3)  6 (4.3) 10 (12.4) 0.03 
    Renal dysfunction†  17 (5.9)  3 (2.1) 3 (3.7) 0.67 
    Previous cardiac surgery  48 (16.7)  14 (10.0) 25 (30.9) <0.001 
Aetiology       
    Degenerative  147 (51.2)  72 (51.4) 44 (54.3) 0.68 
    Non-degenerative  138 (48.1)  67 (47.9) 37 (45.7) 0.75 
    Iatrogenic  2 (0.7)  1 (0.7) 0 (0) >0.99 
Priority       
    Non-elective procedure  66 (23.0%)  - - - 
Extent of arch       
    Total arch  117 (40.8)  - 81 (100) - 
    Hemi-arch  170 (59.2)  140 (100) - - 
Concomitant procedures       
    Aortic valve replacement  220 (76.7)  122 (87.1) 52 (64.2) <0.001 
    Mitral valve replacement/ 
    repair 
 4 (1.4) 
 
2 (1.4) 1 (1.2) 
>0.99 
    Tricuspid valve  2 (0.7)  1 (0.7) 1 (1.2) >0.99 
    Pulmonary valve  1 (0.4)  0 (0) 1 (1.2) >0.99 
    CABG  46 (16.0)  26 (18.6) 10 (12.4) 0.23 
    Aortic root  220 (76.7)  114 (81.4) 58 (71.6) 0.09 
    Thoracic aorta  18 (6.3)  1 (0.7) 2 (2.5) 0.56 
Operative times       
    Circulatory arrest  38 (24, 68)  28 (20, 34.5) 68 (45, 99) <0.001 
    Cardiopulmonary bypass  330 (272, 394)  299 (256, 341) 358 (280, 434) <0.001 
    Aortic cross clamp   185 (140, 238)   174 (138, 207) 201 (135.5, 267.5) 0.02 
 
Categorical variables shown as n (%) 
Continuous variables shown as median (25th percentile, 75th percentile) 
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Table 12.5.6b. Pre- And Peri-Operative Patient Data In Non-Elective Hemi-
Arch (HAAR) And Total Arch (TAAR) Repair 
Variables 
Non-elective HAAR Non-elective TAAR 
p-value 
(n=30) (n=36) 
Age at operation (years) 60.6 (52.1, 74.3) 59.3 (53.1, 67.2) 0.58 
Female gender 10 (33.3) 17 (47.2) 0.25 
Comorbidities    
    Body mass index (kg/m2) 27.8 (24.2, 31.6) 26.7 (24.1, 29.0) 0.28 
    Left ventricular ejection fraction 
<50% 
10 (33.3) 8 (22.2) 
0.31 
    NYHA class ≥ III 8 (26.7) 7 (19.4) 0.49 
    Current smoker 2 (6.7) 12 (33.3) 0.008 
    Diabetes 2 (6.7) 2 (5.6) >0.99 
    Hypercholesterolaemia 7 (23.3) 13 (36.1) 0.26 
    Hypertension 16 (53.3) 20 (55.6) 0.86 
    Cerebrovascular disease 3 (10.0) 2 (5.6) 0.65 
    Respiratory disease 9 (30.0) 5 (13.9) 0.11 
    Peripheral vascular disease 4 (13.3) 1 (2.8) 0.17 
    Renal dysfunction 6 (20.0) 5 (13.9) 0.51 
    Previous cardiac surgery 4 (13.3) 5 (13.9) >0.99 
Etiology    
    Degenerative 13 (43.3) 18 (50.0) 0.59 
    Non-degenerative 17 (56.7) 17 (47.2) 0.44 
    Iatrogenic 0 (0) 1 (2.8) >0.99 
Concomitant procedures    
    Aortic valve replacement 24 (80.0) 22 (61.1) 0.10 
    Mitral valve replacement / 
repair 
0 (0) 1 (2.8) 
>0.99 
    Tricuspid valve 0 (0) 0 (0) - 
    Pulmonary valve 0 (0) 0 (0) - 
    CABG 5 (16.7) 5 (13.9) >0.99 
    Aortic root 22 (73.3) 26 (72.2) 0.92 
    Thoracic aorta 0 (0) 1 (2.8) >0.99 
Operative times    
    Circulatory arrest 44 (25, 56) 79.5 (52, 114) <0.001 
    Cardiopulmonary bypass 340 (283, 440) 399 (348.5, 473) 0.01 
    Aortic crossclamp 184 (147, 207) 223 (157, 309) 0.04 
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Table 12.5.11a. In-Hospital And Follow-Up Outcomes In All Patients And Elective Hemi-Arch (HAAR) And Total Arch (TAAR) 
Repair 
Variables 
  All AAR   Elective HAAR Elective TAAR 
p-value 
 (n=287)  (n=140) (n=81) 
Intubation time (hours)  16 (11, 28)  16 (10.5, 23) 16 (12, 38) 0.17 
ITU stay (days)  3 (2, 6)  2 (1, 4) 4 (2, 7) <0.001 
Post-operative stay (days)  11 (8, 17)  10 (7, 14) 12 (9, 21) <0.001 
Re-intubation  22 (7.7)  6 (4.3) 9 (11.1) 0.052 
Prolonged ventilation (> 48h)  35 (12.2)  12 (8.6) 13 (16.1) 0.09 
Acute renal failure  21 (7.3)  6 (4.3) 5 (6.2) 0.54 
Deep sternal wound infection  1 (0.4)  0 (0) 1 (1.2) 0.37 
Re-exploration for bleeding  18 (6.3)  6 (4.3) 4 (4.9) >0.99 
All stroke  16 (5.6)  4 (2.9) 4 (4.9) 0.47 
    CVA  13 (4.5)  3 (2.1) 4 (4.9) 0.26 
    TIA / RIND  3 (1.1)  1 (0.7) 0 (0) >0.99 
Confusion  19 (6.6)  5 (3.6) 10 (12.4) 0.01 
In-hospital mortality  23 (8.0)  3 (2.1) 5 (6.2) 0.15 
30 day mortality  19 (6.6)  3 (2.1) 3 (3.7) 0.67 
1 year mortality  36 (12.5)  11 (7.9) 9 (11.1) 0.42 
5 year mortality   60 (20.9)   22 (15.7) 21 (25.9) 0.065 
 
Categorical variables shown as n (%) 
Continuous variables shown as median (25th percentile, 75th percentile) 
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Table 12.5.11b. In-Hospital And Follow-Up Outcomes In Non-Elective Hemi-Arch (HAAR) And Total Arch (TAAR) Repair 
 
 
 
Variables 
Non-elective HAAR Non-elective TAAR 
p-value 
(n=30) (n=36) 
Intubation time (hours) 10 (8, 24) 27 (14, 79) 0.03 
ITU stay (days) 4 (3, 11.5) 5 (2, 8.5) 0.81 
Post-operative stay (days) 11 (8, 19) 11 (9, 19.5) 0.62 
Re-intubation 4 (13.3) 3 (8.3) 0.69 
Prolonged ventilation (> 48h) 3 (10.0) 7 (19.4) 0.33 
Acute renal failure 2 (6.7) 8 (22.2) 0.10 
Deep sternal wound infection 0 (0) 0 (0) - 
Re-exploration for bleeding 5 (16.7) 3 (8.3) 0.45 
All stroke 3 (10.0) 5 (13.9) 0.72 
    CVA 2 (6.7) 4 (11.1) 0.68 
    TIA / RIND 1 (3.3) 1 (2.8) >0.99 
Confusion 1 (3.3) 3 (8.3) 0.62 
In-hospital mortality 6 (20.0) 9 (25.0) 0.63 
30 day mortality 5 (16.7) 8 (22.2) 0.57 
1 year mortality 7 (23.3) 9 (25.0) 0.88 
5 year mortality 8 (26.7) 9 (25.0) 0.88 
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Table 12.5.12a. Univariate Analysis Showing Significant Risk Factors For 
Follow Up Survival In All AAR Patients 
Variables 
Patients 
Median 
Follow up 
Survival Rate % 
p-value 
n (Months) 1 Year 3 Years 5 Years 
Total 287 33.4 87.5 80.8 79.1  
Age at operation (years)       
    ≤65 155 35.3 90.3 85.2 84.5 
0.007 
    >65 132 27.2 84.1 75.8 72.7 
NYHA class ≥ III       
    No 211 33.8 89.1 84.4 83.4 
0.002 
    Yes 76 29.7 82.9 71.1 67.1 
Diabetes       
    No 271 34.8 88.2 81.9 80.1 
0.038 
    Yes 16 14.8 75 62.5 62.5 
Respiratory disease       
    No 187 31.6 89.3 84.5 84 
0.02 
    Yes 100 35.3 84 74 70 
Peripheral vascular disease       
    No 266 34.5 88.4 82.3 81.2 
<0.001 
    Yes 21 25.6 76.2 61.9 52.4 
Preoperative renal 
dysfunction 
      
    No 270 35.4 89.6 82.6 80.7 
<0.001 
    Yes 17 6 52.9 52.9 52.9 
Concomitant CABG 
procedure 
     
 
    No 241 33.8 89.6 83.4 81.7 
0.029 
    Yes 46 28.4 76.1 67.4 65.2 
Circulatory arrest (minutes)       
    ≤100 251 37.5 88.8 83.3 81.3 
0.001 
    >100 36 18.8 77.8 63.9 63.9 
Cardiopulmonary bypass 
(minutes) 
      
    ≤450 251 35.1 90.4 84.5 82.5 
<0.001 
    >450 36 19.3 66.7 55.6 55.6 
 
 
 252 
 
Table 12.5.12b. Multivariable Analysis Showing Risk Factors For Follow Up Survival In All AAR Patients 
 
Risk Factors Hazard Ratio 95% CI p-value 
Pre operative renal dysfunction 
 
3.11 1.44, 6.73 <0.001 
NYHA class ≥ III 
 
2.25 
1.38, 3.67 0.002 
Circulatory arrest time > 100 minutes 
 
2.92 
1.57, 5.43 0.001 
Peripheral vascular disease 
 
2.44 
1.25, 4.74 0.004 
Concomitant CABG operation 2.14 1.20, 3.80 0.008 
 
C-index = 0.72 
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Table 12.5.13. Elephant trunk (ET) post-operative complications 
Variable 
Total Arch Replacement 
Elective  Non-elective  
p-value 
(n=81) (n=36) 
Conventional ET 37 (49.3) 13 (37.1) 0.23 
    Stroke 2/37 (5.4) 1/13 (7.7) >0.99 
    In-hospital mortality 4/37 (10.8) 1/13 (7.7) >0.99 
    30 day mortality 3/37 (8.1) 1/13 (7.7) >0.99 
    
Frozen ET 7 (9.3) 5 (14.3) 0.52 
    Stroke 0/7 (0) 0/5 (0) - 
    In-hospital mortality 0/7 (0) 1/5 (20.0) 0.42 
    30 day mortality 0/7 (0) 1/5 (20.0) 0.42 
    
Reverse ET (2nd stage) 2 (2.7) 0 (0) >0.99 
    Stroke 0/2 (0) 0 (0) - 
    In-hospital mortality 0/2 (0) 0 (0) - 
    30 day mortality 0/2 (0) 0 (0) - 
 
Categorical variables shown as n (%) 
Comparisons made with chi-squared and Fisher’s exact tests as appropriate 
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Figure 2.3.1.  Annual % Expenditure  
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Figure 3.2.  Type of Thoracic Aortic Aneurysms 
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Figure 3.8.  Aneurysmal Disease (indicated by the red arrows) 
 
 
Image taken from St. Roosevelt Aneurysm Centre. USA 
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Figure 7.3a.  Postoperative mortality in Marfan patients as high as 6.8% in those undergoing composite valve grafts in a 
retrospective group of 119 patients (114) 
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Figure 7.3b.  Survival after repair of thoracoabdominal aortic aneurysm among 509 patients, stratified by extent of repair. 
(122) 
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Figure 7.4.  Distribution of interventional activity on all thoracic aortic aneurysms by centre within England 
 
Figure 7.4  
Distribution of interventional activity on all thoracic aortic aneurysms by centre within England (Dr Foster) 
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Figure 7.8a.  Kaplan-Meier Survival Curve Stratified By Urgency Of Surgery.  
Insert, Kaplan-Meier survival curve stratified by urgency for those 
surviving beyond the first 30 postoperative days.  
 
 
From Higgins et al with permission. 
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Figure 7.8b.  Aortic Arch Replacement with a TG: Kaplan–Meier curve of 
152 1-year survivors versus New York State population.  
 
 
 
From Bischoff et al with permissions. 
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Figure 8.1.3.  Kaplan-Meier Cumulative Survival displaying the dismal 
prognosis of unoperated patients with Thoracic Aortic Aneurysms (TAA), 
Thoraco-Abdominal Aneurysms (T-AAA), and Abdominal Aortic 
Aneurysms (AAA). 
 
 
 
From Perko et al173. 
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Figure 8.1.4a.  Kaplan-Meier cumulative survival for 5 year survival in 
TAAs of varying size between 4 to 6cms. 
 
 
From Coady et al171 
  
 265 
 
Figure 8.1.4c.  Kaplan-Meier Cumulative Survival displaying 5 year 
survival for patient suffering from ascending and descending thoracic 
aortic aneurysms.  
 
 
 
From Coady et al171.  
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Figure 8.1.5a.  Kaplan-Meier Cumulative Survival displaying 5 year 
survival for patient suffering from ascending and descending thoracic 
aortic aneurysms.  
 
 
 
From Coady et al171.  
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Figures 8.1.5b. & 8.1.5c.  The Percentage Risk Of Complications for 
Ascending (b) and Descending (c) Aortic Aneurysms according to 
aneurysm size.  
b) Ascending Aortic Aneurysm 
 
c) Descending Aortic Aneurysm 
 
From Coady et al. 
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Figure 12.1.7.  Calibration plot comparing observed and predicted in-
hospital deaths, the bold black line represents perfect calibration 
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Figure 12.2.6a.  Bar chart showing acute dissection volume categories and 
in-hospital mortality rates for UK hospitals, dashed line indicates overall 
mortality rate (17.8%) 
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Figure 12.2.6b.  Scatterplot showing the relationship between acute 
dissection volume and in-hospital mortality for consultant cardiac 
surgeons, each point represents an individual surgeon. (NB: points are 
jittered to highlight overlapping data) 
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Figures 12.3.8a & 12.3.8b.  Unmatched (a) and Matched (b) 5 Year Survival 
a) Unmatched 5 year survival 
         
b) Matched 5 year survival 
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Figure 12.4.4.  Study Flow Chart 
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Figure 12.4.6a.  Kaplan-Meier survival chart – TAAR’s stratified by priority 
 
Figure 12.4.6b. Kaplan-Meier survival chart –Elective TAAR’s stratified by age 
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Figure 12.4.6c.  Kaplan-Meier survival chart – HAAR’s stratified by priority 
 
Figure 12.4.6d. Kaplan-Meier survival chart –Elective HAAR’s stratified by age
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Figure 12.5.11.  Aortic Arch Replacement Kaplan Meier chart with age and sex 
matched general population comparator (note truncated axis) 
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Figure 12.5.15a.  Elective Hemi-AAR chart with age and sex matched general 
population comparator (note truncated axis) 
 
 
 
 
Figure 12.5.15b.  Elective Total-AAR chart with age and sex matched general 
population comparator (note truncated axis) 
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